{
    "questions": [
        {
            "body": "Are super enhancers structurally insulated in chromatin loops?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30285185",
                "http://www.ncbi.nlm.nih.gov/pubmed/29507293",
                "http://www.ncbi.nlm.nih.gov/pubmed/28714474",
                "http://www.ncbi.nlm.nih.gov/pubmed/25263550"
            ],
            "ideal_answer": [
                "Although there is evidence that chromatin neighbourhoods, formed by the zinc-finger protein CTCF, can sequester enhancers and their target genes, there is limited in vivo evidence for CTCF demarcating super-enhancers and preventing cross talk between distinct regulatory elements. CTCF sites are porous borders, allowing a super-enhancer to activate a secondary target.",
                "Although there is evidence that chromatin neighbourhoods, formed by the zinc-finger protein CTCF, can sequester enhancers and their target genes, there is limited in vivo evidence for CTCF demarcating super-enhancers and preventing cross talk between distinct regulatory elements.",
                "Dissecting super-enhancer hierarchy based on chromatin interactions Although there is evidence that chromatin neighbourhoods, formed by the zinc-finger protein CTCF, can sequester enhancers and their target genes, there is limited in vivo evidence for CTCF demarcating super-enhancers and preventing cross talk between distinct regulatory elements.",
                "We also demonstrate that the Wap super-enhancer, which is built on STAT5 and other common transcription factors, retains its exquisite mammary specificity when placed into globally permissive chromatin, suggesting a limited role of chromatin in controlling cell specificity. CTCF sites are porous borders, allowing a super-enhancer to activate a secondary target."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5fdb42b7a43ad31278000025",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "text": "Dissecting super-enhancer hierarchy based on chromatin interactions",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29507293",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 527,
                    "offsetInEndSection": 638,
                    "text": "Genetic ablation of hub enhancers results in profound defects in gene activation and local chromatin landscape.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29507293",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1134,
                    "offsetInEndSection": 1409,
                    "text": "We also demonstrate that the Wap super-enhancer, which is built on STAT5 and other common transcription factors, retains its exquisite mammary specificity when placed into globally permissive chromatin, suggesting a limited role of chromatin in controlling cell specificity. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30285185",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 399,
                    "text": "Although there is evidence that chromatin neighbourhoods, formed by the zinc-finger protein CTCF, can sequester enhancers and their target genes, there is limited in vivo evidence for CTCF demarcating super-enhancers and preventing cross talk between distinct regulatory elements.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28714474",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 909,
                    "offsetInEndSection": 997,
                    "text": "CTCF sites are porous borders, allowing a super-enhancer to activate a secondary target.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28714474",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "Transcription factors and chromatin-remodeling complexes are key determinants of embryonic stem cell (ESC) identity. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25263550",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has Revlimid been approved by the US Food and Drug Administration?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25188481",
                "http://www.ncbi.nlm.nih.gov/pubmed/17996589",
                "http://www.ncbi.nlm.nih.gov/pubmed/25188483",
                "http://www.ncbi.nlm.nih.gov/pubmed/23545923",
                "http://www.ncbi.nlm.nih.gov/pubmed/17076650",
                "http://www.ncbi.nlm.nih.gov/pubmed/17076653",
                "http://www.ncbi.nlm.nih.gov/pubmed/20425391",
                "http://www.ncbi.nlm.nih.gov/pubmed/17242661",
                "http://www.ncbi.nlm.nih.gov/pubmed/18922829",
                "http://www.ncbi.nlm.nih.gov/pubmed/22650376",
                "http://www.ncbi.nlm.nih.gov/pubmed/17020458",
                "http://www.ncbi.nlm.nih.gov/pubmed/20359632"
            ],
            "ideal_answer": [
                "Yes, Revlimid has been approved by the US Food and Drug Administration for treatment of multiple myeloma."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014486"
            ],
            "type": "yesno",
            "id": "56ed0ba22ac5ed1459000007",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 461,
                    "text": "In the past decade, immunomodulatory drugs have been approved by the US Food and Drug Administration for the treatment of multiple myeloma (MM)-and a number of emerging agents that target the cellular pathways or proteins involved in the pathophysiology of MM are currently in development. Lenalidomide (Revlimid) and pomalidomide induce apoptosis and sensitize MM cells while demonstrating superior efficacy and better tolerability than thalidomide (Thalomid).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188483",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 290,
                    "text": "In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188481",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 289,
                    "text": "In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188481",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 697,
                    "offsetInEndSection": 941,
                    "text": "Thalidomide, lenalidomide (Revlimid), and bortezomib (Velcade) are directed not only at MM cells but also at the BM milieu and have moved rapidly from the bench to the bedside and United States Food and Drug Administration approval to treat MM.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17996589",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 303,
                    "text": "Lenalidomide (CC-5013, Revlimid; Celgene Corporation, Summit, NJ), a thalidomide analogue, was granted approval by the U.S. Food and Drug Administration (FDA) on June 29, 2006, for use in combination with dexamethasone in patients with multiple myeloma (MM) who have received at least one prior therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18922829",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 280,
                    "text": "Lenalidomide, an IMiD drug (a novel type of immunomodulating drug) was recently approved by the US Food and Drug Administration for the treatment of transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS) and interstitial deletions of chromosome 5q [del(5q)]",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17242661",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 537,
                    "text": "Lenalidomide, a second-generation immunomodulatory drug (IMiD), is approved by the US Food and Drug Administration for treatment of transfusion-dependent anemia in lower-risk MDS patients with deletion 5q chromosomal abnormality",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20425391",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 290,
                    "text": "In the past decade we have seen four new agents approved by the US Food and Drug Administration for treatment of multiple myeloma: the proteasome inhibitor (PI) bortezomib (Velcade), the immunomodulatory agents lenalidomide (Revlimid) and thalidomide (Thalomid), and liposomal doxorubicin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188481",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 35,
                    "offsetInEndSection": 129,
                    "text": "lenalidomide (CC5103 or revlimid) are recently approved for the treatment of multiple myeloma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22650376",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 462,
                    "text": " In the past decade, immunomodulatory drugs have been approved by the US Food and Drug Administration for the treatment of multiple myeloma (MM)-and a number of emerging agents that target the cellular pathways or proteins involved in the pathophysiology of MM are currently in development. Lenalidomide (Revlimid) and pomalidomide induce apoptosis and sensitize MM cells while demonstrating superior efficacy and better tolerability than thalidomide (Thalomid).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25188483",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is triadin involved in cardiac function?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18206802",
                "http://www.ncbi.nlm.nih.gov/pubmed/17890426",
                "http://www.ncbi.nlm.nih.gov/pubmed/15191886",
                "http://www.ncbi.nlm.nih.gov/pubmed/15023559"
            ],
            "triples": [
                {
                    "p": "http://purl.uniprot.org/core/isolatedFrom",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://purl.uniprot.org/tissues/440"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/440",
                    "o": "Cardiac muscle"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://linkedlifedata.com/resource/#_51323838323000B"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51323838323000B",
                    "o": "Triadin"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/440",
                    "o": "Heart muscle"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/expressedInAnatomicalSystem",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://purl.uniprot.org/tissues/445"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://linkedlifedata.com/resource/#_503832313739006"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_503832313739006",
                    "o": "Triadin"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/445",
                    "o": "Cardiac"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/445",
                    "o": "Cardiac tissue"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/445",
                    "o": "Heart"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://linkedlifedata.com/resource/#_503832313739009"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_503832313739009",
                    "o": "TRDN"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://linkedlifedata.com/resource/#_51313330363100E"
                },
                {
                    "p": "http://purl.uniprot.org/core/recommendedName",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://linkedlifedata.com/resource/#_51313330363100B"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_51313330363100E",
                    "o": "TRDN"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_51313330363100B",
                    "o": "Triadin"
                },
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://linkedlifedata.com/resource/#_51323838323000E"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_51323838323000E",
                    "o": "TRDN"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/expressedInAnatomicalSystem",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://purl.uniprot.org/tissues/440"
                },
                {
                    "p": "http://purl.uniprot.org/core/isolatedFrom",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://purl.uniprot.org/tissues/445"
                },
                {
                    "p": "http://purl.uniprot.org/core/classifiedWith",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://purl.uniprot.org/go/0006936"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/go/0006936",
                    "o": "http://www.geneontology.org/go#GO:0006936"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/go/0006936",
                    "o": "muscle contraction"
                },
                {
                    "p": "http://purl.uniprot.org/core/classifiedWith",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://purl.uniprot.org/keywords/703"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/keywords/703",
                    "o": "Sarcoplasmic reticulum"
                },
                {
                    "p": "http://purl.uniprot.org/core/classifiedWith",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://purl.uniprot.org/keywords/703"
                },
                {
                    "p": "http://purl.uniprot.org/core/classifiedWith",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://purl.uniprot.org/keywords/703"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/participateInBiologicalProcess",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://linkedlifedata.com/resource/geneontology/id/GO:0006936"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/geneontology/id/GO:0006936",
                    "o": "muscle contraction"
                },
                {
                    "p": "http://purl.uniprot.org/core/isolatedFrom",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://purl.uniprot.org/tissues/933"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/933",
                    "o": "Skeletal muscle"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/tissues/933",
                    "o": "Striated muscle"
                },
                {
                    "p": "http://purl.uniprot.org/core/isolatedFrom",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://purl.uniprot.org/tissues/933"
                },
                {
                    "p": "http://purl.uniprot.org/core/isolatedFrom",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://purl.uniprot.org/tissues/933"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/expressedInAnatomicalSystem",
                    "s": "http://purl.uniprot.org/uniprot/P82179",
                    "o": "http://purl.uniprot.org/tissues/933"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/expressedInAnatomicalSystem",
                    "s": "http://purl.uniprot.org/uniprot/Q13061",
                    "o": "http://purl.uniprot.org/tissues/933"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/expressedInAnatomicalSystem",
                    "s": "http://purl.uniprot.org/uniprot/Q28820",
                    "o": "http://purl.uniprot.org/tissues/933"
                }
            ],
            "ideal_answer": [
                "Yes, triadin is involved in the regulation of cardiac excitation-contraction coupling."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/TRDN_RABIT",
                "http://www.uniprot.org/uniprot/TRDN_HUMAN",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0060048",
                "http://www.uniprot.org/uniprot/TRDN_CANFA"
            ],
            "type": "yesno",
            "id": "52b2f09f4003448f55000008",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 349,
                    "text": "Junctin (JCN), a 26-kd sarcoplasmic reticulum (SR) transmembrane protein, forms a quaternary protein complex with the ryanodine receptor, calsequestrin, and triadin in the SR lumen of cardiac muscle. Within this complex, calsequestrin, triadin, and JCN appear to be critical for normal regulation of ryanodine receptor-mediated calcium (Ca) release.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18206802",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 561,
                    "offsetInEndSection": 873,
                    "text": "Recent studies have uncovered functional roles of both JCN and triadin in the mouse heart, using transgenic overexpression strategies, which exhibit varying phenotypes including mild SR structural alterations, prolongation of Ca transient decay, impaired relaxation, and cardiac hypertrophy and/or heart failure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18206802",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "text": "Triadin is involved in the regulation of cardiac excitation-contraction coupling. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17890426",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1686,
                    "offsetInEndSection": 1792,
                    "text": "Thus the maintenance of triadin expression is essential for normal SR Ca cycling and contractile function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17890426",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 215,
                    "text": "Ca2+ release from the cardiac junctional sarcoplasmic reticulum (SR) is regulated by a complex of proteins, including the ryanodine receptor (RyR), calsequestrin (CSQ), junctin (JCN), and triadin 1 (TRD).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15023559",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 287,
                    "text": "Impaired sarcoplasmic reticulum (SR) Ca release has been suggested to contribute to the depressed cardiac function in heart failure. The release of Ca from the SR may be regulated by the ryanodine receptor, triadin, junctin, calsequestrin, and a histidine-rich, Ca-binding protein (HRC).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15191886",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is autosomal dominant inheritanced form of Osteogenesis imperfecta caused by mutations in the genes associated with collagen production?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27312322",
                "http://www.ncbi.nlm.nih.gov/pubmed/2992938",
                "http://www.ncbi.nlm.nih.gov/pubmed/27677223",
                "http://www.ncbi.nlm.nih.gov/pubmed/21567925",
                "http://www.ncbi.nlm.nih.gov/pubmed/22863195",
                "http://www.ncbi.nlm.nih.gov/pubmed/28116328",
                "http://www.ncbi.nlm.nih.gov/pubmed/18566967",
                "http://www.ncbi.nlm.nih.gov/pubmed/27510842",
                "http://www.ncbi.nlm.nih.gov/pubmed/21341209",
                "http://www.ncbi.nlm.nih.gov/pubmed/28820180",
                "http://www.ncbi.nlm.nih.gov/pubmed/12362985",
                "http://www.ncbi.nlm.nih.gov/pubmed/2886666",
                "http://www.ncbi.nlm.nih.gov/pubmed/24928016",
                "http://www.ncbi.nlm.nih.gov/pubmed/29150909",
                "http://www.ncbi.nlm.nih.gov/pubmed/2037280",
                "http://www.ncbi.nlm.nih.gov/pubmed/27762305",
                "http://www.ncbi.nlm.nih.gov/pubmed/21667357",
                "http://www.ncbi.nlm.nih.gov/pubmed/19533842",
                "http://www.ncbi.nlm.nih.gov/pubmed/25402547",
                "http://www.ncbi.nlm.nih.gov/pubmed/20839288",
                "http://www.ncbi.nlm.nih.gov/pubmed/8456806"
            ],
            "ideal_answer": [
                "Osteogenesis imperfecta (OI), also known as brittle bone disease, is a group of genetic disorders that mainly affect the bones. The autosomal dominant form of the disease is cause by a mutation in the COL1A1 or COL1A2 genes which produce type I collagen.",
                "steogenesis imperfecta (OI) is a heterogeneous bone disorder characterized by recurrent fractures. Although most cases of OI have heterozygous mutations inCOL1A1orCOL1A2and show autosomal dominant inheritance,"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4249099",
                "http://www.disease-ontology.org/api/metadata/DOID:0110341",
                "http://www.disease-ontology.org/api/metadata/DOID:0110340",
                "http://www.disease-ontology.org/api/metadata/DOID:0110343",
                "http://www.disease-ontology.org/api/metadata/DOID:0110337",
                "http://www.disease-ontology.org/api/metadata/DOID:0110338",
                "http://www.disease-ontology.org/api/metadata/DOID:0110342",
                "http://www.disease-ontology.org/api/metadata/DOID:0110336",
                "https://meshb.nlm.nih.gov/record/ui?ui=D010013",
                "https://meshb.nlm.nih.gov/record/ui?ui=D005799",
                "http://www.disease-ontology.org/api/metadata/DOID:0110334",
                "http://www.disease-ontology.org/api/metadata/DOID:12347",
                "http://www.disease-ontology.org/api/metadata/DOID:0110335"
            ],
            "type": "yesno",
            "id": "5a6f77d7b750ff4455000051",
            "snippets": [
                {
                    "offsetInBeginSection": 13,
                    "offsetInEndSection": 222,
                    "text": "steogenesis imperfecta (OI) is a heterogeneous bone disorder characterized by recurrent fractures. Although most cases of OI have heterozygous mutations inCOL1A1orCOL1A2and show autosomal dominant inheritance,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28116328",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 274,
                    "text": "Osteogenesis imperfecta (OI) is a group of hereditary disorders characterized by decreased bone mass and increased fracture risk. The majority of OI cases have an autosomal dominant pattern of inheritance and are usually caused by mutations in genes encoding type I collagen",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27762305",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 281,
                    "text": " Osteogenesis imperfecta (OI) is a group of hereditary disorders characterized by low bone mass and recurrent fractures. Most OI cases follow an autosomal dominant pattern of inheritance and are attributed to mutations in genes encoding type I collagen (COL1A1/COL1A2). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27312322",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 268,
                    "text": "Osteogenesis imperfecta (OI) is a genetic disorder characterised by low bone mineral density resulting in fractures. 85-90% of patients with OI carry a variant in the type 1 collagen genes, COL1A1 and COL1A2, which follows an autosomal dominant pattern of inheritance.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27677223",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 385,
                    "text": "Osteogenesis imperfecta (OI) comprises a heterogeneous group of disorders that are characterized by susceptibility to bone fractures, and range in severity from a subtle increase in fracture frequency to death in the perinatal period. Most patients have defects in type I collagen biosynthesis with autosomal-dominant inheritance, but many autosomal-recessive genes have been reported.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25402547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 159,
                    "text": "To investigate mutation of COL1A1 gene and analyze the relationship between genotype and clinical phenotype in a family with osteogenesis imperfecta",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24928016",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Dominant inheritance of osteogenesis imperfecta (OI) is caused by mutations in COL1A1 or COL1A2, the genes that encode type I collagen,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21667357",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 805,
                    "text": "Osteogenesis imperfecta (OI) is a heterogeneous group of inherited disorders of bone formation, resulting in low bone mass and an increased propensity to fracture. It exhibits a broad spectrum of clinical severity, ranging from multiple fractures in utero and perinatal death, to normal adult stature and low fracture incidence. Extra-skeletal features of OI include blue sclera, hearing loss, skin hyperlaxity, joint hyperextensibility, and dentinogenesis imperfecta. The pro\u03b11(I) and pro\u03b12(I) chains of collagen 1 are encoded by the COL1A1 and COL1A2 genes, respectively; quantitative or qualitative defects in type I collagen synthesis usually manifest as types of OI or some sub-types of EDS. The majority of patients (about 90%) with a clinical diagnosis of OI have a mutation in the COL1A1 or COL1A2",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21567925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 478,
                    "text": "Osteogenesis imperfecta (OI) type I is characterized by bone fragility without significant deformity, osteopenia, normal stature, blue sclerae, and autosomal dominant inheritance. Dermal fibroblasts from most affected individuals produce about half the expected amount of type I collagen, suggesting that the OI type I phenotype results from a variety of mutations which alter the apparent expression of either COL1A1 or COL1A2, the genes encoding the chains of type I collagen.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8456806",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "Autosomal dominant osteogenesis imperfecta is caused by mutations in the COL1A2 and COL1A1 genes of type I collagen. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2886666",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 352,
                    "offsetInEndSection": 544,
                    "text": "Osteogenesis imperfecta is caused by dominant autosomal mutations in the type I collagen coding genes (COL1A1 and COL1A2) in about 85% of individuals, affecting collagen quantity or structure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28820180",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "text": "Osteogenesis imperfecta (OI) is a heterogeneous group of disorders of connective tissue, mainly caused by mutations in the collagen type I genes (COL1A1 and COL1A2).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27510842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Autosomal dominant osteogenesis imperfecta (OI) is caused by mutations in the genes (COL1A1 or COL1A2) encoding the chains of type I collagen.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18566967",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 326,
                    "text": "In approximately 90% of individuals with osteogenesis imperfecta, mutations in either of the genes encoding the pro-alpha1 or pro-alpha2 chains of type I collagen (COL1A1 or COL1A2) can be identified.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19533842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 187,
                    "offsetInEndSection": 303,
                    "text": "Autosomal dominant OI is caused by mutations in the genes (COL1A1 or COL1A2) encoding the chains of type I collagen.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20839288",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 265,
                    "offsetInEndSection": 659,
                    "text": "ext-generation sequencing technology was used to screen a panel of known OI genes.RESULTS: In 41 probands, we identified 28 different disease-causing variants of 9 different known OI genes. Eleven of the variants are novel. Ten of the 28 variants are located in COL1A1, five in COL1A2, three in BMP1, three in FKBP10, two in TMEM38B, two in P3H1, and one each in CRTAP, SERPINF1, and SERPINH1. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29150909",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 307,
                    "text": "Osteogenesis imperfecta (OI) is a clinically and genetically heterogeneous disorder associated with bone fragility and susceptibility to fractures after minimal trauma. OI type V has an autosomal-dominant pattern of inheritance and is not caused by mutations in the type I collagen genes COL1A1 and COL1A2. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22863195",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "Detection of a high frequency RsaI polymorphism in the human pro alpha 2(I) collagen gene which is linked to an autosomal dominant form of osteogenesis imperfecta.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2992938",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "Osteogenesis imperfecta due to recurrent point mutations at CpG dinucleotides in the COL1A1 gene of type I collagen.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2037280",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 375,
                    "text": "Osteogenesis imperfecta (OI), commonly known as \"brittle bone disease\", is a dominant autosomal disorder characterized by bone fragility and abnormalities of connective tissue. Biochemical and molecular genetic studies have shown that the vast majority of affected individuals have mutations in either the COL1A1 or COL1A2 genes that encode the chains of type I procollagen. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12362985",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "text": "Osteogenesis imperfecta is normally caused by an autosomal dominant mutation in the type I collagen genes COL1A1 and COL1A2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21341209",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can you computationally predict Molecular Recognition Features (MoRFs) regions in Intrinsically Disordered Proteins (IDPs)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30324701",
                "http://www.ncbi.nlm.nih.gov/pubmed/30298407",
                "http://www.ncbi.nlm.nih.gov/pubmed/25637562",
                "http://www.ncbi.nlm.nih.gov/pubmed/26517836",
                "http://www.ncbi.nlm.nih.gov/pubmed/29360926",
                "http://www.ncbi.nlm.nih.gov/pubmed/29042212"
            ],
            "ideal_answer": [
                "Yes. There are various tools available in the literature that enable computational identification of Molecular Recognition Features (MoRFs) regions in intrinsically disordered protein sequences."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c6d9a157c78d69471000041",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 58,
                    "text": "Predicting Functions of Disordered Proteins with MoRFpred.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30298407",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 949,
                    "text": "Intrinsically disordered proteins and regions are involved in a wide range of cellular functions, and they often facilitate protein-protein interactions. Molecular recognition features (MoRFs) are segments of intrinsically disordered regions that bind to partner proteins, where binding is concomitant with a transition to a structured conformation. MoRFs facilitate translation, transport, signaling, and regulatory processes and are found across all domains of life. A popular computational tool, MoRFpred, accurately predicts MoRFs in protein sequences. MoRFpred is implemented as a user-friendly web server that is freely available at http://biomine.cs.vcu.edu/servers/MoRFpred/ . We describe this predictor, explain how to run the web server, and show how to interpret the results it generates. We also demonstrate the utility of this web server based on two case studies, focusing on the relevance of evolutionary conservation of MoRF regions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30298407",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "text": "MoRFPred-plus: Computational Identification of MoRFs in Protein Sequences using Physicochemical Properties and HMM profiles.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042212",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 1777,
                    "text": "Intrinsically Disordered Proteins (IDPs) lack stable tertiary structure and they actively participate in performing various biological functions. These IDPs expose short binding regions called Molecular Recognition Features (MoRFs) that permit interaction with structured protein regions. Upon interaction they undergo a disorder-to-order transition as a result of which their functionality arises. Predicting these MoRFs in disordered protein sequences is a challenging task.METHOD: In this study, we present MoRFpred-plus, an improved predictor over our previous proposed predictor to identify MoRFs in disordered protein sequences. Two separate independent propensity scores are computed via incorporating physicochemical properties and HMM profiles, these scores are combined to predict final MoRF propensity score for a given residue. The first score reflects the characteristics of a query residue to be part of MoRF region based on the composition and similarity of assumed MoRF and flank regions. The second score reflects the characteristics of a query residue to be part of MoRF region based on the properties of flanks associated around the given residue in the query protein sequence. The propensity scores are processed and common averaging is applied to generate the final prediction score of MoRFpred-plus.RESULTS: Performance of the proposed predictor is compared with available MoRF predictors, MoRFchibi, MoRFpred, and ANCHOR. Using previously collected training and test sets used to evaluate the mentioned predictors, the proposed predictor outperforms these predictors and generates lower false positive rate. In addition, MoRFpred-plus is a downloadable predictor, which makes it useful as it can be used as input to other computational tools.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29042212",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 79,
                    "text": "OPAL: prediction of MoRF regions in intrinsically disordered protein sequences.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29360926",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 1433,
                    "text": "Intrinsically disordered proteins lack stable 3-dimensional structure and play a crucial role in performing various biological functions. Key to their biological function are the molecular recognition features (MoRFs) located within long disordered regions. Computationally identifying these MoRFs from disordered protein sequences is a challenging task. In this study, we present a new MoRF predictor, OPAL, to identify MoRFs in disordered protein sequences. OPAL utilizes two independent sources of information computed using different component predictors. The scores are processed and combined using common averaging method. The first score is computed using a component MoRF predictor which utilizes composition and sequence similarity of MoRF and non-MoRF regions to detect MoRFs. The second score is calculated using half-sphere exposure (HSE), solvent accessible surface area (ASA) and backbone angle information of the disordered protein sequence, using information from the amino acid properties of flanks surrounding the MoRFs to distinguish MoRF and non-MoRF residues.Results: OPAL is evaluated using test sets that were previously used to evaluate MoRF predictors, MoRFpred, MoRFchibi and MoRFchibi-web. The results demonstrate that OPAL outperforms all the available MoRF predictors and is the most accurate predictor available for MoRF prediction. It is available at http://www.alok-ai-lab.com/tools/opal/.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29360926",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "OPAL+: Length-Specific MoRF Prediction in Intrinsically Disordered Protein Sequences.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30324701",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 972,
                    "text": "Intrinsically disordered proteins (IDPs) contain long unstructured regions, which play an important role in their function. These intrinsically disordered regions (IDRs) participate in binding events through regions called molecular recognition features (MoRFs). Computational prediction of MoRFs helps identify the potentially functional regions in IDRs. In this study, OPAL+, a novel MoRF predictor, is presented. OPAL+ uses separate models to predict MoRFs of varying lengths along with incorporating the hidden Markov model (HMM) profiles and physicochemical properties of MoRFs and their flanking regions. Together, these features help OPAL+ achieve a marginal performance improvement of 0.4-0.7% over its predecessor for diverse MoRF test sets. This performance improvement comes at the expense of increased run time as a result of the requirement of HMM profiles. OPAL+ is available for download at https://github.com/roneshsharma/OPAL-plus/wiki/OPAL-plus-Download.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30324701",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "Computational Identification of MoRFs in Protein Sequences Using Hierarchical Application of Bayes Rule.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26517836",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 131,
                    "offsetInEndSection": 1810,
                    "text": "Key to their regulatory function is often the binding to globular protein domains via sequence elements known as molecular recognition features (MoRFs). Development of computational tools for the identification of candidate MoRF locations in amino acid sequences is an important task and an area of growing interest. Given the relative sparseness of MoRFs in protein sequences, the accuracy of the available MoRF predictors is often inadequate for practical usage, which leaves a significant need and room for improvement. In this work, we introduce MoRFCHiBi_Web, which predicts MoRF locations in protein sequences with higher accuracy compared to current MoRF predictors.METHODS: Three distinct and largely independent property scores are computed with component predictors and then combined to generate the final MoRF propensity scores. The first score reflects the likelihood of sequence windows to harbour MoRFs and is based on amino acid composition and sequence similarity information. It is generated by MoRFCHiBi using small windows of up to 40 residues in size. The second score identifies long stretches of protein disorder and is generated by ESpritz with the DisProt option. Lastly, the third score reflects residue conservation and is assembled from PSSM files generated by PSI-BLAST. These propensity scores are processed and then hierarchically combined using Bayes rule to generate the final MoRFCHiBi_Web predictions.RESULTS: MoRFCHiBi_Web was tested on three datasets. Results show that MoRFCHiBi_Web outperforms previously developed predictors by generating less than half the false positive rate for the same true positive rate at practical threshold values.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26517836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 59,
                    "text": "Computational identification of MoRFs in protein sequences.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25637562",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 429,
                    "offsetInEndSection": 1580,
                    "text": "In this study, we introduce MoRFCHiBi, a new computational approach for fast and accurate prediction of MoRFs in protein sequences. MoRFCHiBi combines the outcomes of two support vector machine (SVM) models that take advantage of two different kernels with high noise tolerance. The first, SVMS, is designed to extract maximal information from the general contrast in amino acid compositions between MoRFs, their surrounding regions (Flanks), and the remainders of the sequences. The second, SVMT, is used to identify similarities between regions in a query sequence and MoRFs of the training set.RESULTS: We evaluated the performance of our predictor by comparing its results with those of two currently available MoRF predictors, MoRFpred and ANCHOR. Using three test sets that have previously been collected and used to evaluate MoRFpred and ANCHOR, we demonstrate that MoRFCHiBi outperforms the other predictors with respect to different evaluation metrics. In addition, MoRFCHiBi is downloadable and fast, which makes it useful as a component in other computational prediction tools.AVAILABILITY AND IMPLEMENTATION: http://www.chibi.ubc.ca/morf/.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25637562",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "OPAL: prediction of MoRF regions in intrinsically disordered protein sequences.Supplementary data are available at Bioinformatics online.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29360926",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 263,
                    "offsetInEndSection": 355,
                    "text": "Computational prediction of MoRFs helps identify the potentially functional regions in IDRs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30324701",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Miller-Dieker syndrome associated with abnormalities of chromosome 1?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18989166",
                "http://www.ncbi.nlm.nih.gov/pubmed/9063734",
                "http://www.ncbi.nlm.nih.gov/pubmed/10655551",
                "http://www.ncbi.nlm.nih.gov/pubmed/11579431",
                "http://www.ncbi.nlm.nih.gov/pubmed/2740347",
                "http://www.ncbi.nlm.nih.gov/pubmed/1968707",
                "http://www.ncbi.nlm.nih.gov/pubmed/29858378",
                "http://www.ncbi.nlm.nih.gov/pubmed/29628935",
                "http://www.ncbi.nlm.nih.gov/pubmed/3993677",
                "http://www.ncbi.nlm.nih.gov/pubmed/10406660",
                "http://www.ncbi.nlm.nih.gov/pubmed/7573359",
                "http://www.ncbi.nlm.nih.gov/pubmed/19584063",
                "http://www.ncbi.nlm.nih.gov/pubmed/2903661",
                "http://www.ncbi.nlm.nih.gov/pubmed/27644460",
                "http://www.ncbi.nlm.nih.gov/pubmed/10787042",
                "http://www.ncbi.nlm.nih.gov/pubmed/28380362",
                "http://www.ncbi.nlm.nih.gov/pubmed/23326253",
                "http://www.ncbi.nlm.nih.gov/pubmed/3189330",
                "http://www.ncbi.nlm.nih.gov/pubmed/29707411",
                "http://www.ncbi.nlm.nih.gov/pubmed/21239872",
                "http://www.ncbi.nlm.nih.gov/pubmed/8355785",
                "http://www.ncbi.nlm.nih.gov/pubmed/6834189",
                "http://www.ncbi.nlm.nih.gov/pubmed/3963054",
                "http://www.ncbi.nlm.nih.gov/pubmed/28186603"
            ],
            "ideal_answer": [
                "No. Miller-Dieker syndrome is caused by a heterozygous deletion of chromosome 17p13.3 involving the genes LIS1 and YWHAE and leads to malformations during cortical development."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c72f8557c78d69471000080",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "A complete ophthalmic examination is not routinely performed on infants with Miller-Dieker syndrome (MDS, chromosome 17p13.3 microdeletion). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29707411",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 199,
                    "offsetInEndSection": 332,
                    "text": "Chromosome microdeletions within 17p13.3 can result in either isolated lissencephaly sequence (ILS) or Miller-Dieker syndrome (MDS). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29628935",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 288,
                    "offsetInEndSection": 876,
                    "text": "We report a fetus with lissencephaly diagnosed as Miller-Dieker Syndrome postnatally. G banded chromosome analysis revealed 45,X,psu dic(17;Y)(p13;p11.32).ish dic (17;Y)(LIS1-,RARA+, SRY+, DYZ3+) by G-banding analysis using high resolution banding technique. Fetal delayed cortical development will be the findings to perform further investigations including fluorescence in situ hybridization analysis for MDS, a 17p13.3 microdeletion syndrome, pre/postnatally. This will be the first case of MDS with unbalanced translocation between deleted short arm of chromosome 17 and Y chromosome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27644460",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 132,
                    "offsetInEndSection": 345,
                    "text": " We report the finding of a 2.5-Mb gene region quadruplication of Chromosome 17p13.3. This region is well characterized for the deletion leading to Miller-Dieker syndrome but has an unclear replication phenotype. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29858378",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 763,
                    "offsetInEndSection": 1076,
                    "text": "Both deletions have overlapped with the critical region of Miller-Dieker syndrome (MDS) and involved candidate genes such as PAFAH1B1, YWHAE and CRK. In addition, SNP array and FISH analyses on the parental peripheral blood samples demonstrated that both 17p13.3 and 17p13.3p13.2 deletions were of de novo origin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28186603",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "text": "Miller-Dieker syndrome (MDS) is caused by a heterozygous deletion of chromosome 17p13.3 involving the genes LIS1 and YWHAE (coding for 14.3.3\u03b5) and leads to malformations during cortical development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28380362",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 260,
                    "text": "We studied after death a 3-month-old girl whose karyotype was 45,XX,-15,-17,+der(17),t(15;17)(q13;p13.3) and thus combines abnormalities of chromosome 15 associated with the Prader-Willi syndrome and of chromosome 17 associated with the Miller-Dieker syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3993677",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 235,
                    "text": "The Miller-Dieker syndrome (MDS), a syndrome with lissencephaly, distinctive craniofacial features, growth impairment, and profound developmental failure, has been associated with a deletion of the distal part of chromosome band 17p13.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2903661",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "The Miller-Dieker syndrome (type I lissencephaly) is a neuronal migration disorder which is associated with microdeletions in the short arm of chromosome 17.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10787042",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Detection of submicroscopic deletions in band 17p13 in patients with the Miller-Dieker syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2903661",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "text": "A 15-month-old girl with Miller-Dieker syndrome, a contiguous gene deletion syndrome involving chromosome 17p13.3 and resulting in lissencephaly, was diagnosed with precursor B-cell acute lymphoblastic leukemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18989166",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 530,
                    "offsetInEndSection": 737,
                    "text": "A computed tomography scan revealed evidence of lissencephaly, and chromosomal analysis showed a microdeletion on the short arm of chromosome 17 (17p13.3), confirming the diagnosis as Miller-Dieker syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10787042",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "Familial Miller-Dieker syndrome associated with pericentric inversion of chromosome 17.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3963054",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 848,
                    "offsetInEndSection": 1052,
                    "text": "The Miller-Dieker syndrome (MDS), a rare congenital disorder manifested by characteristic facial abnormalities and lissencephaly (smooth brain), is associated with microdeletions of the distal 17p region.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1968707",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 224,
                    "text": "Miller-Dieker syndrome (MDS), a disorder manifesting the severe brain malformation lissencephaly (\"smooth brain\"), is caused, in the majority of cases, by a chromosomal microdeletion of the distal short arm of chromosome 17.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3189330",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "text": "The Miller-Dieker syndrome (MDS), composed of characteristic facial abnormalities and a severe neuronal migration disorder affecting the cerebral cortex, is caused by visible or submicroscopic deletions of chromosome band 17p13.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2740347",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "Microdeletions including YWHAE in the Miller-Dieker syndrome region on chromosome 17p13.3 result in facial dysmorphisms, growth restriction, and cognitive impairment.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19584063",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "Identification of the functional profilin gene, its localization to chromosome subband 17p13.3, and demonstration of its deletion in some patients with Miller-Dieker syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1968707",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 268,
                    "text": "HIC1 is a candidate tumor suppressor gene which is frequently hypermethylated in human tumors, and its location within the Miller-Dieker syndrome's critical deletion region at chromosome 17p13.3 makes it a candidate gene for involvement in this gene deletion syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10655551",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "A complete ophthalmic examination is not routinely performed on infants with Miller-Dieker syndrome (MDS, chromosome 17p13.3 microdeletion).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29707411",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 425,
                    "offsetInEndSection": 614,
                    "text": "About 15% of patients with isolated lissencephaly and more than 90% of patients with Miller-Dieker syndrome have microdeletions in a critical 350-kilobase region in chromosome 17p13.3 (ref.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8355785",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 911,
                    "offsetInEndSection": 1340,
                    "text": "Chromosome aberrations in which epilepsy is a major and consistent finding include Angelman syndrome due to loss of the maternal 15q11.2-q12 segment, tetrasomy of the maternal segment 15pter-q13 due to an additional inv dup chromosome, Miller-Dieker syndrome due to deletion of the 17p13.3 segment including the lissencephaly1 gene, ring chromosome 20, and Wolf-Hirschhorn syndrome due to deletion of at least the 4p16.3 segment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11579431",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "Miller-Dieker syndrome and trisomy 5p in a child carrying a derivative chromosome with a microdeletion in 17p13.3 telomeric to the LIS1 and the D17S379 loci.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10406660",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 107,
                    "text": "The Miller-Dieker syndrome, a disorder of neuronal migration, is caused by deletions of chromosome 17p13.3.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7573359",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 513,
                    "offsetInEndSection": 781,
                    "text": "The girl was diagnosed by subtelomeric FISH and array-CGH, showing a 4.43-Mb heterozygous deletion on chromosome 10p that involved 14 genes and a 3.22-Mb single-copy gain on chromosome 17p, which includes the critical region of the Miller-Dieker syndrome and 61 genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326253",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 331,
                    "text": "Detection of submicroscopic deletions in band 17p13 in patients with the Miller-Dieker syndrome.The Miller-Dieker syndrome (MDS), a syndrome with lissencephaly, distinctive craniofacial features, growth impairment, and profound developmental failure, has been associated with a deletion of the distal part of chromosome band 17p13. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2903661",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 338,
                    "text": "Microdeletions including YWHAE in the Miller-Dieker syndrome region on chromosome 17p13.3 result in facial dysmorphisms, growth restriction, and cognitive impairment.Microdeletions of chromosome 17p13.3 involving YWHAE present with growth restriction, craniofacial dysmorphisms, structural abnormalities of brain and cognitive impairment. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19584063",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 374,
                    "text": "Unbalanced translocation (15;17)(q13;13.3) with apparent Prader-Willi syndrome but without Miller-Dieker syndrome.We studied after death a 3-month-old girl whose karyotype was 45,XX,-15,-17,+der(17),t(15;17)(q13;p13.3) and thus combines abnormalities of chromosome 15 associated with the Prader-Willi syndrome and of chromosome 17 associated with the Miller-Dieker syndrome. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3993677",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1023,
                    "offsetInEndSection": 1227,
                    "text": "The Miller-Dieker syndrome (MDS), a rare congenital disorder manifested by characteristic facial abnormalities and lissencephaly (smooth brain), is associated with microdeletions of the distal 17p region. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1968707",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 232,
                    "text": "A revision of the lissencephaly and Miller-Dieker syndrome critical regions in chromosome 17p13.3.Miller-Dieker syndrome (MDS) is a multiple malformation syndrome characterized by classical lissencephaly and a characteristic facies. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9063734",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 258,
                    "text": "Case Report of Proliferative Peripheral Retinopathy in Two Familial Lissencephaly Infants with Miller-Dieker Syndrome.A complete ophthalmic examination is not routinely performed on infants with Miller-Dieker syndrome (MDS, chromosome 17p13.3 microdeletion). ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29707411",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 279,
                    "text": "Identification of the functional profilin gene, its localization to chromosome subband 17p13.3, and demonstration of its deletion in some patients with Miller-Dieker syndrome.Profilin is a conserved actin-monomer-binding protein which is found in all eukaryotes, including yeast. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1968707",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 380,
                    "offsetInEndSection": 600,
                    "text": "We propose that essentially no loss of 17p material has occurred and confirm previous reports that the critical region for the production of the Miller-Dieker phenotype is located subterminally in the 17p13.3 region.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3993677",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 396,
                    "offsetInEndSection": 533,
                    "text": "A review of the literature revealed five additional patients in three families, who had Miller-Dieker syndrome and an abnormality of 17p.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6834189",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 380,
                    "offsetInEndSection": 596,
                    "text": "We propose that essentially no loss of 17p material has occurred and confirm previous reports that the critical region for the production of the Miller-Dieker phenotype is located subterminally in the 17p13.3 region.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3993677",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 55,
                    "text": "Miller-Dieker syndrome: lissencephaly and monosomy 17p.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6834189",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 534,
                    "offsetInEndSection": 639,
                    "text": "Thus, we propose that monosomy of distal 17p may be the cause of Miller-Dieker syndrome in some patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6834189",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "Miller-Dieker syndrome with der(17)t(12;17)(q24.33;p13.3)pat presenting with a potential risk of mis-identification as a de novo submicroscopic deletion of 17p13.3.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21239872",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 407,
                    "offsetInEndSection": 486,
                    "text": "Most cases of Miller-Dieker syndrome have a de novo deletion involving 17p13.3.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21239872",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can NEECHAM Confusion Scale be used for evaluation of postoperative delirium?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15792498",
                "http://www.ncbi.nlm.nih.gov/pubmed/16732742",
                "http://www.ncbi.nlm.nih.gov/pubmed/24928237",
                "http://www.ncbi.nlm.nih.gov/pubmed/18282269",
                "http://www.ncbi.nlm.nih.gov/pubmed/11915156",
                "http://www.ncbi.nlm.nih.gov/pubmed/25337310",
                "http://www.ncbi.nlm.nih.gov/pubmed/23121489",
                "http://www.ncbi.nlm.nih.gov/pubmed/10701282",
                "http://www.ncbi.nlm.nih.gov/pubmed/19711147",
                "http://www.ncbi.nlm.nih.gov/pubmed/22441728",
                "http://www.ncbi.nlm.nih.gov/pubmed/27576903",
                "http://www.ncbi.nlm.nih.gov/pubmed/21511473",
                "http://www.ncbi.nlm.nih.gov/pubmed/21539718",
                "http://www.ncbi.nlm.nih.gov/pubmed/15038935",
                "http://www.ncbi.nlm.nih.gov/pubmed/1811781",
                "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                "http://www.ncbi.nlm.nih.gov/pubmed/17394635",
                "http://www.ncbi.nlm.nih.gov/pubmed/24175169",
                "http://www.ncbi.nlm.nih.gov/pubmed/10095647",
                "http://www.ncbi.nlm.nih.gov/pubmed/16351715",
                "http://www.ncbi.nlm.nih.gov/pubmed/15077440"
            ],
            "ideal_answer": [
                "Yes, NEECHAM Confusion Scale can be used for evaluation of postoperative delirium."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D023362",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003693",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000067290",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D063189",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011569"
            ],
            "type": "yesno",
            "id": "5886222a3b87a8a738000005",
            "snippets": [
                {
                    "offsetInBeginSection": 361,
                    "offsetInEndSection": 473,
                    "text": "Sampling was achieved in a nonrandomized targeted manner and delirium was assessed using NeeCham questionnaire. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25337310",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "Delirium in older patients: a diagnostic study of NEECHAM Confusion Scale in surgical intensive care unit.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121489",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "AIMS AND OBJECTIVES: To estimate the diagnostic value and determine the feasibility of the NEECHAM Confusion Scale on critically ill older patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121489",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1447,
                    "offsetInEndSection": 1845,
                    "text": "CONCLUSIONS: Findings from this study confirm the good diagnostic value and ease of application of the NEECHAM scale with nonventilated intensive care patients.RELEVANCE TO CLINICAL PRACTICE: The NEECHAM scale can be used to detect delirium during the routine nursing assessment of nonintubated older patients as it requires minimal demand and stress on the patient as well as on the bedside nurse.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23121489",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 540,
                    "offsetInEndSection": 647,
                    "text": "The NEECHAM Confusion Scale and the validated chart review instrument were used for diagnosis of delirium. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22441728",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 344,
                    "offsetInEndSection": 594,
                    "text": "Among the various screening instruments, NEECHAM confusion scale and delirium observation scale appear to be most suitable screening instrument for patients' in general medical and surgical wards, depending on the type of rater (physician or nurse). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24175169",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 662,
                    "offsetInEndSection": 894,
                    "text": "Use of NEECHAM scaling enabled medical staff to identify cases of possible confusion early, indicating that the NEECHAM confusion scale should be useful for the detection of postoperative delirium and confusion in the surgical ward.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Early detection of postoperative delirium and confusion in a surgical ward using the NEECHAM confusion scale.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 406,
                    "offsetInEndSection": 696,
                    "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 114,
                    "text": "Assessment of the risk of postoperative delirium in elderly patients using E-PASS and the NEECHAM Confusion Scale.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 659,
                    "text": "The aim of this study was to determine which of the two delirium observation screening scales, the NEECHAM Confusion Scale or the Delirium Observation Screening (DOS) scale, has the best discriminative capacity for diagnosing delirium and which is more practical for daily use by nurses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1121,
                    "offsetInEndSection": 1205,
                    "text": "For delirium diagnosis and severity assessment, we used the NEECHAM Confusion Scale.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 666,
                    "offsetInEndSection": 898,
                    "text": "Use of NEECHAM scaling enabled medical staff to identify cases of possible confusion early, indicating that the NEECHAM confusion scale should be useful for the detection of postoperative delirium and confusion in the surgical ward.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 546,
                    "offsetInEndSection": 684,
                    "text": "The NEECHAM Confusion Scale was performed upon admission and prior to discharge.RESULTS: The incidence of DSM-IV related delirium was 24%.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539718",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "A comparison of the CAM-ICU and the NEECHAM Confusion Scale in intensive care delirium assessment: an observational study in non-intubated patients.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18282269",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "Predictive value and validation of the NEECHAM Confusion Scale using DSM-IV criteria for delirium as gold standard.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21539718",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Early detection of postoperative delirium and confusion in a surgical ward using the NEECHAM confusion scale",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 753,
                    "text": "The aim of this study was to determine which of the two delirium observation screening scales, the NEECHAM Confusion Scale or the Delirium Observation Screening (DOS) scale, has the best discriminative capacity for diagnosing delirium and which is more practical for daily use by nurses.The project was conducted on four wards of a university hospital; 87 patients were included",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 597,
                    "offsetInEndSection": 909,
                    "text": "In addition, we scored the participants on the NEECHAM Scale and evaluated their postoperative delirium and postoperative arrhythmia.On the nights of Days 4 and 5, the amount of activity of the exposure group was significantly lower and The sympathetic nervous index was significantly lower on the night of Day 5",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21511473",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 422,
                    "offsetInEndSection": 713,
                    "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1207,
                    "offsetInEndSection": 1381,
                    "text": "The cut-off value of the NEECHAM score was established as 20 points, and patients showing values less than this after surgery were regarded as having postoperative delirium. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 504,
                    "offsetInEndSection": 663,
                    "text": "Identification of delirium was based on evaluation of the level of consciousness with the NEECHAM Confusion Scale and/or a chart-based instrument for delirium.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19711147",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1100,
                    "offsetInEndSection": 1184,
                    "text": "For delirium diagnosis and severity assessment, we used the NEECHAM Confusion Scale.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 777,
                    "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS.The subjects were 160 patients aged more than 75 years who underwent surgery.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 280,
                    "offsetInEndSection": 414,
                    "text": "In this study a nursing screening instrument, the NEECHAM confusion scale, was studied for early recognition of delirium ICU patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351715",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1644,
                    "offsetInEndSection": 1775,
                    "text": "The psychometric characteristics and the ease of use of the NEECHAM confusion scale enables ICU nurses to early recognize delirium.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16351715",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 665,
                    "text": "The trends of the NEECHAM scores in the 3 groups were compared, and the relationship between the NEECHAM scores and suspected clinical risk factors for delirium was investigated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1836,
                    "offsetInEndSection": 2171,
                    "text": "In groups showing an MMSE score of less than 25 or a preoperative NEECHAM score of less than 27, the incidence of postoperative delirium was 76%.CONCLUSION: The results suggest that E-PASS and the NEECHAM score facilitate assessment of the risk of postoperative delirium in elderly patients, contributing to early prevention/treatment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 700,
                    "text": "In this study, we investigated whether the early detection of postoperative delirium in elderly patients is possible using a simple, useful behavior-assessing scale, the NEECHAM Confusion Scale, and a method for comprehensively evaluating elderly persons' stress related to surgery, E-PASS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 666,
                    "offsetInEndSection": 899,
                    "text": "Use of NEECHAM scaling enabled medical staff to identify cases of possible confusion early, indicating that the NEECHAM confusion scale should be useful for the detection of postoperative delirium and confusion in the surgical ward..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Early detection of postoperative delirium and confusion in a surgical ward using the NEECHAM confusion scale.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15038935",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 115,
                    "text": "Assessment of the risk of postoperative delirium in elderly patients using E-PASS and the NEECHAM Confusion Scale.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1101,
                    "offsetInEndSection": 1185,
                    "text": "For delirium diagnosis and severity assessment, we used the NEECHAM Confusion Scale.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19319925",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 137,
                    "text": "The Neecham Confusion Scale and the Delirium Observation Screening Scale: capacity to discriminate and ease of use in clinical practice.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 662,
                    "text": "The aim of this study was to determine which of the two delirium observation screening scales, the NEECHAM Confusion Scale or the Delirium Observation Screening (DOS) scale, has the best discriminative capacity for diagnosing delirium and which is more practical for daily use by nurses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17394635",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are organisms in the genus Morexella associated with sepsis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24669633"
            ],
            "ideal_answer": [
                "Moraxella species may cause neonatal sepsis"
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D000071074",
                "https://meshb.nlm.nih.gov/record/ui?ui=D018805"
            ],
            "type": "yesno",
            "id": "5a679be1b750ff4455000005",
            "snippets": [
                {
                    "offsetInBeginSection": 889,
                    "offsetInEndSection": 1390,
                    "text": "Out of 130 culture proven cases of neonatal sepsis, gram negative bacteria were found in 71 (54.6%) cases and gram positive bacteria in 59 (45.4%) cases. Staphylococcus aureus was the most common bacteria found in 35 (26.9%) cases followed by Escherichia coli in 30 (23.1%) cases. Acinetobacter species, Staphylococcus epidermidis, Klebseila, Streptococci, Enterobacter cloacae and Morexella species were found in 17 (13.1%), 17 (13.1%), 13 (10%), 7 (5.4%), 6 (4.6%), and 5 (3.8%) cases respectively. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are cutaneous porphyrias inherited with a recessive pattern?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15868463",
                "http://www.ncbi.nlm.nih.gov/pubmed/11202049",
                "http://www.ncbi.nlm.nih.gov/pubmed/12859407"
            ],
            "ideal_answer": [
                "No, cutaneous porphyrias are inherited in a dominant (not recessive) pattern."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "58e11b9b6fddd3e83e00000b",
            "snippets": [
                {
                    "offsetInBeginSection": 464,
                    "offsetInEndSection": 728,
                    "text": "Five of the porphyrias are low-penetrance autosomal dominant conditions in which clinical expression results from additional factors that act by increasing demand for haem or by causing an additional decrease in enzyme activity or by a combination of these effects",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15868463",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 57,
                    "text": "Molecular mechanisms of dominant expression in porphyria.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15868463",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 262,
                    "text": "Variegate porphyria (VP) is an autosomal-dominant disorder that is caused by inheritance of a partial deficiency of the enzyme protoporphyrinogen oxidase (EC 1.3.3.4). It is characterized by cutaneous photosensitivity and/or various neurological manifestations. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12859407",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "The acute porphyrias constitute a group of metabolic disorders engaging enzymes in the haem synthetic chain and generally following dominant inheritance patterns.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11202049",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the SDHAF2 gene encoding a protein necessary for flavination of SDHA?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21752896",
                "http://www.ncbi.nlm.nih.gov/pubmed/23036115",
                "http://www.ncbi.nlm.nih.gov/pubmed/19732718",
                "http://www.ncbi.nlm.nih.gov/pubmed/23061808"
            ],
            "ideal_answer": [
                "Yes, SDHAF2 or hSDH5, is the gene encoding the enzyme responsible for the flavination of SDHA.",
                "Yes, SDHAF2 is required for flavination of SDHA."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "571e06447de986d80d000016",
            "snippets": [
                {
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 198,
                    "text": "Pheochromocytoma-paraganglioma syndrome is caused by mutations in SDHB, SDHC, and SDHD, encoding subunits of succinate dehydrogenase (SDH), and in SDHAF2, required for flavination of SDHA. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 381,
                    "offsetInEndSection": 786,
                    "text": "At present, these are RET proto-oncogene, von Hippel-Lindau disease tumor suppressor gene (VHL), neurofibromatosis type 1 tumor suppressor gene (NF1), genes encoding the succinate dehydrogenase (SDH) complex subunits SDHB, SDHC, and SDHD, but also SDHA, the gene encoding the enzyme responsible for the flavination of SDHA (SDHAF2 or hSDH5), and the newly described TMEM127 and MAX tumor suppressor genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23061808",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 635,
                    "offsetInEndSection": 721,
                    "text": "the gene encoding the enzyme responsible for the flavination of SDHA (SDHAF2 or hSDH5)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23061808",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 196,
                    "text": "SDHAF2, required for flavination of SDHA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 784,
                    "offsetInEndSection": 1189,
                    "text": "At present, these are RET proto-oncogene, von Hippel-Lindau disease tumor suppressor gene (VHL), neurofibromatosis type 1 tumor suppressor gene (NF1), genes encoding the succinate dehydrogenase (SDH) complex subunits SDHB, SDHC, and SDHD, but also SDHA, the gene encoding the enzyme responsible for the flavination of SDHA (SDHAF2 or hSDH5), and the newly described TMEM127 and MAX tumor suppressor genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23061808",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "text": "Pheochromocytoma-paraganglioma syndrome is caused by mutations in SDHB, SDHC, and SDHD, encoding subunits of succinate dehydrogenase (SDH), and in SDHAF2, required for flavination of SDHA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 249,
                    "offsetInEndSection": 407,
                    "text": "In a recent issue of Science, Rutter and coworkers showed that SDH5 is required for the flavination of SDHA, which is necessary for SDH assembly and function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19732718",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 381,
                    "offsetInEndSection": 785,
                    "text": "At present, these are RET proto-oncogene, von Hippel-Lindau disease tumor suppressor gene (VHL), neurofibromatosis type 1 tumor suppressor gene (NF1), genes encoding the succinate dehydrogenase (SDH) complex subunits SDHB, SDHC, and SDHD, but also SDHA, the gene encoding the enzyme responsible for the flavination of SDHA (SDHAF2 or hSDH5), and the newly described TMEM127 and MAX tumor suppressor genes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23061808",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "Pheochromocytoma-paraganglioma syndrome is caused by mutations in SDHB, SDHC, and SDHD, encoding subunits of succinate dehydrogenase (SDH), and in SDHAF2, required for flavination of SDHA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "CONTEXT: Pheochromocytoma-paraganglioma syndrome is caused by mutations in SDHB, SDHC, and SDHD, encoding subunits of succinate dehydrogenase (SDH), and in SDHAF2, required for flavination of SDHA. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 413,
                    "offsetInEndSection": 647,
                    "text": "This gene is co-expressed with a number of genes encoding mitochondrial proteins, including SDH1-1, and has low partial sequence similarity to human SDHAF2, a protein required for flavin-adenine dinucleotide (FAD) insertion into SDH. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23036115",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 382,
                    "offsetInEndSection": 787,
                    "text": "At present, these are RET proto-oncogene, von Hippel-Lindau disease tumor suppressor gene (VHL), neurofibromatosis type 1 tumor suppressor gene (NF1), genes encoding the succinate dehydrogenase (SDH) complex subunits SDHB, SDHC, and SDHD, but also SDHA, the gene encoding the enzyme responsible for the flavination of SDHA (SDHAF2 or hSDH5), and the newly described TMEM127 and MAX tumor suppressor genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23061808",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "Pheochromocytoma-paraganglioma syndrome is caused by mutations in SDHB, SDHC, and SDHD, encoding subunits of succinate dehydrogenase (SDH), and in SDHAF2, required for flavination of SDHA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21752896",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is p100 the precursor protein molecule of the NF-kappaB transcription factor subunit p50?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11158290",
                "http://www.ncbi.nlm.nih.gov/pubmed/12505990",
                "http://www.ncbi.nlm.nih.gov/pubmed/15677466",
                "http://www.ncbi.nlm.nih.gov/pubmed/12894228",
                "http://www.ncbi.nlm.nih.gov/pubmed/16223731",
                "http://www.ncbi.nlm.nih.gov/pubmed/17693123",
                "http://www.ncbi.nlm.nih.gov/pubmed/20363924",
                "http://www.ncbi.nlm.nih.gov/pubmed/12556537",
                "http://www.ncbi.nlm.nih.gov/pubmed/22282470",
                "http://www.ncbi.nlm.nih.gov/pubmed/8649779",
                "http://www.ncbi.nlm.nih.gov/pubmed/19302050",
                "http://www.ncbi.nlm.nih.gov/pubmed/8398903",
                "http://www.ncbi.nlm.nih.gov/pubmed/10207090",
                "http://www.ncbi.nlm.nih.gov/pubmed/13679070",
                "http://www.ncbi.nlm.nih.gov/pubmed/10597218",
                "http://www.ncbi.nlm.nih.gov/pubmed/15485830",
                "http://www.ncbi.nlm.nih.gov/pubmed/11726516",
                "http://www.ncbi.nlm.nih.gov/pubmed/8710364"
            ],
            "ideal_answer": [
                "No, the precursor molecule for NF-kappaB p50 is p105 and not p100. Nfkb2 encodes two members of the NF-kappa B/Rel family of proteins: p52 and p100. The p100 polypeptide has been proposed to serve as a precursor of p52 (and not of p50), which corresponds to the N-terminal half of p100. NF-kappaB functions as a hetero- or homo-dimer which can be formed from five NF-kappaB subunits, NF-kappaB1 (p50 and its precursor p105), NF-kappaB2 (p52 and its precursor p100), RelA (p65), RelB and c-Rel."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "55088e412e93f0133a000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 325,
                    "text": "We previously reported that alymphoplasia (aly/aly) mice, which have a natural loss-of-function mutation in the Nik gene, which encodes a kinase essential for the processing of p100 to p52 in the alternative nuclear factor-\u03baB (NF-\u03baB) pathway, show mild osteopetrosis with an increase in several parameters of bone formation: ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22282470",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 188,
                    "text": "Proteolytic processing of the nuclear factor (NF)-kappaB2 precursor protein p100 generates the active NF-kappaB2 subunit p52, which in turn transcriptionally up-regulates p100 expression. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20363924",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 391,
                    "text": "The mammalian Rel/NF-kappaB family of transcription factors, including RelA, c-Rel, RelB, NF-kappaB1 (p50 and its precursor p105), and NF-kappaB2 (p52 and its precursor p100), plays a central role in the immune system by regulating several processes ranging from the development and survival of lymphocytes and lymphoid organs to the control of immune responses and malignant transformation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19302050",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 334,
                    "text": "NF-kappaB functions as a hetero- or homo-dimer which can be formed from five NF-kappaB subunits, NF-kappaB1 (p50 and its precursor p105), NF-kappaB2 (p52 and its precursor p100), RelA (p65), RelB and c-Rel.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17693123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "text": "The non-canonical pathway based on processing of NF-kappaB2 precursor protein p100 to generate p52 plays a critical role in controlling B cell function and lymphoid organogenesis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16223731",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "text": "Processing of NF-kappaB2 precursor protein p100 to generate p52 is tightly controlled, which is important for proper function of NF-kappaB.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15677466",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "Processing of NF-kappa B2 precursor protein p100 to generate p52 is tightly regulated. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15485830",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Processing of the NF-kappaB2 precursor protein p100 to generate p52 is an important step of NF-kappaB regulation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12894228",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "Targeted disruption of the Rel/NF-kappaB family members NF-kappaB2, encoding p100/p52, and RelB in mice results in anatomical defects of secondary lymphoid tissues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12505990",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 280,
                    "offsetInEndSection": 541,
                    "text": "Here, we show that in T cells infected with the human T-cell leukemia virus (HTLV), IKKalpha is targeted to a novel signaling pathway that mediates processing of the nfkappab2 precursor protein p100, resulting in active production of the NF-kappaB subunit, p52.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11726516",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 202,
                    "text": "nfkb2 encodes two members of the NF-kappa B/Rel family of proteins: p52 and p100. The p100 polypeptide has been proposed to serve as a precursor of p52, which corresponds to the N-terminal half of p100.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10597218",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 834,
                    "offsetInEndSection": 985,
                    "text": "In most cells, small amounts of p52 are produced relative to the levels of p100, unlike the usually balanced production of nfkb1-derived p50 and p105. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10597218",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 385,
                    "offsetInEndSection": 686,
                    "text": "The alternative or second pathway proceeded via NF-kappaB-inducing kinase (NIK)-, IKKalpha-, and protein synthesis-dependent processing of the inhibitory NF-kappaB2 p100 precursor protein to the p52 form and resulted in a delayed but sustained activation of primarily RelB-containing NF-kappaB dimers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12556537",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 174,
                    "offsetInEndSection": 421,
                    "text": "In one exceptional case, generation of the p50 subunit of the transcriptional regulator NF-kappaB, the precursor protein p105 is processed in a limited manner: the N-terminal domain yields the p50 subunit, whereas the C-terminal domain is degraded",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10207090",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Proteolytic processing of the p105 precursor (NF-kappa B1) generates the p50 subunit of NF-kappa B",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8710364",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "p105 (NFKB1) acts in a dual way as a cytoplasmic IkappaB molecule and as the source of the NF-kappaB p50 subunit upon processing",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11158290",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "text": "The p50 subunit of NF-kappa B is derived from the amino terminus of a 105 kilodalton precursor",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8398903",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "Regulation of the transcription factor NF-kappaB involves proteasome-mediated processing of the NF-kappaB1 p105 precursor protein, which generates the p50 subunit of NF-kappaB",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8649779",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 518,
                    "text": "This effort identified NF-kappaB1 (p105), an atypical IkappaB molecule and the precursor of NF-kappaB subunit p50",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/13679070",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 333,
                    "text": "NF-kappaB functions as a hetero- or homo-dimer which can be formed from five NF-kappaB subunits, NF-kappaB1 (p50 and its precursor p105), NF-kappaB2 (p52 and its precursor p100), RelA (p65), RelB and c-Rel",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17693123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 390,
                    "text": "The mammalian Rel/NF-kappaB family of transcription factors, including RelA, c-Rel, RelB, NF-kappaB1 (p50 and its precursor p105), and NF-kappaB2 (p52 and its precursor p100), plays a central role in the immune system by regulating several processes ranging from the development and survival of lymphocytes and lymphoid organs to the control of immune responses and malignant transformation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19302050",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there an association between borna virus and brain tumor?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/10483922",
                "http://www.ncbi.nlm.nih.gov/pubmed/10227422",
                "http://www.ncbi.nlm.nih.gov/pubmed/1731117",
                "http://www.ncbi.nlm.nih.gov/pubmed/17020949",
                "http://www.ncbi.nlm.nih.gov/pubmed/17306587",
                "http://www.ncbi.nlm.nih.gov/pubmed/11507219",
                "http://www.ncbi.nlm.nih.gov/pubmed/11070091",
                "http://www.ncbi.nlm.nih.gov/pubmed/21937656",
                "http://www.ncbi.nlm.nih.gov/pubmed/8917593",
                "http://www.ncbi.nlm.nih.gov/pubmed/15596826",
                "http://www.ncbi.nlm.nih.gov/pubmed/8184547",
                "http://www.ncbi.nlm.nih.gov/pubmed/10518583",
                "http://www.ncbi.nlm.nih.gov/pubmed/11907227",
                "http://www.ncbi.nlm.nih.gov/pubmed/22848506"
            ],
            "ideal_answer": [
                "There is no data to suggest an association between borna virus and brain tumor. Borna disease virus establishes a persistent infection in the central nervous system of vertebrate animal species as well as in tissue cultures causing cellular damage. Infected neural cells, include astrocytes, neurons, oligodendroglioma cell line. Borna disease virus replicates and can cause damage of brain cells."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001890",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001891",
                "http://www.disease-ontology.org/api/metadata/DOID:1319",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001932",
                "http://www.disease-ontology.org/api/metadata/DOID:5154"
            ],
            "type": "yesno",
            "id": "530f685c329f5fcf1e000002",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "text": "Borna disease virus (BDV), a nonsegmented, negative-strand RNA virus, infects a wide variety of mammalian species and readily establishes a long-lasting, persistent infection in brain cells. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21937656",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 242,
                    "text": "To investigate the biological characteristics of field isolates of Borna disease virus (BDV), as well as to understand BDV infections outside endemic countries, we isolated the virus from brain samples of a heifer with Borna disease in Japan.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17306587",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "text": "Neonatal Borna disease virus (BDV) infection of the rat brain is associated with microglial activation and damage to the certain neuronal populations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17020949",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1204,
                    "offsetInEndSection": 1677,
                    "text": "In addition, compared to uninfected mixed cultures, activation of microglia in BDV-infected mixed cultures was associated with a significantly greater lipopolysaccharide-induced release of tumor necrosis factor alpha, interleukin 1beta, and interleukin 10. Taken together, the present data are the first in vitro evidence that persistent BDV infection of neurons and astrocytes rather than direct exposure to the virus or dying neurons is critical for activating microglia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17020949",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 613,
                    "offsetInEndSection": 708,
                    "text": "Usually, Borna disease virus is not cleared from the brain but rather persists in neural cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15596826",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "Varied persistent life cycles of Borna disease virus in a human oligodendroglioma cell line.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11907227",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "Borna disease virus (BDV) establishes a persistent infection in the central nervous system of vertebrate animal species as well as in tissue cultures. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11907227",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1553,
                    "offsetInEndSection": 1719,
                    "text": "Thus, our findings show that BDV may have established a persistent infection at low levels of viral expression in OL cells with the possibility of a latent infection.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11907227",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1726,
                    "offsetInEndSection": 1899,
                    "text": "These results suggested that BDV infection may cause direct damage in the developing brain by inhibiting the function of amphoterin due to binding by the p24 phosphoprotein.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11507219",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 280,
                    "offsetInEndSection": 462,
                    "text": "We describe a model for investigating disorders of central nervous system development based on neonatal rat infection with Borna disease virus, a neurotropic noncytolytic RNA virus. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10518583",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 222,
                    "text": "Borna disease virus (BDV) replicates in brain cells. The neonatally infected rat with BDV exhibits developmental-neuromorphological abnormalities, neuronal cytolysis, and multiple behavioral and physiological alterations. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10483922",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "text": "Borna disease virus (BDV) causes central nervous system (CNS) disease in several vertebrate species, which is frequently accompanied by behavioral abnormalities.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10227422",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Intrinsic responses to Borna disease virus infection of the central nervous system.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8917593",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 160,
                    "text": "Immune cells invading the central nervous system (CNS) in response to Borna disease virus (BDV) antigens are central to the pathogenesis of Borna disease (BD). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8917593",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 281,
                    "offsetInEndSection": 439,
                    "text": "We report here the partial purification and characterization of cell-free BDV from the tissue culture supernatant of infected human neuroblastoma SKNSH cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8184547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "We have used the reverse transcriptase-polymerase chain reaction technique to gain insight into the pathogenesis of encephalitis caused by Borna disease virus (BDV). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1731117",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 850,
                    "offsetInEndSection": 1064,
                    "text": "In contrast, in the BDV-infected primary mixed cultures, we observed proliferation of microglia cells that acquired the round morphology and expressed major histocompatibility complex molecules of classes I and II.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17020949",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do honey contain diastases/amylases?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/595894",
                "http://www.ncbi.nlm.nih.gov/pubmed/17995872",
                "http://www.ncbi.nlm.nih.gov/pubmed/32424606",
                "http://www.ncbi.nlm.nih.gov/pubmed/22483889"
            ],
            "ideal_answer": [
                "Yes\nhoney contain the protein amylase."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "60354a7b1cb411341a000154",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "A new rapid method for the determination of honey diastase activity using direct potentiometric principles has been proposed. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22483889",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 52,
                    "text": "The major alpha-amylase in honey was characterized. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17995872",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 29,
                    "offsetInEndSection": 56,
                    "text": "Separation of honey amylase",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/595894",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Are thyroid hormone receptor alpha1 mutations  implicated in thyroid hormone resistance syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23528896",
                "http://www.ncbi.nlm.nih.gov/pubmed/23633213",
                "http://www.ncbi.nlm.nih.gov/pubmed/12750454"
            ],
            "ideal_answer": [
                "thyroid hormone receptor alpha1 mutations are implicated in thyroid hormone resistance syndrome"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018382",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021"
            ],
            "type": "yesno",
            "id": "52ecd56198d023950500002b",
            "snippets": [
                {
                    "offsetInBeginSection": 844,
                    "offsetInEndSection": 1050,
                    "text": "Mutations in human TR\u03b11 mediate RTH with features of hypothyroidism in particular tissues (e.g. skeleton, gastrointestinal tract), but are not associated with a markedly dysregulated pituitary-thyroid axis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23528896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "Clinical phenotype of a new type of thyroid hormone resistance caused by a mutation of the TR\u03b11 receptor",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633213",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is the ACE inhibitor indicated for lung cancer treatment?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18837885",
                "http://www.ncbi.nlm.nih.gov/pubmed/22300564"
            ],
            "ideal_answer": [
                "No, the angiotensin converting enzyme (ACE) inhibitors are used widely as antihypertensive agents. On the contrary, it has been suggested that they decrease the risk of some cancers, although available data are conflicting. One study proposes that captopril could be a promising option for the treatment of lung cancer. Furthermore, angiotensin-converting enzyme (ACE) inhibitors have been shown to mitigate radiation-induced lung injury in preclinical models"
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.uniprot.org/uniprot/ACE_MOUSE",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009369",
                "http://www.uniprot.org/uniprot/ACE_THETS",
                "http://www.uniprot.org/uniprot/ACE_HUMAN",
                "http://www.disease-ontology.org/api/metadata/DOID:3683",
                "http://www.uniprot.org/uniprot/ACE_CHICK",
                "http://www.disease-ontology.org/api/metadata/DOID:1324",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000806",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008175",
                "http://www.disease-ontology.org/api/metadata/DOID:850",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008171",
                "http://www.uniprot.org/uniprot/ACE_BOVIN",
                "http://www.disease-ontology.org/api/metadata/DOID:162",
                "http://www.uniprot.org/uniprot/ACE_HAEIX",
                "http://www.uniprot.org/uniprot/ACE_RABIT",
                "http://www.uniprot.org/uniprot/ACE_RAT",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008168"
            ],
            "type": "yesno",
            "id": "530cf4fe960c95ad0c000005",
            "snippets": [
                {
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 311,
                    "text": "The angiotensin converting enzyme (ACE) inhibitors are used widely as antihypertensive agents, and it has been suggested that they decrease the risk of some cancers, although available data are conflicting. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18837885",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1182,
                    "offsetInEndSection": 1561,
                    "text": "Using cell viability and fluorescent activated cell sorting analysis tests, we demonstrated that captopril inhibited the viability of LNM35 cells by inducing apoptosis, providing insight about the mechanisms underlying its antitumorigenic activities. In view of these experimental findings, we conclude that captopril could be a promising option for the treatment of lung cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18837885",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 790,
                    "offsetInEndSection": 1181,
                    "text": "In order to determine the mechanism by which captopril inhibited tumor growth, we investigated the impact of this drug on cell proliferation, apoptosis, and angiogenesis. Immunohistochemical analysis demonstrated that captopril treatment significantly reduced the number of proliferating cells (Ki-67) in the tumor samples but was not associated with inhibition of tumor angiogenesis (CD31).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18837885",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 484,
                    "offsetInEndSection": 697,
                    "text": "Using this model, we demonstrated that daily IP administration of captopril (2.8 mg/mouse) for 3 weeks resulted in a remarkable reduction of tumor growth (58%, P < 0.01) and lymph node metastasis (50%, P= 0.088). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18837885",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 135,
                    "text": "Angiotensin-converting enzyme (ACE) inhibitors have been shown to mitigate radiation-induced lung injury in preclinical models",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300564",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2023,
                    "offsetInEndSection": 2147,
                    "text": "ACE inhibitors may decrease the incidence of radiation pneumonitis in patients receiving thoracic radiation for lung cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22300564",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are proteasome inhibitors good candidates for treatment of leukemia and solid tumors?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22057347",
                "http://www.ncbi.nlm.nih.gov/pubmed/17145882",
                "http://www.ncbi.nlm.nih.gov/pubmed/22012631",
                "http://www.ncbi.nlm.nih.gov/pubmed/15169797",
                "http://www.ncbi.nlm.nih.gov/pubmed/20160034",
                "http://www.ncbi.nlm.nih.gov/pubmed/20219102",
                "http://www.ncbi.nlm.nih.gov/pubmed/19712963",
                "http://www.ncbi.nlm.nih.gov/pubmed/17431003",
                "http://www.ncbi.nlm.nih.gov/pubmed/19821999",
                "http://www.ncbi.nlm.nih.gov/pubmed/22134540",
                "http://www.ncbi.nlm.nih.gov/pubmed/23477519",
                "http://www.ncbi.nlm.nih.gov/pubmed/16135477",
                "http://www.ncbi.nlm.nih.gov/pubmed/23181572",
                "http://www.ncbi.nlm.nih.gov/pubmed/22353937",
                "http://www.ncbi.nlm.nih.gov/pubmed/22995770",
                "http://www.ncbi.nlm.nih.gov/pubmed/12171876"
            ],
            "ideal_answer": [
                "Yes, several compounds that inhibit different members of the proteasome pathway (for example Bortezomib) are on trial for treatment of leukemia and solid tumors. It seems that a combination with other drugs may be a useful therapy for solid tumors."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D061988",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007938"
            ],
            "type": "yesno",
            "id": "517179718ed59a060a00000e",
            "snippets": [
                {
                    "offsetInBeginSection": 824,
                    "offsetInEndSection": 1115,
                    "text": "We show that treatment with b-AP15 inhibited tumor progression in four different in vivo solid tumor models and inhibited organ infiltration in an acute myeloid leukemia model. Our results show that the deubiquitinating activity of the 19S regulatory particle is a new anticancer drug target",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22057347",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1126,
                    "offsetInEndSection": 1464,
                    "text": "We further found that ATO targets AME via both myelodysplastic syndrome 1 (MDS1) and EVI1 moieties and degrades EVI1 via the ubiquitin-proteasome pathway and MDS1 in a proteasome-independent manner. Our results suggest that ATO could be used as a part of targeted therapy for AME-, AML1/MDS1-, MDS1/EVI1-, and EVI1-positive human cancers.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17145882",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 795,
                    "text": "Previously we had shown the synergic effect of bortezomib and thiostrepton in breast cancer cells in vitro, where sub-apoptotic concentrations of both proteasome inhibitors resulted in synergic increase in cell death when combined as a treatment. Here, we administered such a combination to MDA-MB-231 xenograft tumors in vivo, and found that the effect of complementary proteasome inhibitors reduced tumor growth rates more efficiently than compared with when administered alone.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22353937",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1477,
                    "offsetInEndSection": 1678,
                    "text": "Addition of a proteasome inhibitor to anti-hormonal therapy resulted in a clinical benefit rate of 22% in a limited number of patients with endocrine resistant and progressive metastatic breast cancer.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22134540",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1168,
                    "offsetInEndSection": 1288,
                    "text": "Taken together, these data support the clinical development of MLN9708 for both hematologic and solid tumor indications.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20160034",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1584,
                    "offsetInEndSection": 1690,
                    "text": "Bortezomib has minimal activity as a single-agent in the treatment of recurrent platinum-sensitive EOC/PPC",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19712963",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1421,
                    "offsetInEndSection": 1762,
                    "text": "Our study indicates a molecular mechanism by which the sensitivity of thyroid cancer cells is regulated by the level of GRP78 as well as preferential induction of GRP78 or CHOP upon treatment with proteasome inhibitors. Our experiments therefore suggest a novel approach toward sensitization of thyroid cancer cells to proteasome inhibitors.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17431003",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1270,
                    "offsetInEndSection": 1511,
                    "text": "Bortezomib (PS-341) is a novel antineoplastic agent that is well tolerated at doses not exceeding 3.0 mg (equivalent to 1.75 mg/m2), repeated on D1 and D4 every other week. This dose correlates with 70% inhibition of 20S proteasome activity.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16135477",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1459,
                    "offsetInEndSection": 1709,
                    "text": "The maximum-tolerated dose and recommended phase II dose of bortezomib in this schedule is 1.6 mg/m(2). Biologic activity (inhibition of nuclear factor-kappa B-related markers) and antitumor activity is seen in AIPCa at tolerated doses of bortezomib.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15169797",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1278,
                    "text": "Given the results of this trial, it is safe and reasonable to recommend treatment with PS341 on the schedule used in this trial at 1.56 mg/m2/dose in Phase II trials. Particular care should be taken with patients with preexisting neuropathy",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171876",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 518,
                    "offsetInEndSection": 647,
                    "text": "The successes of proteasome inhibitors in MM are now being translated to other hematologic malignancies, including acute leukemia",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23477519",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 843,
                    "offsetInEndSection": 1048,
                    "text": "Such efforts have led to bortezomib, the first FDA approved proteasome inhibitor now used as a frontline treatment for newly diagnosed multiple myeloma (MM), relapsed/refractory MM and mantle cell lymphoma",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23181572",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 383,
                    "offsetInEndSection": 696,
                    "text": "We recently reported the impact and mechanisms of carfilzomib and oprozomib, second-in-class proteasome inhibitors with higher specificities and reduced toxicities, against head and neck squamous cell carcinoma (HNSCC). Carfilzomib and oprozomib potently inhibit HNSCC cell survival and the growth of HNSCC tumors",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22995770",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Can ATAC-Seq be employed in single-cell mode?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/30451828",
                "http://www.ncbi.nlm.nih.gov/pubmed/28138849",
                "http://www.ncbi.nlm.nih.gov/pubmed/32637041",
                "http://www.ncbi.nlm.nih.gov/pubmed/32029740",
                "http://www.ncbi.nlm.nih.gov/pubmed/32620137",
                "http://www.ncbi.nlm.nih.gov/pubmed/26294014",
                "http://www.ncbi.nlm.nih.gov/pubmed/32029221",
                "http://www.ncbi.nlm.nih.gov/pubmed/30936163",
                "http://www.ncbi.nlm.nih.gov/pubmed/31594952",
                "http://www.ncbi.nlm.nih.gov/pubmed/31428792",
                "http://www.ncbi.nlm.nih.gov/pubmed/30580963",
                "http://www.ncbi.nlm.nih.gov/pubmed/26083756",
                "http://www.ncbi.nlm.nih.gov/pubmed/29686426",
                "http://www.ncbi.nlm.nih.gov/pubmed/30335168",
                "http://www.ncbi.nlm.nih.gov/pubmed/30559361"
            ],
            "ideal_answer": [
                "Single-cell ATAC-seq detects open chromatin in individual cells.",
                "When done at single-cell resolution, ATAC-seq provides an insight into the cell-to-cell variability that emerges from otherwise identical DNA sequences by identifying the variability in the genomic location of open chromatin sites in each of the cells.",
                "Yes. When done at single-cell resolution, ATAC-seq provides an insight into the cell-to-cell variability that emerges from otherwise identical DNA sequences by identifying the variability in the genomic location of open chromatin sites in each of the cells.",
                "Single-cell ATAC-seq: strength in numbers. When done at single-cell resolution, ATAC-seq provides an insight into the cell-to-cell variability that emerges from otherwise identical DNA sequences by identifying the variability in the genomic location of open chromatin sites in each of the cells.",
                "Yes. The method can be also employed in single-cell mode, allowing the analysis of cell-based epigenetic changes only.",
                "Yes, ATAC-seq can be employed in single-cell mode.",
                "Yes, single-cell ATAC-seq can be used to detect genome-wide the binding sites of RNA binding proteins in individual cells.",
                "Yes. ATAC-seq can be used as a primary method for analyzing genome-wide open chromatin structure within single-cell populations."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5fe31319a43ad31278000046",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 42,
                    "text": "Single-cell ATAC-seq: strength in numbers.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26294014",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 86,
                    "offsetInEndSection": 121,
                    "text": "Assembly, and Single-Cell ATAC-Seq.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28138849",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Single cell RNA-seq and ATAC-seq analysis of cardiac progenitor cell transition states and lineage settlement.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30451828",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 474,
                    "text": " Here, we comprehensively characterize mouse cardiac progenitor cells (CPCs) marked by Nkx2-5 and Isl1 expression from E7.5 to E9.5 using single-cell RNA sequencing and transposase-accessible chromatin profiling (ATAC-seq).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30451828",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 68,
                    "text": "Classifying cells with Scasat, a single-cell ATAC-seq analysis tool.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30335168",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 213,
                    "offsetInEndSection": 465,
                    "text": "When done at single-cell resolution, ATAC-seq provides an insight into the cell-to-cell variability that emerges from otherwise identical DNA sequences by identifying the variability in the genomic location of open chromatin sites in each of the cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30335168",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "text": "Single-cell ATAC-Seq in human pancreatic islets and deep learning upscaling of rare cells reveals cell-specific type 2 diabetes regulatory signatures.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029221",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 935,
                    "offsetInEndSection": 1138,
                    "text": "THODS: We present genome-wide single-cell chromatin accessibility profiles in >1,600 cells derived from a human pancreatic islet sample using single-cell combinatorial indexing ATAC-seq (sci-ATAC-seq). W",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029221",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "text": "Contiguity-Preserving Transposition Sequencing (CPT-Seq) for Genome-Wide Haplotyping, Assembly, and Single-Cell ATAC-Seq.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28138849",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "SCALE method for single-cell ATAC-seq analysis via latent feature extraction.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31594952",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "Single-cell ATAC-seq (scATAC-seq) profiles the chromatin\u00a0accessibility landscape at single cell level, thus revealing cell-to-cell variability in gene regulation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31594952",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 447,
                    "text": "The recently developed low-input and single-cell regulome mapping technologies such as ATAC-seq and single-cell ATAC-seq (scATAC-seq) allow analyses of small-cell-number and single-cell samples, but their signals remain highly discrete or noisy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31428792",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 466,
                    "offsetInEndSection": 596,
                    "text": "This paper presents Scasat (single-cell ATAC-seq analysis tool), a complete pipeline to process scATAC-seq data with simple steps.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30335168",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 252,
                    "offsetInEndSection": 474,
                    "text": "Here, we comprehensively characterize mouse cardiac progenitor cells (CPCs) marked by Nkx2-5 and Isl1 expression from E7.5 to E9.5 using single-cell RNA sequencing and transposase-accessible chromatin profiling (ATAC-seq).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30451828",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 700,
                    "offsetInEndSection": 886,
                    "text": "Single-cell ATAC-seq (scATAC-seq) technology has also been developed to study cell type-specific chromatin accessibility in tissue samples containing a heterogeneous cellular population.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32637041",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 207,
                    "offsetInEndSection": 459,
                    "text": "Here we combined sequencing of the TCR-encoding genes with assay for transposase-accessible chromatin with sequencing (ATAC-seq) analysis at the single-cell level to provide information on the TCR specificity and epigenomic state of individual T cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29686426",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 126,
                    "offsetInEndSection": 301,
                    "text": "Substantial advances of this work include the optimization of a single-cell combinatorial indexing assay for transposase accessible chromatin (sci-ATAC-seq); a software suite,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30936163",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "The accessible chromatin landscape of the murine hippocampus at single-cell resolution.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30936163",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Here we present a comprehensive map of the accessible chromatin landscape of the mouse hippocampus at single-cell resolution.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30936163",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1530,
                    "offsetInEndSection": 1743,
                    "text": "We expect this review will provide a guideline for successful data generation and analysis methods using appropriate software tools and databases for the study of chromatin accessibility at single-cell resolution.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32637041",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "text": "Single-cell sequencing assay for transposase-accessible chromatin (scATAC-seq) is the state-of-the-art technology for analyzing genome-wide regulatory landscapes in single cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32620137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 266,
                    "text": "Single-cell ATAC-seq data are sparse and noisy, and analyzing such data is challenging.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32620137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 393,
                    "text": "Here, we introduce a method for analyzing scATAC-seq data, called Single-Cell ATAC-seq analysis via Latent feature Extraction (SCALE).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31594952",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "text": "Single-cell ATAC-seq signal extraction and enhancement with SCATE.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32620137",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "Single-cell ATAC-seq detects open chromatin in individual cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26294014",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 65,
                    "offsetInEndSection": 203,
                    "text": "Currently data are sparse, but combining information from many single cells can identify determinants of cell-to-cell chromatin variation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26294014",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 909,
                    "offsetInEndSection": 1045,
                    "text": "Predictions based on single-cell RNA-seq (scRNA-seq) can more accurately reconstruct bulk chromatin accessibility than using scATAC-seq.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31428792",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "text": "Global prediction of chromatin accessibility using small-cell-number and single-cell RNA-seq.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31428792",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 647,
                    "offsetInEndSection": 849,
                    "text": "Single-cell ATAC-seq (scATAC-seq) maps from hundreds of single cells in aggregate closely resemble accessibility profiles from tens of millions of cells and provide insights into cell-to-cell variation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26083756",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 256,
                    "text": "However, very few studies have been performed at the single cell level (scATAC-seq) due to technical challenges.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30559361",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 319,
                    "text": "Here, we present Perturb-ATAC, a method that combines multiplexed CRISPR interference or knockout with genome-wide chromatin accessibility profiling in single cells based on the simultaneous detection of CRISPR guide RNAs and open chromatin sites by assay of transposase-accessible chromatin with sequencing (ATAC-seq).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30580963",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 773,
                    "offsetInEndSection": 1014,
                    "text": "Additionally, the same workflow can be used to aid de novo assembly (Adey et al., Genome Res 24(12):2041-2049, 2014), detect structural variants, and perform single cell ATAC-seq analysis (Cusanovich et al., Science 348(6237):910-914, 2015).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28138849",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 718,
                    "offsetInEndSection": 857,
                    "text": "ChromA can analyze single cell ATAC-seq data, correcting many biases generated by the sparse sampling inherent in single cell technologies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029740",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 741,
                    "offsetInEndSection": 1116,
                    "text": " circuits. Existing chromatin profiling methods such as ATAC-seq and DNase-seq, applied to islets in bulk, produce aggregate profiles that mask important cellular and regulatory heterogeneity.METHODS: We present genome-wide single-cell chromatin accessibility profiles in >1,600 cells derived from a human pancreatic islet sample using single-cell combinatorial indexing ATAC",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029221",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "ATAC-seq has become a leading technology for probing the chromatin landscape of single and aggregated cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32029740",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there plasma membrane receptors for thyroid hormones?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/11117200",
                "http://www.ncbi.nlm.nih.gov/pubmed/22986150",
                "http://www.ncbi.nlm.nih.gov/pubmed/20658515",
                "http://www.ncbi.nlm.nih.gov/pubmed/24113777",
                "http://www.ncbi.nlm.nih.gov/pubmed/6290538",
                "http://www.ncbi.nlm.nih.gov/pubmed/22945636",
                "http://www.ncbi.nlm.nih.gov/pubmed/169249",
                "http://www.ncbi.nlm.nih.gov/pubmed/18329679",
                "http://www.ncbi.nlm.nih.gov/pubmed/227209",
                "http://www.ncbi.nlm.nih.gov/pubmed/23137442",
                "http://www.ncbi.nlm.nih.gov/pubmed/23926648",
                "http://www.ncbi.nlm.nih.gov/pubmed/19900468",
                "http://www.ncbi.nlm.nih.gov/pubmed/22414628",
                "http://www.ncbi.nlm.nih.gov/pubmed/6093898",
                "http://www.ncbi.nlm.nih.gov/pubmed/17570630",
                "http://www.ncbi.nlm.nih.gov/pubmed/23021374",
                "http://www.ncbi.nlm.nih.gov/pubmed/20051527",
                "http://www.ncbi.nlm.nih.gov/pubmed/12165107",
                "http://www.ncbi.nlm.nih.gov/pubmed/17983645",
                "http://www.ncbi.nlm.nih.gov/pubmed/2534509",
                "http://www.ncbi.nlm.nih.gov/pubmed/23943159",
                "http://www.ncbi.nlm.nih.gov/pubmed/19755667",
                "http://www.ncbi.nlm.nih.gov/pubmed/8936679",
                "http://www.ncbi.nlm.nih.gov/pubmed/1747413",
                "http://www.ncbi.nlm.nih.gov/pubmed/6312037",
                "http://www.ncbi.nlm.nih.gov/pubmed/20232113"
            ],
            "ideal_answer": [
                "Receptors for thyroid hormones are present on plasma membrane of cells; in particular thyroid hormones bind integrin that is a heterodimeric component of plasma membrane"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002462",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0070324",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0005886",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=GO:0016020",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037021",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011989",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056921"
            ],
            "type": "yesno",
            "id": "532c169ed6d3ac6a3400001f",
            "snippets": [
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 150,
                    "text": "ntegrins are heterodimeric structural components of the plasma membrane whose ligands include a large number of extracellular matrix (ECM) proteins. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23943159",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 405,
                    "offsetInEndSection": 660,
                    "text": "Recently, integrin \u03b1v\u03b23 has been shown to have a panel of previously unappreciated small molecule receptor sites for thyroid hormone and hormone analogues, for dihydrotestosterone, and for resveratrol, a polyphenol that has certain estrogen-like features.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23943159",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1541,
                    "offsetInEndSection": 1666,
                    "text": "The integrin receptor activation by T4 may take a role in plasma membrane processes involved in the male reproductive system.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23137442",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 665,
                    "offsetInEndSection": 839,
                    "text": "Rapid signaling via this plasma membrane binding site appears to be responsible for many nongenomic effects of thyroid hormones, independent of the classic nuclear receptors.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22414628",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there any Decision support systems for chronic pain management ?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21249951",
                "http://www.ncbi.nlm.nih.gov/pubmed/20385018",
                "http://www.ncbi.nlm.nih.gov/pubmed/11524346",
                "http://www.ncbi.nlm.nih.gov/pubmed/24073031",
                "http://www.ncbi.nlm.nih.gov/pubmed/23601912"
            ],
            "ideal_answer": [
                "Yes, there is a variety of decision support systems for chronic pain management.",
                "Clinical decision support systems are promising tools for improving behavioral medicine care for chronic pain.The use of a computer-based decision support system facilitates primary care physicians' management of chronic pain."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "54fefbbc6ad7dcbc1200000a",
            "snippets": [
                {
                    "offsetInBeginSection": 422,
                    "offsetInEndSection": 590,
                    "text": "a project to operationalize the 2003 VA/DOD Clinical Practice Guideline for Opioid Therapy for Chronic Non-Cancer Pain into a computerized decision support system (DSS)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20385018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 666,
                    "offsetInEndSection": 709,
                    "text": "We based the DSS on the existing ATHENA-DSS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20385018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1773,
                    "offsetInEndSection": 1846,
                    "text": "Use of this iterative process led to development of a multifunctional DSS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20385018",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 890,
                    "offsetInEndSection": 927,
                    "text": "interactive decision dashboard format",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23601912",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1077,
                    "offsetInEndSection": 1144,
                    "text": "We created a computerized, interactive clinical decision dashboard ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23601912",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2211,
                    "offsetInEndSection": 2333,
                    "text": "Interactive decision dashboards can be adapted for clinical use and have the potential to foster informed decision making.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23601912",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1080,
                    "offsetInEndSection": 1190,
                    "text": "Clinical decision support systems are promising tools for improving behavioral medicine care for chronic pain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24073031",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Improving Patient Safety Using ATHENA-Decision Support System Technology: ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249951",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 470,
                    "text": "ATHENA-DSS is an automated decision support system developed in a collaboration between Stanford University and the U.S. Department of Veterans Affairs (VA) to increase guideline-adherent prescribing and to change physician behavior.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21249951",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "The use of a computer-based decision support system facilitates primary care physicians' management of chronic pain.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11524346",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1298,
                    "offsetInEndSection": 1459,
                    "text": "The use of a CBDS system may improve the ability of PCPs to manage chronic pain and may also facilitate screening of consults to optimize specialist utilization.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11524346",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can methylenetetrahydrofolate reductase (MTHFR) gene mutations cause homocystinuria?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16629766",
                "http://www.ncbi.nlm.nih.gov/pubmed/27130656",
                "http://www.ncbi.nlm.nih.gov/pubmed/10980581",
                "http://www.ncbi.nlm.nih.gov/pubmed/23095199",
                "http://www.ncbi.nlm.nih.gov/pubmed/10923034",
                "http://www.ncbi.nlm.nih.gov/pubmed/21626167",
                "http://www.ncbi.nlm.nih.gov/pubmed/2629632",
                "http://www.ncbi.nlm.nih.gov/pubmed/17457696",
                "http://www.ncbi.nlm.nih.gov/pubmed/12673793",
                "http://www.ncbi.nlm.nih.gov/pubmed/11592438",
                "http://www.ncbi.nlm.nih.gov/pubmed/9490685",
                "http://www.ncbi.nlm.nih.gov/pubmed/23533858",
                "http://www.ncbi.nlm.nih.gov/pubmed/20532821",
                "http://www.ncbi.nlm.nih.gov/pubmed/9453374",
                "http://www.ncbi.nlm.nih.gov/pubmed/10679944",
                "http://www.ncbi.nlm.nih.gov/pubmed/24461181",
                "http://www.ncbi.nlm.nih.gov/pubmed/14656017",
                "http://www.ncbi.nlm.nih.gov/pubmed/20236116",
                "http://www.ncbi.nlm.nih.gov/pubmed/22521626",
                "http://www.ncbi.nlm.nih.gov/pubmed/9781030",
                "http://www.ncbi.nlm.nih.gov/pubmed/11181567",
                "http://www.ncbi.nlm.nih.gov/pubmed/17349292",
                "http://www.ncbi.nlm.nih.gov/pubmed/8124871"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0066357",
                    "o": "MTHFR"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_5034323839380027",
                    "o": "MTHFR"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_5135534E573500F",
                    "o": "MTHFR"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/drugbank/molecule/3917",
                    "o": "Methylenetetrahydrofolate reductase"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://linkedlifedata.com/resource/drugbank/molecule/3917",
                    "o": "http://purl.uniprot.org/uniprot/P42898"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://purl.uniprot.org/uniprot/P42898",
                    "o": "MTHR_HUMAN"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://purl.uniprot.org/uniprot/P42898",
                    "o": "http://purl.uniprot.org/uniprot/P42898"
                }
            ],
            "ideal_answer": [
                "Yes, several methylenetetrahydrofolate reductase (MTHFR) gene mutations can cause homocystinuria and hyperhomocysteinemia."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/MTHR_MOUSE",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006712",
                "http://www.uniprot.org/uniprot/MTHR_BOVIN",
                "http://www.disease-ontology.org/api/metadata/DOID:9263",
                "http://www.uniprot.org/uniprot/MTHR_MACFA",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009154",
                "http://www.uniprot.org/uniprot/MTHR_HUMAN"
            ],
            "type": "yesno",
            "id": "58d8d0cc8acda34529000008",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Methylenetetrahydrofolate reductase (MTHFR) deficiency is a rare autosomal recessive disorder. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461181",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 136,
                    "offsetInEndSection": 391,
                    "text": "Several mutations seen in methylenetetrahydrofolate reductase (MTHFR) give rise to the formation of hyperhomocysteinemia and homocystinuria, a considerable risk factor for cardiovascular and cerebrovascular disorders, by leading to enzymatic inactivation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23533858",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 551,
                    "offsetInEndSection": 764,
                    "text": "At admission, he had significantly elevated plasma and urine levels of total homocysteine, significantly decreased levels of folate in serum and cerebrospinal fluid, and a normal blood concentration of methionine.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461181",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 814,
                    "text": "Response to treatment demonstrated B(6)-non-responsive homocystinuria. Molecular study showed compound heterozygous T353\u00a0N and D444\u00a0N mutations of the cystathionine beta-synthase (CBS) gene, and also a C667T homozygous mutation of the methylenetetrahydrofolate-reductase (MTHFR) gene. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21626167",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1121,
                    "offsetInEndSection": 1374,
                    "text": "Our case is atypical because of the absence of thromboembolism and the mild phenotype, in spite of being B(6)-non-responsive, and the association of a rare compound heterozygous mutation of the CBS gene and also an homozygous mutation of the MTHFR gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21626167",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Molecular characterization of five patients with homocystinuria due to severe methylenetetrahydrofolate reductase deficiency.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236116",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 457,
                    "text": "Methylenetetrahydrofolate reductase (MTHFR) is a key regulatory enzyme in folate and homocysteine metabolism. Research performed during the past decade has clarified our understanding of MTHFR deficiencies that cause homocystinuria or mild hyperhomocysteinemia. Our cloning of the MTHFR coding sequence was initially followed by the identification of the first deleterious mutations in MTHFR, in patients with homocystinuria and marked hyperhomocysteinemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 320,
                    "text": "Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the regulation of plasma homocysteine levels. MTHFR deficiency, an autosomal recessive disorder, results in homocystinuria and hypomethioninaemia and presents with highly variable symptoms affecting many organs but predominantly the central nervous system. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17457696",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Some methylenetetrahydrofolate reductase (MTHFR) gene mutations cause hyperhomocysteinemia and homocystinuria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16629766",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 431,
                    "text": "Rare mutations in the MTHFR gene have been associated with autosomal recessive MTHFR deficiency leading to homocystinuria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27130656",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679944",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 414,
                    "text": "Five patients suspected of having non-classical homocystinuria due to MTHFR deficiency were examined with respect to their symptoms, MTHFR enzyme activity and genotypes of the MTHFR gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236116",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1171,
                    "offsetInEndSection": 1417,
                    "text": "The results of our study render the full-length characterisation of affected alleles in severe homocystinuria and moderate hyperhomocysteinaemia due to MTHFR deficiency and provide a basis for investigating the regulation of the human MTHFR gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10980581",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 260,
                    "offsetInEndSection": 455,
                    "text": "Our cloning of the MTHFR coding sequence was initially followed by the identification of the first deleterious mutations in MTHFR, in patients with homocystinuria and marked hyperhomocysteinemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 166,
                    "offsetInEndSection": 385,
                    "text": "Different MTHFR mutations lead either to severe homocystinuria as a multisystem disorder or to moderate hyperhomocysteinaemia, which is a common risk factor for disorders ranging from cardiovasculopathy to spina bifida.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10980581",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 435,
                    "offsetInEndSection": 712,
                    "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 807,
                    "offsetInEndSection": 1094,
                    "text": "On the contrary, thermolabile MTHFR caused by the 677C-->T mutation, was frequently observed among homocystinuria patients, especially among those with thromboembolic complications: three of six homocystinuria patients who had suffered from a thromboembolic event had thermolabile MTHFR.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 715,
                    "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Some methylenetetrahydrofolate reductase (MTHFR) gene mutations cause hyperhomocysteinemia and homocystinuria",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16629766",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 714,
                    "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679944",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 278,
                    "text": "The most common genetic cause of hyperhomocysteinemia is the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11181567",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 444,
                    "text": "The 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinemia, but this polymorphism does not seem to be a risk factor for venous thrombosis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "Hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) gene mutation have been postulated as a possible cause of recurrent miscarriage (RM)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23095199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 276,
                    "offsetInEndSection": 403,
                    "text": "The 677C>T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinaemia",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14656017",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 716,
                    "text": "We studied 24 patients with homocystinuria caused by homozygous CBS deficiency from 18 unrelated kindreds for FVL and for the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene and investigated their possible interaction in the risk of venous thrombosis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "AIM: Some methylenetetrahydrofolate reductase (MTHFR) gene mutations cause hyperhomocysteinemia and homocystinuria. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16629766",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Betaine for treatment of homocystinuria caused by methylenetetrahydrofolate reductase deficiency.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2629632",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "Severe deficiency of methylenetetrahydrofolate reductase (MTHFR) with homocystinuria can result in early demise or later-onset neurological impairment, including developmental delay, motor dysfunction, and seizures. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20532821",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Deficiency of 5,10-methylenetetrahydrofolate reductase (MTHFR) leads to deficient remethylation of homocysteine and is one of the causes of homocystinuria. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8124871",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 369,
                    "text": "Neurological disturbances have been described in homocystinuria caused by severe MTHFR deficiency. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22521626",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 237,
                    "offsetInEndSection": 445,
                    "text": "The 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinemia, but this polymorphism does not seem to be a risk factor for venous thrombosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11592438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 261,
                    "text": "Research performed during the past decade has clarified our understanding of MTHFR deficiencies that cause homocystinuria or mild hyperhomocysteinemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 276,
                    "offsetInEndSection": 404,
                    "text": "The 677C>T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene is an important cause of mild hyperhomocysteinaemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14656017",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 279,
                    "text": "The most common genetic cause of hyperhomocysteinemia is the 677C-->T mutation in the methylenetetrahydrofolate reductase (MTHFR) gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11181567",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 262,
                    "offsetInEndSection": 457,
                    "text": "Our cloning of the MTHFR coding sequence was initially followed by the identification of the first deleterious mutations in MTHFR, in patients with homocystinuria and marked hyperhomocysteinemia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17349292",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10679944",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Molecular characterization of five patients with homocystinuria due to severe methylenetetrahydrofolate reductase deficiency.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20236116",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 812,
                    "offsetInEndSection": 1099,
                    "text": "On the contrary, thermolabile MTHFR caused by the 677C-->T mutation, was frequently observed among homocystinuria patients, especially among those with thromboembolic complications: three of six homocystinuria patients who had suffered from a thromboembolic event had thermolabile MTHFR.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9490685",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can pets affect infant microbiomed?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28381231"
            ],
            "ideal_answer": [
                "Yes, exposure to household furry pets influences the gut microbiota of infants."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5be47bff133db5eb78000018",
            "snippets": [
                {
                    "offsetInBeginSection": 160,
                    "offsetInEndSection": 359,
                    "text": "Since there is some evidence that pets also alter the gut microbial composition of infants, changes to the gut microbiome are putative pathways by which pet exposure can reduce these risks to health.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381231",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2111,
                    "offsetInEndSection": 2359,
                    "text": "The impact of pet ownership varies under different birth scenarios; however, in common, exposure to pets increased the abundance of two bacteria, Ruminococcus and Oscillospira, which have been negatively associated with childhood atopy and obesity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381231",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1315,
                    "offsetInEndSection": 1949,
                    "text": "As a common effect in all birth scenarios, pre- and postnatal pet exposure enriched the abundance of Oscillospira and/or Ruminococcus (P\u2009<\u20090.05) with more than a twofold greater likelihood of high abundance. Among vaginally born infants with maternal intrapartum antibiotic prophylaxis exposure, Streptococcaceae were substantially and significantly reduced by pet exposure (P\u2009<\u20090.001, FDRp\u2009=\u20090.03), reflecting an 80% decreased likelihood of high abundance (OR 0.20, 95%CI, 0.06-0.70) for pet exposure during pregnancy alone and a 69% reduced likelihood (OR 0.31, 95%CI, 0.16-0.58) for exposure in the pre- and postnatal time periods.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381231",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 121,
                    "text": "Exposure to household furry pets influences the gut microbiota of infant at 3-4\u00a0months following various birth scenarios.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381231",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Have C12orf65 mutations been associated with axonal neuropathy and optic atrophy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
                "http://www.ncbi.nlm.nih.gov/pubmed/23188110",
                "http://www.ncbi.nlm.nih.gov/pubmed/25519961",
                "http://www.ncbi.nlm.nih.gov/pubmed/24284555",
                "http://www.ncbi.nlm.nih.gov/pubmed/24424123"
            ],
            "ideal_answer": [
                "Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy",
                "The association of neuropathy and optic atrophy (also known as Charcot-Marie-Tooth [CMT] disease type 6) has been described with autosomal dominant, recessive and X-linked modes of inheritance. Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6. Phosphoribosylpyrophosphate synthetase-I mutations cause X-linked CMT6, whereas a protein-truncating mutation in the C12orf65 gene, which codes for a protein involved in mitochondrial translation, was found to be the cause of an autosomal recessive form of the disease, with childhood onset neuropathy and optic atrophy."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5713c7dd1174fb1755000014",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 1031,
                    "text": "Charcot-Marie Tooth disease (CMT) forms a clinically and genetically heterogeneous group of disorders. Although a number of disease genes have been identified for CMT, the gene discovery for some complex form of CMT has lagged behind. The association of neuropathy and optic atrophy (also known as CMT type 6) has been described with autosomaldominant, recessive and X-linked modes of inheritance. Mutations in Mitofusin 2 have been found to cause dominant forms of CMT6. Phosphoribosylpyrophosphate synthetase-I mutations cause X-linked CMT6, but until now, mutations in the recessive forms of disease have never been identified.METHODS: We here describe a family with three affected individuals who inherited in an autosomal recessive fashion a childhood onset neuropathy and optic atrophy. Using homozygosity mapping in the family and exome sequencing in two affected individuals we identified a novel protein-truncating mutation in the C12orf65 gene, which encodes for a protein involved in mitochondrial translation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "text": "Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1376,
                    "offsetInEndSection": 1553,
                    "text": "Our study broadens the phenotypic spectrum of C12orf65 defects and highlights the triad of optic atrophy, axonal neuropathy and spastic paraparesis as its key clinical features.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 475,
                    "text": "C12orf65 participates in the process of mitochondrial translation and has been shown to be associated with a spectrum of phenotypes, including early onset optic atrophy, progressive encephalomyopathy, peripheral neuropathy, and spastic paraparesis.We used whole-genome homozygosity mapping as well as exome sequencing and targeted gene sequencing to identify novel C12orf65 disease-causing mutations in seven affected individuals originating from two consanguineous families.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "A homozygous mutation of C12orf65 causes spastic paraplegia with optic atrophy and neuropathy (SPG55).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23188110",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Optic atrophy and a Leigh-like syndrome due to mutations in the c12orf65 gene: report of a novel mutation and review of the literature.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24284555",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 526,
                    "offsetInEndSection": 712,
                    "text": "Recently, we identified the causative gene, C12orf65, that was reported the gene for Leigh syndrome, for autosomal recessive spastic paraplegia with optic atrophy and neuropathy (SPG55).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25519961",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 438,
                    "offsetInEndSection": 705,
                    "text": "We describe 2 siblings with compound heterozygous mutations in the recently identified C12orf65 gene who presented with optic atrophy and mild developmental delays and subsequently developed bilateral, symmetric lesions in the brainstem reminiscent of Leigh syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24284555",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 474,
                    "text": "C12orf65 participates in the process of mitochondrial translation and has been shown to be associated with a spectrum of phenotypes, including early onset optic atrophy, progressive encephalomyopathy, peripheral neuropathy, and spastic paraparesis.We used whole-genome homozygosity mapping as well as exome sequencing and targeted gene sequencing to identify novel C12orf65 disease-causing mutations in seven affected individuals originating from two consanguineous families",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1210,
                    "offsetInEndSection": 1386,
                    "text": "Our study broadens the phenotypic spectrum of C12orf65 defects and highlights the triad of optic atrophy, axonal neuropathy and spastic paraparesis as its key clinical features",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1574,
                    "offsetInEndSection": 1759,
                    "text": "CONCLUSIONS: This work describes a mutation in the C12orf65 gene that causes recessive form of CMT6 and confirms the role of mitochondrial dysfunction in this complex axonal neuropathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 476,
                    "text": "C12orf65 participates in the process of mitochondrial translation and has been shown to be associated with a spectrum of phenotypes, including early onset optic atrophy, progressive encephalomyopathy, peripheral neuropathy, and spastic paraparesis.We used whole-genome homozygosity mapping as well as exome sequencing and targeted gene sequencing to identify novel C12orf65 disease-causing mutations in seven affected individuals originating from two consanguineous families. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1204,
                    "offsetInEndSection": 1382,
                    "text": "Our study broadens the phenotypic spectrum of C12orf65 defects and highlights the triad of optic atrophy, axonal neuropathy and spastic paraparesis as its key clinical features. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1129,
                    "offsetInEndSection": 1264,
                    "text": "We described a large consanguineous family with neuropathy and optic atrophy carrying a loss of function mutation in the C12orf65 gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1080,
                    "offsetInEndSection": 1381,
                    "text": "In these patients, we identified a homozygous splice mutation, g.21043\u2009T>A (c.282+2\u2009T>A) which leads to skipping of exon 2. Our study broadens the phenotypic spectrum of C12orf65 defects and highlights the triad of optic atrophy, axonal neuropathy and spastic paraparesis as its key clinical features.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1545,
                    "offsetInEndSection": 1717,
                    "text": "This work describes a mutation in the C12orf65 gene that causes recessive form of CMT6 and confirms the role of mitochondrial dysfunction in this complex axonal neuropathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1205,
                    "offsetInEndSection": 1382,
                    "text": "Our study broadens the phenotypic spectrum of C12orf65 defects and highlights the triad of optic atrophy, axonal neuropathy and spastic paraparesis as its key clinical features.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 79,
                    "text": "Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1548,
                    "offsetInEndSection": 1721,
                    "text": "This work describes a mutation in the C12orf65 gene that causes recessive form of CMT6 and confirms the role of mitochondrial dysfunction in this complex axonal neuropathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24198383",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "text": "A homozygous mutation of C12orf65 causes spastic paraplegia with optic atrophy and neuropathy (SPG55).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23188110",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 476,
                    "text": "C12orf65 participates in the process of mitochondrial translation and has been shown to be associated with a spectrum of phenotypes, including early onset optic atrophy, progressive encephalomyopathy, peripheral neuropathy, and spastic paraparesis.We used whole-genome homozygosity mapping as well as exome sequencing and targeted gene sequencing to identify novel C12orf65 disease-causing mutations in seven affected individuals originating from two consanguineous families.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24424123",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does the CTCF protein co-localize with cohesin?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22780989",
                "http://www.ncbi.nlm.nih.gov/pubmed/23010778",
                "http://www.ncbi.nlm.nih.gov/pubmed/19158269",
                "http://www.ncbi.nlm.nih.gov/pubmed/22550178",
                "http://www.ncbi.nlm.nih.gov/pubmed/19109133",
                "http://www.ncbi.nlm.nih.gov/pubmed/23204437",
                "http://www.ncbi.nlm.nih.gov/pubmed/18623068",
                "http://www.ncbi.nlm.nih.gov/pubmed/21876668",
                "http://www.ncbi.nlm.nih.gov/pubmed/19308701",
                "http://www.ncbi.nlm.nih.gov/pubmed/21444719",
                "http://www.ncbi.nlm.nih.gov/pubmed/24257606",
                "http://www.ncbi.nlm.nih.gov/pubmed/20133600",
                "http://www.ncbi.nlm.nih.gov/pubmed/21880767",
                "http://www.ncbi.nlm.nih.gov/pubmed/21106760",
                "http://www.ncbi.nlm.nih.gov/pubmed/23945083",
                "http://www.ncbi.nlm.nih.gov/pubmed/22952237",
                "http://www.ncbi.nlm.nih.gov/pubmed/19369356",
                "http://www.ncbi.nlm.nih.gov/pubmed/18550811",
                "http://www.ncbi.nlm.nih.gov/pubmed/21948239",
                "http://www.ncbi.nlm.nih.gov/pubmed/21970734",
                "http://www.ncbi.nlm.nih.gov/pubmed/22440186",
                "http://www.ncbi.nlm.nih.gov/pubmed/24321385",
                "http://www.ncbi.nlm.nih.gov/pubmed/20219941",
                "http://www.ncbi.nlm.nih.gov/pubmed/21628529",
                "http://www.ncbi.nlm.nih.gov/pubmed/23295672",
                "http://www.ncbi.nlm.nih.gov/pubmed/21606361",
                "http://www.ncbi.nlm.nih.gov/pubmed/23804403",
                "http://www.ncbi.nlm.nih.gov/pubmed/23498937"
            ],
            "ideal_answer": [
                "Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin.",
                "Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin  "
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/CTCF_RAT",
                "http://www.uniprot.org/uniprot/CTCFL_HUMAN"
            ],
            "type": "yesno",
            "id": "5344310baeec6fbd0700000c",
            "snippets": [
                {
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 560,
                    "text": "To investigate cohesin-non-CTCF (CNC) binding events in vivo we mapped cohesin and CTCF, as well as a collection of tissue-specific and ubiquitous transcriptional regulators using ChIP-seq in primary mouse liver.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22780989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 886,
                    "text": "In contrast to regions of the genome where cohesin and CTCF colocalize, CNC sites coincide with the binding of master regulators and enhancer-markers and are significantly associated with liver-specific expressed genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22780989",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 415,
                    "offsetInEndSection": 541,
                    "text": "Here we report that cohesins colocalize with CTCF at two additional imprinted loci, the Dlk1-Dio3 and the Kcnq1/Kcnq1ot1 loci.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21628529",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 598,
                    "offsetInEndSection": 834,
                    "text": "By use of human hepatocellular carcinoma cells (HepG2), we found that liver-specific transcription factors colocalize with cohesin independently of CTCF at liver-specific targets that are distinct from those found in breast cancer cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20219941",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 687,
                    "offsetInEndSection": 879,
                    "text": "Because cohesin can colocalize with CTCF, we performed chromatin immunoprecipitation for the cohesin subunit Rad21 and found lineage and stage-specific Rad21 recruitment to CTCF in all Ig loci",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19109133",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 486,
                    "text": "Here we show that zebrafish runx1 is directly bound by cohesin and CCCTC binding factor (CTCF) at the P1 and P2 promoters, and within the intron between P1 and P2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321385",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 669,
                    "offsetInEndSection": 866,
                    "text": "The intronic binding sites for cohesin and CTCF coincide with histone modifications that confer enhancer-like properties, and two of the cohesin/CTCF sites behaved as insulators in an in vivo assay",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321385",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 868,
                    "offsetInEndSection": 1023,
                    "text": "The identified cohesin and CTCF binding sites are likely to be cis-regulatory elements (CREs) for runx1 since they also recruit RNA polymerase II (RNAPII).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24321385",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 157,
                    "offsetInEndSection": 387,
                    "text": "We have found that CTCF and cohesin are highly enriched at the convergent and partially overlapping transcripts for the LMP1 and LMP2A genes, but it is not yet known how CTCF and cohesin may coordinately regulate these transcripts",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24257606",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 124,
                    "text": "haracterization of constitutive CTCF/cohesin loci: a possible role in establishing topological domains in mammalian genomes",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945083",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 744,
                    "offsetInEndSection": 890,
                    "text": "Our analysis revealed: 1) constitutive CTCF loci were located in constitutive open chromatin and often co-localized with constitutive cohesin loci",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23945083",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 738,
                    "offsetInEndSection": 922,
                    "text": "In brain, a third of CTCF and cohesin binding sites coincide, consistent with the potential for many interactions between cohesin and CTCF but also many instances of independent action",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23804403",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 389,
                    "text": "Here, we focus on the emerging roles of CTCF and the cohesin in coordinating long-range interactions between regulatory elements",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23498937",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 750,
                    "offsetInEndSection": 1018,
                    "text": "Chromatin immunoprecipitation for CTCF and the cohesin subunits RAD21 and SMC3 reveals evolutionarily conserved binding sites within unmethylated regions \u223c5 kb downstream of the PLAGL1 differentially methylated region and within the PLAGL1 3' untranslated region (UTR)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23295672",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 42,
                    "text": "TCF physically links cohesin to chromatin",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18550811",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 65,
                    "text": "ohesin and CTCF: cooperating to control chromosome conformation?",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18623068",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 222,
                    "offsetInEndSection": 374,
                    "text": "Recently, three groups mapped numerous cohesin-binding sites in mammalian chromosomes and found substantial overlap with the CCCTC-binding factor (CTCF)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18623068",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 516,
                    "offsetInEndSection": 644,
                    "text": "We found that each site contains a conserved CTCF consensus sequence, binds CTCF, and recruits the cohesin subunit Rad21 in vivo",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19158269",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 273,
                    "offsetInEndSection": 408,
                    "text": "Recent experiments have revealed that cohesin binds to the same sites in mammalian genomes as the zinc finger transcription factor CTCF",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19308701",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 765,
                    "text": "Here we review what is known about the roles of cohesin and CTCF in regulating gene expression in mammalian cells, and we discuss how cohesin might mediate the insulator function of CTCF",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19308701",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 674,
                    "text": "Previous studies have shown that this major latency control region is occupied by the cellular chromatin boundary factor CTCF and chromosome structural maintenance proteins SMC1, SMC3, and RAD21, which comprise the cohesin complex",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 961,
                    "offsetInEndSection": 1070,
                    "text": "Cohesin subunits assembled at the CTCF binding sites and bound CTCF proteins in a cell cycle-dependent manner",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1533,
                    "offsetInEndSection": 1788,
                    "text": "We propose that the CTCF-cohesin complex plays a critical role in regulating the cell cycle control of viral gene expression during latency and that failure to maintain cell cycle control of latent transcripts inhibits host cell proliferation and survival",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19369356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 91,
                    "offsetInEndSection": 298,
                    "text": "We used chromosome conformation capture to determine long-range interactions among CTCF/cohesin sites over 2 Mb on human chromosome 11 encompassing the beta-globin locus and flanking olfactory receptor genes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20133600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 920,
                    "offsetInEndSection": 1115,
                    "text": "These results support a genome-wide role for CTCF/cohesin sites through loop formation that both influences transcription and contributes to cell-type-specific chromatin organization and function",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20133600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 741,
                    "offsetInEndSection": 892,
                    "text": "Increased methylation at this promoter triggered the dissociation of the insulator protein CTCF as well as the accompanying cohesin from the BDNF locus",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21106760",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 152,
                    "text": "icotinamide adenine dinucleotide (NAD)-regulated DNA methylation alters CCCTC-binding factor (CTCF)/cohesin binding and transcription at the BDNF locus",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21106760",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 234,
                    "text": "ecent studies have shown that the protein CTCF, which plays an important role in insulation and in large-scale organization of chromatin within the eukaryotic nucleus, depends for both activities on recruitment of the cohesin complex",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 411,
                    "text": "We show here that the interaction of CTCF with the cohesin complex involves direct contacts between the cohesin subunit SA2 and specific regions of the C-terminal tail of CTCF",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 743,
                    "offsetInEndSection": 885,
                    "text": "Taken together, our results demonstrate that specific sites on the C terminus of CTCF are essential for cohesin binding and insulator function",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 887,
                    "offsetInEndSection": 1004,
                    "text": "The only direct interaction between CTCF and cohesin involves contact with SA2, which is external to the cohesin ring",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21444719",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 626,
                    "offsetInEndSection": 788,
                    "text": "These numerous CTCF/cohesin sites potentially form the bases of the multiloop rosette structures at the Igh locus that compact during Ig heavy chain rearrangement",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21606361",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 399,
                    "text": "We have previously shown that the Kaposi's Sarcoma-Associated Herpesvirus (KSHV) major latency transcripts encoding LANA, vCyclin, vFLIP, v-miRNAs, and Kaposin are regulated, in part, by a chromatin organizing element that binds CTCF and cohesins",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876668",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 757,
                    "offsetInEndSection": 924,
                    "text": "Mutation of the CTCF-cohesin binding site reduced or eliminated the chromatin conformation linkages, and deregulated viral transcription and genome copy number control",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876668",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1282,
                    "offsetInEndSection": 1483,
                    "text": "Our findings indicate that KSHV genomes are organized into chromatin loops mediated by CTCF and cohesin interactions, and that these inter-chromosomal linkages coordinate latent and lytic gene control.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21876668",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 491,
                    "text": "We show here that GA disrupts an RNA polymerase II (RNAPII) complex that accumulates at the CTCF-cohesin binding site within the first intron of the latency transcript.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 492,
                    "offsetInEndSection": 638,
                    "text": "GA altered the enrichment of the RNAPII pausing complex, along with pausing factors SPT5 and NELF-A, at the intragenic CTCF-cohesin binding sites.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 960,
                    "offsetInEndSection": 1116,
                    "text": "GA treatment also inhibited the transcription of some cellular genes, like c-myc, which contain a similar CTCF-cohesin binding site within the first intron.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1223,
                    "offsetInEndSection": 1499,
                    "text": "These findings suggest that RNAPII pauses at intragenic CTCF-cohesin binding sites and that abrogation of this pausing by GA leads to loss of proper mRNA production and defects in sister chromatid cohesion, a process important for both viral and cellular chromosome stability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21880767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 120,
                    "text": "TCF and cohesin cooperatively mediate the cell-type specific interchromatin interaction between Bcl11b and Arhgap6 loci",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21948239",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 467,
                    "offsetInEndSection": 648,
                    "text": "Additional experiments verified that the interchromatin interaction between the Bcl11b and Arhgap6 loci was cell-type specific, which was cooperatively mediated by CTCF and cohesin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21948239",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1,
                    "offsetInEndSection": 118,
                    "text": "enome-wide studies of CCCTC-binding factor (CTCF) and cohesin provide insight into chromatin structure and regulation",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952237",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 315,
                    "offsetInEndSection": 544,
                    "text": "Recent genome-wide studies mapping the binding sites of CTCF and its interacting partner, cohesin, using chromatin immunoprecipitation coupled with deep sequencing (ChIP-seq) revealded that CTCF globally co-localizes with cohesin",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22952237",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 165,
                    "offsetInEndSection": 375,
                    "text": "Here, we show by ChIP-Seq that most human subtelomeres contain a CTCF- and cohesin-binding site within \u223c1-2\u2009kb of the TTAGGG repeat tract and adjacent to a CpG-islands implicated in TERRA transcription control.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23010778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 974,
                    "offsetInEndSection": 1155,
                    "text": "These findings indicate that CTCF and cohesin are integral components of most human subtelomeres, and important for the regulation of TERRA transcription and telomere end protection",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23010778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 517,
                    "offsetInEndSection": 731,
                    "text": "In addition, we show that this DNA looping requires specific binding of the CTCF/cohesin complex to two symmetrically aligned binding sites in both the transcriptionally active promoters and in one of the enhancers",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23204437",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Doxorubicin cardiotoxic?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24382354",
                "http://www.ncbi.nlm.nih.gov/pubmed/25885550",
                "http://www.ncbi.nlm.nih.gov/pubmed/21057569",
                "http://www.ncbi.nlm.nih.gov/pubmed/19103993",
                "http://www.ncbi.nlm.nih.gov/pubmed/6734434",
                "http://www.ncbi.nlm.nih.gov/pubmed/6407163",
                "http://www.ncbi.nlm.nih.gov/pubmed/9923553",
                "http://www.ncbi.nlm.nih.gov/pubmed/12679799",
                "http://www.ncbi.nlm.nih.gov/pubmed/12865930",
                "http://www.ncbi.nlm.nih.gov/pubmed/19920767",
                "http://www.ncbi.nlm.nih.gov/pubmed/23843850",
                "http://www.ncbi.nlm.nih.gov/pubmed/24714774",
                "http://www.ncbi.nlm.nih.gov/pubmed/20060872",
                "http://www.ncbi.nlm.nih.gov/pubmed/19660469",
                "http://www.ncbi.nlm.nih.gov/pubmed/26507774",
                "http://www.ncbi.nlm.nih.gov/pubmed/24484915",
                "http://www.ncbi.nlm.nih.gov/pubmed/17875725",
                "http://www.ncbi.nlm.nih.gov/pubmed/25660617",
                "http://www.ncbi.nlm.nih.gov/pubmed/22343424",
                "http://www.ncbi.nlm.nih.gov/pubmed/24902966",
                "http://www.ncbi.nlm.nih.gov/pubmed/8647872",
                "http://www.ncbi.nlm.nih.gov/pubmed/26164096",
                "http://www.ncbi.nlm.nih.gov/pubmed/17888722",
                "http://www.ncbi.nlm.nih.gov/pubmed/10507317",
                "http://www.ncbi.nlm.nih.gov/pubmed/24916696",
                "http://www.ncbi.nlm.nih.gov/pubmed/8402643",
                "http://www.ncbi.nlm.nih.gov/pubmed/3029137",
                "http://www.ncbi.nlm.nih.gov/pubmed/15515283",
                "http://www.ncbi.nlm.nih.gov/pubmed/1531780",
                "http://www.ncbi.nlm.nih.gov/pubmed/27735842"
            ],
            "ideal_answer": [
                "Doxorubicin (DOXO) is widely used to treat solid tumors. However, its clinical use is limited by side effects including serious cardiotoxicity due to cardiomyocyte damage",
                "Doxorubicin (DOXO) is widely used to treat solid tumors. However, its clinical use is limited by side effects including serious cardiotoxicity due to cardiomyocyte damage. "
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4269440",
                "http://www.biosemantics.org/jochem#4085749",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004317",
                "http://www.biosemantics.org/jochem#4269440",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054715",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D066126"
            ],
            "type": "yesno",
            "id": "58cdb80302b8c60953000043",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "Doxorubicin (DOXO) is widely used to treat solid tumors. However, its clinical use is limited by side effects including serious cardiotoxicity due to cardiomyocyte damage. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27735842",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1366,
                    "offsetInEndSection": 1464,
                    "text": "The results provide direct evidence for the role of catalase in doxorubicin cardiotoxic responses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8647872",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 582,
                    "offsetInEndSection": 710,
                    "text": "These results do not support the possibility that mitomycin C potentiates the acute cardiotoxic effects produced by doxorubicin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6407163",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "The anthracycline chemotherapeutic agent doxorubicin is converted by the enzyme carbonyl reductase 1 (CBR1) into its cardiotoxic metabolite doxorubicinol",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22343424",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "The clinical efficiency of the highly potent antitumor agent doxorubicin is limited by cardiotoxic effects",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25660617",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "Doxorubicin (DOX), a highly active chemotherapeutic drug, faces limitations in clinical application due to severe cardiotoxic effects (mainly through increased oxidative stress)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25885550",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "Clinical uses of doxorubicin (DOX), a highly active anticancer agent, are limited by its severe cardiotoxic side effects associated with increased oxidative stress and apoptosis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20060872",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Doxorubicin (DOX) and trastuzumab (TRZ) are highly effective chemotherapeutic agents in the breast cancer setting, limited by their cardiotoxic side effects",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24484915",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24916696",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2666,
                    "offsetInEndSection": 2769,
                    "text": "Cardiotoxic effects were reported in 15 (5%) of 291 children receiving treatment including doxorubicin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26164096",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1857,
                    "offsetInEndSection": 2173,
                    "text": "On the other hand, pretreatment of rats with hesperidin protected cardiac tissues against the cardiotoxic effects of doxorubicin as evidenced from amelioration of histopathological changes and normalization of cardiac biochemical parameters.Hesperidin may have a protective effect against DOX-induced cardiotoxicity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21057569",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 233,
                    "text": "However, with cumulative doses, doxorubicin also is known to have cardiotoxic effects, including cardiomyopathy and heart failure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15515283",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 196,
                    "offsetInEndSection": 363,
                    "text": "Methods of reducing or preventing doxorubicin-induced cardiotoxicity have been suggested, including an investigational doxorubicin analog, mitoxantrone ( Novantrone ).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6734434",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 777,
                    "offsetInEndSection": 972,
                    "text": "The most cardiotoxic drug, doxorubicin, is the most potent inducer of superoxide generation, while epirubicin, which is less cardiotoxic, has a relatively limited effect on superoxide production.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3029137",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 164,
                    "offsetInEndSection": 330,
                    "text": "The mechanism of doxorubicin cardiotoxicity is likely multifactorial and most importantly, the genetic factors predisposing to doxorubicin cardiotoxicity are unknown.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24714774",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "As doxorubicin cardiotoxicity is considered irreversible, early detection of cardiotoxicity and prevention of overt heart failure is essential.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23843850",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 144,
                    "offsetInEndSection": 299,
                    "text": "Although there are monitoring guidelines for cardiotoxicity, optimal timing for early detection of subclinical doxorubicin cardiotoxicity is still obscure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23843850",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi-1 expression.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24902966",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 85,
                    "offsetInEndSection": 171,
                    "text": "However, doxorubicin cardiotoxicity of the heart has largely limited its clinical use.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26507774",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24714774",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "text": "Doxorubicin-based chemotherapy induces cardiotoxicity, which limits its clinical application.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24902966",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 21,
                    "offsetInEndSection": 166,
                    "text": "he clinical use of doxorubicin (DOX) and other anthracyclines is limited by a dosage-dependent cardiotoxicity, which can lead to cardiomyopathy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17888722",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 213,
                    "text": "Besides its cardiotoxic effect, doxorubicin also elicits inflammatory effects in vivo. 7-Monohydroxyethylrutoside (monoHER) has recently been used as a protector against doxorubicin-induced cardiotoxicity in vivo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12865930",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Doxorubicin is an effective antineoplastic agent, but it frequently causes dose-related cardiotoxic effects. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1531780",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 305,
                    "text": "Among these analogs, idarubicin (4-demethoxy-daunorubicin) was shown to be less cardiotoxic than doxorubicin i",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10507317",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 260,
                    "text": "Verapamil has also been suggested to potentiate the cardiotoxicity of doxorubicin. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8402643",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 69,
                    "offsetInEndSection": 149,
                    "text": "Doxorubicin treatment is associated with both acute and chronic cardiotoxicity. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19103993",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 247,
                    "offsetInEndSection": 329,
                    "text": "cardiac effects of diclofenac sodium on doxorubicin-induced cardiomyopathy in rats",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19920767",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does teplizumab hold promise for diabetes prevention?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23086558",
                "http://www.ncbi.nlm.nih.gov/pubmed/30569273",
                "http://www.ncbi.nlm.nih.gov/pubmed/25941654",
                "http://www.ncbi.nlm.nih.gov/pubmed/31533907",
                "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
                "http://www.ncbi.nlm.nih.gov/pubmed/31523950",
                "http://www.ncbi.nlm.nih.gov/pubmed/20095914",
                "http://www.ncbi.nlm.nih.gov/pubmed/23231526",
                "http://www.ncbi.nlm.nih.gov/pubmed/23835333",
                "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
                "http://www.ncbi.nlm.nih.gov/pubmed/21719095"
            ],
            "ideal_answer": [
                "Yes, teplizumab is promising for diabetes prevention."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e30f638fbd6abf43b000045",
            "snippets": [
                {
                    "offsetInBeginSection": 2377,
                    "offsetInEndSection": 2474,
                    "text": "Anti-CD3 teplizumab and anti-CD3 otelixizumab have been shown to provide C-peptide preservation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25941654",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1207,
                    "offsetInEndSection": 1284,
                    "text": "Underway are secondary prevention studies with teplizumab and with abatacept.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23231526",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2371,
                    "offsetInEndSection": 2731,
                    "text": "INTERPRETATION: Findings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 39,
                    "text": "Teplizumab therapy for type 1 diabetes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20095914",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 53,
                    "text": "Teplizumab for treatment of type 1 diabetes mellitus.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 775,
                    "offsetInEndSection": 950,
                    "text": "TAKE HOME MESSAGE\n\nIn Phase I/II randomized control trials, in patients with new onset T1D, teplizumab slowed the rate of loss of beta-cell function over 2 years of follow-up.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20095914",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Teplizumab for treatment of type 1 diabetes (Prot\u00e9g\u00e9 study): 1-year results from a randomised, placebo-controlled trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2377,
                    "offsetInEndSection": 2737,
                    "text": "INTERPRETATION\n\nFindings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "Treatment of new onset type 1 diabetes with teplizumab: successes and pitfalls in development.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 761,
                    "offsetInEndSection": 983,
                    "text": "AREAS COVERED\n\nIn this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1783,
                    "offsetInEndSection": 1906,
                    "text": "CONCLUSIONS Teplizumab is an anti-CD3 human monoclonal antibody with promising activity in treatment of patients with T1DM.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22968521",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 681,
                    "offsetInEndSection": 891,
                    "text": "The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31533907",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2377,
                    "offsetInEndSection": 2737,
                    "text": "INTERPRETATION\nFindings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 224,
                    "text": "Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23835333",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23086558",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 672,
                    "offsetInEndSection": 883,
                    "text": "The results from the TN-10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a FcR non-binding monoclonal antibody to CD3 in people at high risk for disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31533907",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2343,
                    "offsetInEndSection": 2687,
                    "text": "Findings of exploratory analyses suggest that future studies of immunotherapeutic intervention with teplizumab might have increased success in prevention of a decline in \u03b2-cell function (measured by C-peptide) and provision of glycaemic control at reduced doses of insulin if they target patients early after diagnosis of diabetes and children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21719095",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 252,
                    "offsetInEndSection": 571,
                    "text": "Despite decades of research and clinical trials, no treatment exists yet to prevent or cure T1D. A recent prevention trial using the anti-CD3 antibody teplizumab in individuals at a high risk of developing T1D has provided the first piece of evidence that a safe and transient intervention may be able to delay disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31523950",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 746,
                    "offsetInEndSection": 953,
                    "text": "In this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24517093",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7\u00a0years from diagnosis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30569273",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Can LB-100 downregulate miR-33?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28588271"
            ],
            "ideal_answer": [
                "No, LB-100 has been reported to modulate (upregulate) only miR-181b-1."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e2a04feaa19d74431000009",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "PP2A inhibition from LB100 therapy enhances daunorubicin cytotoxicity in secondary acute myeloid leukemia via miR-181b-1 upregulation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28588271",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 683,
                    "offsetInEndSection": 989,
                    "text": "LB100 profoundly upregulates miR-181b-1, which we show directly binds to the 3' untranslated region of Bcl-2 mRNA leading to its translational inhibition. MiR-181b-1 ectopic overexpression further diminishes Bcl-2 expression leading to suppression of sAML cell growth, and enhancement of DNR cytotoxicity. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28588271",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does neuroglobin has neuroprotective properties in the setting of traumatic brain injury?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23658829",
                "http://www.ncbi.nlm.nih.gov/pubmed/24491879",
                "http://www.ncbi.nlm.nih.gov/pubmed/20345238",
                "http://www.ncbi.nlm.nih.gov/pubmed/20476562",
                "http://www.ncbi.nlm.nih.gov/pubmed/20544857",
                "http://www.ncbi.nlm.nih.gov/pubmed/25624825",
                "http://www.ncbi.nlm.nih.gov/pubmed/21915648",
                "http://www.ncbi.nlm.nih.gov/pubmed/22703519",
                "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                "http://www.ncbi.nlm.nih.gov/pubmed/24642455"
            ],
            "ideal_answer": [
                "Yes, neuroglobin has neuroprotective properties in the setting of traumatic brain injury."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "56c1d846ef6e39474100002e",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 164,
                    "text": "Neuroglobin has shown rich neuroprotective effects against cerebral hypoxia, and therefore has the potential to impact outcomes after traumatic brain injury (TBI). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345238",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Neuroglobin (Ngb) is proposed to be a neuron-specific, hypoxia-responsive, neuroprotective protein. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20544857",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 796,
                    "offsetInEndSection": 1081,
                    "text": "CONCLUSION: The increased expression of neuroglobin in traumatic brain injury informed us that neuroglobin had anti-apoptosis action in post-injury neuron. It could protect the neuron from traumatic stress and secondary ischemia and hypoxia insults during ultra-early and acute stages.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20476562",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 71,
                    "text": "Neuroglobin-overexpression reduces traumatic brain lesion size in mice.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22703519",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "BACKGROUND: Accumulating evidence has demonstrated that over-expression of Neuroglobin (Ngb) is neuroprotective against hypoxic/ischemic brain injuries. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22703519",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1071,
                    "offsetInEndSection": 1201,
                    "text": "CONCLUSION: Ngb over-expression reduced traumatic lesion volume, which might partially be achieved by decreasing oxidative stress.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22703519",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Neuroglobin upregulation offers neuroprotection in traumatic brain injury.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "text": "OBJECTIVES: The aim of this study was to investigate rat neuroglobin (rNGB) expression level after traumatic brain injury (TBI) and further study its neuroprotective effects in TBI when it was overexpressed in adenoviral vector.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 955,
                    "offsetInEndSection": 1060,
                    "text": "CONCLUSIONS: NGB was upregulated in TBI and overexpressed rNGB had a significant neuroprotection in TBI. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1101,
                    "offsetInEndSection": 1189,
                    "text": "This study suggested that rNGB overexpression may be a new strategy for treating of TBI.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "Neuroglobin has shown rich neuroprotective effects against cerebral hypoxia, and therefore has the potential to impact outcomes after traumatic brain injury (TBI).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20345238",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "The aim of this study was to investigate rat neuroglobin (rNGB) expression level after traumatic brain injury (TBI) and further study its neuroprotective effects in TBI when it was overexpressed in adenoviral vector.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22664218",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Accumulating evidence has demonstrated that over-expression of Neuroglobin (Ngb) is neuroprotective against hypoxic/ischemic brain injuries.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22703519",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 171,
                    "offsetInEndSection": 334,
                    "text": "Various studies seem to indicate that neuroglobin is a neuroprotective agent when overexpressed, acting as a potent inhibitor of oxidative and nitrosative stress. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24491879",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can AGY be used as antidiuretic replacement therapy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28035551"
            ],
            "ideal_answer": [
                "No, AGY is an oral egg yolk anti-gliadin antibody used to neutralize gluten. It is used in patients with celiac disease."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e764732c6a8763d23000017",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "AGY, a Novel Egg Yolk-Derived Anti-gliadin Antibody, Is Safe for Patients with Celiac Disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28035551",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 253,
                    "offsetInEndSection": 377,
                    "text": "Oral egg yolk anti-gliadin antibody (AGY) is a novel treatment to neutralize gluten and may improve the efficacy of the GFD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28035551",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 383,
                    "offsetInEndSection": 472,
                    "text": "To determine the safety, tolerability, and potential efficacy of AGY in patients with CD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28035551",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1234,
                    "offsetInEndSection": 1431,
                    "text": "Most patients had fewer celiac symptoms (especially tiredness, headache, and bloating), improved quality of life, lowered antibodies, and lowered LMER when taking AGY compared to the run-in period.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28035551",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1443,
                    "offsetInEndSection": 1562,
                    "text": "In our cohort, AGY was safe and potentially associated with improved CD-related outcome measures in patients on a GFD. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28035551",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Fibroblast Growth Factor 23 a phosphaturic hormone?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24991914",
                "http://www.ncbi.nlm.nih.gov/pubmed/24466013",
                "http://www.ncbi.nlm.nih.gov/pubmed/25380933",
                "http://www.ncbi.nlm.nih.gov/pubmed/24434184",
                "http://www.ncbi.nlm.nih.gov/pubmed/25007710",
                "http://www.ncbi.nlm.nih.gov/pubmed/24980542",
                "http://www.ncbi.nlm.nih.gov/pubmed/25636143",
                "http://www.ncbi.nlm.nih.gov/pubmed/25404658",
                "http://www.ncbi.nlm.nih.gov/pubmed/26131357"
            ],
            "ideal_answer": [
                "Yes, fbroblast growth factor 23 (FGF23) is a phosphaturic hormone."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "570a5c27cf1c325851000023",
            "snippets": [
                {
                    "offsetInBeginSection": 498,
                    "offsetInEndSection": 609,
                    "text": "PTH can induce skeletal synthesis of another potent phosphaturic hormone, fibroblast growth factor 23 (FGF23), ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26131357",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 978,
                    "offsetInEndSection": 1114,
                    "text": " Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone that has recently been identified as a CKD-related factor affecting CRS. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25636143",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1080,
                    "offsetInEndSection": 1148,
                    "text": " circulating phosphaturic hormone fibroblast growth factor-23 levels",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25404658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 199,
                    "text": " Fibroblast growth factor (FGF) 23 is one of the most recently discovered FGFs. This phosphaturic hormone produced in bones is a risk factor for cardiovascular diseases and thus mortality.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25380933",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 68,
                    "offsetInEndSection": 179,
                    "text": "fibroblast growth factor 23 (FGF23), a phosphaturic hormone and regulator of 1,25(OH)2 vitamin D3 (1,25VitD3). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24466013",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 295,
                    "offsetInEndSection": 368,
                    "text": "fibroblast growth factor-23 (FGF23), a bone-derived phosphaturic hormone.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24434184",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 158,
                    "offsetInEndSection": 264,
                    "text": " the phosphaturic hormone fibroblast growth factor 23 (FGF23) and soluble Klotho with all-cause mortality.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24991914",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 713,
                    "text": "In particular, diseases caused by changes in the expression and proteolytic control of the phosphaturic hormone fibroblast growth factor-23 (FGF23) have come to the forefront in terms of directing new models explaining mineral metabolism",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24980542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 787,
                    "offsetInEndSection": 864,
                    "text": "serum levels of a phosphaturic hormone, fibroblast growth factor 23 (Fgf23), ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25007710",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is lumican a secreted protein?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17050378",
                "http://www.ncbi.nlm.nih.gov/pubmed/22814255",
                "http://www.ncbi.nlm.nih.gov/pubmed/27126993",
                "http://www.ncbi.nlm.nih.gov/pubmed/22266188",
                "http://www.ncbi.nlm.nih.gov/pubmed/26351669"
            ],
            "ideal_answer": [
                "Yes, Lumican is a secreted proteoglycan that regulates collagen fibril assembly."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5ad255210340b9f058000018",
            "snippets": [
                {
                    "offsetInBeginSection": 296,
                    "offsetInEndSection": 442,
                    "text": "fibroblasts stimulated with the fibrocyte-secreted inflammatory signal tumor necrosis factor-\u03b1 secrete the small leucine-rich proteoglycan lumican",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26351669",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "text": "TNF-\u03b1-stimulated fibroblasts secrete lumican to promote fibrocyte differentiation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26351669",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Secreted 70kDa lumican stimulates growth and inhibits invasion of human pancreatic cancer.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22266188",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1185,
                    "offsetInEndSection": 1359,
                    "text": "the elevated level of lumican secretion to extracellular space leads to actin cytoskeletal remodeling followed by an increase in migration capacity of human colon LS180 cells",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22814255",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 375,
                    "offsetInEndSection": 450,
                    "text": "Lumican is a secreted proteoglycan that regulates collagen fibril assembly.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27126993",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1071,
                    "offsetInEndSection": 1180,
                    "text": "This is the first time that the synthesis and secretion of lumican in human melanoma cell lines is reported. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17050378",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does inactivation of CYLD help in colorectal cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27042826"
            ],
            "ideal_answer": [
                "\u039d\u03bf. Inactivation of CYLD in intestinal epithelial cells exacerbates colitis-associated colorectal carcinogenesis."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "6027dc011cb411341a0000eb",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Inactivation of CYLD in intestinal epithelial cells exacerbates colitis-associated colorectal carcinogenesis - a short report.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27042826",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 1773,
                    "text": "CYLD is a tumor suppressor that has been linked to the development of various human malignancies, including colon cancer. The tumor-suppressing function of CYLD is associated with its deubiquitinating activity, which maps to the carboxyl-terminal region of the protein. In the present study we evaluated the role of intestinal epithelial CYLD in colitis-associated cancer using a conditional mouse CYLD inactivation model.METHODS: In order to evaluate the role of CYLD in intestinal epithelial carcinogenesis, mice (IEC-Cyld (\u03949) mice) that carry a mutation that eliminates the deubiquitinating domain of CYLD in intestinal epithelial cells (IEC) were generated by crossing Villin-Cre transgenic mice to previously generated mice carrying a loxP-flanked Cyld exon 9 (Cyld (flx9) mice).RESULTS: We found that IEC-Cyld (\u03949) mice did not present spontaneous intestinal abnormalities up to one year of age. However, upon challenge with a combination of genotoxic (AOM) and pro-inflammatory (DSS) agents we found that the number of adenomas in the IEC-Cyld (\u03949) mice was dramatically increased compared to the control mice. Inactivation of CYLD in intestinal epithelial cells did not affect the classical nuclear factor-kappaB (NF-\u03baB) and c-Jun kinase (JNK) activation pathways under physiological conditions, suggesting that these pathways do not predispose CYLD-deficient intestinal epithelia to colorectal cancer development before the onset of genotoxic and/or pro-inflammatory stress.CONCLUSIONS: Our findings underscore a critical tumor-suppressing role for functional intestinal epithelial CYLD in colitis-associated carcinogenesis. CYLD expression and its associated pathways in intestinal tumors may be exploited for future prognostic and therapeutic purposes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27042826",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Inactivation of CYLD in intestinal epithelial cells exacerbates colitis-associated colorectal carcinogenesis - a short report",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27042826",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Do carmustine wafers improve survival of glioblastoma patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/18366283",
                "http://www.ncbi.nlm.nih.gov/pubmed/23118709",
                "http://www.ncbi.nlm.nih.gov/pubmed/18240917",
                "http://www.ncbi.nlm.nih.gov/pubmed/15937647",
                "http://www.ncbi.nlm.nih.gov/pubmed/21983866",
                "http://www.ncbi.nlm.nih.gov/pubmed/16482400",
                "http://www.ncbi.nlm.nih.gov/pubmed/25054300",
                "http://www.ncbi.nlm.nih.gov/pubmed/17938702",
                "http://www.ncbi.nlm.nih.gov/pubmed/21390826",
                "http://www.ncbi.nlm.nih.gov/pubmed/21344976",
                "http://www.ncbi.nlm.nih.gov/pubmed/23662801",
                "http://www.ncbi.nlm.nih.gov/pubmed/18035958",
                "http://www.ncbi.nlm.nih.gov/pubmed/12074689",
                "http://www.ncbi.nlm.nih.gov/pubmed/22715955",
                "http://www.ncbi.nlm.nih.gov/pubmed/25085219",
                "http://www.ncbi.nlm.nih.gov/pubmed/22718138",
                "http://www.ncbi.nlm.nih.gov/pubmed/21479583",
                "http://www.ncbi.nlm.nih.gov/pubmed/10414561",
                "http://www.ncbi.nlm.nih.gov/pubmed/17350791",
                "http://www.ncbi.nlm.nih.gov/pubmed/18636295",
                "http://www.ncbi.nlm.nih.gov/pubmed/21300471",
                "http://www.ncbi.nlm.nih.gov/pubmed/19123896",
                "http://www.ncbi.nlm.nih.gov/pubmed/15069758",
                "http://www.ncbi.nlm.nih.gov/pubmed/20155992",
                "http://www.ncbi.nlm.nih.gov/pubmed/23535992",
                "http://www.ncbi.nlm.nih.gov/pubmed/17334672",
                "http://www.ncbi.nlm.nih.gov/pubmed/19046047",
                "http://www.ncbi.nlm.nih.gov/pubmed/23350777",
                "http://www.ncbi.nlm.nih.gov/pubmed/21330749",
                "http://www.ncbi.nlm.nih.gov/pubmed/12672279",
                "http://www.ncbi.nlm.nih.gov/pubmed/25269031",
                "http://www.ncbi.nlm.nih.gov/pubmed/21756557",
                "http://www.ncbi.nlm.nih.gov/pubmed/20706757",
                "http://www.ncbi.nlm.nih.gov/pubmed/20511192",
                "http://www.ncbi.nlm.nih.gov/pubmed/24246204",
                "http://www.ncbi.nlm.nih.gov/pubmed/19514083",
                "http://www.ncbi.nlm.nih.gov/pubmed/15015668"
            ],
            "ideal_answer": [
                "Yes, it has been documented that implantation of carmustine wafers improves survival of newly diagnosed and recurrent glioblastoma patients."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4275776"
            ],
            "type": "yesno",
            "id": "54d630283706e89528000004",
            "snippets": [
                {
                    "offsetInBeginSection": 338,
                    "offsetInEndSection": 472,
                    "text": "At recurrence, treatment options include repeat surgery (with or without Gliadel wafer placement), reirradiation or systemic therapy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25054300",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1563,
                    "offsetInEndSection": 1909,
                    "text": "DISCUSSION: Carmustine wafers for primary HGG surgery in accordance with the NICE TA121 were associated with a median survival of 15.3 months; this is improved compared with previously reported randomised trials. Multimodal treatment with carmustine wafers, radical radiotherapy and concomitant temozolomide was associated with improved survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22715955",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 642,
                    "offsetInEndSection": 886,
                    "text": "Gliadel wafer is a new approach to the treatment of glioblastoma, which involves controlled release delivery of carmustine from biodegradable polymer wafers. It has shown promising results and provides a silver lining for glioblastoma patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21330749",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 613,
                    "offsetInEndSection": 745,
                    "text": "For patient with and without Gliadel, median and 1-year RFS were 12.9 months and 52% vs. 14 months and 42%, respectively (p = 0.89).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1276,
                    "offsetInEndSection": 1371,
                    "text": "According to pathology, Gliadel did not influence OS of patients with Grade III or glioblastoma",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1821,
                    "offsetInEndSection": 1945,
                    "text": "CONCLUSION: In patients with high-grade gliomas, adding Gliadel before performing a Stupp protocol did not improve survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21300471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 219,
                    "text": "Randomized phase III trials have shown significant improvement of survival 1, 2, and 3 years after implantation of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers for patients with newly diagnosed malignant glioma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20706757",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2138,
                    "offsetInEndSection": 2438,
                    "text": "CONCLUSIONS: The combination of aggressive resection, Gliadel wafer implantation, and GKS in addition to standard fractionated RT in selected patients resulted in increased local control and increased survival compared with a historical control group treated with surgery and involved-field RT alone.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19123896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 230,
                    "text": "OBJECT: Gliadel (BCNU) wafer and concomitant temozolomide (TMZ) therapy, when used individually as adjuvant therapies, extend survival from that achieved by resection and radiation therapy (XRT) for glioblastoma multiforme (GBM). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19046047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "text": "BACKGROUND: Gliadel (polifeprosan 20 with carmustine [BCNU] implant) is commonly used for local delivery of BCNU to high-grade gliomas after resection and is associated with increased survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18636295",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 546,
                    "offsetInEndSection": 719,
                    "text": "Temozolomide administered according to this protocol produced a median survival benefit of 2 months in glioblastomas, and carmustine a similar benefit in high-grade gliomas.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17350791",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 283,
                    "offsetInEndSection": 455,
                    "text": "Analysis of a large trial by Westphal and colleagues (n = 240) showed a 29% risk reduction (P = 0.03) in the BCNU wafer-treated group over the course of the 30-month trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16482400",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1032,
                    "offsetInEndSection": 1360,
                    "text": "Median survival of patients treated with BCNU wafers was 13.8 months vs 11.6 months in placebo-treated patients (P = 0.017) with a hazard ratio of 0.73 (P = 0.018), representing a 27% significant risk reduction. This survival advantage was maintained at 1, 2, and 3 years and was statistically significant (P = 0.01) at 3 years.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16482400",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1474,
                    "offsetInEndSection": 1689,
                    "text": "CONCLUSION: Malignant glioma patients treated with BCNU wafers at the time of initial surgery in combination with radiation therapy demonstrated a survival advantage at 2 and 3 years follow-up compared with placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16482400",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 210,
                    "text": "OBJECTIVE: Recently a randomized placebo-controlled phase III trial of biodegradable polymers containing carmustine has demonstrated a significant survival benefit for patients treated with local chemotherapy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15015668",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1810,
                    "offsetInEndSection": 2051,
                    "text": "CONCLUSION: In this subgroup analysis of a phase III trial population both the clinical progression and radiological progression were significantly delayed in patients treated with local chemotherapy, resulting in an increased survival time.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15015668",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 399,
                    "text": "A previous placebo-controlled trial has shown that biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers (Gliadel wafers) prolong survival in patients with recurrent glioblastoma multiforme. A previously completed phase 3 trial, also placebo controlled, in 32 patients with newly diagnosed malignant glioma also demonstrated a survival benefit in those patients treated with BCNU wafers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672279",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 815,
                    "offsetInEndSection": 1198,
                    "text": "Median survival in the intent-to-treat group was 13.9 months for the BCNU wafer-treated group and 11.6 months for the placebo-treated group (log-rank P -value stratified by country = 0.03), with a 29% reduction in the risk of death in the treatment group. When adjusted for factors affecting survival, the treatment effect remained positive with a risk reduction of 28% ( P = 0.03). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672279",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 253,
                    "text": "Controlled release delivery of carmustine from biodegradable polymer wafers was approved as an adjunct to surgical resection in the treatment of recurrent glioblastoma multiforme after it was shown in clinical trials to be well tolerated and effective. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12074689",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 349,
                    "offsetInEndSection": 513,
                    "text": "Clinical trials have demonstrated significant improvements in survival and quality of life for patients after complete tumour resection and BCNU wafer implantation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20155992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1553,
                    "offsetInEndSection": 1767,
                    "text": "BCNU wafers are an effective means of increasing survival and quality of life in patients diagnosed with malignant glioma, and are a valuable addition to the overall multimodal treatment strategy for these tumours.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20155992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1520,
                    "offsetInEndSection": 1717,
                    "text": "CONCLUSIONS: Carmustine wafer with concurrent TMZ and radiation followed by rotational chemotherapy is a well tolerated, effective therapy, and has a survival benefit compared with radiation alone.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19514083",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1297,
                    "offsetInEndSection": 1518,
                    "text": "Median overall survival in 14 studies of newly-diagnosed patients suggested a modest improvement versus resection followed by Stupp protocol or resection with BCNU wafers, with an acceptable and manageable safety profile.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23535992",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 103,
                    "text": "The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756557",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1607,
                    "offsetInEndSection": 1826,
                    "text": "DISCUSSION: Older patients with GBM may benefit from carmustine wafers. The survival for older patients who received carmustine wafers is significantly longer than matched patients who did not receive carmustine wafers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756557",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 668,
                    "offsetInEndSection": 958,
                    "text": "For glioblastoma patients who received \u226590% resection in the BCNU wafer study, median survival increased for BCNU wafer versus placebo (14.5 versus 12.4\u00a0months, respectively; P\u2009=\u20090.02), but no survival increase was found for <90% resection (11.7 versus 10.6\u00a0months, respectively; P\u2009=\u20090.98).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21479583",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1923,
                    "offsetInEndSection": 2144,
                    "text": "A wafer impregnated with carmustine, for use as an implant after surgical removal of recurrent GBM showed a prolongation in the median survival time of only 2 mo, from 20 to 28 wk in a study with a total of 222 patients. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390826",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1620,
                    "offsetInEndSection": 1696,
                    "text": "No clear survival benefit associated with wafer implantation was identified.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10414561",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 710,
                    "offsetInEndSection": 866,
                    "text": "In three of the trials, patients with GBM who received carmustine wafers had significantly longer median survival than patients who did not receive wafers. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25269031",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1142,
                    "offsetInEndSection": 1298,
                    "text": "TMZ and carmustine (BCNU) biodegradable wafer (Gliadel) are the only adjuvant chemotherapies that have improved survival in randomised GB clinical trials . ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246204",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 519,
                    "text": "The carmustine implant wafer was demonstrated to improve survival in blinded placebo-controlled trials in selected patients with newly diagnosed or recurrent malignant glioma, with little increased risk of adverse events. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1365,
                    "offsetInEndSection": 1644,
                    "text": "For patients undergoing repeat resection for malignant glioma, a randomized, blinded, placebo-controlled trial demonstrated a median survival for 110 patients who received carmustine polymers of 31 weeks compared with 23 weeks for 122 patients who only received placebo polymers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1977,
                    "offsetInEndSection": 2261,
                    "text": "Median survival was improved from 11.6 to 13.9 months (P = 0.03), with a 29% reduction in the risk of death. When patients with glioblastoma multiforme alone were analyzed, the median survival improved from 11.4 to 13.5 months, but this improvement was not statistically significant. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 252,
                    "text": "OBJECT: Locoregional chemotherapy with carmustine wafers, positioned at surgery and followed by radiation therapy, has been shown to prolong survival in patients with newly diagnosed glioblastoma, as has concomitant radiochemotherapy with temozolomide.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23350777",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 250,
                    "text": "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17334672",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 518,
                    "text": "The carmustine implant wafer was demonstrated to improve survival in blinded placebo-controlled trials in selected patients with newly diagnosed or recurrent malignant glioma, with little increased risk of adverse events.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1154,
                    "offsetInEndSection": 1266,
                    "text": "However, patients with carmustine wafers demonstrated prolonged survival as compared to patients without wafers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756557",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1267,
                    "offsetInEndSection": 1414,
                    "text": "The median survival for patients with carmustine wafers was 8.7 months, while median survival for patients without wafers was 5.5 months (P=0.007).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756557",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1415,
                    "offsetInEndSection": 1606,
                    "text": "Likewise, in subgroup analysis, patients older than 70 years (P=0.0003) and 75 years (P=0.04) who had carmustine wafers had significantly longer survival than matched patients without wafers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21756557",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 865,
                    "offsetInEndSection": 954,
                    "text": "Implantation of carmustine wafers did not significantly improve progression-free survival",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25269031",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 709,
                    "offsetInEndSection": 863,
                    "text": "In three of the trials, patients with GBM who received carmustine wafers had significantly longer median survival than patients who did not receive wafers",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25269031",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "text": "A previous placebo-controlled trial has shown that biodegradable 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) wafers (Gliadel wafers) prolong survival in patients with recurrent glioblastoma multiforme",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672279",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 397,
                    "text": "A previously completed phase 3 trial, also placebo controlled, in 32 patients with newly diagnosed malignant glioma also demonstrated a survival benefit in those patients treated with BCNU wafers",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12672279",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 249,
                    "text": "Following the resection of newly diagnosed or recurrent glioblastomas, local implantation of carmustine-impregnated biodegradable wafers (Gliadel) in the resection cavity constitutes an adjuvant therapy that can improve the possibilities of survival",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17334672",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1722,
                    "offsetInEndSection": 1854,
                    "text": "Multimodal treatment with carmustine wafers, radical radiotherapy and concomitant temozolomide was associated with improved survival",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22715955",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 297,
                    "offsetInEndSection": 517,
                    "text": "The carmustine implant wafer was demonstrated to improve survival in blinded placebo-controlled trials in selected patients with newly diagnosed or recurrent malignant glioma, with little increased risk of adverse events",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23118709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1142,
                    "offsetInEndSection": 1296,
                    "text": "TMZ and carmustine (BCNU) biodegradable wafer (Gliadel) are the only adjuvant chemotherapies that have improved survival in randomised GB clinical trials ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24246204",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does Serca2a bind PLN in the heart?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20484118",
                "http://www.ncbi.nlm.nih.gov/pubmed/12763867",
                "http://www.ncbi.nlm.nih.gov/pubmed/9182523",
                "http://www.ncbi.nlm.nih.gov/pubmed/17515962",
                "http://www.ncbi.nlm.nih.gov/pubmed/11854448",
                "http://www.ncbi.nlm.nih.gov/pubmed/12424227",
                "http://www.ncbi.nlm.nih.gov/pubmed/12610310",
                "http://www.ncbi.nlm.nih.gov/pubmed/22693651",
                "http://www.ncbi.nlm.nih.gov/pubmed/12589804",
                "http://www.ncbi.nlm.nih.gov/pubmed/8702967",
                "http://www.ncbi.nlm.nih.gov/pubmed/9603928",
                "http://www.ncbi.nlm.nih.gov/pubmed/17241641",
                "http://www.ncbi.nlm.nih.gov/pubmed/22155237",
                "http://www.ncbi.nlm.nih.gov/pubmed/22129433",
                "http://www.ncbi.nlm.nih.gov/pubmed/22659291"
            ],
            "ideal_answer": [
                "Yes, Serca2a bind PLN in the heart."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D053498",
                "http://www.uniprot.org/uniprot/PPLA_HUMAN"
            ],
            "type": "yesno",
            "id": "51680b05298dcd4e51000064",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155237",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1259,
                    "offsetInEndSection": 1338,
                    "text": "Moreover, PLN-R14Del did not co-immunoprecipitate with SERCA2a (as did WT-PLN),",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22155237",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 441,
                    "offsetInEndSection": 695,
                    "text": "n this review, we attempted to highlight the functional significance of PLN in vertebrate cardiac physiology. We will refer to the huge literature on mammals in order to describe the molecular characteristics of this protein, its interaction with SERCA2a",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22129433",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "There is clear evidence for direct regulatory protein-protein interactions between phospholamban (PLN) and the Ca2+-ATPase of cardiac sarcoplasmic reticulum (SERCA2a) in cytoplasmic domains",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8702967",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1216,
                    "offsetInEndSection": 1447,
                    "text": "These results suggest that PLN modulates the apparent Ca2+ affinity of SERCA2a through intramembrane interactions, which are disrupted at long range and in concert with disruption of the well characterized cytoplasmic interactions.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8702967",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Phospholamban (PLN), a homopentameric, integral membrane protein, reversibly inhibits cardiac sarcoplasmic reticulum Ca2+-ATPase (SERCA2a) activity through intramembrane interactions.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9182523",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1247,
                    "offsetInEndSection": 1493,
                    "text": "The concentration of this inhibited complex is determined by the dissociation constant for the PLN pentamer (which is mutation-sensitive) and by the dissociation constant for the PLN/SERCA2a heterodimer (which is likely to be mutation-sensitive).",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9182523",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1439,
                    "offsetInEndSection": 1634,
                    "text": "These results support the proposal that PLN inhibition of SERCA2a involves, first, depolymerization of PLN and, second, the formation of inhibitory interactions between monomeric PLN and SERCA2a.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9603928",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 979,
                    "offsetInEndSection": 1162,
                    "text": "SLN and PLN appear to bind to the same regulatory site in SERCA. However, in a ternary complex, PLN occupies the regulatory site and SLN binds to the exposed side of PLN and to SERCA.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12763867",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 595,
                    "offsetInEndSection": 707,
                    "text": "Cellular and biochemical studies revealed that, unlike wild-type PLN, PLN(R9C) did not directly inhibit SERCA2a.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12610310",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 789,
                    "offsetInEndSection": 997,
                    "text": ". Conversely, using anti-SERCA2a antibody, both PLN and acylphosphatase were co-immunoprecipitated with SERCA2a, and the PLN amount in the precipitate decreased with increasing acylphosphatase concentrations.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12589804",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Reconstitution of the cytoplasmic interaction between phospholamban and Ca(2+)-ATPase of cardiac sarcoplasmic reticulum.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11854448",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 235,
                    "text": "Phospholamban (PLN) reversibly inhibits the Ca(2+)-ATPase of cardiac sarcoplasmic reticulum (SERCA2a) through a direct protein-protein interaction, playing a pivotal role in the regulation of intracellular Ca(2+) in heart muscle cells.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11854448",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 258,
                    "text": "Phospholamban (PLN) is a key regulator of Ca(2+) homeostasis and contractility in the heart. Its regulatory effects are mediated through its interaction with the sarcoplasmic reticulum Ca(2+)-ATPase, (SERCA2a), resulting in alterations of its Ca(2+)-affinity",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17241641",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1138,
                    "offsetInEndSection": 1284,
                    "text": "In a co-immunoprecipitation of PLN with SERCA2a, the physical interaction between the two proteins was increased in PUGNAc-treated cardiomyocytes.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20484118",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is Loss of function one of the cardinal signs of inflammation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12776909",
                "http://www.ncbi.nlm.nih.gov/pubmed/28282278",
                "http://www.ncbi.nlm.nih.gov/pubmed/29135930",
                "http://www.ncbi.nlm.nih.gov/pubmed/12799851"
            ],
            "ideal_answer": [
                "Functio Laesa also known as loss of function is considered to be the 5th cardinal sign of inflammation."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a7a44b4faa1ab7d2e000010",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "text": "The concept of the four cardinal signs of acute inflammation comes from antiquity as rubor et tumor cum calore et dolore, (redness and swelling with heat and pain) extended later by functio laesa (loss of function).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12776909",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 60,
                    "offsetInEndSection": 255,
                    "text": "As early as 2000 years ago, the Roman encyclopaedist Aulus Cornelius Celsus recognised four cardinal signs of this response-redness, heat, swelling and pain; a fifth sign is loss of function.[...",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1008,
                    "offsetInEndSection": 1195,
                    "text": "It was Galen who added the disturbance of function (functio laesa) as the fifth cardinal sign of inflammation to the four well-known cardinal signs of Celsus (rubor, calor, tumor, dolor).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12799851",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 245,
                    "text": "Tumor, calor, rubor, and dolor describe four cardinal signs of inflammation. The fifth-functio laesa, or loss of function-was promulgated by Rudolf Virchow, who, in the 19th century, also noted an intricate link between inflammation and cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is G3BP1 found in stress granules?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31956030",
                "http://www.ncbi.nlm.nih.gov/pubmed/31704836",
                "http://www.ncbi.nlm.nih.gov/pubmed/29463567"
            ],
            "ideal_answer": [
                "Yes,\nRAS GTPase-activating protein-binding protein (G3BP1) is an RNA-binding protein that is essential for assembling stress granules."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "604fc22894d57fd879000008",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 142,
                    "text": "RAS GTPase-activating protein-binding protein (G3BP1) is an RNA-binding protein that is essential for assembling stress granules. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31704836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 562,
                    "offsetInEndSection": 749,
                    "text": "Within SGs, single-molecule localization microscopy revealed distributed hotspots of immobilized G3BP1 and IMP1 that reflect the presence of relatively immobile nanometer-sized nanocores.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29463567",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 528,
                    "offsetInEndSection": 698,
                    "text": "Using super-resolution and expansion microscopy, we find that the SG component UBAP2L [11, 12] and the core protein G3BP1 [5, 11-13] occupy different domains inside SGs. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31956030",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Solanezumab effective for Alzheimer's Disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29067346",
                "http://www.ncbi.nlm.nih.gov/pubmed/26238576",
                "http://www.ncbi.nlm.nih.gov/pubmed/28593105",
                "http://www.ncbi.nlm.nih.gov/pubmed/28649604",
                "http://www.ncbi.nlm.nih.gov/pubmed/24450890",
                "http://www.ncbi.nlm.nih.gov/pubmed/26990863",
                "http://www.ncbi.nlm.nih.gov/pubmed/26815584",
                "http://www.ncbi.nlm.nih.gov/pubmed/27223100",
                "http://www.ncbi.nlm.nih.gov/pubmed/27239541"
            ],
            "ideal_answer": [
                "No. Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in patients with Alzheimer's Disease."
            ],
            "exact_answer": "no",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D000544",
                "http://www.disease-ontology.org/api/metadata/DOID:10652"
            ],
            "type": "yesno",
            "id": "5a70e1d999e2c3af26000007",
            "snippets": [
                {
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 704,
                    "text": "An analysis of publicly available data from the Phase II studies for bapineuzumab and solanezumab indicates that neither compound produced compelling evidence of drug-like behavior that would justify their progression into pivotal trials. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29067346",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 783,
                    "text": "Notably, a recent study of solanezumab, an amyloid \u03b2 monoclonal antibody, raises hope for the further therapeutic potential of immunotherapy, not only in Alzheimer's disease, but also for other neurodegenerative disorders, including Parkinson's disease. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28649604",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 563,
                    "offsetInEndSection": 734,
                    "text": "For example, Eli Lilly announced a major change to its closely watched clinical trial for the Alzheimer's drug solanezumab which failed to reach statistical significance. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28593105",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 738,
                    "text": "Areas covered: This contradiction prompted us to review all study phases of Intravenous Immunoglobulin (IVIG), Bapineuzumab, Solanezumab, Avagacestat and Dimebolin to shed more light on these recent failures. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27223100",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 87,
                    "offsetInEndSection": 441,
                    "text": " Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing. Subsequent analysis of pooled data from both phase III trials with solanezumab showed a reduction in cognitive decline in patients with mild AD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26815584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 664,
                    "offsetInEndSection": 869,
                    "text": "Secondary analyses of EXPEDITION studies suggested a smaller functional effect of solanezumab relative to cognition. An increasing effect of solanezumab over 18\u00a0months was shown for cognition and function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27239541",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 517,
                    "offsetInEndSection": 862,
                    "text": "RESULTS: In the mild AD population, less cognitive and functional decline was observed with solanezumab (n\u00a0=\u00a0659) versus placebo (n\u00a0=\u00a0663), measured by Alzheimer's Disease Assessment Scale Cognitive subscale, Mini-Mental State Examination, and Alzheimer's Disease Cooperative Study-Activities of Daily Living functional scale Instrumental ADLs. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26238576",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "text": "The promising results obtained with aducanumab and solanezumab against Alzheimer's disease (AD) strengthen the vaccine approach to prevent AD, despite of the many clinical setbacks. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26990863",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2247,
                    "offsetInEndSection": 2376,
                    "text": "CONCLUSIONS: Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24450890",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 298,
                    "text": "Results from phase III clinical trials in mild-to-moderate Alzheimer's disease (AD) patients with two monoclonal antibodies bapineuzumab and solanezumab and intravenous immunoglobulin have been disappointing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26815584",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does TUC.338 inhibit colorectal cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27914101"
            ],
            "ideal_answer": [
                "No. TUC.338 is significantly up-regulated in colorectal cancers (CRC) tissue and CRC cell lines, and the up-regulated TUC.338 is associated with lymph node metastasis. TUC.338 acts as a novel oncogene by targeting the TIMP-1 gene thus promoting colorectal cancer cell migration and invasion."
            ],
            "exact_answer": "no",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D015179",
                "http://www.disease-ontology.org/api/metadata/DOID:6981",
                "http://www.disease-ontology.org/api/metadata/DOID:9256",
                "https://meshb.nlm.nih.gov/record/ui?ui=D003123",
                "http://www.disease-ontology.org/api/metadata/DOID:0080199"
            ],
            "type": "yesno",
            "id": "5a6d23ccb750ff4455000035",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 62,
                    "text": "TUC.338 promotes invasion and metastasis in colorectal cancer.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 441,
                    "offsetInEndSection": 701,
                    "text": "Until now, the role of TUC.338 in colorectal cancers remains undefined. This study revealed that TUC.338 is significantly up-regulated in colorectal cancers (CRC) tissue and CRC cell lines, and the up-regulated TUC.338 is associated with lymph node metastasis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1293,
                    "offsetInEndSection": 1453,
                    "text": " Thus, these findings suggested that TUC.338 acts as a novel oncogene by targeting the TIMP-1 gene thus promoting colorectal cancer cell migration and invasion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1294,
                    "offsetInEndSection": 1453,
                    "text": "Thus, these findings suggested that TUC.338 acts as a novel oncogene by targeting the TIMP-1 gene thus promoting colorectal cancer cell migration and invasion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 513,
                    "offsetInEndSection": 701,
                    "text": "This study revealed that TUC.338 is significantly up-regulated in colorectal cancers (CRC) tissue and CRC cell lines, and the up-regulated TUC.338 is associated with lymph node metastasis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 63,
                    "text": "TUC.338 promotes invasion and metastasis in colorectal cancer.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27914101",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is Alpers disease inherited in an autosomal recessive mode?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22000311",
                "http://www.ncbi.nlm.nih.gov/pubmed/15122711",
                "http://www.ncbi.nlm.nih.gov/pubmed/22006280",
                "http://www.ncbi.nlm.nih.gov/pubmed/1861211",
                "http://www.ncbi.nlm.nih.gov/pubmed/21451360",
                "http://www.ncbi.nlm.nih.gov/pubmed/16181814",
                "http://www.ncbi.nlm.nih.gov/pubmed/7897414"
            ],
            "ideal_answer": [
                "Alpers disease is a fatal neurogenetic disorder first described more than 70 years ago. It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial DNA polymerase gamma (POLG) catalytic activity, refractory seizures, neurodegeneration, and liver disease.",
                "Alpers-Huttenlocher syndrome (AHS) is a very rare autosomal recessive disorder"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5718a69e7de986d80d00000a",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "text": "Alpers-Huttenlocher syndrome (AHS) is a very rare autosomal recessive disorder",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22006280",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "Alpers syndrome is an autosomal recessive mitochondrial DNA depletion disorder that affects children and young adults",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16181814",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 321,
                    "text": "Alpers' syndrome is a fatal neurogenetic disorder first described more than 70 years ago. It is an autosomal recessive, developmental mitochondrial DNA depletion disorder characterized by deficiency in mitochondrial DNA polymerase gamma (POLG) catalytic activity, refractory seizures, neurodegeneration, and liver disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15122711",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 448,
                    "offsetInEndSection": 883,
                    "text": "Histopathological findings in both patients ((a) chronic hepatitis with prominent bile duct proliferation, fatty change, and fibrosis; (b) in the brain a patchy destruction of the cerebral cortex, predominantly involving striate cortex) were characteristic of progressive neuronal degeneration of childhood with liver disease--Alpers-Huttenlocher syndrome--a rare autosomal recessive disorder usually seen in infants and young children",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7897414",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 881,
                    "offsetInEndSection": 1317,
                    "text": "Histopathological findings in both patients ((a) chronic hepatitis with prominent bile duct proliferation, fatty change, and fibrosis; (b) in the brain a patchy destruction of the cerebral cortex, predominantly involving striate cortex) were characteristic of progressive neuronal degeneration of childhood with liver disease--Alpers-Huttenlocher syndrome--a rare autosomal recessive disorder usually seen in infants and young children.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7897414",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "Alpers syndrome is a rare autosomal recessive hepatocerebral degenerative disorder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22000311",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "Alpers disease is a recessive mitochondrial disorder caused by mutations in POLG1 and characterized primarily by progressive neurological and hepatic degeneration.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21451360",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Alpers syndrome is an autosomal recessive mitochondrial DNA depletion disorder that affects children and young adults.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16181814",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1596,
                    "offsetInEndSection": 1829,
                    "text": "We conclude that Alpers disease can be a cause of rapidly progressive liver failure in early childhood. Although the cause of this autosomal recessive disease is not known, it does not appear to be related to peroxisomal dysfunction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1861211",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Have thyronamines  effects on fat tissue?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17912534",
                "http://www.ncbi.nlm.nih.gov/pubmed/17204552",
                "http://www.ncbi.nlm.nih.gov/pubmed/6094171",
                "http://www.ncbi.nlm.nih.gov/pubmed/20880963",
                "http://www.ncbi.nlm.nih.gov/pubmed/20005733",
                "http://www.ncbi.nlm.nih.gov/pubmed/18486124",
                "http://www.ncbi.nlm.nih.gov/pubmed/19273499",
                "http://www.ncbi.nlm.nih.gov/pubmed/22016721",
                "http://www.ncbi.nlm.nih.gov/pubmed/21664427",
                "http://www.ncbi.nlm.nih.gov/pubmed/19116337",
                "http://www.ncbi.nlm.nih.gov/pubmed/21490071",
                "http://www.ncbi.nlm.nih.gov/pubmed/17579492"
            ],
            "ideal_answer": [
                "There is not clear evidence that thyronamines have direct effect on adipose tissue"
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000273",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D050153",
                "http://www.biosemantics.org/jochem#4251308",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019358",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014024",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005218",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005223",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017667"
            ],
            "type": "yesno",
            "id": "532c147bd6d3ac6a3400001e",
            "snippets": [
                {
                    "offsetInBeginSection": 1523,
                    "offsetInEndSection": 1598,
                    "text": "In conclusion, trace amines and thyronamines are negative inotropic agents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18486124",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 99,
                    "offsetInEndSection": 229,
                    "text": "Their in vivo administration induces effects opposite to those induced by thyroid hormone, including lowering of body temperature.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21664427",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has strimvelis been approved by the European Medicines Agency?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29625577"
            ],
            "ideal_answer": [
                "Yes, the gene therapy Strimvelis has been approved by the European Medicines Agency."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c8972d4d558e5f232000006",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 342,
                    "text": "Strimvelis (autologous CD34+ cells transduced to express adenosine deaminase [ADA]) is the first ex vivo stem cell gene therapy approved by the European Medicines Agency (EMA), indicated as a single treatment for patients with ADA-severe combined immunodeficiency (ADA-SCID) who lack a suitable matched related bone marrow donor. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29625577",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there a link between rare variants in PPARG and type 1 diabetes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25157153"
            ],
            "ideal_answer": [
                "No. Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes.",
                "No. Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes"
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "602905e81cb411341a000108",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25157153",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 585,
                    "offsetInEndSection": 1521,
                    "text": "By sequencing PPARG in 19,752 T2D cases and controls drawn from multiple studies and ethnic groups, we identified 49 previously unidentified, nonsynonymous PPARG variants (MAF < 0.5%). Considered in aggregate (with or without computational prediction of functional consequence), these rare variants showed no association with T2D (OR = 1.35; P = 0.17). The function of the 49 variants was experimentally tested in a novel high-throughput human adipocyte differentiation assay, and nine were found to have reduced activity in the assay. Carrying any of these nine LOF variants was associated with a substantial increase in risk of T2D (OR = 7.22; P = 0.005). The combination of large-scale DNA sequencing and functional testing in the laboratory reveals that approximately 1 in 1,000 individuals carries a variant in PPARG that reduces function in a human adipocyte differentiation assay and is associated with a substantial risk of T2D.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25157153",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does the chromatin remodeling complex, RSC target H2A.Z nucleosomes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21266479",
                "http://www.ncbi.nlm.nih.gov/pubmed/19410542",
                "http://www.ncbi.nlm.nih.gov/pubmed/25813039",
                "http://www.ncbi.nlm.nih.gov/pubmed/22122340",
                "http://www.ncbi.nlm.nih.gov/pubmed/18268003"
            ],
            "ideal_answer": [
                "H2A.Z probably helps RSC in keeping the gene nucleosome-free.",
                "H2A.Z probably helps RSC in keeping the gene nucleosome-fre",
                "Yes, the chromatin remodeling complex, RSC, uses H2A. Z nucleosomes to remodel chromatin.",
                "yes, Accordingly, the absence of SWR-C or histone H2A.Z results in compromised chromatin remodeling and impaired gene expression in the absence of RSC and H3K4 methylation.",
                "H2A.Z probably helps RSC in keeping the gene nucleosome-fre Accordingly, the absence of SWR-C or histone H2A.Z results in compromised chromatin remodeling and impaired gene expression in the absence of RSC and H3K4 methylation."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5d385f717bc3fee31f00001a",
            "snippets": [
                {
                    "offsetInBeginSection": 646,
                    "offsetInEndSection": 927,
                    "text": "In contrast, the upstream nucleosome which covers the TATA box under repressed conditions is shifted approximately 50 bp further upstream by the ATP-dependent chromatin remodeler RSC upon activation. It is marked with the histone variant H2A.Z and H4K16 acetylation in active state",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18268003",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 576,
                    "text": "In RSC-depleted cells, NFRs shrink such that the average positions of flanking nucleosomes move toward predicted sites.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19410542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 746,
                    "offsetInEndSection": 819,
                    "text": "In contrast, H2A.Z deposition is dispensable for nucleosome positioning. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19410542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 384,
                    "offsetInEndSection": 723,
                    "text": "Emerging lines of evidence indicate that histone variants (H2AX and H2A.Z), histone post-translational modifications (acetylation, phosphorylation, methylation and ubiquitination) and chromatin-remodeling complexes (INO80, SWR1, SWI/SNF, RSC and NuRD) are important and direct players in the DNA double-strand break (DSB) response as well.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22122340",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 865,
                    "text": "H2A.Z probably helps RSC in keeping the gene nucleosome-fre",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21266479",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 925,
                    "offsetInEndSection": 1092,
                    "text": "Accordingly, the absence of SWR-C or histone H2A.Z results in compromised chromatin remodeling and impaired gene expression in the absence of RSC and H3K4 methylation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25813039",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do plant genomes contain CpG islands?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15733327",
                "http://www.ncbi.nlm.nih.gov/pubmed/12857799",
                "http://www.ncbi.nlm.nih.gov/pubmed/16283384",
                "http://www.ncbi.nlm.nih.gov/pubmed/12054347",
                "http://www.ncbi.nlm.nih.gov/pubmed/21548945",
                "http://www.ncbi.nlm.nih.gov/pubmed/11489175",
                "http://www.ncbi.nlm.nih.gov/pubmed/16453856"
            ],
            "ideal_answer": [
                "In plant genomes, there exist discrete regions rich in CpG dinucleotides, namely CpG clusters. In rice, most of these CpG clusters are associated with genes. Rice genes are grouped into one of the five classes according to the position of an associated CpG cluster. Among them, class 1 genes, which harbor a CpG cluster at the 5 -terminus, share similarities with human genes having CpG islands  ",
                "Yes. In plant genomes, there exist discrete regions rich in CpG dinucleotides, namely CpG clusters. In rice, most of these CpG clusters are associated with genes. Rice genes are grouped into one of the five classes according to the position of an associated CpG cluster."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018745",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044404",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018899"
            ],
            "type": "yesno",
            "id": "553d0005f321868558000011",
            "snippets": [
                {
                    "offsetInBeginSection": 1711,
                    "offsetInEndSection": 2070,
                    "text": "This study represents the first systematic genome-scale analysis of DNA curvature, CpG islands and tandem repeats at the DNA sequence level in plant genomes, and finds that not all of the chromosomes in plants follow the same rules common to other eukaryote organisms, suggesting that some of these genomic properties might be considered as specific to plants",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548945",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 394,
                    "text": "In plant genomes, there exist discrete regions rich in CpG dinucleotides, namely CpG clusters. In rice, most of these CpG clusters are associated with genes. Rice genes are grouped into one of the five classes according to the position of an associated CpG cluster. Among them, class 1 genes, which harbor a CpG cluster at the 5'-terminus, share similarities with human genes having CpG islands",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16283384",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Segmental distribution of genes harboring a CpG island-like region on rice chromosomes",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16283384",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1986,
                    "offsetInEndSection": 2516,
                    "text": "Highly-expressed Arabidopsis genes had overall a more marked GC-skew in the TSS compared to genes with low expression levels. We therefore propose that the GC-skew around the TSS in some plants and fungi is related to transcription. It might be caused by mutations during transcription initiation or the frequent use of transcription factor-biding sites having a strand preference. In addition, GC-skew is a good candidate index for TSS prediction in plant genomes, where there is a lack of correlation among CpG islands and genes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15733327",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1610,
                    "offsetInEndSection": 2066,
                    "text": "Preliminary analysis shows that promoter location based on the detection of potential CpG/CpNpG islands in the Arabidopsis genome is not straightforward. Nevertheless, because the landscape of CpG/CpNpG islands differs considerably between promoters and introns on the one side and exons (whether coding or not) on the other, more sophisticated approaches can probably be developed for the successful detection of \"putative\" CpG and CpNpG islands in plants",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12857799",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1664,
                    "offsetInEndSection": 2024,
                    "text": "This study represents the first systematic genome-scale analysis of DNA curvature, CpG islands and tandem repeats at the DNA sequence level in plant genomes, and finds that not all of the chromosomes in plants follow the same rules common to other eukaryote organisms, suggesting that some of these genomic properties might be considered as specific to plants.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548945",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 648,
                    "offsetInEndSection": 818,
                    "text": "These plant CpG-rich clusters satisfied the criteria used for identifying human CpG islands, which suggests that these CpG clusters may be regarded as plant CpG islands.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11489175",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1698,
                    "offsetInEndSection": 2071,
                    "text": "CONCLUSIONS: This study represents the first systematic genome-scale analysis of DNA curvature, CpG islands and tandem repeats at the DNA sequence level in plant genomes, and finds that not all of the chromosomes in plants follow the same rules common to other eukaryote organisms, suggesting that some of these genomic properties might be considered as specific to plants.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548945",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "In plant genomes, there exist discrete regions rich in CpG dinucleotides, namely CpG clusters.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16283384",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 657,
                    "offsetInEndSection": 826,
                    "text": "These plant CpG-rich clusters satisfied the criteria used for identifying human CpG islands, which suggests that these CpG clusters may be regarded as plant CpG islands.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11489175",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "text": "Unmethylated CpG islands associated with genes in higher plant DNA.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16453856",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1679,
                    "offsetInEndSection": 2039,
                    "text": "This study represents the first systematic genome-scale analysis of DNA curvature, CpG islands and tandem repeats at the DNA sequence level in plant genomes, and finds that not all of the chromosomes in plants follow the same rules common to other eukaryote organisms, suggesting that some of these genomic properties might be considered as specific to plants.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21548945",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 657,
                    "offsetInEndSection": 825,
                    "text": "These plant CpG-rich clusters satisfied the criteria used for identifying human CpG islands, which suggests that these CpG clusters may be regarded as plant CpG islands",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11489175",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 175,
                    "text": "We screened plant genome sequences, primarily from rice and Arabidopsis thaliana, for CpG islands, and identified DNA segments rich in CpG dinucleotides within these sequences",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11489175",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are de novo mutations in regulatory elements responsible for neurodevelopmental disorders?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29562236"
            ],
            "ideal_answer": [
                "Yes. De novo mutations in highly evolutionarily conserved fetal brain-active elements are significantly and specifically enriched in neurodevelopmental disorders. It is estimated that, genome-wide, 1-3% of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain-active regulatory elements and that only 0.15% of all possible mutations within highly conserved fetal brain-active elements cause neurodevelopmental disorders with a dominant mechanism."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c643485e842deac67000015",
            "snippets": [
                {
                    "offsetInBeginSection": 137,
                    "offsetInEndSection": 1008,
                    "text": "The role of de novo mutations in regulatory elements affecting genes associated with developmental disorders, or other genes, has been essentially unexplored. We identified de novo mutations in three classes of putative regulatory elements in almost 8,000 patients with developmental disorders. Here we show that de novo mutations in highly evolutionarily conserved fetal brain-active elements are significantly and specifically enriched in neurodevelopmental disorders. We identified a significant twofold enrichment of recurrently mutated elements. We estimate that, genome-wide, 1-3% of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain-active regulatory elements and that only 0.15% of all possible mutations within highly conserved fetal brain-active elements cause neurodevelopmental disorders with a dominant mechanism.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29562236",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 688,
                    "offsetInEndSection": 1008,
                    "text": "We estimate that, genome-wide, 1-3% of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain-active regulatory elements and that only 0.15% of all possible mutations within highly conserved fetal brain-active elements cause neurodevelopmental disorders with a dominant mechanism.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29562236",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 432,
                    "offsetInEndSection": 607,
                    "text": "Here we show that de novo mutations in highly evolutionarily conserved fetal brain-active elements are significantly and specifically enriched in neurodevelopmental disorders.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29562236",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 761,
                    "offsetInEndSection": 1081,
                    "text": "We estimate that, genome-wide, 1-3% of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain-active regulatory elements and that only 0.15% of all possible mutations within highly conserved fetal brain-active elements cause neurodevelopmental disorders with a dominant mechanism. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29562236",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 505,
                    "offsetInEndSection": 680,
                    "text": "Here we show that de novo mutations in highly evolutionarily conserved fetal brain-active elements are significantly and specifically enriched in neurodevelopmental disorders. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29562236",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "De novo mutations in regulatory elements in neurodevelopmental disorders.We previously estimated that 42% of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29562236",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Has IVIG been tested in clinical trials for the treatment of Alzheimer's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24760112"
            ],
            "ideal_answer": [
                "Yes, IVIG has been tested in clinical trials for the treatment of Alzheimer's disease."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a7d54adfaa1ab7d2e000019",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 70,
                    "text": "Clinical trials of intravenous immunoglobulin for Alzheimer's disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 176,
                    "offsetInEndSection": 577,
                    "text": "Preclinical and clinical studies have shown that IVIG has anti-amyloid and immune modulatory properties relevant to treating neurodegenerative disorders. In early stage AD clinical trials, IVIG was found to reduce cognitive decline and increase brain glucose metabolism. Unfortunately, IVIG failed to meet primary outcome objectives in the North American Phase 3 clinical trial in mild to moderate AD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1070,
                    "offsetInEndSection": 1324,
                    "text": "While the results of clinical trials to date do not provide support for the use of IVIG to treat AD at the doses tested, additional studies of IVIG's mechanisms are warranted and may guide the development of more effective therapies for AD in the future.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760112",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is protein Fbw7 a SCF type of E3 ubiquitin ligase?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22665065",
                "http://www.ncbi.nlm.nih.gov/pubmed/21349854",
                "http://www.ncbi.nlm.nih.gov/pubmed/23507969",
                "http://www.ncbi.nlm.nih.gov/pubmed/20826802",
                "http://www.ncbi.nlm.nih.gov/pubmed/20935640",
                "http://www.ncbi.nlm.nih.gov/pubmed/21282377",
                "http://www.ncbi.nlm.nih.gov/pubmed/22124735",
                "http://www.ncbi.nlm.nih.gov/pubmed/14672936",
                "http://www.ncbi.nlm.nih.gov/pubmed/18094723",
                "http://www.ncbi.nlm.nih.gov/pubmed/19679664",
                "http://www.ncbi.nlm.nih.gov/pubmed/22608923",
                "http://www.ncbi.nlm.nih.gov/pubmed/23820376",
                "http://www.ncbi.nlm.nih.gov/pubmed/23776410",
                "http://www.ncbi.nlm.nih.gov/pubmed/21827743"
            ],
            "ideal_answer": [
                "Fbxw7 (also known as Fbw7, SEL-10, hCdc4, or hAgo) is the F-box protein subunit of an Skp1-Cul1-F-box protein (SCF)-type ubiquitin ligase complex that plays a central role in the degradation of Notch family members.The F-box protein Fbw7 (also known as Fbxw7, hCdc4 and Sel-10) functions as a substrate recognition component of a SCF-type E3 ubiquitin ligase. SCF(Fbw7) facilitates polyubiquitination and subsequent degradation of various proteins such as Notch, cyclin E, c-Myc and c-Jun.",
                "The F-box protein Fbw7 (also known as Fbxw7, hCdc4 and Sel-10) functions as a substrate recognition component of a SCF-type E3 ubiquitin ligase. SCF(Fbw7) facilitates polyubiquitination and subsequent degradation of various proteins such as Notch, cyclin E, c-Myc and c-Jun."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044843",
                "http://www.uniprot.org/uniprot/SKP1_ASPFN",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D044767"
            ],
            "type": "yesno",
            "id": "550ae16bc2af5d5b70000009",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "FBW7 (F-box and WD repeat domain-containing 7) is the substrate recognition component of an evolutionary conserved SCF (complex of SKP1, CUL1 and F-box protein)-type ubiquitin ligase.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18094723",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 359,
                    "offsetInEndSection": 700,
                    "text": "However, very few E3 ubiquitin ligases are known to target G-CSFR for ubiquitin-proteasome pathway. Here we identified F-box and WD repeat domain-containing 7 (Fbw7), a substrate recognizing component of Skp-Cullin-F box (SCF) E3 ubiquitin Ligase physically associates with G-CSFR and promotes its ubiquitin-mediated proteasomal degradation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23820376",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "FBW7 is a crucial component of an SCF-type E3 ubiquitin ligase, which mediates degradation of an array of different target proteins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776410",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 225,
                    "text": "F-box and WD repeat domain-containing 7 (FBW7), the substrate-binding subunit of E3 ubiquitin ligase SCF(FBW7) (a complex of SKP1, cullin-1 and FBW7), plays important roles in various physiological and pathological processes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23507969",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 232,
                    "text": "The tumor suppressor Fbxw7 (also known as Sel-10, hCdc4, hAgo, or Fbw7) is an F-box protein that functions as the substrate-recognition subunit of an SCF ubiquitin ligase complex and targets a group of oncoproteins for degradation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22665065",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "text": "Fbw7 is the substrate recognition component of the Skp1-Cullin-F-box (SCF)-type E3 ligase complex and a well-characterized tumor suppressor that targets numerous oncoproteins for destruction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22608923",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Fbw7 is a member of F-box family proteins, which constitute one subunit of Skp1, Cul1, and F-box protein (SCF) ubiquitin ligase complex.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22124735",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 274,
                    "text": "The F-box protein Fbw7 (also known as Fbxw7, hCdc4 and Sel-10) functions as a substrate recognition component of a SCF-type E3 ubiquitin ligase. SCF(Fbw7) facilitates polyubiquitination and subsequent degradation of various proteins such as Notch, cyclin E, c-Myc and c-Jun.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21827743",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 270,
                    "offsetInEndSection": 485,
                    "text": "Fbxw7 (also known as Fbw7, SEL-10, hCdc4, or hAgo) is the F-box protein subunit of an Skp1-Cul1-F-box protein (SCF)-type ubiquitin ligase complex that plays a central role in the degradation of Notch family members.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21349854",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 314,
                    "text": "The Fbxw7 (F-box/WD repeat-containing protein 7; also called CDC4, Sel10, Ago, and Fbw7) component of the SCF (Skp1/Cullin/F-box protein) E3 ubiquitin ligase complex acts as a tumor suppressor in several tissues and targets multiple transcriptional activators and protooncogenes for ubiquitin-mediated degradation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21282377",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "The F-box protein Fbw7 (also known as Fbxw7, hCdc4 and Sel-10) functions as a substrate recognition component of a SCF-type E3 ubiquitin ligase.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21827743",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 227,
                    "offsetInEndSection": 475,
                    "text": "We demonstrate here that Fbw7 (F-box and WD repeat domain containing-7), the substrate recognition component of an SCF (complex of SKP1, CUL1 and F-box protein)-type E3 ubiquitin ligase, is a key regulator of NSC/NPC viability and differentiation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20935640",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "The SCF(Fbw7) ubiquitin ligase complex plays important roles in cell growth, survival, and differentiation via the ubiquitin-proteasome-mediated regulation of protein stability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19679664",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 271,
                    "text": "F-box and WD-40 domain protein 7 (Fbw7) provides substrate specificity for the Skp1-Cullin1-F-box protein (SCF) ubiquitin ligase complex that targets multiple oncoproteins for degradation, including cyclin E, c-Myc, c-Jun, Notch, and mammalian target of rapamycin (mTOR).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20826802",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "text": "Mammalian Fbw7 (also known as Sel-10, hCdc4, or hAgo) is the F-box protein component of an SCF (Skp1-Cul1-F-box protein-Rbx1)-type ubiquitin ligase, and the mouse Fbw7 is expressed prominently in the endothelial cell lineage of embryos.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14672936",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "The F-box protein Fbw7 (also known as Fbxw7, hCdc4 and Sel-10) functions as a substrate recognition component of a SCF-type E3 ubiquitin ligase",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21827743",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 230,
                    "offsetInEndSection": 476,
                    "text": "We demonstrate here that Fbw7 (F-box and WD repeat domain containing-7), the substrate recognition component of an SCF (complex of SKP1, CUL1 and F-box protein)-type E3 ubiquitin ligase, is a key regulator of NSC/NPC viability and differentiation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20935640",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 459,
                    "offsetInEndSection": 699,
                    "text": "Here we identified F-box and WD repeat domain-containing 7 (Fbw7), a substrate recognizing component of Skp-Cullin-F box (SCF) E3 ubiquitin Ligase physically associates with G-CSFR and promotes its ubiquitin-mediated proteasomal degradation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23820376",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "FBW7 is a crucial component of an SCF-type E3 ubiquitin ligase, which mediates degradation of an array of different target proteins",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23776410",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can fetal aneuploidy be detected with non-invasive prenatal testing?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23765643",
                "http://www.ncbi.nlm.nih.gov/pubmed/25478006",
                "http://www.ncbi.nlm.nih.gov/pubmed/25044397",
                "http://www.ncbi.nlm.nih.gov/pubmed/23712453",
                "http://www.ncbi.nlm.nih.gov/pubmed/24603453",
                "http://www.ncbi.nlm.nih.gov/pubmed/25543032",
                "http://www.ncbi.nlm.nih.gov/pubmed/23553438",
                "http://www.ncbi.nlm.nih.gov/pubmed/25138112",
                "http://www.ncbi.nlm.nih.gov/pubmed/24482806",
                "http://www.ncbi.nlm.nih.gov/pubmed/21749753",
                "http://www.ncbi.nlm.nih.gov/pubmed/23299662",
                "http://www.ncbi.nlm.nih.gov/pubmed/22863603",
                "http://www.ncbi.nlm.nih.gov/pubmed/24783433",
                "http://www.ncbi.nlm.nih.gov/pubmed/26252102",
                "http://www.ncbi.nlm.nih.gov/pubmed/17186566",
                "http://www.ncbi.nlm.nih.gov/pubmed/10655451",
                "http://www.ncbi.nlm.nih.gov/pubmed/26080919",
                "http://www.ncbi.nlm.nih.gov/pubmed/25449088",
                "http://www.ncbi.nlm.nih.gov/pubmed/21574485",
                "http://www.ncbi.nlm.nih.gov/pubmed/24990604",
                "http://www.ncbi.nlm.nih.gov/pubmed/24312358",
                "http://www.ncbi.nlm.nih.gov/pubmed/23526649",
                "http://www.ncbi.nlm.nih.gov/pubmed/24352524",
                "http://www.ncbi.nlm.nih.gov/pubmed/21076134",
                "http://www.ncbi.nlm.nih.gov/pubmed/24667696",
                "http://www.ncbi.nlm.nih.gov/pubmed/22500971",
                "http://www.ncbi.nlm.nih.gov/pubmed/21749752",
                "http://www.ncbi.nlm.nih.gov/pubmed/23089167",
                "http://www.ncbi.nlm.nih.gov/pubmed/26237478",
                "http://www.ncbi.nlm.nih.gov/pubmed/23470070",
                "http://www.ncbi.nlm.nih.gov/pubmed/25238658"
            ],
            "ideal_answer": [
                "Yes, the non-invasive preanatal test of cell-free fetal DNA is being used for fetal aneuploidy screening."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004247",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011296"
            ],
            "type": "yesno",
            "id": "57136cbf1174fb1755000007",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "Non-invasive prenatal testing with cell-free DNA: US physician attitudes toward implementation in clinical practice.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23526649",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 200,
                    "text": "The aim of this study was to assess awareness, potential adoption, and current utilization of non-invasive prenatal testing (NIPT) analysis for common fetal aneuploidies among obstetricians",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23526649",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 161,
                    "text": "Cell-free DNA has been used for fetal rhesus factor and sex determination, fetal aneuploidy screening, cancer diagnostics and monitoring, and other applications.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25543032",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "text": "The recent release of new, non-invasive prenatal tests for fetal aneuploidy using cell-free fetal DNA (cffDNA) has been hailed as a revolution in prenatal testing and has triggered significant commercial interest in the field.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22863603",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "Non-invasive prenatal testing (NIPT) for aneuploidy using cell-free DNA in maternal plasma is revolutionizing prenatal screening and diagnosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23765643",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23712453",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Non-invasive prenatal testing (NIPT) of cell-free fetal DNA in maternal plasma is a novel approach, designed for detecting common aneuploidies in the fetus.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25138112",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "This study aimed to develop a single-nucleotide polymorphism-based and informatics-based non-invasive prenatal test that detects sex chromosome aneuploidies early in pregnancy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23712453",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "text": "RAPIDR: an analysis package for non-invasive prenatal testing of aneuploidy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 82,
                    "text": "Non-invasive prenatal testing for aneuploidy: current status and future prospects.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23765643",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Non-invasive prenatal testing of fetal whole chromosome aneuploidy by massively parallel sequencing.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23299662",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 99,
                    "text": "Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24603453",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "[Non-invasive prenatal test in the diagnosis of aneuploidy 13, 18 and 21--theoretical and practical aspects].",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21574485",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 112,
                    "text": "To track and analyze two false positive cases from non-invasive prenatal testing for potential fetal aneuploidy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25449088",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal DNA is becoming part of routine clinical practice.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 173,
                    "text": "To report secondary or additional findings arising from introduction of non-invasive prenatal testing (NIPT) for aneuploidy by whole genome sequencing as a clinical service.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23553438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Israeli Society of Medical Genetics NIPT Committee Opinion 072013: Non-invasive prenatal testing of cell-free DNA in maternal plasma for detection of fetal aneuploidy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25138112",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 420,
                    "offsetInEndSection": 956,
                    "text": "In recent years, technical advances in the molecular analysis of fetal DNA (e.g., digital PCR and massively parallel sequencing (MPS)) has enabled the successful implementation of noninvasive testing into clinical practice, such as fetal sex assessment, RhD genotyping, and fetal chromosomal aneuploidy detection.With the ability to decipher the entire fetal genome from maternal plasma DNA, we foresee that an increased number of non-invasive prenatal tests will be available for detecting many single-gene disorders in the near future",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24482806",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 237,
                    "text": "First identified in 1997, cell-free fetal DNA (cffDNA) has just recently been used to detect fetal aneuploidy of chromosomes 13, 18, and 21, showing its potential to revolutionize prenatal genetic testing as a non-invasive screening tool",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24352524",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "Non-invasive prenatal testing (NIPT) using cell-free fetal DNA in maternal plasma has been developed for the detection of fetal aneuploidy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25238658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "Israeli Society of Medical Genetics NIPT Committee Opinion 072013: Non-invasive prenatal testing of cell-free DNA in maternal plasma for detection of fetal aneuploidy",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25138112",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 88,
                    "text": "Non-invasive prenatal testing for fetal aneuploidies in the first trimester of pregnancy",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25044397",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 122,
                    "text": "To explore the value of next-generation sequencing for the non-invasive prenatal testing of fetal chromosomal aneuploidies",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252102",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "Secondary findings from non-invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23553438",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "To report secondary or additional findings arising from introduction of non-invasive prenatal testing (NIPT) for aneuploidy by whole genome sequencing as a clinical service",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23553438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 133,
                    "text": "Secondary findings from non-invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23553438",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 162,
                    "text": "Motivations for undertaking DNA sequencing-based non-invasive prenatal testing for fetal aneuploidy: a qualitative study with early adopter patients in Hong Kong.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24312358",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "OBJECTIVE: To determine whether non-invasive prenatal testing by maternal plasma DNA sequencing can uncover all fetal chromosome aneuploidies in one simple sequencing event. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23299662",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 203,
                    "text": "Non-invasive prenatal diagnosis of fetal aneuploidies using massively parallel sequencing-by-ligation and evidence that cell-free fetal DNA in the maternal plasma originates from cytotrophoblastic cells.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22500971",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "text": "Non-invasive prenatal testing (NIPT) using cell-free fetal DNA in maternal plasma has been developed for the detection of fetal aneuploidy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25238658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "Non-invasive prenatal testing (NIPT) of cell-free fetal DNA in maternal plasma is a novel approach, designed for detecting common aneuploidies in the fetus.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25138112",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 28,
                    "offsetInEndSection": 227,
                    "text": "non-invasive prenatal tests for fetal aneuploidy using cell-free fetal DNA (cffDNA) has been hailed as a revolution in prenatal testing and has triggered significant commercial interest in the field.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22863603",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 296,
                    "text": " Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal DNA is becoming part of routine clinical practice. RAPIDR (Reliable Accurate Prenatal non-Invasive Diagnosis R package) is an easy-to-use open-source R package that implements several published NIPT analysis methods.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 268,
                    "offsetInEndSection": 564,
                    "text": "The clinical data collected thus far indicate that NIPT is highly sensitive in detecting trisomies 21 and 18, and fairly sensitive in detecting trisomy 13 and sex chromosome aneuploidies. Because false-positive results may occur, an abnormal result must be validated by invasive prenatal testing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25138112",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 3503,
                    "offsetInEndSection": 3811,
                    "text": "When non-invasive prenatal screening for aneuploidy is available, maternal age alone should not be an indication for invasive prenatal diagnosis in a twin pregnancy. (II-2A) If non-invasive prenatal screening is not available, invasive prenatal diagnosis in twins should be offered to women aged 35 and over.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21749753",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 272,
                    "offsetInEndSection": 958,
                    "text": "Therefore, methods with high sensitivity and precision are required to detect and differentiate fetal DNA from the large background of maternal DNA. In recent years, technical advances in the molecular analysis of fetal DNA (e.g., digital PCR and massively parallel sequencing (MPS)) has enabled the successful implementation of noninvasive testing into clinical practice, such as fetal sex assessment, RhD genotyping, and fetal chromosomal aneuploidy detection.With the ability to decipher the entire fetal genome from maternal plasma DNA, we foresee that an increased number of non-invasive prenatal tests will be available for detecting many single-gene disorders in the near future.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24482806",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Non-invasive prenatal testing for fetal aneuploidies in the first trimester of pregnancy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25044397",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "Secondary findings from non-invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23553438",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "text": "To explore the value of next-generation sequencing for the non-invasive prenatal testing of fetal chromosomal aneuploidies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26252102",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "[Cell-free nucleic acid-based non-invasive prenatal diagnosis of fetal aneuploidies].",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23089167",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 3931,
                    "offsetInEndSection": 4149,
                    "text": "Maternal age alone is a poor minimum standard for prenatal screening for aneuploidy, and it should not be used a basis for recommending invasive testing when non-invasive prenatal screening for aneuploidy is available.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21749752",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 168,
                    "text": "Israeli Society of Medical Genetics NIPT Committee Opinion 072013: Non-invasive prenatal testing of cell-free DNA in maternal plasma for detection of fetal aneuploidy.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25138112",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Attitudes towards non-invasive prenatal testing for aneuploidy among US adults of reproductive age.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24603453",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 227,
                    "text": "The recent release of new, non-invasive prenatal tests for fetal aneuploidy using cell-free fetal DNA (cffDNA) has been hailed as a revolution in prenatal testing and has triggered significant commercial interest in the field.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22863603",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 130,
                    "text": "Non-invasive prenatal testing (NIPT) of fetal aneuploidy using cell-free fetal DNA is becoming part of routine clinical practice.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24990604",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Non-invasive prenatal testing (NIPT) by massively parallel sequencing is a useful clinical test for the detection of common fetal aneuploidies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24667696",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 268,
                    "offsetInEndSection": 455,
                    "text": "The clinical data collected thus far indicate that NIPT is highly sensitive in detecting trisomies 21 and 18, and fairly sensitive in detecting trisomy 13 and sex chromosome aneuploidies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25138112",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does  thyroid hormone receptor beta1 affect insulin secretion?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17293442"
            ],
            "ideal_answer": [
                "No"
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011988",
                "http://www.uniprot.org/uniprot/THBA_XENLA",
                "http://www.uniprot.org/uniprot/INS_APLCA",
                "http://www.uniprot.org/uniprot/THB_SHEEP",
                "http://www.uniprot.org/uniprot/THB_PAROL",
                "http://www.uniprot.org/uniprot/THB_CHICK",
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0004887",
                "http://www.uniprot.org/uniprot/THB_DANRE",
                "http://www.uniprot.org/uniprot/THB_RAT",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013963",
                "http://www.uniprot.org/uniprot/THB_HUMAN",
                "http://www.uniprot.org/uniprot/THB_CAIMO",
                "http://www.uniprot.org/uniprot/THB_MOUSE",
                "http://www.uniprot.org/uniprot/THB_LITCT",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D037042"
            ],
            "type": "yesno",
            "id": "516c0e08298dcd4e5100006d",
            "snippets": [
                {
                    "offsetInBeginSection": 282,
                    "offsetInEndSection": 434,
                    "text": "We demonstrated that thyroid hormone T3 rapidly induces Akt activation in pancreatic beta cells rRINm5F and hCM via thyroid hormone receptor (TR) beta1.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17293442",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 890,
                    "offsetInEndSection": 1014,
                    "text": "The silencing of TRbeta1 expression through RNAi confirmed this receptor to be crucial for the T3-induced activation of Akt.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17293442",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1149,
                    "offsetInEndSection": 1385,
                    "text": "T3 is able to specifically activate Akt in the islet beta cells rRINm5F and hCM through the interaction between TRbeta1 and PI3K p85alpha, demonstrating the involvement of TRbeta1 in this novel T3 non-genomic action in islet beta cells.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17293442",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Does metformin alleviate atherosclerosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25552600",
                "http://www.ncbi.nlm.nih.gov/pubmed/17307426",
                "http://www.ncbi.nlm.nih.gov/pubmed/29878903",
                "http://www.ncbi.nlm.nih.gov/pubmed/25527624",
                "http://www.ncbi.nlm.nih.gov/pubmed/29499335",
                "http://www.ncbi.nlm.nih.gov/pubmed/29452166",
                "http://www.ncbi.nlm.nih.gov/pubmed/22672501",
                "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
                "http://www.ncbi.nlm.nih.gov/pubmed/27737949"
            ],
            "ideal_answer": [
                "Yes. Metformin has been shown to decrease frequency of atherosclerosis-associated adverse effects in statin-intolerant patients and to slow the pathogenesis of type 2 diabetes mellitus.",
                "Metformin Suppresses Diabetes-Accelerated Atherosclerosis via the Inhibition of Drp1-Mediated Mitochondrial Fission.",
                "Yes. Metformin has been shown to decrease frequency of atherosclerosis-associated adverse effects in statin-intolerant patients and to slow the pathogenesis of type 2 diabetes.",
                "Coupled with their proven good safety profile these findings could translate into a significant clinical benefit. Our results suggest that metformin impeded the progression of atherosclerosis, possibly by suppressing macrophage infiltration and inflammatory responses.",
                "Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses Our results suggest that metformin impeded the progression of atherosclerosis, possibly by suppressing macrophage infiltration and inflammatory responses.",
                "Yes. Metformin has been shown in a number of clinical trial to prevent and attenuate atherosclerosis.",
                "Several recently completed randomized clinical trials have reported effects of metformin on surrogate measures of atherosclerotic vascular disease. Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory response."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5d38462b7bc3fee31f000012",
            "snippets": [
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 184,
                    "text": "Metformin and rosiglitazone both improve glycemic control in type 2 diabetes mellitus, however may possess different anti-inflammatory and anti-atherosclerotic properties. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17307426",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1152,
                    "offsetInEndSection": 1407,
                    "text": "Demonstrating antiatherothrombotic properties of dipeptidyl peptidase-4 inhibitors on proven markers is of substantial clinical significance. Coupled with their proven good safety profile these findings could translate into a significant clinical benefit.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22672501",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 27,
                    "offsetInEndSection": 95,
                    "text": "pleiotropic benefits of metformin in attenuation of atherosclerosis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25527624",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1056,
                    "offsetInEndSection": 1140,
                    "text": "Pleiotropic effects of metformin ameliorate atherosclerosis and vascular senescence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25527624",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation: potential role in atherosclerosis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25552600",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1408,
                    "offsetInEndSection": 1553,
                    "text": "Metformin attenuated Ang-II-induced atheromatous plaque formation and aortic aneurysm in ApoE(-/-) mice partly by reducing monocyte infiltration.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25552600",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 170,
                    "offsetInEndSection": 258,
                    "text": "Metformin, an anti-diabetic drug, was reported to possess anti-atherosclerotic effects. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1226,
                    "offsetInEndSection": 1598,
                    "text": " In cultured macrophages, co-treatment with metformin and atorvastatin promoted cholesterol efflux and up-regulated expression of ATP-binding cassette transporters A1 and G1. Taken together, our results suggest that atorvastatin/metformin combination therapy may achieve additional anti-atherosclerotic benefits likely through increasing cholesterol efflux in macrophages.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28526884",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 116,
                    "text": "Metformin Suppresses Diabetes-Accelerated Atherosclerosis via the Inhibition of Drp1-Mediated Mitochondrial Fission.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737949",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 236,
                    "offsetInEndSection": 366,
                    "text": "metformin abated the progression of diabetes-accelerated atherosclerosis by inhibiting mitochondrial fission in endothelial cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737949",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1548,
                    "offsetInEndSection": 1681,
                    "text": "metformin attenuated the development of atherosclerosis by reducing Drp1-mediated mitochondrial fission in an AMPK-dependent manner. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27737949",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 119,
                    "offsetInEndSection": 276,
                    "text": "metformin's effects on lipids and atherosclerotic vascular disease and/or provide insights into the drug's mechanisms of action on the heart and vasculature.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29878903",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 354,
                    "offsetInEndSection": 500,
                    "text": "Several recently completed randomized clinical trials have reported effects of metformin on surrogate measures of atherosclerotic vascular disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29878903",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Metformin treatment prevents SREBP2-mediated cholesterol uptake and improves lipid homeostasis during oxidative stress-induced atherosclerosis",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29499335",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 123,
                    "text": "Metformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29452166",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1605,
                    "offsetInEndSection": 1759,
                    "text": "Our results suggest that metformin impeded the progression of atherosclerosis, possibly by suppressing macrophage infiltration and inflammatory responses.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29452166",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is SATB1 expressed in thymocytes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27454343",
                "http://www.ncbi.nlm.nih.gov/pubmed/15814699",
                "http://www.ncbi.nlm.nih.gov/pubmed/12692553",
                "http://www.ncbi.nlm.nih.gov/pubmed/9340009",
                "http://www.ncbi.nlm.nih.gov/pubmed/9886398"
            ],
            "ideal_answer": [
                "A thymocyte factor SATB1 suppresses transcription of stably integrated matrix-attachment region-linked reporter genes. SATB1 is a homeodomain protein and is predominantly expressed in thymocytes. In this study we show that special AT-rich binding protein 1 (SATB1), a T lineage-enriched chromatin organizer and regulator, is induced in response to TCR signaling during early thymocyte development",
                "Yes, SATB1 is expressed in thymocytes and has a major role in the regulation of cell differentiation.",
                "yes,  This was shown by fluorescence in situ hybridization on wild-type and Satb1-null thymocytes using in vivo SATB1-bound sequences as probes. ",
                "SATB1 is a homeodomain protein and is predominantly expressed in thymocytes. ",
                "SATB1 is a homeodomain protein and is predominantly expressed in thymocytes.",
                "SATB1 is a homeodomain protein and is predominantly expressed in thymocytes. SATB1 is a cell-type specific nuclear protein that recruits chromatin-remodeling factors and regulates numerous genes during thymocyte differentiation.",
                "A thymocyte factor SATB1 suppresses transcription of stably integrated matrix-attachment region-linked reporter genes."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5d35c227b3a6380763000007",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "A thymocyte factor SATB1 suppresses transcription of stably integrated matrix-attachment region-linked reporter genes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9340009",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 338,
                    "text": "SATB1 is a homeodomain protein and is predominantly expressed in thymocytes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9340009",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 162,
                    "offsetInEndSection": 313,
                    "text": "SATB1 is a cell-type specific nuclear protein that recruits chromatin-remodeling factors and regulates numerous genes during thymocyte differentiation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12692553",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 496,
                    "offsetInEndSection": 636,
                    "text": " This was shown by fluorescence in situ hybridization on wild-type and Satb1-null thymocytes using in vivo SATB1-bound sequences as probes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12692553",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1090,
                    "offsetInEndSection": 1175,
                    "text": "By contrast, in Satb1-null thymocytes, this site is marked by methylation at H3 Lys9.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12692553",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "text": "Regulation of SATB1 during thymocyte development by TCR signaling.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454343",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 451,
                    "text": "In this study we show that special AT-rich binding protein 1 (SATB1), a T lineage-enriched chromatin organizer and regulator, is induced in response to TCR signaling during early thymocyte development",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454343",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 453,
                    "offsetInEndSection": 590,
                    "text": "SATB1 expression profile coincides with T lineage commitment and upregulation of SATB1 correlates with positive selection of thymocytes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454343",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 712,
                    "offsetInEndSection": 910,
                    "text": " We also demonstrate that GATA3, the key transcriptional regulator of \u03b1\u03b2 T cells positively regulates SATB1 expression in thymocytes suggesting an important role for SATB1 during T cell development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27454343",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 147,
                    "text": "High level expression of the Xlr nuclear protein in immature thymocytes and colocalization with the matrix-associated region-binding SATB1 protein.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886398",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "text": "A role for SATB1, a nuclear matrix association region-binding protein, in the development of CD8SP thymocytes and peripheral T lymphocytes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15814699",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 301,
                    "offsetInEndSection": 531,
                    "text": "Because homozygous SATB1-null mice do not survive to adulthood due to non-thymus autonomous defects, mice were produced that were homozygous for a T cell-specific SATB1-antisense transgene and heterozygous for a SATB1-null allele.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15814699",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 532,
                    "offsetInEndSection": 735,
                    "text": "Thymic SATB1 protein was reduced significantly in these mice, and the major cellular phenotype observed was a significant reduction in the percentage of CD8SP T cells in thymus, spleen, and lymph nodes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15814699",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 963,
                    "offsetInEndSection": 1199,
                    "text": "The reduction in thymic SATB1 does not lead to the variegated expression of CD8-negative single positive thymocytes seen upon deletion of several regulatory elements and suggested by others to reflect failure to activate the CD8 locus. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15814699",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there any association of the chromosomal region harboring the gene ITIH3 with schizophrenia?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22614287",
                "http://www.ncbi.nlm.nih.gov/pubmed/24373612",
                "http://www.ncbi.nlm.nih.gov/pubmed/25136889",
                "http://www.ncbi.nlm.nih.gov/pubmed/25414627",
                "http://www.ncbi.nlm.nih.gov/pubmed/24618187",
                "http://www.ncbi.nlm.nih.gov/pubmed/24461634",
                "http://www.ncbi.nlm.nih.gov/pubmed/21926972",
                "http://www.ncbi.nlm.nih.gov/pubmed/21926974"
            ],
            "triples": [
                {
                    "p": "http://purl.uniprot.org/core/encodedBy",
                    "s": "http://purl.uniprot.org/uniprot/P56652",
                    "o": "http://linkedlifedata.com/resource/#_5035363635320014"
                },
                {
                    "p": "http://purl.uniprot.org/core/shortName",
                    "s": "http://linkedlifedata.com/resource/#_5035363635320011",
                    "o": "Inter-alpha-inhibitor heavy chain 3"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#prefLabel",
                    "s": "http://linkedlifedata.com/resource/#_5035363635320014",
                    "o": "ITIH3"
                },
                {
                    "p": "http://purl.uniprot.org/core/shortName",
                    "s": "http://linkedlifedata.com/resource/#_5035363635320011",
                    "o": "ITI-HC3"
                },
                {
                    "p": "http://purl.uniprot.org/core/fullName",
                    "s": "http://linkedlifedata.com/resource/#_5035363635320011",
                    "o": "Inter-alpha-trypsin inhibitor heavy chain H3"
                },
                {
                    "p": "http://purl.uniprot.org/core/shortName",
                    "s": "http://linkedlifedata.com/resource/#_5035363635320011",
                    "o": "ITI heavy chain H3"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11649840",
                    "o": "6168"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11649841",
                    "o": "H3P"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17763944",
                    "o": "ITIH3"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16692007",
                    "o": "pre-alpha (globulin) inhibitor, H3 polypeptide"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1416508",
                    "o": "http://linkedlifedata.com/resource/umls/label/A12006059"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6901933",
                    "o": "ITIH3 gene"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A12006059",
                    "o": "INTER-ALPHA-TRYPSIN INHIBITOR, HEAVY CHAIN 3"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1416508",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11649841"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1416508",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16692008"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1416508",
                    "o": "http://linkedlifedata.com/resource/umls/label/A17748015"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11649840",
                    "o": "inter-alpha (globulin) inhibitor H3"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1416508",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16692007"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1416508",
                    "o": "http://linkedlifedata.com/resource/umls/label/A17763944"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1416508",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11948666"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1416508",
                    "o": "http://linkedlifedata.com/resource/umls/label/A17748015"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16692008",
                    "o": "inter-alpha-trypsin inhibitor heavy chain H3"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1416508",
                    "o": "http://linkedlifedata.com/resource/umls/label/A6901933"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1416508",
                    "o": "http://linkedlifedata.com/resource/umls/label/A11649840"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11649841",
                    "o": "6168"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16692007",
                    "o": "6168"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16692008",
                    "o": "6168"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17748015",
                    "o": "6168"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17763944",
                    "o": "6168"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#narrower",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0063693",
                    "o": "http://linkedlifedata.com/resource/umls/id/C1453112"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A11866112",
                    "o": "Inter alpha trypsin inhibitor"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6956473",
                    "o": "inter-alpha-trypsin inhibitor, heavy chain"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0195956",
                    "o": "inter-alpha-inhibitor"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1453112",
                    "o": "http://linkedlifedata.com/resource/umls/label/A7833732"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1453112",
                    "o": "http://linkedlifedata.com/resource/umls/label/A6970526"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6956403",
                    "o": "SHAP protein"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7833732",
                    "o": "ITIH3 protein, human"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1453112",
                    "o": "http://linkedlifedata.com/resource/umls/label/A7833732"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0235686",
                    "o": "Trypsin inhibitor, inter-alpha-"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6988771",
                    "o": "pre-alpha (globulin) inhibitor, H3 polypeptide, human"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A6970526",
                    "o": "Inter-alpha-inhibitor heavy chain 3 protein, human"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1453112",
                    "o": "http://linkedlifedata.com/resource/umls/label/A6988771"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A0195957",
                    "o": "inter-alpha-trypsin inhibitor"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R115190989",
                    "o": "http://linkedlifedata.com/resource/umls/id/C1416508"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1416508",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R109169453"
                }
            ],
            "ideal_answer": [
                "Yes, genome-wide significant associations in schizophrenia has been linked to the locus harboring the ITIH3/4 genes."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:1229",
                "http://www.uniprot.org/uniprot/ITIH3_HUMAN",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012559",
                "http://www.uniprot.org/uniprot/ITIH3_RABIT",
                "http://www.biosemantics.org/jochem#4252946",
                "http://www.uniprot.org/uniprot/ITIH3_PONAB",
                "http://www.disease-ontology.org/api/metadata/DOID:5419",
                "http://www.uniprot.org/uniprot/ITIH3_MESAU"
            ],
            "type": "yesno",
            "id": "54d63d873706e89528000006",
            "snippets": [
                {
                    "offsetInBeginSection": 807,
                    "offsetInEndSection": 1000,
                    "text": "The most widely shared subset of genes-common to five of six disorders-included ANK3, AS3MT, CACNA1C, CACNB2, CNNM2, CSMD1, DPCR1, ITIH3, NT5C2, PPP1R11, SYNE1, TCF4, TENM4, TRIM26, and ZNRD1. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25414627",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "Genome-wide significant associations in schizophrenia to ITIH3/4, CACNA1C and SDCCAG8, and extensive replication of associations reported by the Schizophrenia PGC.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22614287",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 852,
                    "offsetInEndSection": 1053,
                    "text": "After combining the new schizophrenia data with those of the PGC, variants at three loci (ITIH3/4, CACNA1C and SDCCAG8) that had not previously been GWS in schizophrenia attained that level of support.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22614287",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 916,
                    "offsetInEndSection": 1195,
                    "text": "In a joint analysis with a bipolar disorder sample (16,374 affected individuals and 14,044 controls), three loci reached genome-wide significance: CACNA1C (rs4765905, P = 7.0 \u00d7 10(-9)), ANK3 (rs10994359, P = 2.5 \u00d7 10(-8)) and the ITIH3-ITIH4 region (rs2239547, P = 7.8 \u00d7 10(-9)).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926974",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 728,
                    "offsetInEndSection": 901,
                    "text": "Finally, a combined GWAS analysis of schizophrenia and bipolar disorder yielded strong association evidence for SNPs in CACNA1C and in the region of NEK4-ITIH1-ITIH3-ITIH4. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926972",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 191,
                    "text": "A recent genome-wide analysis indicated that a polymorphism (rs2535629) of ITIH3 showed the strongest association signal with susceptibility to psychiatric disorders in Caucasian populations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24373612",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1170,
                    "offsetInEndSection": 1336,
                    "text": "We detected a novel association between suicide attempt and the ITIH3/4-region in a combined group of patients with BD, SCZ and related psychosis spectrum disorders. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24461634",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 908,
                    "offsetInEndSection": 1221,
                    "text": "These include variations in chromosomal structure at 16p11.2, rare de novo point mutations at the gene SCN2A, and common single nucleotide polymorphisms (SNPs) mapping near loci encoding the genes ITIH3, AS3MT, CACNA1C and CACNB2. These selected examples point to the challenges to current diagnostic approaches. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24618187",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1073,
                    "offsetInEndSection": 1271,
                    "text": "STAB1 is located in close proximity to PBMR1 and the NEK4-ITIH1-ITIH3-ITIH4 region, which are the top findings from GWAS meta-analyses of mood disorder, and a combined BD and schizophrenia data set.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25136889",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1364,
                    "offsetInEndSection": 1499,
                    "text": "Our findings suggest that rs2535629 influences the susceptibility to psychiatric disorders by affecting the expression level of GLT8D1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24373612",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has ATF4 transcription factor been linked to cancer and neoplastic transformation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17297441",
                "http://www.ncbi.nlm.nih.gov/pubmed/27211800",
                "http://www.ncbi.nlm.nih.gov/pubmed/28797581",
                "http://www.ncbi.nlm.nih.gov/pubmed/25883982",
                "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                "http://www.ncbi.nlm.nih.gov/pubmed/24681956",
                "http://www.ncbi.nlm.nih.gov/pubmed/28843961",
                "http://www.ncbi.nlm.nih.gov/pubmed/17466566"
            ],
            "ideal_answer": [
                "Yes, ATF4 transcription factor has been linked to cancer and neoplastic transformation."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/ATF4_BOVIN",
                "http://www.uniprot.org/uniprot/ATF4_RAT",
                "http://www.biosemantics.org/jochem#4250481",
                "https://meshb.nlm.nih.gov/record/ui?ui=D051701"
            ],
            "type": "yesno",
            "id": "5a773c50faa1ab7d2e000002",
            "snippets": [
                {
                    "offsetInBeginSection": 1367,
                    "offsetInEndSection": 1603,
                    "text": "aken together, we discovered a novel axis of BCL10-regulated OSCC progression via STAT1/ATF4/S100P/P65 signaling, which could predict the prognosis of OSCC and will be beneficial for developing therapeutic strategy against advanced OSCC",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681956",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 421,
                    "offsetInEndSection": 708,
                    "text": "s a result, the level of phosphorylated Eukaryotic Initiation Factor 2 alpha (eIF2\u03b1) is markedly elevated, resulting in the promotion of a pro-adaptive signaling pathway by the inhibition of global protein synthesis and selective translation of Activating Transcription Factor 4 (ATF4). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27211800",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 410,
                    "text": "Many cancers overexpress ATF4, a stress-induced transcription factor that promotes cell survival under hypoxic conditions and other stresses of the tumor microenvironment, but the potential contributions of ATF4 to oncogenesis itself have been little explored. Here, we report that ATF4 promotes oncogene-induced neoplastic transformation by suppressing the expression of cellular senescence-associated genes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 409,
                    "text": "Here, we report that ATF4 promotes oncogene-induced neoplastic transformation by suppressing the expression of cellular senescence-associated genes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 888,
                    "text": "Elevated levels of ATF4 were sufficient to suppress expression of these proteins and drive oncogenic transformation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1013,
                    "offsetInEndSection": 1159,
                    "text": "Our findings define a central function for ATF4 in promoting oncogenic transformation by suppressing a central pathway of cellular senescence.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 971,
                    "offsetInEndSection": 1012,
                    "text": "ATF4 expression is upregulated in cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17466566",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "Activating transcription factor 4 (ATF4), an endoplasmic reticulum stress-inducible transcription factor, plays important roles in cancer progression and resistance to therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28843961",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "Activating transcription factor 4 (ATF4) is a stress-induced transcription factor that is frequently upregulated in cancer cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28797581",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1013,
                    "offsetInEndSection": 1155,
                    "text": "Our findings define a central function for ATF4 in promoting oncogenic transformation by suppressing a central pathway of cellular senescence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Stress-regulated transcription factor ATF4 promotes neoplastic transformation by suppressing expression of the INK4a/ARF cell senescence factors.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22102693",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 251,
                    "offsetInEndSection": 379,
                    "text": "Activating transcription factor 4 (ATF4), a member of the ATF/CREB family, has been reported to be related to tumor angiogenesis",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25883982",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the BAGEL algorithm used for arrayed CRISPR screens?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27083490"
            ],
            "ideal_answer": [
                "No. BAGEL (Bayesian Analysis of Gene EssentiaLity) is a supervised learning method for analyzing pooled library gene knockout screens. It offers significantly greater sensitivity than current methods, while computational optimizations reduce runtime by an order of magnitude."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e30b56efbd6abf43b000037",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "text": "BAGEL: a computational framework for identifying essential genes from pooled library screens.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27083490",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 923,
                    "text": "The adaptation of the CRISPR-Cas9 system to pooled library gene knockout screens in mammalian cells represents a major technological leap over RNA interference, the prior state of the art. New methods for analyzing the data and evaluating results are needed.RESULTS: We offer BAGEL (Bayesian Analysis of Gene EssentiaLity), a supervised learning method for analyzing gene knockout screens. Coupled with gold-standard reference sets of essential and nonessential genes, BAGEL offers significantly greater sensitivity than current methods, while computational optimizations reduce runtime by an order of magnitude.CONCLUSIONS: Using BAGEL, we identify ~2000 fitness genes in pooled library knockout screens in human cell lines at 5 % FDR, a major advance over competing platforms. BAGEL shows high sensitivity and specificity even across screens performed by different labs using different libraries and reagents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27083490",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 628,
                    "offsetInEndSection": 794,
                    "text": "CONCLUSIONS\n\nUsing BAGEL, we identify ~2000 fitness genes in pooled library knockout screens in human cell lines at 5 % FDR, a major advance over competing platforms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27083490",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 92,
                    "text": "BAGEL: a computational framework for identifying essential genes from pooled library screens",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27083490",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 628,
                    "offsetInEndSection": 794,
                    "text": "CONCLUSIONS\nUsing BAGEL, we identify ~2000 fitness genes in pooled library knockout screens in human cell lines at 5 % FDR, a major advance over competing platforms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27083490",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 624,
                    "offsetInEndSection": 790,
                    "text": "CONCLUSIONS: Using BAGEL, we identify ~2000 fitness genes in pooled library knockout screens in human cell lines at 5 % FDR, a major advance over competing platforms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27083490",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 624,
                    "offsetInEndSection": 789,
                    "text": "Conclusions Using BAGEL, we identify ~2000 fitness genes in pooled library knockout screens in human cell lines at 5 % FDR, a major advance over competing platforms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27083490",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is bapineuzumab effective for treatment of patients with Alzheimer's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20189881",
                "http://www.ncbi.nlm.nih.gov/pubmed/21263194",
                "http://www.ncbi.nlm.nih.gov/pubmed/24255592",
                "http://www.ncbi.nlm.nih.gov/pubmed/22357853",
                "http://www.ncbi.nlm.nih.gov/pubmed/24086465",
                "http://www.ncbi.nlm.nih.gov/pubmed/24216217",
                "http://www.ncbi.nlm.nih.gov/pubmed/20929585",
                "http://www.ncbi.nlm.nih.gov/pubmed/24434253",
                "http://www.ncbi.nlm.nih.gov/pubmed/23861639",
                "http://www.ncbi.nlm.nih.gov/pubmed/22529838",
                "http://www.ncbi.nlm.nih.gov/pubmed/19674435",
                "http://www.ncbi.nlm.nih.gov/pubmed/23299380",
                "http://www.ncbi.nlm.nih.gov/pubmed/22506132",
                "http://www.ncbi.nlm.nih.gov/pubmed/23582316",
                "http://www.ncbi.nlm.nih.gov/pubmed/23847530",
                "http://www.ncbi.nlm.nih.gov/pubmed/21091109",
                "http://www.ncbi.nlm.nih.gov/pubmed/23555764",
                "http://www.ncbi.nlm.nih.gov/pubmed/21592055",
                "http://www.ncbi.nlm.nih.gov/pubmed/22815077",
                "http://www.ncbi.nlm.nih.gov/pubmed/23874844",
                "http://www.ncbi.nlm.nih.gov/pubmed/23574434",
                "http://www.ncbi.nlm.nih.gov/pubmed/23894286",
                "http://www.ncbi.nlm.nih.gov/pubmed/20205639",
                "http://www.ncbi.nlm.nih.gov/pubmed/23931438",
                "http://www.ncbi.nlm.nih.gov/pubmed/23809364",
                "http://www.ncbi.nlm.nih.gov/pubmed/20154508",
                "http://www.ncbi.nlm.nih.gov/pubmed/23210837",
                "http://www.ncbi.nlm.nih.gov/pubmed/23599675",
                "http://www.ncbi.nlm.nih.gov/pubmed/19585948",
                "http://www.ncbi.nlm.nih.gov/pubmed/20388189",
                "http://www.ncbi.nlm.nih.gov/pubmed/20497044",
                "http://www.ncbi.nlm.nih.gov/pubmed/23416764",
                "http://www.ncbi.nlm.nih.gov/pubmed/23085451",
                "http://www.ncbi.nlm.nih.gov/pubmed/22339463",
                "http://www.ncbi.nlm.nih.gov/pubmed/23568994",
                "http://www.ncbi.nlm.nih.gov/pubmed/23255116",
                "http://www.ncbi.nlm.nih.gov/pubmed/23663286",
                "http://www.ncbi.nlm.nih.gov/pubmed/22957288",
                "http://www.ncbi.nlm.nih.gov/pubmed/19923550",
                "http://www.ncbi.nlm.nih.gov/pubmed/24489866",
                "http://www.ncbi.nlm.nih.gov/pubmed/22305802",
                "http://www.ncbi.nlm.nih.gov/pubmed/20122289",
                "http://www.ncbi.nlm.nih.gov/pubmed/21501112"
            ],
            "ideal_answer": [
                "Clinical trials have demonstrated that bapineuzumab, a humanized monoclonal antibody against the end terminus of amyloid plaques, is not effective for treatment of patients with Alzheimer's disease. The burden of beta amyloid plaques was reduced in response to bapineuzumab therapy. However, bapineuzumab therapy did not improve cognitive functioning and was associated with significant adverse effects in Alzheimer's disease patients."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D016896",
                "http://www.disease-ontology.org/api/metadata/DOID:10652",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D000544"
            ],
            "type": "yesno",
            "id": "530cefaaad0bf1360c000004",
            "snippets": [
                {
                    "offsetInBeginSection": 517,
                    "offsetInEndSection": 666,
                    "text": " Thus far, results from two large phase 3 trial programs with bapineuzumab and solaneuzumab, respectively, have brought rather disappointing results.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24216217",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 806,
                    "offsetInEndSection": 1043,
                    "text": "More recently, in phase III studies, bapineuzumab has been discontinued because it did not prove clinically effective (despite its significant effect on biomarkers), while solaneuzumab has been found effective in slowing AD progression. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23931438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 830,
                    "offsetInEndSection": 1137,
                    "text": "Passive immunotherapy with monoclonal antibodies (mAbs) against A\u03b2 is in late clinical development but recently the two most advanced mAbs, Bapineuzumab and Solanezumab, targeting an N-terminal or central epitope, respectively, failed to meet their target of improving or stabilizing cognition and function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23663286",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 294,
                    "offsetInEndSection": 607,
                    "text": "The marginal effects observed in recent clinical studies of solanezumab, targeting monomeric A\u03b2, and bapineuzumab, targeting amyloid plaques, prompted expert comments that drug discovery efforts in Alzheimer's disease should focus on soluble forms of A\u03b2 rather than fibrillar A\u03b2 deposits found in amyloid plaques.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582316",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 649,
                    "offsetInEndSection": 852,
                    "text": "Phase III trials showed that bapineuzumab failed to improve cognitive and functional performances in AD patients, and was associated with a high incidence of amyloid-related imaging abnormalities (ARIA).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23574434",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 809,
                    "offsetInEndSection": 990,
                    "text": "Clinical trials on various drugs, including AN1792, bapineuzumab, and solanezumab, have been carried out; however, all trials have failed to demonstrate apparent clinical benefits. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23568994",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1790,
                    "offsetInEndSection": 1904,
                    "text": "Despite the alteration in biochemical composition, all 3 immunized subjects exhibited continued cognitive decline.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23555764",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 213,
                    "text": "Despite negative topline phase 3 clinical trial results for bapineuzumab and solanezumab in mild to moderate AD, findings from these trials and recent advances suggest renewed optimism for anti-amyloid therapies. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23299380",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 372,
                    "text": "The lack of progress in the development of disease-modifying therapy in Alzheimer's disease (AD) was highlighted recently by the cessation of a phase 3 clinical trial studying the effects of bapineuzumab on mild to moderate disease. No treatment benefit was apparent, whereas several serious side effects occurred more commonly in the treatment group compared to placebo. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23085451",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 107,
                    "offsetInEndSection": 595,
                    "text": "Clinical studies using the N-terminal-directed anti-A\u03b2 antibody bapineuzumab have demonstrated reduced brain PET-Pittsburg-B signals, suggesting the reduction of A\u03b2 plaques, and reduced levels of total and phosphorylated tau protein in the CSF of treated AD patients. Preclinical studies using 3D6 (the murine form of bapineuzumab) have demonstrated resolution of A\u03b2 plaque and vascular burdens, neuritic dystrophy, and preservation of synaptic density in the transgenic APP mouse models.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22357853",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1083,
                    "offsetInEndSection": 1424,
                    "text": "The clinical results of the initial studies with bapineuzumab were equivocal in terms of cognitive benefit. The occurrence of vasogenic edema after bapineuzumab, and more rarely brain microhemorrhages (especially in Apo E \u03b54 carriers), has raised concerns on the safety of these antibodies directed against the N-terminus of the A\u03b2 peptide. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22339463",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 852,
                    "offsetInEndSection": 1330,
                    "text": " The most advanced of these immunological approaches is bapineuzumab, composed of humanized anti-A\u03b2 monoclonal antibodies, that has been tested in two Phase II trials, demonstrating to reduce A\u03b2 burden in the brain of AD patients. However, the preliminary cognitive efficacy of bapineuzumab appears uncertain. The occurrence of vasogenic edema, especially in apolipoprotein E 4 carriers, may limit its clinical use and have led to abandon the highest dose of the drug (2 mg/kg).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21592055",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 216,
                    "offsetInEndSection": 523,
                    "text": "However, the preliminary cognitive efficacy of bapineuzumab, a humanized anti-A\u03b2 monoclonal antibody, appears uncertain. Moreover, the occurrence of vasogenic edema and, more rarely, brain microhemorrhages, especially in apolipoprotein E \u03f54 carriers, have led to abandoning of the highest dose of the drug. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501112",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 852,
                    "offsetInEndSection": 1118,
                    "text": "However, the preliminary equivocal cognitive results obtained with bapineuzumab as well as the detrimental cognitive effects observed with semagacestat, a potent \u03b3-secretase inhibitor, raise the possibility that targeting A\u03b2 may not be clinically efficacious in AD. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21501112",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 398,
                    "offsetInEndSection": 1209,
                    "text": "The patient received four bapineuzumab infusions over a 39 week period. During the course of this treatment, there was no remarkable change in cognitive impairment as determined by MMSE scores. Forty-eight days after the fourth bapineuzumab infusion was given, MRI revealed that the patient had developed lacunar infarcts and possible vasogenic edema, probably related to immunotherapy, but a subsequent MRI scan 38 days later demonstrated resolution of vasogenic edema. The patient expired due to acute congestive heart failure complicated by progressive AD and cerebrovascular accident 378 days after the first bapineuzumab infusion and 107 days after the end of therapy. Neuropathological and biochemical analysis did not produce evidence of lasting plaque regression or clearance of A\u03b2 due to immunotherapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21263194",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1543,
                    "offsetInEndSection": 1726,
                    "text": "These results suggest that, in this particular case, bapineuzumab immunotherapy neither resulted in detectable clearance of amyloid plaques nor prevented further cognitive impairment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21263194",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 805,
                    "offsetInEndSection": 1027,
                    "text": "Bapineuzumab has been shown to reduce A\u03b2 burden in the brain of AD patients. However, its preliminary cognitive efficacy appears uncertain, particularly in ApoE \u03b54 carriers, and vasogenic edema may limit its clinical use. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21091109",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 938,
                    "offsetInEndSection": 1276,
                    "text": "Bapineuzumab appears capable of reducing the cerebral beta-amyloid peptide burden in patients with Alzheimer's disease. However, particularly in APOE 4 carriers, its ability to slow disease progression remains uncertain, and vasogenic edema - a dose-limiting and potentially severe adverse reaction - may limit its clinical applicability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20497044",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 161,
                    "offsetInEndSection": 634,
                    "text": "The first is a phase 2 study of passive immunotherapy with bapineuzumab, a humanized anti-Abeta monoclonal antibody directed against the N-terminus of Abeta. This trial showed no differences within dose cohorts on the primary efficacy analysis. Exploratory analyses showed potential treatment differences on cognitive and functional endpoints in study completers and apolipoprotein E epsilon4 noncarriers. A safety concern was the occurrence of reversible vasogenic edema. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20388189",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 529,
                    "offsetInEndSection": 836,
                    "text": "The first passive immunotherapy trial with bapineuzumab, a humanized monoclonal antibody against the end terminus of Abeta, also encountered some dose dependent adverse events during the Phase II portion of the study, vasogenic edema in 12 cases, which were significantly over represented in ApoE4 carriers.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20205639",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is actin present in the nucleus?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29568381",
                "http://www.ncbi.nlm.nih.gov/pubmed/30193156",
                "http://www.ncbi.nlm.nih.gov/pubmed/30019087",
                "http://www.ncbi.nlm.nih.gov/pubmed/29925947",
                "http://www.ncbi.nlm.nih.gov/pubmed/30312531"
            ],
            "ideal_answer": [
                "Yes,\nThe revitalization of research into nuclear actin occurred after it was found that cellular stresses induce the nuclear localization and alter the structure of actin."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5ca0fdb0ecadf2e73f000049",
            "snippets": [
                {
                    "offsetInBeginSection": 641,
                    "offsetInEndSection": 812,
                    "text": "Moreover, inhibition of ATM kinase or deficiency in nuclear actin polymerization causes carcinogenic RET/PTC chromosome rearrangements after DSBs induction in human cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29568381",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1024,
                    "offsetInEndSection": 1209,
                    "text": " Our findings establish that nuclear actin-based mobility shapes chromatin organization by generating repair domains that are essential for homology-directed repair in eukaryotic cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29925947",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 579,
                    "offsetInEndSection": 751,
                    "text": "The discovery of nuclear actin opened new perspective on the field, suggesting that the nuclear activities of actin reflect the functions of primordial actin-like proteins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30019087",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 114,
                    "offsetInEndSection": 282,
                    "text": " The revitalization of research into nuclear actin occurred after it was found that cellular stresses induce the nuclear localization and alter the structure of actin. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30312531",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 190,
                    "text": "While it is long known that actin is part of the nuclear proteome, its properties and functions as regulated, functional and dynamically assembled actin filaments are only recently emerging.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30193156",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can Freund's complete adjuvant induce arthritis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31857078",
                "http://www.ncbi.nlm.nih.gov/pubmed/31721330",
                "http://www.ncbi.nlm.nih.gov/pubmed/32048253",
                "http://www.ncbi.nlm.nih.gov/pubmed/32043729"
            ],
            "ideal_answer": [
                "Yes, Rheumatoid arthritis (RA) was induced by Freund's Complete Adjuvant (FCA; 1 mg/0.1 ml paraffin oil), injected subcutaneously on days 0, 30 and 40"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "60328f351cb411341a000145",
            "snippets": [
                {
                    "offsetInBeginSection": 243,
                    "offsetInEndSection": 286,
                    "text": "complete Freund's adjuvant (CFA) induced RA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31721330",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 203,
                    "offsetInEndSection": 266,
                    "text": "The RA model was established using Freund's complete adjuvant, ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31857078",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 400,
                    "offsetInEndSection": 546,
                    "text": " Rheumatoid arthritis (RA) was induced by Freund's Complete Adjuvant (FCA; 1\u00a0mg/0.1\u00a0ml paraffin oil), injected subcutaneously on days 0, 30 and 40",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32048253",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 443,
                    "offsetInEndSection": 586,
                    "text": "The rats were made arthritic using a subcutaneous injection with 0.1\u2009ml complete Freund's adjuvant (CFA) into the footpad of the left hind paw.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32043729",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "SGOT is an abbreviation for an enzyme other wise known as alanine amino transferase, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/5470040",
                "http://www.ncbi.nlm.nih.gov/pubmed/15803962",
                "http://www.ncbi.nlm.nih.gov/pubmed/589307",
                "http://www.ncbi.nlm.nih.gov/pubmed/21375200",
                "http://www.ncbi.nlm.nih.gov/pubmed/17880731"
            ],
            "ideal_answer": [
                "patients with aspartate amino transferase (SGOT), alanine amino transferase (SGPT),",
                "Aspartate transaminase or aspartate aminotransferase, also known as AspAT/ASAT/AAT/AST  is also known as  serum glutamic oxaloacetic transaminase SGOT",
                "patients with aspartate amino transferase (SGOT), alanine amino transferase (SGPT), aspartate aminotransferase (AST-SGOT), alanine amino-transferase (ALT-SGPT)",
                "patients with aspartate amino transferase (SGOT), alanine amino transferase (SGPT), Alanine amino transferase (SGPT), "
            ],
            "exact_answer": "no",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D004798"
            ],
            "type": "yesno",
            "id": "5a67b48cb750ff4455000010",
            "snippets": [
                {
                    "offsetInBeginSection": 433,
                    "offsetInEndSection": 516,
                    "text": "patients with aspartate amino transferase (SGOT), alanine amino transferase (SGPT),",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21375200",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 376,
                    "offsetInEndSection": 410,
                    "text": "Alanine amino transferase (SGPT), ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17880731",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 474,
                    "offsetInEndSection": 549,
                    "text": "aspartate aminotransferase (AST-SGOT), alanine amino-transferase (ALT-SGPT)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15803962",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 550,
                    "text": "Mean values of glutamate dehydrogenase (GDH), serum aspartate and alanine transferase (SGOT and SGPT), ornithine carbamoyltransferase (OCT), and gamma-glutamyltranspeptidase (gamma-GTP) tended to rise with increasing liver cell necrosis, though values of SGOT, SGPT, OCT, and gamma-GTP showed considerable overlap between the 32 patients with histologically proved hepatitis and the 68 without.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/589307",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 229,
                    "text": "Serum aspartate aminotransferase (SGOT), alanine aminotransferase (SGPT), creatinine phosphokinase (CPK), and butyric acid dehydrogenase (BDH) were determined in 94 patients before, 1(1/2) hours, and 24 hours after cardioversion.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/5470040",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 379,
                    "offsetInEndSection": 627,
                    "text": "The study excluded by screening for AntiHCV, HBsAg and patients with aspartate amino transferase (SGOT), alanine amino transferase (SGPT), GGT levels more than three times the normal and subject with a total leukocyte count more than 10,000/microl.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21375200",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 293,
                    "offsetInEndSection": 488,
                    "text": "Complete blood picture, differential leukocyte count, and serum levels of Estrogen, Alanine amino transferase (SGPT), Aspartate amino transferase (SGOT), total protein and albumin were estimated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17880731",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there an association between carcinoid syndrome and mitral valve disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/7453210",
                "http://www.ncbi.nlm.nih.gov/pubmed/11568027",
                "http://www.ncbi.nlm.nih.gov/pubmed/22364692",
                "http://www.ncbi.nlm.nih.gov/pubmed/8131775",
                "http://www.ncbi.nlm.nih.gov/pubmed/26564596",
                "http://www.ncbi.nlm.nih.gov/pubmed/7236050",
                "http://www.ncbi.nlm.nih.gov/pubmed/261962"
            ],
            "ideal_answer": [
                "Yes, mitral valve damage was reported in patients with carcinoid syndrome."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D001244",
                "http://www.disease-ontology.org/api/metadata/DOID:8600"
            ],
            "type": "yesno",
            "id": "5a67a550b750ff4455000009",
            "snippets": [
                {
                    "offsetInBeginSection": 831,
                    "offsetInEndSection": 1076,
                    "text": "Other concomitant operations included mitral valve procedure (11%), aortic valve procedure (9%), patent foramen ovale or atrial septal defect closure (23%), cardiac metastasectomies or biopsy (4%), and simultaneous coronary artery bypass (11%). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26564596",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 847,
                    "offsetInEndSection": 994,
                    "text": "High circulating serotonin (carcinoid syndrome) and serotoninergic drugs are known to cause valvulopathy that shares pathologic features with DMVD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22364692",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 794,
                    "offsetInEndSection": 1054,
                    "text": "Surgery included tricuspid valve replacement in all patients, pulmonary valve replacement in 3 and valvectomy in 7, mitral valve replacement in 6 and repair in 1, aortic valve replacement in 4 and repair in 2, CABG in 2, and patent foramen ovale closure in 5. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11568027",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 410,
                    "text": "We report two observations of significant left heart involvement in patients with the carcinoid syndrome assessed by transthoracic and transoesophageal echocardiography. Echocardiographic lesions of this kind have only been reported twice. In the present cases, there was mitral involvement with mitral regurgitation in one case and a mitro-aortic involvement with mitral and aortic regurgitation in the other.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8131775",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 311,
                    "text": "An observation of carcinoid syndrome in a woman of 47 suffering from malignant carcinoid of the ileum with metastases into the liver and right ovary is described. The clinical picture included diarrhea, heat waves, bronchospasms, hypertension, hyperserotoninemia, affection of the mitral valve and left atrium. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7236050",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 276,
                    "text": "A case of carcinoid syndrome, stemming from a tumor of the large intestine with hepatic metastases, is reported. Clinical features included cardiac disease with triple valvular lesion: tricuspid insufficiency with stenosis, pulmonary artery stenosis and mitral insufficiency. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/261962",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 848,
                    "offsetInEndSection": 994,
                    "text": "High circulating serotonin (carcinoid syndrome) and serotoninergic drugs are known to cause valvulopathy that shares pathologic features with DMVD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22364692",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is galcanezumab effective for treatment of migraine?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29616494",
                "http://www.ncbi.nlm.nih.gov/pubmed/30341990",
                "http://www.ncbi.nlm.nih.gov/pubmed/29310444",
                "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
                "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
                "http://www.ncbi.nlm.nih.gov/pubmed/30182284",
                "http://www.ncbi.nlm.nih.gov/pubmed/29089894",
                "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
                "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
                "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
                "http://www.ncbi.nlm.nih.gov/pubmed/29848108",
                "http://www.ncbi.nlm.nih.gov/pubmed/30446596",
                "http://www.ncbi.nlm.nih.gov/pubmed/30378008"
            ],
            "ideal_answer": [
                "Yes. Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide that is used for migraine prevention."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c6f15577c78d69471000053",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 173,
                    "text": "Importance: Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2102,
                    "offsetInEndSection": 2353,
                    "text": "Conclusions and Relevance: Monthly subcutaneous injections of galcanezumab, both 120 mg and 300 mg, demonstrated efficacy (repeated-measures analysis) for the preventive treatment of migraine and support further development in larger phase 3 studies. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 288,
                    "text": "PURPOSE OF REVIEW: Monoclonal antibodies (mAbs) targeting the calcitonin-gene-related peptide (CGRP) pathway have been developed for episodic and chronic migraine prevention, either through binding the CGRP ligand (eptinezumab, fremanezumab, galcanezumab) or the CGRP receptor (erenumab).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29432219",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "Background Safety findings from a Phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene-related peptide, for prevention of migraine (NCT02163993) are reported here.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310444",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29310444",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1160,
                    "offsetInEndSection": 1633,
                    "text": "Currently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene-related peptide (eptinezumab, galcanezumab, fremanezumab) and the calcitonin gene-related peptide receptor (erenumab). To date, these monoclonal antibodies have shown promising efficacy in clinical trials, with no major safety concerns. If ongoing long-term studies show that their efficacy can be maintained, this may herald a new era for effective antimigraine therapies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29697153",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 778,
                    "text": "CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 118,
                    "offsetInEndSection": 360,
                    "text": "Four monoclonal antibodies (mAbs) targeting the CGRP pathway are currently under evaluation for the prevention of episodic and chronic migraine: eptinezumab (ALD403), fremanezumab (TEV-48125), galcanezumab (LY2951742), and erenumab (AMG334). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29616494",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-related peptide, used for migraine prevention.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29848108",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Efficacy and safety of galcanezumab for the prevention of episodic migraine: Results of the EVOLVE-2 Phase 3 randomized controlled clinical trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29848108",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 516,
                    "offsetInEndSection": 723,
                    "text": "Galcanezumab induced a robust, dose-dependent, and durable inhibition of capsaicin-induced increase in DBF, supporting the continued clinical development of galcanezumab for prophylaxis in migraine patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29089894",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 276,
                    "text": "The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.Based on the results of this meta-analysis, CGRP monoclonal antibodies significantly reduced the monthly migraine days and acute migraine-specific medication. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30182284",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "Importance\nGalcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1709,
                    "offsetInEndSection": 1817,
                    "text": "Galcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446596",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 366,
                    "text": "BACKGROUND\nGalcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (CGRP) and has demonstrated efficacy in reducing migraine headache days (MHD) in patients with episodic and chronic migraine.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30341990",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 297,
                    "text": "BACKGROUND\nGalcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (\u22646-month of treatment) a reduction in the number of migraine headache days and improved patients' functioning.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2033,
                    "offsetInEndSection": 2210,
                    "text": "CONCLUSION\nTwelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 522,
                    "offsetInEndSection": 777,
                    "text": "CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2114,
                    "offsetInEndSection": 2363,
                    "text": "Conclusions and Relevance\nMonthly subcutaneous injections of galcanezumab, both 120 mg and 300 mg, demonstrated efficacy (repeated-measures analysis) for the preventive treatment of migraine and support further development in larger phase 3 studies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "Importance Galcanezumab (LY2951742), a monoclonal antibody against calcitonin gene-related peptide (CGRP), is one of a novel class of new medicines for migraine prevention.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29255900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 297,
                    "text": "BACKGROUND Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies (\u22646-month of treatment) a reduction in the number of migraine headache days and improved patients' functioning.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 120,
                    "offsetInEndSection": 366,
                    "text": "BACKGROUND Galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide (CGRP) and has demonstrated efficacy in reducing migraine headache days (MHD) in patients with episodic and chronic migraine.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30341990",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1026,
                    "offsetInEndSection": 1333,
                    "text": "Both galcanezumab dose groups demonstrated greater overall mean reduction in the number of monthly MHDs compared to placebo (placebo -2.7, galcanezumab 120 mg -4.8, galcanezumab 240 mg -4.6) (<br><b>CONCLUSIONS</b>: Both doses of galcanezumab were superior to placebo in reducing the number of monthly MHDs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446596",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1334,
                    "offsetInEndSection": 1678,
                    "text": "Galcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.<br><b>CLINICALTRIALSGOV IDENTIFIER</b>: NCT02614261.<br><b>CLASSIFICATION OF EVIDENCE</b>: This interventional study provides Class I evidence that galcanezumab is superior to placebo in the reduction of the number of monthly MHDs.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446596",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 268,
                    "offsetInEndSection": 412,
                    "text": "In September 2018, the US FDA approved galcanezumab as a once-monthly subcutaneous injection for the preventive treatment of migraine in adults.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30378008",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 701,
                    "offsetInEndSection": 860,
                    "text": "This article summarizes the milestones in the development of galcanezumab leading to its first approval for the preventive treatment of migraine in adults.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30378008",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1678,
                    "offsetInEndSection": 1786,
                    "text": "Galcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30446596",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 701,
                    "offsetInEndSection": 856,
                    "text": "This article summarizes the milestones in the development of galcanezumab leading to its first approval for the preventive treatment of migraine in adults.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30378008",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2003,
                    "offsetInEndSection": 2169,
                    "text": "Twelve months of treatment with self-administered injections of galcanezumab was safe and associated with a reduction in the number of monthly migraine headache days.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30413151",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can gene therapy restore auditory function?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28165476"
            ],
            "ideal_answer": [
                "Yes, gene therapy can restore auditory function."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5be94b87133db5eb78000020",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Gene therapy restores auditory and vestibular function in a mouse model of Usher syndrome type 1c.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28165476",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 706,
                    "offsetInEndSection": 1102,
                    "text": "We demonstrate recovery of gene and protein expression, restoration of sensory cell function, rescue of complex auditory function and recovery of hearing and balance behavior to near wild-type levels. The data represent unprecedented recovery of inner ear function and suggest that biological therapies to treat deafness may be suitable for translation to humans with genetic inner ear disorders.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28165476",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has tocilizumab been assessed against Covid-19?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/33262810"
            ],
            "ideal_answer": [
                "Preliminary clinical results have indicated that tocilizumab, can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "60258ebe1cb411341a0000a8",
            "snippets": [
                {
                    "offsetInBeginSection": 398,
                    "offsetInEndSection": 673,
                    "text": "Preliminary clinical results have indicated that antagonism of the IL-6 receptor (IL-6R), including with the FDA-approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33262810",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is vemurafenib used for thyroid cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27460442",
                "http://www.ncbi.nlm.nih.gov/pubmed/27554612",
                "http://www.ncbi.nlm.nih.gov/pubmed/27754804",
                "http://www.ncbi.nlm.nih.gov/pubmed/24987354",
                "http://www.ncbi.nlm.nih.gov/pubmed/23489023",
                "http://www.ncbi.nlm.nih.gov/pubmed/26751190",
                "http://www.ncbi.nlm.nih.gov/pubmed/24756795",
                "http://www.ncbi.nlm.nih.gov/pubmed/26735176",
                "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                "http://www.ncbi.nlm.nih.gov/pubmed/26284586",
                "http://www.ncbi.nlm.nih.gov/pubmed/22649416",
                "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
                "http://www.ncbi.nlm.nih.gov/pubmed/26636651",
                "http://www.ncbi.nlm.nih.gov/pubmed/27127178",
                "http://www.ncbi.nlm.nih.gov/pubmed/24262022",
                "http://www.ncbi.nlm.nih.gov/pubmed/27432558",
                "http://www.ncbi.nlm.nih.gov/pubmed/25467940"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/rxnorm/id/1147220",
                    "o": "VEMURAFENIB"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C3192263",
                    "o": "http://linkedlifedata.com/resource/umls/label/A20020623"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A20020623",
                    "o": "VEMURAFENIB"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/rxnorm/id/1147220",
                    "o": "http://linkedlifedata.com/resource/rxnorm/label/4224011"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/rxnorm/label/4224011",
                    "o": "VEMURAFENIB"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/chembl/synonym/691867_Vemurafenib_USAN",
                    "o": "Vemurafenib"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C3192263",
                    "o": "http://linkedlifedata.com/resource/umls/label/A19613644"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A19613644",
                    "o": "Vemurafenib"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C3192263",
                    "o": "http://linkedlifedata.com/resource/umls/label/A19649207"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A19649207",
                    "o": "Vemurafenib"
                }
            ],
            "ideal_answer": [
                "Yes. Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:3963",
                "http://www.disease-ontology.org/api/metadata/DOID:1781",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013964"
            ],
            "type": "yesno",
            "id": "58848ea5e56acf517600000e",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 193,
                    "text": "Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 117,
                    "offsetInEndSection": 314,
                    "text": "Vemurafenib, an oncogenic BRAF kinase inhibitor approved for BRAF-positive melanoma, showed clinical benefit in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2338,
                    "offsetInEndSection": 2559,
                    "text": "INTERPRETATION: Vemurafenib showed antitumour activity in patients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodine who had never been treated with a multikinase inhibitor. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27460442",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "Efficacy and tolerability of vemurafenib in patients with BRAF(V600E) -positive papillary thyroid cancer: M.D. Anderson Cancer Center off label experience.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1685,
                    "offsetInEndSection": 1840,
                    "text": "CONCLUSIONS: Vemurafenib is a potentially effective and well-tolerated treatment strategy in patients with advanced PTC harboring the BRAF(V600E) mutation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 459,
                    "text": "The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine-refractory BRAF-mutant papillary thyroid cancer suggest response rates of approximately 30-40%.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25467940",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "text": "Use of vemurafenib in anaplastic thyroid carcinoma: a case report.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26176686",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1212,
                    "offsetInEndSection": 1361,
                    "text": "Finally, we found that propranolol can amplify the cytotoxicity of vemurafenib and sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 399,
                    "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.OBJECTIVE: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.DESIGN: A retrospective review at MD Anderson Cancer Center.METHODS: The best responses were evaluated using RECIST v1.1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 361,
                    "text": "Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.A retrospective review at MD Anderson Cancer Center.The best responses were evaluated using RECIST v1.1",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 400,
                    "text": "CONTEXT: Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.OBJECTIVE: To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.DESIGN: A retrospective review at MD Anderson Cancer Center.METHODS: The best responses were evaluated using RECIST v1.1. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1220,
                    "offsetInEndSection": 1369,
                    "text": "Finally, we found that propranolol can amplify the cytotoxicity of vemurafenib and sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1237,
                    "offsetInEndSection": 1415,
                    "text": "Metformin or rapamycin adjuvant treatment may provide clinical benefits with minimal side effects to BRAFV600E-positive advanced thyroid cancer patients treated with vemurafenib.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 362,
                    "text": "Vemurafenib, a selective BRAF inhibitor, appears to have promising clinical activity in patients with papillary thyroid cancer (PTC) harboring the BRAF(V600E) mutation.To determine the efficacy and safety of vemurafenib when used outside of a clinical trial.A retrospective review at MD Anderson Cancer Center.The best responses were evaluated using RECIST v1.1.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25353071",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1515,
                    "offsetInEndSection": 1727,
                    "text": "Our data demonstrate that vemurafenib induces ER stress response-mediated autophagy in thyroid cancer and autophagy inhibition may be a beneficial strategy to sensitize BRAF-mutant thyroid cancer to vemurafenib..",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 552,
                    "offsetInEndSection": 729,
                    "text": "Combination of vemurafenib and metformin decreased cell viability and increased apoptosis in both BCPAP papillary thyroid cancer cells and 8505c anaplastic thyroid cancer cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 74,
                    "text": "Targeting autophagy sensitizes BRAF-mutant thyroid cancer to vemurafenib.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27432558",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 83,
                    "text": "mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26284586",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1010,
                    "offsetInEndSection": 1092,
                    "text": "Vemurafenib induced a high level of autophagy in BRAF-mutant thyroid cancer cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27754804",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can the iPS cell technology be used in Fanconi anemia therapy?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20224565",
                "http://www.ncbi.nlm.nih.gov/pubmed/19483674"
            ],
            "ideal_answer": [
                "iPS cell technology can be used for the generation of disease-corrected, patient-specific cells with potential value for cell therapy applications in Fanconi anemia."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D057026",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051856",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005199",
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D064987",
                "http://www.disease-ontology.org/api/metadata/DOID:13636"
            ],
            "type": "yesno",
            "id": "54edef0594afd6150400000d",
            "snippets": [
                {
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 507,
                    "text": "We explain a protocol for the reproducible generation of genetically corrected iPSCs starting from the skin biopsies of Fanconi anemia patients using retroviral transduction with OCT4, SOX2 and KLF4",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20224565",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 509,
                    "offsetInEndSection": 645,
                    "text": "Before reprogramming, the fibroblasts and/or keratinocytes of the patients are genetically corrected with lentiviruses expressing FANCA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20224565",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 96,
                    "text": "Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19483674",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 610,
                    "text": "Here we show that, on correction of the genetic defect, somatic cells from Fanconi anaemia patients can be reprogrammed to pluripotency to generate patient-specific iPS cells. These cell lines appear indistinguishable from human embryonic stem cells and iPS cells from healthy individuals",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19483674",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 612,
                    "offsetInEndSection": 823,
                    "text": "Most importantly, we show that corrected Fanconi-anaemia-specific iPS cells can give rise to haematopoietic progenitors of the myeloid and erythroid lineages that are phenotypically normal, that is, disease-free",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19483674",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Turcot syndrome associated with glioblastoma?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24310308",
                "http://www.ncbi.nlm.nih.gov/pubmed/9505220",
                "http://www.ncbi.nlm.nih.gov/pubmed/2165772",
                "http://www.ncbi.nlm.nih.gov/pubmed/20657316",
                "http://www.ncbi.nlm.nih.gov/pubmed/10921328",
                "http://www.ncbi.nlm.nih.gov/pubmed/8127448",
                "http://www.ncbi.nlm.nih.gov/pubmed/11339660",
                "http://www.ncbi.nlm.nih.gov/pubmed/3032534",
                "http://www.ncbi.nlm.nih.gov/pubmed/8025896",
                "http://www.ncbi.nlm.nih.gov/pubmed/16000562",
                "http://www.ncbi.nlm.nih.gov/pubmed/11907360",
                "http://www.ncbi.nlm.nih.gov/pubmed/22676959",
                "http://www.ncbi.nlm.nih.gov/pubmed/2540108",
                "http://www.ncbi.nlm.nih.gov/pubmed/16144131",
                "http://www.ncbi.nlm.nih.gov/pubmed/19822006",
                "http://www.ncbi.nlm.nih.gov/pubmed/16960645",
                "http://www.ncbi.nlm.nih.gov/pubmed/11975096",
                "http://www.ncbi.nlm.nih.gov/pubmed/9343324",
                "http://www.ncbi.nlm.nih.gov/pubmed/15701281",
                "http://www.ncbi.nlm.nih.gov/pubmed/6307612",
                "http://www.ncbi.nlm.nih.gov/pubmed/23119205",
                "http://www.ncbi.nlm.nih.gov/pubmed/8387650",
                "http://www.ncbi.nlm.nih.gov/pubmed/9695069",
                "http://www.ncbi.nlm.nih.gov/pubmed/17138070",
                "http://www.ncbi.nlm.nih.gov/pubmed/23320220",
                "http://www.ncbi.nlm.nih.gov/pubmed/19156169",
                "http://www.ncbi.nlm.nih.gov/pubmed/7515658",
                "http://www.ncbi.nlm.nih.gov/pubmed/10223463",
                "http://www.ncbi.nlm.nih.gov/pubmed/6274254",
                "http://www.ncbi.nlm.nih.gov/pubmed/23729388",
                "http://www.ncbi.nlm.nih.gov/pubmed/9508118"
            ],
            "triples": [
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PMSL2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "Turcot syndrome with glioblastoma, 276300"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PMSL2",
                    "o": "PMSL2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/COCA2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "Turcot syndrome with glioblastoma, 276300"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/COCA2",
                    "o": "COCA2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MLH1"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MLH1",
                    "o": "MLH1"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/MLH1",
                    "o": "http://www.dbpedia.org/resource/MLH1"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HNPCC4"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HNPCC4",
                    "o": "HNPCC4"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HNPCC2"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/HNPCC2",
                    "o": "HNPCC2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/associatedGene",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PMS2"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PMS2",
                    "o": "PMS2"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/genes/PMS2",
                    "o": "http://www.dbpedia.org/resource/PMS2"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/diseaseSubtypeOf",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1156"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#exactMatch",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1156",
                    "o": "http://www.dbpedia.org/resource/Turcot_syndrome"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/name",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1156",
                    "o": "Turcot_syndrome"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/diseaseSubtypeOf",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/1156"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/treat",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/primaryAccessionNo",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "DB03431"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "Adenosine-5'-Diphosphate"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/secondaryAccessionNumber",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "expt00436"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/chemicalIupacName",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/possibleDiseaseTarget",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB03431",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/possibleDrug",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/chemicalIupacName",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl (dihydroxyphosphinothioyloxy-hydroxyphosphoryl) hydrogen phosphate"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/primaryAccessionNo",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "DB02930"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "Phosphothiophosphoric Acid-Adenylate Ester"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/secondaryAccessionNumber",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "expt00458"
                },
                {
                    "p": "http://linkedlifedata.com/resource/relationontology/treat",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugbank/possibleDiseaseTarget",
                    "s": "http://www4.wiwiss.fu-berlin.de/drugbank/resource/drugs/DB02930",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7628038",
                    "o": "C3938"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608078",
                    "o": "MMRCS"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615647",
                    "o": "BRAIN TUMOR-POLYPOSIS SYNDROME 1"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16608079"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18467817",
                    "o": "Turcot syndrome"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608080",
                    "o": "BTPS1"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16608080"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16615647"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16608078"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16608081"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/prefMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16749653"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A7628038"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7628038",
                    "o": "Turcot Syndrome"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608079",
                    "o": "MMR DEFICIENCY"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615646",
                    "o": "CHILDHOOD CANCER SYNDROME"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16609958",
                    "o": "BTP1 SYNDROME"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18458641"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16749653",
                    "o": "Turcot syndrome (disorder)"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458641",
                    "o": "CNS tumors with Familial polyposis of the colon"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16615646"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A18467817"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16611904",
                    "o": "MISMATCH REPAIR CANCER SYNDROME"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16619491"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16609958"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608081",
                    "o": "TURCOT SYNDROME"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/altMetaMap",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/label/A16611904"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16619491",
                    "o": "MISMATCH REPAIR DEFICIENCY"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458641",
                    "o": "C536928"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18467817",
                    "o": "C536928"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608078",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608079",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608080",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608081",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16609958",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16611904",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615646",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615647",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16619491",
                    "o": "276300"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608078",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608079",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608080",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16608081",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16609958",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16611904",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615646",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16615647",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16619491",
                    "o": "OMIM"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18458641",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A18467817",
                    "o": "MeSH"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7628038",
                    "o": "NCI Thesaurus"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A16749653",
                    "o": "Metathesaurus Names"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#definition",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "NCI: The syndrome of polyposis coli, colon cancer and brain tumors."
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520870"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R69865242",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108937798"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/omim",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://bio2rdf.org/omim:120436"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R119892539",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54264357",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527990"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520871"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108533303",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108535497",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54326923"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108512677",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527985",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108535496",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/chromosomalLocation",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/3p21.3"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292285"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108508498",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108533841",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/omim",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://bio2rdf.org/omim:600259"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108535497"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108533304"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292286"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108513938",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520859"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108507257",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/omimPage",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=600259"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527988",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292287"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527984",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108533841"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R69798948",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108537658"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292288"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108513096",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108533302"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226085",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R69830643"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520857"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226396",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108514384",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108535496"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108507331",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108533303"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292289"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54393456"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108514872"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226673",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108541476",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520869"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527986",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520858"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54263586",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527985"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108512676",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527989",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520868"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R119807587"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108533302",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108513097",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R120073491",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527986"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520867"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226105",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108512678",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108508077",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108537658",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108506793",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520856"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R119807589"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520866"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527987"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54438032"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108541476"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108512226",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108510291",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520865"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R69877248",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108536636",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527984"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520855"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R119807588"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527988"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226224",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54438031"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527990",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520864"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520854"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R113837386",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108527987",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108508424",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108527989"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108536636"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108508968",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#inScheme",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R69826314"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520863"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520874"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R113845414"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520862"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54226336",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108533304",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108507918",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R119979672",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54166689",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/chromosomalLocation",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/chromosomalLocation/7p22"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520861"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108507347",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108508425",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R108937799",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520872"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R54292290"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R69817576"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/class",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4101",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Cancer"
                },
                {
                    "p": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseasome/class",
                    "s": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseases/4102",
                    "o": "http://www4.wiwiss.fu-berlin.de/diseasome/resource/diseaseClass/Cancer"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relatedConcept",
                    "s": "http://linkedlifedata.com/resource/umls/relation/R54228336",
                    "o": "http://linkedlifedata.com/resource/umls/id/C0265325"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520860"
                },
                {
                    "p": "http://linkedlifedata.com/resource/umls/relation",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0265325",
                    "o": "http://linkedlifedata.com/resource/umls/relation/R108520873"
                }
            ],
            "ideal_answer": [
                "Yes, Turcot syndrome is associated with glioblastoma. Turcot syndrome is an autosomal recessive disorder clinically characterized by the occurrence of primary glial tumors of the central nervous system, including glioblastoma, and adenomatous colonic polyps during the first or second decades of life, with a spectrum of clinical features such as \"caf\u00e9-au-lait\" spots, axillary freckling, and hyperpigmented spots."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:3073",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013577",
                "http://www.disease-ontology.org/api/metadata/DOID:225",
                "http://www.disease-ontology.org/api/metadata/DOID:3068",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005909"
            ],
            "type": "yesno",
            "id": "533581f5d6d3ac6a3400004d",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 330,
                    "text": "Turcot syndrome is an autosomal recessive disorder clinically characterized by the occurrence of primary tumors of the central nervous system and adenomatous colonic polyps during the first or second decades of life, with a spectrum of clinical features such as \"caf\u00e9-au-lait\" spots, axillary freckling, and hyperpigmented spots. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23320220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 397,
                    "offsetInEndSection": 541,
                    "text": "We present the case of a 20-year-old male with a clinical presentation of both glioblastoma multiforme and multiple adenomatous colonic polyps. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23320220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 316,
                    "text": "Turcot syndrome (TS) is a rare hereditary disorder clinically characterized by the occurrence of primary tumors of the colon and the central nervous system (CNS). Here we present the case of an 11-year-old boy with a synchronous clinical presentation of both glioblastoma multiforme (GBM) and colonic adenocarcinoma.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23119205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 494,
                    "offsetInEndSection": 681,
                    "text": "Based on this case study, the synchronous presentation of glioblastoma multiforme and adenocarcinoma of the colon might suggest a shorter survival rate for patients with Turcot syndrome. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23119205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 526,
                    "text": "A 15-year-old boy was admitted with the diagnosis of colonic polyposis, and during a 2-year follow-up, he underwent operation for right parieto-occipital anaplastic astrocytoma, left-side colonic non-Hodgkin lymphoma (NHL) and cerebella glioblastoma which were all confirmed by histology. Although cases of Turcot's syndrome (TS) (colonic polyposis and primary brain tumour occurring in the same patient) have been previously described, association with haematological malignancy is rare. We hereby report such a case with TS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22676959",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "Type A microsatellite instability in pediatric gliomas as an indicator of Turcot syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156169",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 567,
                    "offsetInEndSection": 696,
                    "text": " Biallelic mutations of MMR genes are associated with pediatric cancers, including glial tumors, in Turcot syndrome type 1 (TS1).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19156169",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 135,
                    "text": "Glioblastomas with giant cell and sarcomatous features in patients with Turcot syndrome type 1: a clinicopathological study of 3 cases.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657316",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 141,
                    "text": "Turcot syndrome (TS) is a rare genetic disorder of DNA mismatch repair predisposing to glioblastoma (GBM) in the type 1 variant. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657316",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 242,
                    "text": "We report the clinicopathological and genetic features of 3 gliomas in TS type 1 patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657316",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1527,
                    "offsetInEndSection": 1739,
                    "text": "We conclude that 1) the giant cell variant of GBM is overrepresented in TS; 2) gliosarcomas may also be encountered; and 3) survival is often favorable, despite histological anaplasia and exuberant proliferation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20657316",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 120,
                    "text": "Malignant transformation of high-grade astrocytoma associated with neurocysticercosis in a patient with Turcot syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17138070",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "text": "A 45-year-old woman with anaplastic astrocytoma was clinically diagnosed with Turcot syndrome, and subsequently developed simultaneous neurocysticercosis and malignant transformation to glioblastoma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17138070",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "Familial glioblastoma multiforme is a rather uncommon entity, being in most cases associated to known genetic disorders (as Turcot syndrome, Li-Fraumeni syndrome, neurofibromatosis, etc.). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16960645",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 124,
                    "offsetInEndSection": 331,
                    "text": "Turcot syndrome (MIM276300) has been described as the association of central nervous system malignant tumors and familial colorectal cancer and has been reported to be both a dominant and recessive disorder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16000562",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1380,
                    "offsetInEndSection": 1568,
                    "text": "We report here the first identification of a homozygous mutation in MSH6 in a family with childhood-onset brain tumor, lymphoma, colorectal cancer, and neurofibromatosis type 1 phenotype. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16000562",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1141,
                    "offsetInEndSection": 1388,
                    "text": "Of the 21 patients, 12 have died (10 after relapse, with a median time to progression for the whole series of 14 months; one with intratumoral bleeding at 40 months after diagnosis; and one affected by Turcot syndrome for duodenal cancer relapse).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15701281",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "[Glioblastoma multiforme as a manifestation of Turcot syndrome].",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11975096",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 273,
                    "offsetInEndSection": 451,
                    "text": "In the present case, a 60-year-old patient with glioblastoma multiforme and a history of hereditary malignomas is described as an example of a HNPCC-associated Turcot's syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11975096",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 426,
                    "text": "Computed tomography brain scan and computed tomography-guided biopsy revealed a left frontoparietal glioblastoma multiforme. This case illustrates the rare presentation of Turcot syndrome-a hereditary colorectal polyposis syndrome-in an older adult.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11907360",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Turcot syndrome is the association of colorectal polyposis with primary neuroepithelial tumors of the central nervous system such as glioblastoma and medulloblastoma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10921328",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 771,
                    "offsetInEndSection": 879,
                    "text": "Brain tumor is mainly diagnosed as glioblastoma or astrocytoma and mismatch repair genes might be involved. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10921328",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 348,
                    "text": "Patients with Turcot syndrome (TS) are predisposed to colon tumors and primary brain tumors, typically glioblastomas or medulloblastomas. The authors describe a patient with TS featuring a known germline mutation of exon 5 of the hPMS2 mismatch repair gene who developed two metachronous glioblastomas, both with distinct oligodendroglial features.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10223463",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 602,
                    "offsetInEndSection": 831,
                    "text": "Because this patient had an unusual underlying condition and his tumor had a unique histological appearance for TS, it was hypothesized that this genetic defect may predispose to malignant gliomas with oligodendroglial features. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10223463",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 273,
                    "offsetInEndSection": 407,
                    "text": "Turcot Syndrome caused by APC gene develops medulloblastoma and Turcot Syndrome caused by mismatch repair gene develops glioblastoma. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9695069",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 271,
                    "text": "It is characterized by central nervous system (CNS) neoplasms and gastrointestinal polyposis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9508118",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 427,
                    "offsetInEndSection": 563,
                    "text": "Seven months after resection of this Dukes' C2 adenocarcinoma, she presented with a second primary CNS tumor, a glioblastoma multiforme.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9508118",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 129,
                    "text": "The Turcot syndrome has been defined as the simultaneous presence of multiple polyposis of the colon and a malignant brain tumor.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9505220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 283,
                    "offsetInEndSection": 485,
                    "text": "The case of a 47-year-old man submitted to a right hemicolectomy for cancer and polyposis, following a series of endoscopic polypectomies and, finally, removal of left temporal glioma is here presented.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9505220",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2254,
                    "offsetInEndSection": 2381,
                    "text": " Two of 13 showed microsatellite instability, one of which in a patient with Turcot syndrome, the other in gliomatosis cerebri.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9343324",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "text": "The Turcot syndrome (TS) is a rare, probably autosomal recessive, disorder characterized by development of primary neuroepithelial tumors of the central nervous system (CNS) and numerous adenomatous colorectal polyps. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7515658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 668,
                    "offsetInEndSection": 857,
                    "text": "However, no somatic mutations in APC were found among 91 neuroepithelial tumors (medulloblastoma, glioblastoma, astrocytoma, and oligodendroglioma), whether sporadic or associated with TS. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7515658",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 378,
                    "text": "Such syndromes include neurofibromatosis type 2, neurofibromatosis type 1, Li-Fraumeni syndrome, as well as von Hippel-Lindau disease, tuberous sclerosis, and Turcot syndrome. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8025896",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 76,
                    "offsetInEndSection": 242,
                    "text": "This patient's case deals with the association between a glioblastoma, anaplastic glioma (WHO Grade III) and colonic adenocarcinoma based on familial polyposis coli. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8127448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "The authors describe two patients with the association of polyposis-coli and central nervous system tumor (Turcot's syndrome). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2165772",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "We report a case of Turcot's syndrome in a 20-year old man with multiple adenomatous polyps of the colon and glioblastoma multiforme. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2540108",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "Another unusual autopsy case of the Turcot syndrome is reported in a 23-year-old woman with polyposis coli, who developed primary carcinoma of the jejunum and glioblastoma multiforme of the left frontal lobe. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6307612",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 291,
                    "text": "Turcot syndrome represents the unique and discrete occurrence of polyposis coli with glioblastoma multiforme, medulloblastoma, or both.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6274254",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is diphosphatidylglycerol (cardiolipin) a phospholipid of the mitochondrial membranes?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21599656",
                "http://www.ncbi.nlm.nih.gov/pubmed/26028302",
                "http://www.ncbi.nlm.nih.gov/pubmed/24905496",
                "http://www.ncbi.nlm.nih.gov/pubmed/6717095",
                "http://www.ncbi.nlm.nih.gov/pubmed/4322761",
                "http://www.ncbi.nlm.nih.gov/pubmed/2397096",
                "http://www.ncbi.nlm.nih.gov/pubmed/6257342",
                "http://www.ncbi.nlm.nih.gov/pubmed/7794966",
                "http://www.ncbi.nlm.nih.gov/pubmed/3668386",
                "http://www.ncbi.nlm.nih.gov/pubmed/8143741",
                "http://www.ncbi.nlm.nih.gov/pubmed/23200781",
                "http://www.ncbi.nlm.nih.gov/pubmed/26301254",
                "http://www.ncbi.nlm.nih.gov/pubmed/6509920",
                "http://www.ncbi.nlm.nih.gov/pubmed/26396268",
                "http://www.ncbi.nlm.nih.gov/pubmed/6807345",
                "http://www.ncbi.nlm.nih.gov/pubmed/16971584",
                "http://www.ncbi.nlm.nih.gov/pubmed/9370332",
                "http://www.ncbi.nlm.nih.gov/pubmed/20336283",
                "http://www.ncbi.nlm.nih.gov/pubmed/24007978",
                "http://www.ncbi.nlm.nih.gov/pubmed/1213878",
                "http://www.ncbi.nlm.nih.gov/pubmed/9843887",
                "http://www.ncbi.nlm.nih.gov/pubmed/7459841",
                "http://www.ncbi.nlm.nih.gov/pubmed/3548756",
                "http://www.ncbi.nlm.nih.gov/pubmed/22634369",
                "http://www.ncbi.nlm.nih.gov/pubmed/7378435",
                "http://www.ncbi.nlm.nih.gov/pubmed/25182746",
                "http://www.ncbi.nlm.nih.gov/pubmed/3718705",
                "http://www.ncbi.nlm.nih.gov/pubmed/15460113",
                "http://www.ncbi.nlm.nih.gov/pubmed/25843549",
                "http://www.ncbi.nlm.nih.gov/pubmed/1550861",
                "http://www.ncbi.nlm.nih.gov/pubmed/24443516",
                "http://www.ncbi.nlm.nih.gov/pubmed/20637181",
                "http://www.ncbi.nlm.nih.gov/pubmed/8977117",
                "http://www.ncbi.nlm.nih.gov/pubmed/1247555",
                "http://www.ncbi.nlm.nih.gov/pubmed/24769127"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0202177",
                    "o": "Phospholipid"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0007188",
                    "o": "http://linkedlifedata.com/resource/umls/label/A17997459"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17997459",
                    "o": "Cardiolipins"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/rxnorm/id/2083",
                    "o": "http://linkedlifedata.com/resource/rxnorm/label/3130515"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/rxnorm/label/3130515",
                    "o": "Cardiolipins"
                },
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0007188",
                    "o": "cardiolipin"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/rxnorm/id/2083",
                    "o": "http://linkedlifedata.com/resource/rxnorm/label/3130514"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/rxnorm/label/3130514",
                    "o": "Cardiolipin"
                }
            ],
            "ideal_answer": [
                "Yes, diphosphatidylglycerol (cardiolipin) is a phospholipid of the mitochondrial membranes."
            ],
            "exact_answer": "yes",
            "concepts": [
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002308",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008566",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008563",
                "http://www.biosemantics.org/jochem#http://www.biosemantics.org/jochem#:4244279",
                "http://www.biosemantics.org/jochem#4001026",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008928",
                "http://www.biosemantics.org/jochem#4244279",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D051336"
            ],
            "type": "yesno",
            "id": "58d90f228acda3452900000f",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 341,
                    "text": "A unique organelle for studying membrane biochemistry is the mitochondrion whose functionality depends on a coordinated supply of proteins and lipids. Mitochondria are capable of synthesizing several lipids autonomously such as phosphatidylglycerol, cardiolipin and in part phosphatidylethanolamine, phosphatidic acid and CDP-diacylglycerol.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24007978",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 474,
                    "text": "A small decrease of diphosphatidylglycerol also occurred in the hepatoma mitochondria inner membrane. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7459841",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 492,
                    "offsetInEndSection": 624,
                    "text": "Diphosphatidylglycerol was confined to the mitochondrial fraction, where it represented about 7% of the total phosphoacylglycerols. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6807345",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 401,
                    "text": "Mitochondrial membranes were isolated from the myocardium of young (4-month-old) and aged (33-month-old) male Long-Evans rats and compared in terms of cholesterol content and phospholipid and fatty acid composition. In aged rats, as compared to young, the major observations include: markedly higher cholesterol content; increased percentage of sphingomyelin and diphosphatidylglycerol (cardiolipin); ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6717095",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 445,
                    "offsetInEndSection": 632,
                    "text": "The polyglycerophosphatides (typified by diphosphatidylglycerol) were apparently synthesized in situ by intramitochondrial membrane-bound enzymes using CDP-diglycerides as intermediates. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3548756",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 538,
                    "offsetInEndSection": 875,
                    "text": "Both the mitochondrial and microsomal fractions contained significant proportions of solvent front phospholipid (SFP) and whereas the mitochondrial SFP displayed the relatively unsaturated fatty acid composition characteristic of diphosphatidylglycerol (cardiolipin), the fatty acids of the microsomal SFP were distinctly more saturated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6509920",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 456,
                    "offsetInEndSection": 764,
                    "text": "Ten to 15% of microsomal radioactive CDP-diglycerides was transferred to mitochondrial membranes and incorporated into mitochondrial radioactive lipids identified as phosphatidylglycerol, phosphatidylglycerophosphate, and, when [14C]linoleoyl CDP-diglycerides were used, diphosphatidylglycerol (cardiolipin).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3718705",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 295,
                    "text": "The enzyme responsible for the conversion of phosphatidylglycerol to diphosphatidylglycerol (cardiolipin) in the presence of cytidine diphosphate diacylglycerol is firmly associated with mitochondrial membranes and is not extracted with hypotonic or hypertonic media or with nonionic detergents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6257342",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 347,
                    "text": "The mechanism of cardiolipin (diphosphatidylglycerol) biosynthesis was examined in mitochondria and outer and inner mitochondrial membranes prepared from guinea pig and rat livers to determine whether this formation from phosphatidylglycerol was absolutely dependent on cytidinediphosphodiglyceride, as previously reported for intact mitochondria.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 454,
                    "offsetInEndSection": 597,
                    "text": "In isolated mitochondrial outer membranes, cardiolipin (diphosphatidylglycerol) increased CPT1 activity 4-fold and the Km for carnitine 6-fold.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21599656",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 765,
                    "text": "Ten to 15% of microsomal radioactive CDP-diglycerides was transferred to mitochondrial membranes and incorporated into mitochondrial radioactive lipids identified as phosphatidylglycerol, phosphatidylglycerophosphate, and, when [14C]linoleoyl CDP-diglycerides were used, diphosphatidylglycerol (cardiolipin).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3718705",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 499,
                    "offsetInEndSection": 615,
                    "text": "90% or more of the phospholipid, cardiolipin was found in the mitochondrial membranes of wild type and petite yeast.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/4322761",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 629,
                    "offsetInEndSection": 760,
                    "text": "Furthermore, the same mechanism for the biosynthesis of cardiolipin was operational in the outer and inner mitochondrial membranes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 346,
                    "text": "The mechanism of cardiolipin (diphosphatidylglycerol) biosynthesis was examined in mitochondria and outer and inner mitochondrial membranes prepared from guinea pig and rat livers to determine whether this formation from phosphatidylglycerol was absolutely dependent on cytidinediphosphodiglyceride, as previously reported for intact mitochondria",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 65,
                    "offsetInEndSection": 246,
                    "text": "Cardiolipin (CL) is a key phospholipid in mitochondrial membranes, playing important roles in maintaining the functional integrity and dynamics of mitochondria in animals and yeasts",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24443516",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "Cardiolipin, the specific phospholipid of mitochondria, is involved in the biogenesis, the dynamics, and the supramolecular organization of mitochondrial membranes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23200781",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "Cardiolipin (CL), the signature phospholipid of mitochondrial membranes, is crucial for both mitochondrial function and cellular processes outside of the mitochondria",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26301254",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 231,
                    "text": "Since it has been recognized that mitochondria are crucial not only for energy metabolism but also for other cellular functions, there has been a growing interest in cardiolipin, the specific phospholipid of mitochondrial membranes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24769127",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 72,
                    "offsetInEndSection": 259,
                    "text": "Cardiolipin, the main anionic phospholipid in mitochondrial membranes, is expected to be a determinant in this adaptive mechanism since it modulates the activity of most membrane proteins",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25843549",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 457,
                    "offsetInEndSection": 764,
                    "text": "Ten to 15% of microsomal radioactive CDP-diglycerides was transferred to mitochondrial membranes and incorporated into mitochondrial radioactive lipids identified as phosphatidylglycerol, phosphatidylglycerophosphate, and, when [14C]linoleoyl CDP-diglycerides were used, diphosphatidylglycerol (cardiolipin)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3718705",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 247,
                    "offsetInEndSection": 530,
                    "text": "Cardiolipin is normally localized to the inner mitochondrial membrane; however, when cardiolipin becomes externalized to the surface of dysregulated mitochondria, it promotes inflammasome activation and stimulates the elimination of damaged or nonfunctional mitochondria by mitophagy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26396268",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 454,
                    "offsetInEndSection": 598,
                    "text": "In isolated mitochondrial outer membranes, cardiolipin (diphosphatidylglycerol) increased CPT1 activity 4-fold and the Km for carnitine 6-fold. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21599656",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 125,
                    "text": "Increasing levels of cardiolipin differentially influence packing of phospholipids found in the mitochondrial inner membrane.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24905496",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 440,
                    "text": "Here, we used Saccharomyces cerevisiae subjected to conditions that affect mitochondrial metabolism as a model to determine the possible role of cardiolipin in stress adaptation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25843549",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 290,
                    "offsetInEndSection": 684,
                    "text": "This decline of respiration was attributed to a progressive diminution of the number of mitochondria in copper-treated cells, based on the demonstration of the concomitant decline of (1) cardiolipin (diphosphatidylglycerol) and cytochrome aa3 (cytochrome oxidase), two specific markers of mitochondrial inner membrane, and (2) fumarase activity, a specific marker of mitochondrial matrix space.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8977117",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 327,
                    "offsetInEndSection": 477,
                    "text": "Diphosphatidylglycerol (DPG) or cardiolipin, a specific component of the inner mitochondrial membrane, represents about 4% of the total lipid content.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15460113",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 348,
                    "offsetInEndSection": 628,
                    "text": "Experimental results confirmed that the biosynthesis of cardiolipin, from the membrane-bound radioactive phosphatidylglycerol in intact mitochondria isolated from guinea pig and rat liver, was absolutely dependent on CDP-diglycerides and required the addition of divalent cations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2397096",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 561,
                    "offsetInEndSection": 776,
                    "text": "We have shown that decrease of cardiolipin in mitochondrial membrane occurs early during ischemia, and only during the irreversible phase of ischemia are phosphatidylethanolamine and phosphatidylcholine broken down.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7378435",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "Partial purification of diphosphatidylglycerol synthetase from liver mitochondrial membranes.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6257342",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 372,
                    "offsetInEndSection": 473,
                    "text": "A small decrease of diphosphatidylglycerol also occurred in the hepatoma mitochondria inner membrane.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7459841",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is erythropoietin effective for treatment of amyotrophic lateral sclerosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25886781",
                "http://www.ncbi.nlm.nih.gov/pubmed/25595151"
            ],
            "ideal_answer": [
                "No, erythropoietin is not effective for treatment of amyotrophic lateral sclerosis."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c647c52e842deac6700001c",
            "snippets": [
                {
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 853,
                    "text": "This study was performed to validate the ALS-MITOS as a 6-month proxy of survival in 200 ALS patients followed up to 18 months.METHODS: Analyses were performed on data from the recombinant human erythropoietin RCT that failed to demonstrate differences between groups for both primary and secondary outcomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25886781",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1713,
                    "offsetInEndSection": 1787,
                    "text": "CONCLUSIONS: RhEPO 40,000\u2005IU fortnightly did not change the course of ALS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25595151",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1315,
                    "offsetInEndSection": 1602,
                    "text": "At 12\u2005months, the annualised rate of death (rhEPO 0.11, 95% CI 0.06 to 0.20; placebo: 0.08, CI 0.04 to 0.17), tracheotomy or >23\u2005h NIV (rhEPO 0.16, CI 0.10 to 0.27; placebo 0.18, CI 0.11 to 0.30) did not differ between groups, also after stratification by onset and ALSFRS-R at baseline.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25595151",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Has the presence of delayed enhancement been documented in athletes performing strenuous exercise?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22160404",
                "http://www.ncbi.nlm.nih.gov/pubmed/19427448",
                "http://www.ncbi.nlm.nih.gov/pubmed/22798307",
                "http://www.ncbi.nlm.nih.gov/pubmed/8902021",
                "http://www.ncbi.nlm.nih.gov/pubmed/24029371",
                "http://www.ncbi.nlm.nih.gov/pubmed/24326931",
                "http://www.ncbi.nlm.nih.gov/pubmed/19332846"
            ],
            "ideal_answer": [
                "There are contrasting literature data on the presence of delayed enhancement, as a sign of myocardial fibrosis, in healthy athletes. More studies are necessary to define the presence, incidence and severity, as well clinical and prognostic meaning, of delayed enhancement magnetic resonance in healthy athletes."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054874",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D008279",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013177",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056352",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015444"
            ],
            "type": "yesno",
            "id": "531d34be267d7dd053000004",
            "snippets": [
                {
                    "offsetInBeginSection": 1240,
                    "offsetInEndSection": 1491,
                    "text": "Atypical findings such as marked cardiac dilation, reduced deformation, or small patches of delayed gadolinium enhancement may be commonly encountered in well-trained athletes, but, at present, the prognostic significance of such findings is unknown. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24029371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1433,
                    "offsetInEndSection": 1648,
                    "text": "On CMR, DGE localized to the interventricular septum was identified in 5 of 39 athletes who had greater cumulative exercise exposure and lower RVEF (47.1 \u00b1 5.9 vs. 51.1 \u00b1 3.7%, P = 0.042) than those with normal CMR.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22160404",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 623,
                    "offsetInEndSection": 912,
                    "text": "Post-event cardiac MRI demonstrated the interval appearance of delayed enhancement of gadolinium at the inferior insertion of the right ventricle and in the interventricular septum-a novel finding that may represent subtle inflammation secondary to a combined exercise and altitude effect.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22798307",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1335,
                    "offsetInEndSection": 1544,
                    "text": "No evidence of delayed enhancement of the left ventricular myocardium was found on CMR imaging, suggesting that the increase in cardiac biomarkers after the marathon may not have be due to myocardial necrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19427448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1495,
                    "offsetInEndSection": 1891,
                    "text": "Of the 102 runners, five had a CAD pattern of LGE, and seven had a non-CAD pattern of LGE. The CAD pattern of LGE was located in the territory of the left anterior descending coronary artery more frequently than was the non-CAD pattern (P = .0027, Fisher exact test). The prevalence of LGE in runners was higher than that in age-matched control subjects (12% vs 4%; P = .077, McNemar exact test).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19332846",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there any software for automated analysis of FISH images?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21310746",
                "http://www.ncbi.nlm.nih.gov/pubmed/22665392",
                "http://www.ncbi.nlm.nih.gov/pubmed/21656271",
                "http://www.ncbi.nlm.nih.gov/pubmed/16749443",
                "http://www.ncbi.nlm.nih.gov/pubmed/17889539",
                "http://www.ncbi.nlm.nih.gov/pubmed/23903043",
                "http://www.ncbi.nlm.nih.gov/pubmed/15887538",
                "http://www.ncbi.nlm.nih.gov/pubmed/17674627",
                "http://www.ncbi.nlm.nih.gov/pubmed/22935778",
                "http://www.ncbi.nlm.nih.gov/pubmed/22163442",
                "http://www.ncbi.nlm.nih.gov/pubmed/20639591",
                "http://www.ncbi.nlm.nih.gov/pubmed/15351517",
                "http://www.ncbi.nlm.nih.gov/pubmed/11818019",
                "http://www.ncbi.nlm.nih.gov/pubmed/24240725",
                "http://www.ncbi.nlm.nih.gov/pubmed/20966547"
            ],
            "ideal_answer": [
                "FISH is a popular molecular cytogenetic method. The output of a single FISH analysis is a set of several tens or hundreds microscopic images \u2014 a single evaluated sample is of roughly 20mm diameter. The goal of an automated evaluation is to replace the subjective evaluation of images by the laboratory technician to achieve higher uniformity of results. Following explanation of the principle of the method and the typical contents of images, the processing flow of image segmentation is outlined and the results are presented on several example images. Based on results there are software for automated analysis of FISH images."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001331",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D007091",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D012984"
            ],
            "type": "yesno",
            "id": "5311cdcce3eabad021000007",
            "snippets": [
                {
                    "offsetInBeginSection": 1622,
                    "offsetInEndSection": 1770,
                    "text": "he study demonstrated the feasibility of automated FISH signal analysis that applying a CAD scheme to the automated generated 2-D projection images.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22935778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 103,
                    "offsetInEndSection": 1485,
                    "text": "A color imaging technique, multiplex fluorescent in situ hybridization (M-FISH), has been developed to ease the analysis of the process. Using an M-FISH technique each chromosome class (1,2, \u2026,22,X,Y) is stained with a unique color. However, significant variations between images are observed due to a number of factors such as uneven hybridization and spectral overlap among channels. These types of variations influence the pixel classification accuracy of image classification methods which are supervised and require a set of annotated images for training. In this paper, we present a fully unsupervised M-FISH chromosome image classification methodology. Our main contributions are 1) the assumption that the intensity of a chromosome pixel is sampled from multiple Gaussian components [Gaussian mixture model (GMM)] such that each component corresponds to one chromosome class, and 2) the initialization of the GMM model using the emission information of each chromosome class. This is feasible since prior to the M-FISH image acquirement, we already know which chromosome class is emitting to each of the five M-FISH image channels. The method has been tested on a large number of M-FISH images and an overall accuracy of 89.85% is reported. Our method is unsupervised and presents higher classification accuracy even when it is compared with common supervised based methods.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24240725",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 21,
                    "offsetInEndSection": 1620,
                    "text": "hybridization (FISH) tests provide promising molecular imaging biomarkers to more accurately and reliably detect and diagnose cancers and genetic disorders. Since current manual FISH signal analysis is low-efficient and inconsistent, which limits its clinical utility, developing automated FISH image scanning systems and computer-aided detection (CAD) schemes has been attracting research interests. To acquire high-resolution FISH images in a multi-spectral scanning mode, a huge amount of image data with the stack of the multiple three-dimensional (3-D) image slices is generated from a single specimen. Automated preprocessing these scanned images to eliminate the non-useful and redundant data is important to make the automated FISH tests acceptable in clinical applications. In this study, a dual-detector fluorescence image scanning system was applied to scan four specimen slides with FISH-probed chromosome X. A CAD scheme was developed to detect analyzable interphase cells and map the multiple imaging slices recorded FISH-probed signals into the 2-D projection images. CAD scheme was then applied to each projection image to detect analyzable interphase cells using an adaptive multiple-threshold algorithm, identify FISH-probed signals using a top-hat transform, and compute the ratios between the normal and abnormal cells. To assess CAD performance, the FISH-probed signals were also independently visually detected by an observer. The Kappa coefficients for agreement between CAD and observer ranged from 0.69 to 1.0 in detecting/counting FISH signal spots in four testing samples.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22935778",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 1185,
                    "text": " In this paper we developed a sparse representation-based classification (SRC) algorithm based on L1-norm minimization for classifying chromosomes from multicolor fluorescence in situ hybridization (M-FISH) images. The algorithm has been tested on a comprehensive M-FISH database that we established, demonstrating improved performance in classification. When compared with other pixel-wise M-FISH image classifiers such as fuzzy c-means (FCM) clustering algorithms and adaptive fuzzy c-means (AFCM) clustering algorithms that we proposed earlier the current method gave the lowest classification error. In order to evaluate the performance of different SRC for M-FISH imaging analysis, three different sparse representation methods, namely, Homotopy method, Orthogonal Matching Pursuit (OMP), and Least Angle Regression (LARS), were tested and compared. Results from our statistical analysis have shown that Homotopy based method is significantly better than the other two methods. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22665392",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 1397,
                    "text": "Fluorescence in situ hybridization (FISH) is used to study the organization and the positioning of specific DNA sequences within the cell nucleus. Analyzing the data from FISH images is a tedious process that invokes an element of subjectivity. Automated FISH image analysis offers savings in time as well as gaining the benefit of objective data analysis. While several FISH image analysis software tools have been developed, they often use a threshold-based segmentation algorithm for nucleus segmentation. As fluorescence signal intensities can vary significantly from experiment to experiment, from cell to cell, and within a cell, threshold-based segmentation is inflexible and often insufficient for automatic image analysis, leading to additional manual segmentation and potential subjective bias. To overcome these problems, we developed a graphical software tool called FISH Finder to automatically analyze FISH images that vary significantly. By posing the nucleus segmentation as a classification problem, compound Bayesian classifier is employed so that contextual information is utilized, resulting in reliable classification and boundary extraction. This makes it possible to analyze FISH images efficiently and objectively without adjustment of input parameters. Additionally, FISH Finder was designed to analyze the distances between differentially stained FISH probes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21310746",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 1417,
                    "text": "The simultaneous detection of protein expression and gene copy number changes in patient samples, like paraffin-embedded tissue sections, is challenging since the procedures of immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) negatively influence each other which often results in suboptimal staining. Therefore, we developed a novel automated algorithm based on relocation which allows subsequent detection of protein content and gene copy number changes within the same cell. METHODS: Paraffin-embedded tissue sections of colorectal cancers were stained for CD133 expression. IHC images were acquired and image coordinates recorded. Slides were subsequently hybridized with fluorescently labeled DNA probes. FISH images were taken at the previously recorded positions allowing for direct comparison of protein expression and gene copy number signals within the same cells/tissue areas. Relocation, acquisition of the IHC and FISH images, and enumeration of FISH signals in the immunophenotyped tumour areas were done in an automated fashion. RESULTS: Automated FISH analysis was performed on 13 different colon cancer samples that had been stained for CD133; each sample was scored for MYC, ZNF217 and Chromosome 6 in CD133 positive and negative glands. From the 13 cases four (31%) showed amplification for the MYC oncogene and seven of 13 (54%) cases were amplified for ZNF217.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21656271",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 1516,
                    "text": "The simultaneous detection of protein expression and gene copy number changes in patient samples, like paraffin-embedded tissue sections, is challenging since the procedures of immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) negatively influence each other which often results in suboptimal staining.Therefore, we developed a novel automated algorithm based on relocation which allows subsequent detection of protein content and gene copy number changes within the same cell. METHODS: Paraffin-embedded tissue sections of colorectal cancers were stained for CD133 expression. IHC images were acquired and image coordinates recorded. Slides were subsequently hybridized with fluorescently labeled DNA probes. FISH images were taken at the previously recorded positions allowing for direct comparison of protein expression and gene copy number signals within the same cells/tissue areas. Relocation, acquisition of the IHC and FISH images, and enumeration of FISH signals in the immunophenotyped tumour areas were done in an automated fashion. RESULTS: Automated FISH analysis was performed on 13 different colon cancer samples that had been stained for CD133; each sample was scored for MYC, ZNF217 and Chromosome 6 in CD133 positive and negative glands. From the 13 cases four (31%) showed amplification for the MYC oncogene and seven of 13 (54%) cases were amplified for ZNF217. There was no significant difference between CD133 positive tumour and CD133 negative tumour cells. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20966547",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 1513,
                    "text": "The simultaneous detection of protein expression and gene copy number changes in patient samples, like paraffin-embedded tissue sections, is challenging since the procedures of immunohistochemistry (IHC) and Fluorescence in situ Hybridization (FISH) negatively influence each other which often results in suboptimal staining.Therefore, we developed a novel automated algorithm based on relocation which allows subsequent detection of protein content and gene copy number changes within the same cell.Methods: Paraffin-embedded tissue sections of colorectal cancers were stained for CD133 expression. IHC images were acquired and image coordinates recorded. Slides were subsequently hybridized with fluorescently labeled DNA probes. FISH images were taken at the previously recorded positions allowing for direct comparison of protein expression and gene copy number signals within the same cells/tissue areas. Relocation, acquisition of the IHC and FISH images, and enumeration of FISH signals in the immunophenotyped tumour areas were done in an automated fashion.Results: Automated FISH analysis was performed on 13 different colon cancer samples that had been stained for CD133; each sample was scored for MYC, ZNF217 and Chromosome 6 in CD133 positive and negative glands. From the 13 cases four (31%) showed amplification for the MYC oncogene and seven of 13 (54%) cases were amplified for ZNF217. There was no significant difference between CD133 positive tumour and CD133 negative tumour cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20639591",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is the Prostate- Specific Antigen (PSA) test relevant only for prostate cancer?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/12088291",
                "http://www.ncbi.nlm.nih.gov/pubmed/9494603",
                "http://www.ncbi.nlm.nih.gov/pubmed/7544735",
                "http://www.ncbi.nlm.nih.gov/pubmed/24223021",
                "http://www.ncbi.nlm.nih.gov/pubmed/18808732",
                "http://www.ncbi.nlm.nih.gov/pubmed/9494604",
                "http://www.ncbi.nlm.nih.gov/pubmed/20065953",
                "http://www.ncbi.nlm.nih.gov/pubmed/15530599",
                "http://www.ncbi.nlm.nih.gov/pubmed/7687205",
                "http://www.ncbi.nlm.nih.gov/pubmed/9329582",
                "http://www.ncbi.nlm.nih.gov/pubmed/15925651",
                "http://www.ncbi.nlm.nih.gov/pubmed/11583357",
                "http://www.ncbi.nlm.nih.gov/pubmed/17559560",
                "http://www.ncbi.nlm.nih.gov/pubmed/23588999",
                "http://www.ncbi.nlm.nih.gov/pubmed/17489318",
                "http://www.ncbi.nlm.nih.gov/pubmed/23400279",
                "http://www.ncbi.nlm.nih.gov/pubmed/18355899",
                "http://www.ncbi.nlm.nih.gov/pubmed/18569246",
                "http://www.ncbi.nlm.nih.gov/pubmed/17233806",
                "http://www.ncbi.nlm.nih.gov/pubmed/19579539",
                "http://www.ncbi.nlm.nih.gov/pubmed/10697616"
            ],
            "ideal_answer": [
                "No, although the PSA test can detect high levels of PSA that may indicate the presence of prostate cancer, many other conditions, such as an enlarged or inflamed prostate, can also increase PSA levels."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D011471",
                "http://www.uniprot.org/uniprot/KLK3_MACFA",
                "http://www.disease-ontology.org/api/metadata/DOID:10283",
                "http://www.disease-ontology.org/api/metadata/DOID:10286",
                "http://www.uniprot.org/uniprot/KLK3_MACMU",
                "http://www.uniprot.org/uniprot/KLK3_HUMAN"
            ],
            "type": "yesno",
            "id": "5327139ad6d3ac6a3400000d",
            "snippets": [
                {
                    "offsetInBeginSection": 13,
                    "offsetInEndSection": 129,
                    "text": "rostate cancer (PCa) is the most frequently diagnosed malignancy and the second leading cause of cancer death in men",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24223021",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 378,
                    "offsetInEndSection": 436,
                    "text": "PSA is known to be prostate specific, but not PCa specific",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24223021",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 4,
                    "offsetInEndSection": 96,
                    "text": "deficiencies of serum PSA as a prostate-cancer-specific diagnostic test are well recognized.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20065953",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 98,
                    "offsetInEndSection": 206,
                    "text": "medical debate surrounding the use of the prostate-specific antigen (PSA) test for prostate cancer screening",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19579539",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2712,
                    "offsetInEndSection": 2834,
                    "text": "The clinical relevance of this surprisingly high rate of prostate cancer in men with a normal PSA is yet to be determined ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15925651",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 159,
                    "text": "Rapid uptake of prostate-specific antigen (PSA) testing has occurred in the United States despite inconclusive evidence regarding mortality benefit",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15530599",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 173,
                    "text": "Routine cancer screening with prostate-specific antigen (PSA) is controversial, and practice guidelines recommend that men be counseled about its risks and benefits",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12088291",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 895,
                    "offsetInEndSection": 1135,
                    "text": "Prostate carcinoma was histologically confirmed in 14 (0.66%) of the men, nine times in the early stage (T2) and five times in the clinical stage (T3), corresponding to an incidence of circa 650 cases per 100,000 men in the target age group",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11583357",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1150,
                    "offsetInEndSection": 1278,
                    "text": "This newly developed PSA test system can enhance the acceptance rate and effectiveness of medical check-ups for prostate cancer,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11583357",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1484,
                    "offsetInEndSection": 1601,
                    "text": "PSA can be used reliably as a unique tool in the follow-up of patients for the early detection of progressive disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7544735",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 727,
                    "offsetInEndSection": 831,
                    "text": "PSA showed negative predictive values of 82 and 77%, respectively, using 4 and 10 ng/ml as cutoff points",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7544735",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 3,
                    "offsetInEndSection": 200,
                    "text": "have assessed the feasibility of using fixed-limit criteria based on medical relevance and biological variation for evaluating the analytical performance of the prostate-specific antigen (PSA) test",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/7687205",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Obeticholic Acid used for treatment of Primary Biliary Cholangitis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27406083",
                "http://www.ncbi.nlm.nih.gov/pubmed/27906472",
                "http://www.ncbi.nlm.nih.gov/pubmed/27532829",
                "http://www.ncbi.nlm.nih.gov/pubmed/27621676",
                "http://www.ncbi.nlm.nih.gov/pubmed/27700211",
                "http://www.ncbi.nlm.nih.gov/pubmed/27825634",
                "http://www.ncbi.nlm.nih.gov/pubmed/27468093",
                "http://www.ncbi.nlm.nih.gov/pubmed/26312413",
                "http://www.ncbi.nlm.nih.gov/pubmed/27589928"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2000/01/rdf-schema#label",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2825352",
                    "o": "Obeticholic Acid"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C2825352",
                    "o": "http://linkedlifedata.com/resource/umls/label/A17691068"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A17691068",
                    "o": "OBETICHOLIC ACID"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#altLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C0087111",
                    "o": "http://linkedlifedata.com/resource/umls/label/A10762572"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A10762572",
                    "o": "Treatment"
                }
            ],
            "ideal_answer": [
                "Yes, obeticholic acid is a farnesoid-X receptor agonist that is approved for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.disease-ontology.org/api/metadata/DOID:0060643",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013812",
                "https://www.nlm.nih.gov/cgi/mesh/2017/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019468"
            ],
            "type": "yesno",
            "id": "5884722ee56acf5176000006",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 48,
                    "text": "Obeticholic acid in primary biliary cholangitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825634",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 330,
                    "text": "In a double-blind, randomized, placebo-controlled study including 217 patients with primary biliary cholangitis, the authors show that obeticholic acid (a potent farnesoid X agonist) administered with ursodeoxycholic acid or as monotherapy significantly decreases serum alkaline phosphatase and bilirubin when compared to placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825634",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 453,
                    "text": "Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 238,
                    "offsetInEndSection": 400,
                    "text": "Obeticholic Acid (OCA) is a farnesoid X receptor (FXR) agonist which has been evaluated as a second line therapy in PBC and has recently been licenced by the FDA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27589928",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1142,
                    "offsetInEndSection": 1363,
                    "text": "OCA will be the first stratified therapy introduced in PBC, however confirmatory trial and real life data are needed to confirm that suggestive biochemical improvements are matched by improvement in key clinical outcomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27589928",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 124,
                    "text": "Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27621676",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 972,
                    "offsetInEndSection": 1466,
                    "text": "A series of clinical trials of OCA in PBC, primarily in combination with UDCA, have established that OCA leads to significant reductions in serum alkaline phosphatase that are predicted to lead to improved clinical outcomes, while dose-dependent pruritus has been the most common adverse effect. On the basis of these studies, OCA was given conditional approval by the US Food and Drug Administration with plans to establish the long-term clinical efficacy of OCA in patients with advanced PBC.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27621676",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1246,
                    "offsetInEndSection": 1394,
                    "text": "Although obeticholic acid was approved by the FDA for the treatment of PBC in May 2016, this development occurred after the symposium presentation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27700211",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2330,
                    "offsetInEndSection": 2511,
                    "text": "While several agents are being studied in combination with UDCA, monotherapy with the novel agent obeticholic acid, a farnesoid X receptor agonist, has also shown promising results.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27700211",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 452,
                    "text": "Obeticholic acid (Ocaliva(TM)) is a farnesoid-X receptor (FXR) agonist that is being developed by Intercept Pharmaceuticals for the treatment of various liver diseases, and has recently been granted accelerated approval in the USA for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid, or as monotherapy in adults unable to tolerate ursodeoxycholic acid.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "text": "Obeticholic acid for the treatment of primary biliary cholangitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468093",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906472",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "text": "A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532829",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 513,
                    "offsetInEndSection": 654,
                    "text": "This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 67,
                    "text": "Obeticholic acid for the treatment of primary biliary cholangitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27468093",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Long-term Clinical Impact and Cost-Effectiveness of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27906472",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 49,
                    "text": "Obeticholic acid in primary biliary cholangitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27825634",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 79,
                    "text": "A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27532829",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 515,
                    "offsetInEndSection": 656,
                    "text": "This article summarizes the milestones in the development of obeticholic acid leading to this first approval for primary biliary cholangitis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27406083",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are integrins part of the extracellular matrix?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25220424",
                "http://www.ncbi.nlm.nih.gov/pubmed/26029690",
                "http://www.ncbi.nlm.nih.gov/pubmed/26096733",
                "http://www.ncbi.nlm.nih.gov/pubmed/25605337",
                "http://www.ncbi.nlm.nih.gov/pubmed/24965068",
                "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
                "http://www.ncbi.nlm.nih.gov/pubmed/25631868",
                "http://www.ncbi.nlm.nih.gov/pubmed/25886986",
                "http://www.ncbi.nlm.nih.gov/pubmed/25759527",
                "http://www.ncbi.nlm.nih.gov/pubmed/25460334",
                "http://www.ncbi.nlm.nih.gov/pubmed/26089687"
            ],
            "ideal_answer": [
                "Yes, \tintegrins are a central family of extracellular matrix receptors."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "56e83a2342442bac75000001",
            "snippets": [
                {
                    "offsetInBeginSection": 314,
                    "offsetInEndSection": 451,
                    "text": "Several constituents of the ECM provide adhesive cues, which serve as binding sites for cell trans-membrane receptors, such as integrins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26029690",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1026,
                    "offsetInEndSection": 1129,
                    "text": "We also determined that blocking \u03b21integrins, the major class of receptors for all ECM proteins tested,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26067407",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 135,
                    "offsetInEndSection": 298,
                    "text": "Here, we elucidate a cross-scale mechanism for tissue assembly and ECM remodeling involving Cadherin 2, the ECM protein Fibronectin, and its receptor Integrin \u03b15. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26096733",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 410,
                    "offsetInEndSection": 604,
                    "text": "due to the diverse functions and variable expression of proteoglycans, matrix proteins, and integrins, it is rather difficult to identify a comprehensive therapeutic target among ECM components.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26089687",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Integrin-dependent cell-extracellular matrix (ECM) adhesion is a determinant of spindle orientation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25605337",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "text": "The extracellular matrix component periostin is a secreted protein that functions as both a cell attachment protein and an autocrine or paracrine factor that signals through the cell adhesion molecule integrins \u03b1v\u03b23 and \u03b1v\u03b25. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25759527",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "Integrin receptors connect the extracellular matrix to the cell cytoskeleton to provide essential forces and signals. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25460334",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 690,
                    "offsetInEndSection": 839,
                    "text": " the integrin, talin, and actin filament form a linear complex of which both ends are typically anchored to the extracellular matrices via integrins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24965068",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 338,
                    "text": "Integrins, a central family of cellular ECM receptors, have been implicated in these processes but their specific role in ES cell self-renewal remains unclear.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25886986",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 446,
                    "text": "Attachment to the extracellular matrix is mediated by a complex of adhesion proteins, including integrins, signaling molecules, actin and actin-binding proteins, and scaffolding proteins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25631868",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "Beta 1 integrin binding plays a role in the constant traction force generation in response to varying stiffness for cells grown on mature cardiac extracellular matrix.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25220424",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Does gavestinel improve outcomes of stroke patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
                "http://www.ncbi.nlm.nih.gov/pubmed/10859040",
                "http://www.ncbi.nlm.nih.gov/pubmed/11277826",
                "http://www.ncbi.nlm.nih.gov/pubmed/15243144",
                "http://www.ncbi.nlm.nih.gov/pubmed/15032709",
                "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
                "http://www.ncbi.nlm.nih.gov/pubmed/16340185"
            ],
            "ideal_answer": [
                "No. In a randomized clinical trial, treatment with gavestinel within 6 hours of acute ischaemic stroke did not improve outcome."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e44c18648dab47f2600001f",
            "snippets": [
                {
                    "offsetInBeginSection": 1332,
                    "offsetInEndSection": 1463,
                    "text": "CONCLUSION: Consistent with the clinical outcomes in the GAIN trials, no effects of gavestinel on ischemic infarction was observed.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16340185",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1058,
                    "offsetInEndSection": 1149,
                    "text": "No effects of gavestinel on infarct volume were observed in the primary or other analyses. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16340185",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 396,
                    "text": "Both trials reported that gavestinel was ineffective in ischemic stroke. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1286,
                    "offsetInEndSection": 1493,
                    "text": "CONCLUSIONS: These observations from the combined GAIN International and GAIN Americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 413,
                    "text": "Glutamate N-methyl-D-aspartate (NMDA) receptor antagonists such as Selfotel, Aptiganel, Gavestinel and others failed to show neuroprotective efficacy in human clinical trials or produced intolerable central nervous system adverse effects.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15032709",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 481,
                    "offsetInEndSection": 934,
                    "text": "METHODS: We studied all patients of the Glycine Antagonist (gavestinel) In Neuroprotection (GAIN) International Trial with ischemic stroke alive at day 7, excluding patients with hemorrhagic events and deaths from nonstroke-related causes. The GAIN International Trial was a randomized, double-blind, placebo-controlled, and parallel-group trial; because the study drug had no effect on stroke outcome, treatment groups were combined for this analysis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15243144",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 64,
                    "text": "Gavestinel produces no benefit for stroke patients, study finds.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 40,
                    "offsetInEndSection": 287,
                    "text": "The wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1753,
                    "offsetInEndSection": 1856,
                    "text": "INTERPRETATION: Treatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10859040",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1759,
                    "offsetInEndSection": 1862,
                    "text": "INTERPRETATION\n\nTreatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10859040",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2271,
                    "offsetInEndSection": 2414,
                    "text": "CONCLUSION\n\nIn this study, gavestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome at 3 months.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11277826",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 394,
                    "text": "Both trials reported that gavestinel was ineffective in ischemic stroke.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1753,
                    "offsetInEndSection": 1855,
                    "text": "INTERPRETATION Treatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10859040",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 323,
                    "offsetInEndSection": 395,
                    "text": "Both trials reported that gavestinel was ineffective in ischemic stroke.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15831831",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 66,
                    "text": "Gavestinel produces no benefit for stroke patients , study finds .",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 40,
                    "offsetInEndSection": 287,
                    "text": "The wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 40,
                    "offsetInEndSection": 286,
                    "text": "The wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11727452",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1725,
                    "offsetInEndSection": 1812,
                    "text": "Treatment with gavestinel within 6 h of acute ischaemic stroke did not improve outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10859040",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2171,
                    "offsetInEndSection": 2302,
                    "text": "In this study, gavestinel administered up to 6 hours after an acute ischemic stroke did not improve functional outcome at 3 months.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11277826",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Tecovirimat effective for smallpox?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20393639",
                "http://www.ncbi.nlm.nih.gov/pubmed/25480757",
                "http://www.ncbi.nlm.nih.gov/pubmed/23530860",
                "http://www.ncbi.nlm.nih.gov/pubmed/30120738",
                "http://www.ncbi.nlm.nih.gov/pubmed/24100494",
                "http://www.ncbi.nlm.nih.gov/pubmed/29773767",
                "http://www.ncbi.nlm.nih.gov/pubmed/25896687",
                "http://www.ncbi.nlm.nih.gov/pubmed/29982575",
                "http://www.ncbi.nlm.nih.gov/pubmed/29972742"
            ],
            "ideal_answer": [
                "Yes, tecovirimat FDA approved for treatment of smallpox."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c58923c86df2b9174000005",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 47,
                    "text": "Oral Tecovirimat for the Treatment of Smallpox.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972742",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2001,
                    "offsetInEndSection": 2206,
                    "text": "CONCLUSIONS: On the basis of its efficacy in two animal models and pharmacokinetic and safety data in humans, tecovirimat is being advanced as a therapy for smallpox in accordance with the FDA Animal Rule.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29972742",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "Background: Tecovirimat (ST-246) is being developed as an antiviral therapeutic for smallpox for use in the event of an accidental or intentional release. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29982575",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1065,
                    "offsetInEndSection": 1384,
                    "text": "Conclusions: Tecovirimat treatment initiated up to 8 days following a lethal aerosol MPXV challenge improves survival and, when initiated earlier than 5 days after challenge, provides protection from clinical effects of disease, supporting the conclusion that it is a promising smallpox antiviral therapeutic candidate.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29982575",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 35,
                    "text": "Tecovirimat: First Global Approval.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120738",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 444,
                    "offsetInEndSection": 618,
                    "text": "In July 2018, oral tecovirimat was approved in the USA for the treatment of human smallpox disease caused by variola virus in adults and paediatric patients weighing \u2265\u00a013\u00a0kg.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120738",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 756,
                    "offsetInEndSection": 873,
                    "text": "An intravenous formulation of tecovirimat is undergoing phase I development for the treatment of smallpox infection. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/30120738",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 692,
                    "offsetInEndSection": 1084,
                    "text": "Brincidofovir, an oral antiviral in late stage development, has proven effective against orthopoxviruses in vitro and in vivo, has a different mechanism of action from tecovirimat (the only oral smallpox antiviral currently in the US Strategic National Stockpile), and has a resistance profile that reduces concerns in the scenario of a bioterror attack using genetically engineered smallpox.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29773767",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 181,
                    "text": "Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25896687",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 2035,
                    "offsetInEndSection": 2216,
                    "text": "Tecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox-infected humans.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24100494",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there microbes in human breast milk?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27940404"
            ],
            "ideal_answer": [
                "Yes, human milk is a rich source of diverse bacteria."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5be44bef133db5eb78000014",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 213,
                    "text": "Contrary to long-held dogma, human milk is not sterile. Instead, it provides infants a rich source of diverse bacteria, particularly microbes belonging to the Staphylococcus, Streptococcus, and Pseudomonas genera.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940404",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 440,
                    "offsetInEndSection": 627,
                    "text": "The origins of the bacteria in milk are thought to include the maternal gastrointestinal tract (via an entero-mammary pathway) and through bacterial exposure of the breast during nursing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27940404",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is muscle lim protein (MLP) involved in cardiomyopathies?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16228909",
                "http://www.ncbi.nlm.nih.gov/pubmed/22421737",
                "http://www.ncbi.nlm.nih.gov/pubmed/15978612",
                "http://www.ncbi.nlm.nih.gov/pubmed/15639480",
                "http://www.ncbi.nlm.nih.gov/pubmed/11788418",
                "http://www.ncbi.nlm.nih.gov/pubmed/21562304",
                "http://www.ncbi.nlm.nih.gov/pubmed/21484537",
                "http://www.ncbi.nlm.nih.gov/pubmed/15205937",
                "http://www.ncbi.nlm.nih.gov/pubmed/18083727",
                "http://www.ncbi.nlm.nih.gov/pubmed/22371524",
                "http://www.ncbi.nlm.nih.gov/pubmed/14567970",
                "http://www.ncbi.nlm.nih.gov/pubmed/16352453",
                "http://www.ncbi.nlm.nih.gov/pubmed/12642359",
                "http://www.ncbi.nlm.nih.gov/pubmed/18505755",
                "http://www.ncbi.nlm.nih.gov/pubmed/12397030",
                "http://www.ncbi.nlm.nih.gov/pubmed/17535853",
                "http://www.ncbi.nlm.nih.gov/pubmed/24860983"
            ],
            "ideal_answer": [
                "The skeletal muscle LIM protein 1 (SLIM1) is highly expressed in skeletal and cardiac muscle, and its expression is downregulated significantly in dilated human cardiomyopathy. Loss of murine MLP results in dilated cardiomyopathy, and mutations in human MLP lead to cardiac hypertrophy, indicating a critical role for MLP in maintaining normal cardiac function.",
                "Yes, Muscle LIM protein is involved in cardiomyopathies. In specific, the skeletal muscle LIM protein 1 (SLIM1) is highly expressed in skeletal and cardiac muscle, and its expression is downregulated significantly in dilated human cardiomyopathy. Mutations in the human MLP gene are associated with hypertrophic and dilated cardiomyopathy. MLP became an important model for experimental cardiology when it was first demonstrated that MLP deficiency leads to myocardial hypertrophy followed by a dilated cardiomyopathy and heart failure phenotype."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2015/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009202",
                "http://www.disease-ontology.org/api/metadata/DOID:0050700"
            ],
            "type": "yesno",
            "id": "54f704b630767eb92e000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 339,
                    "text": "Muscle LIM protein (MLP) has been proposed to be a central player in the pathogenesis of heart muscle disease. In line with this notion, the homozygous loss of MLP results in cardiac hypertrophy and dilated cardiomyopathy. Moreover, MLP is induced in several models of cardiac hypertrophy such as aortic banding and myocardial infarction. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22421737",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 6,
                    "offsetInEndSection": 100,
                    "text": "Muscle LIM protein (MLP) null mice are often used as a model for human dilated cardiomyopathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371524",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1710,
                    "offsetInEndSection": 1858,
                    "text": "A lack of MLP leads to an age-dependent impairment of excitation-contraction coupling with resulting contractile dysfunction and secondary fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22371524",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 133,
                    "offsetInEndSection": 317,
                    "text": "Loss of murine MLP results in dilated cardiomyopathy, and mutations in human MLP lead to cardiac hypertrophy, indicating a critical role for MLP in maintaining normal cardiac function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21562304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1276,
                    "offsetInEndSection": 1390,
                    "text": "Our data indicate that MLP contributes to muscle stiffness and is necessary for maximum work and power generation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21562304",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 616,
                    "offsetInEndSection": 1110,
                    "text": "Interestingly, MLP was also found to be down-regulated in humans with heart failure (Zolk et al. Circulation 101:2674-2677, 2000) and MLP mutations are able to cause hypertrophic and dilated forms of cardiomyopathy in humans (Bos et al. Mol Genet Metab 88:78-85, 2006; Geier et al. Circulation 107:1390-1395, 2003; Hershberger et al. Clin Transl Sci 1:21-26, 2008; Kn\u00f6ll et al. Cell 111:943-955, 2002; Kn\u00f6ll et al. Circ Res 106:695-704, 2010; Mohapatra et al. Mol Genet Metab 80:207-215, 2003).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21484537",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 264,
                    "offsetInEndSection": 513,
                    "text": "MLP soon became an important model for experimental cardiology when it was first demonstrated that MLP deficiency leads to myocardial hypertrophy followed by a dilated cardiomyopathy and heart failure phenotype (Arber et al. Cell 88:393-403, 1997). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21484537",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 218,
                    "offsetInEndSection": 459,
                    "text": "Previous studies have shown an association between CSRP3 missense mutations and either dilated cardiomyopathy (DCM) or HCM, but all these studies were unable to provide comprehensive genetic evidence for a causative role of CSRP3 mutations. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18505755",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 709,
                    "offsetInEndSection": 1124,
                    "text": "We used a newly designed monoclonal antibody to show that muscle LIM protein (MLP), the protein encoded by CSRP3, is mainly a cytosolic component of cardiomyocytes and not tightly anchored to sarcomeric structures. Our functional data from both in vitro and in vivo analyses suggest that at least one of MLP's mutated forms seems to be destabilized in the heart of HCM patients harbouring a CSRP3 missense mutation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18505755",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 180,
                    "text": "Muscle LIM protein (MLP) is a cytoskeletal protein located at the Z-disc of sarcomeres. Mutations in the human MLP gene are associated with hypertrophic and dilated cardiomyopathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18083727",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 923,
                    "offsetInEndSection": 1156,
                    "text": "Our data demonstrate that Mlp84B is essential for normal cardiac function and establish the Drosophila model for the investigation of the mechanisms connecting defective cardiac Z-disc components to the development of cardiomyopathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18083727",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 148,
                    "text": "Muscle LIM protein (MLP) is a cytoskeletal LIM-only protein expressed in striated muscle. Mutations in human MLP are associated with cardiomyopathy;",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17535853",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 370,
                    "text": "TTN-encoded titin, CSRP3-encoded muscle LIM protein, and TCAP-encoded telethonin are Z-disc proteins essential for the structural organization of the cardiac sarcomere and the cardiomyocyte's stretch sensor. All three genes have been established as cardiomyopathy-associated genes for both dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16352453",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1548,
                    "offsetInEndSection": 1883,
                    "text": "Approximately 4.1% of unrelated patients had HCM-associated MLP or TCAP mutations. MLP/TCAP-HCM phenotypically mirrors myofilament-HCM and is more severe than the subset of patients who still remain without a disease-causing mutation. The precise role of W4R-MLP in the pathogenesis of either DCM or HCM warrants further investigation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16352453",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1274,
                    "offsetInEndSection": 1487,
                    "text": "MLP (muscle-LIM-protein) deficient mice develop DCM and changes in the mechanical coupling of cardiomyocytes result in alterations at the intercalated disks and enhanced accumulation of adherens junction proteins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16228909",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 144,
                    "text": "Targeted deletion of cytoskeletal muscle LIM protein (MLP) in mice consistently leads to dilated cardiomyopathy (DCM) after one or more months. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15978612",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1307,
                    "offsetInEndSection": 1660,
                    "text": "In summary, young MLPKO mice revealed substantial alterations in passive myocardial properties and relaxation time, but not in most systolic characteristics. These results indicate that the progression to heart failure in the MLPKO model may be driven by diastolic myocardial dysfunction and abnormal passive properties rather than systolic dysfunction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15978612",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 139,
                    "offsetInEndSection": 280,
                    "text": "Mice lacking the muscle LIM protein (MLP) develop morphological and clinical signs resembling human dilated cardiomyopathy and heart failure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15639480",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1375,
                    "offsetInEndSection": 1772,
                    "text": "Our results show that the absence of MLP causes a local loss of mitochondria. We hypothesize that this is caused by a disturbed interaction between cytoskeleton and mitochondria, which interferes with energy sensing and energy transfer. Recovery of energy depletion by stimulating mitochondrial biogenesis might be a useful therapeutic strategy for improving the energy imbalance in heart failure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15639480",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 317,
                    "text": "Previous work has shown that mutations in muscle LIM protein (MLP) can cause hypertrophic cardiomyopathy (HCM). In order to gain an insight into the molecular basis of the disease phenotype, we analysed the binding characteristics of wild-type MLP and of the (C58G) mutant MLP that causes hypertrophic cardiomyopathy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15205937",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 915,
                    "offsetInEndSection": 1092,
                    "text": "The molecular basis for HCM-causing mutations in the MLP gene might therefore be an alteration in the equilibrium of interactions of the ternary complex MLP-N-RAP-alpha-actinin.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15205937",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 219,
                    "offsetInEndSection": 572,
                    "text": "Muscle LIM protein (MLP) is a member of the cysteine-rich protein (CRP) family and has been implicated in both myogenesis and sarcomere assembly. In the latter role, it binds zyxin and alpha-actinin, both of which are involved in actin organization. An MLP-deficient mouse has been described; these mice develop dilated cardiomyopathy and heart failure.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14567970",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 770,
                    "offsetInEndSection": 896,
                    "text": "We identified a patient with DCM and EFE, having a mutation in MLP with the residue lysine 69 substituted by arginine (K69R). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/14567970",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 195,
                    "offsetInEndSection": 402,
                    "text": "MLP-knockout mice develop a marked cardiac hypertrophy reaction and dilated cardiomyopathy (DCM). MLP is therefore a candidate gene for heritable forms of hypertrophic cardiomyopathy (HCM) and DCM in humans.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12642359",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1166,
                    "offsetInEndSection": 1365,
                    "text": "Family studies revealed cosegregation of clinically affected individuals with the respective mutations in MLP. CONCLUSION: Here, we present evidence that mutations in the CRP3/MLP gene can cause HCM.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12642359",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 177,
                    "text": "The skeletal muscle LIM protein 1 (SLIM1) is highly expressed in skeletal and cardiac muscle, and its expression is downregulated significantly in dilated human cardiomyopathy. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12397030",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 141,
                    "offsetInEndSection": 412,
                    "text": "Targeted disruption of muscle LIM protein (MLP) has previously been shown to result in dilated cardiomyopathy with many of the clinical signs of heart failure, although the effects of MLP disruption on passive ventricular mechanics and myocyte architecture are not known.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11788418",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 915,
                    "offsetInEndSection": 1189,
                    "text": "These results suggest that the disruption of the cytoskeletal protein MLP results in less compliant passive tissue and concomitant structural alterations in the three-dimensional myocyte architecture that may in part explain the ventricular dysfunction in the dilated heart.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11788418",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 347,
                    "text": " Mutations in cysteine and glycine-rich protein 3 (CSRP3), the gene encoding MLP, have been directly associated with human cardiomyopathies, whereas aberrant expression patterns are reported in human cardiac and skeletal muscle diseases.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24860983",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Muscle LIM protein (MLP) has been proposed to be a central player in the pathogenesis of heart muscle disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22421737",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 110,
                    "text": "Previous work has shown that mutations in muscle LIM protein (MLP) can cause hypertrophic cardiomyopathy (HCM)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15205937",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do genes with monoallelic expression contribute proportionally to genetic diversity in humans?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26808112"
            ],
            "ideal_answer": [
                "No, genes with monoallelic expression contribute disproportionately to genetic diversity in humans.",
                "No. Genes with monoallelic expression contribute disproportionately to genetic diversity in humans."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e51a2d76d0a27794100003a",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 95,
                    "text": "Genes with monoallelic expression contribute disproportionately to genetic diversity in humans.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26808112",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 1097,
                    "text": "An unexpectedly large number of human autosomal genes are subject to monoallelic expression (MAE). Our analysis of 4,227 such genes uncovers surprisingly high genetic variation across human populations. This increased diversity is unlikely to reflect relaxed purifying selection. Remarkably, MAE genes exhibit an elevated recombination rate and an increased density of hypermutable sequence contexts. However, these factors do not fully account for the increased diversity. We find that the elevated nucleotide diversity of MAE genes is also associated with greater allelic age: variants in these genes tend to be older and are enriched in polymorphisms shared by Neanderthals and chimpanzees. Both synonymous and nonsynonymous alleles of MAE genes have elevated average population frequencies. We also observed strong enrichment of the MAE signature among genes reported to evolve under balancing selection. We propose that an important biological function of widespread MAE might be the generation of cell-to-cell heterogeneity; the increased genetic variation contributes to this heterogeneity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26808112",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 94,
                    "text": "Genes with monoallelic expression contribute disproportionately to genetic diversity in humans",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26808112",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Are cyclophilins proteins that bind to prolines?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24831536",
                "http://www.ncbi.nlm.nih.gov/pubmed/12358793",
                "http://www.ncbi.nlm.nih.gov/pubmed/18823995",
                "http://www.ncbi.nlm.nih.gov/pubmed/25967372"
            ],
            "ideal_answer": [
                "Cyclophilins are ubiquitously expressed proteins that bind to prolines."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "56f6a63d09dd18d46b00000c",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 132,
                    "text": "Cyclophilins are ubiquitously expressed proteins that bind to prolines and can catalyse cis/trans isomerization of proline residues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25967372",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 593,
                    "offsetInEndSection": 722,
                    "text": "a characteristic of the cyclophilin family of proteins that bind prolines and often act as cis-trans peptidyl-prolyl isomerases. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823995",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "The cyclophilins are widely expressed enzymes that catalyze the interconversion of the cis and trans peptide bonds of prolines. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24831536",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1468,
                    "offsetInEndSection": 1564,
                    "text": " an immunophilin on the isomerization of critical prolines that are found in the tCHT1 sequence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12358793",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are Mesenchymal stem cells (MSC) multipotent cells?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19886822",
                "http://www.ncbi.nlm.nih.gov/pubmed/27102896"
            ],
            "ideal_answer": [
                "Yes, Mesenchymal stem cells (MSC) are multipotent cells."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c7836dad774d04240000002",
            "snippets": [
                {
                    "offsetInBeginSection": 106,
                    "offsetInEndSection": 160,
                    "text": "multipotent mesenchymal bone marrow-derived stem cells",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27102896",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 868,
                    "offsetInEndSection": 916,
                    "text": "multipotent hESC-derived mesenchymal cells (MCs)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19886822",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is SATB1 positioned close to AT-rich sequences?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24729451",
                "http://www.ncbi.nlm.nih.gov/pubmed/24047082",
                "http://www.ncbi.nlm.nih.gov/pubmed/18408014",
                "http://www.ncbi.nlm.nih.gov/pubmed/28179318",
                "http://www.ncbi.nlm.nih.gov/pubmed/24118100",
                "http://www.ncbi.nlm.nih.gov/pubmed/10629043",
                "http://www.ncbi.nlm.nih.gov/pubmed/8049444",
                "http://www.ncbi.nlm.nih.gov/pubmed/29306014",
                "http://www.ncbi.nlm.nih.gov/pubmed/9548713",
                "http://www.ncbi.nlm.nih.gov/pubmed/27590341"
            ],
            "ideal_answer": [
                "Yes, SATB1 is preferentially located at the start of an AT-rich sequence and is associated with other, more diffuse AT- rich sequences in the genome.",
                "Special AT-rich sequence-binding protein 1 (SATB1), a DNA-binding protein expressed predominantly in thymocytes, recognizes an ATC sequence context that consists of a cluster of sequence stretches with well-mixed A's, T's, and C's without G's on one strand. SATB1 (special AT-rich sequence-binding protein-1) provides a key link between DNA loop organization, chromatin modification/remodeling, and association of transcription factors at matrix attachment regions (MARs).",
                "Special AT-rich sequence-binding protein 1 (SATB1), a DNA-binding protein expressed predominantly in thymocytes, recognizes an ATC sequence context that consists of a cluster of sequence stretches with well-mixed A's, T's, and C's without G's on one strand.",
                "We have purified and identified one of the core factors as the matrix attachment region (MAR) binding protein, SATB1, which is known to bind to AT-rich sequences with a high propensity to unwind"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5d38826ea1e1595105000016",
            "snippets": [
                {
                    "offsetInBeginSection": 416,
                    "offsetInEndSection": 585,
                    "text": " Tryptic cleavage and peptide sequence analysis demonstrated that the 98-kD protein is identical to a recently cloned protein, special A-T-rich binding protein 1 (SATB1)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8049444",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 258,
                    "text": "Special AT-rich sequence-binding protein 1 (SATB1), a DNA-binding protein expressed predominantly in thymocytes, recognizes an ATC sequence context that consists of a cluster of sequence stretches with well-mixed A's, T's, and C's without G's on one strand. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9548713",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 778,
                    "offsetInEndSection": 973,
                    "text": " We have purified and identified one of the core factors as the matrix attachment region (MAR) binding protein, SATB1, which is known to bind to AT-rich sequences with a high propensity to unwind",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10629043",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 214,
                    "text": "SATB1 (special AT-rich sequence-binding protein-1) provides a key link between DNA loop organization, chromatin modification/remodeling, and association of transcription factors at matrix attachment regions (MARs).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18408014",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "Over-expression of the special AT rich sequence binding protein 1 (SATB1) promotes the progression of nasopharyngeal carcinoma: association with EBV LMP-1 expression.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24047082",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 13,
                    "offsetInEndSection": 133,
                    "text": "pecial AT rich sequence binding protein 1 (SATB1) plays a crucial role in the biology of various types of human cancer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24047082",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 58,
                    "text": "Loss of special AT-rich sequence-binding protein 1 (SATB1)",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24118100",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 5,
                    "offsetInEndSection": 164,
                    "text": "Special AT-rich sequence-binding protein 1 (SATB1) is a cell type-specific matrix attachment region binding protein, functioning as a global genome organizer. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24118100",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "SATB1 (special AT-rich binding protein 1) is a global chromatin organizer regulating the expression of a large number of genes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24729451",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "Special AT-rich Sequence-binding Protein 1 (SATB1) Functions as an Accessory Factor in Base Excision Repair.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27590341",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 79,
                    "text": "Rearrangement of the Chromatin Organizer Special AT-rich Binding Protein 1 Gene",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28179318",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 216,
                    "text": "The Special AT-rich Sequence Binding Protein 1 (SATB1) exerts multiple functions, by influencing the structural organization of chromatin and interacting with several co-activators and co-repressors of transcription.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29306014",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "text": "The Special AT-rich Sequence Binding Protein 1 (SATB1) and its role in solid tumors.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29306014",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/20796001",
                "http://www.ncbi.nlm.nih.gov/pubmed/21795448",
                "http://www.ncbi.nlm.nih.gov/pubmed/20136906",
                "http://www.ncbi.nlm.nih.gov/pubmed/22972103",
                "http://www.ncbi.nlm.nih.gov/pubmed/23922354",
                "http://www.ncbi.nlm.nih.gov/pubmed/18979152",
                "http://www.ncbi.nlm.nih.gov/pubmed/20230348",
                "http://www.ncbi.nlm.nih.gov/pubmed/23728680"
            ],
            "ideal_answer": [
                "The rate of falls and the number of fallers was significantly reduced in two studies evaluating the effect of medication on preventing falls; one study (85 participants) compared vitamin D versus placebo in institutionalised women after stroke with low vitamin D levels, and the other study (79 participants) evaluated alendronate versus alphacalcidol in hospitalised people after stroke.\nTwo studies testing vitamin D versus placebo and alendronate versus alphacalcidol found a significant reduction in falls and the number of people falling.\nOverall, vitamin D did not reduce rate of falls (RaR 1.00, 95% CI 0.90 to 1.11; seven trials; 9324 participants) or risk of falling (RR 0.96, 95% CI 0.89 to 1.03; 13 trials; 26,747 participants), but may do so in people with lower vitamin D levels before treatment.\nWe found 26 eligible trials of moderate quality that enrolled 45,782 participants, the majority of which were elderly and female. Vitamin D use was associated with statistically significant reduction in the risk of falls (odds ratio for suffering at least one fall, 0.86; 95% confidence interval, 0.77-0.96)"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014807",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004872",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002762",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014808"
            ],
            "type": "yesno",
            "id": "530cf57efe2466f70c000006",
            "snippets": [
                {
                    "offsetInBeginSection": 503,
                    "offsetInEndSection": 682,
                    "text": "However, apart from the beneficial effects of 800 IU/d of vitamin D3 for reduction of falls in the elderly, causality remains yet unproven in randomized controlled trials (RCTs). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23922354",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2457,
                    "offsetInEndSection": 2845,
                    "text": "The rate of falls and the number of fallers was significantly reduced in two studies evaluating the effect of medication on preventing falls; one study (85 participants) compared vitamin D versus placebo in institutionalised women after stroke with low vitamin D levels, and the other study (79 participants) evaluated alendronate versus alphacalcidol in hospitalised people after stroke.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 3420,
                    "offsetInEndSection": 3573,
                    "text": "Two studies testing vitamin D versus placebo and alendronate versus alphacalcidol found a significant reduction in falls and the number of people falling",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 6029,
                    "offsetInEndSection": 6177,
                    "text": ".Overall, vitamin D supplementation does not appear to reduce falls but may be effective in people who have lower vitamin D levels before treatment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23728680",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2538,
                    "offsetInEndSection": 2803,
                    "text": "Overall, vitamin D did not reduce rate of falls (RaR 1.00, 95% CI 0.90 to 1.11; seven trials; 9324 participants) or risk of falling (RR 0.96, 95% CI 0.89 to 1.03; 13 trials; 26,747 participants), but may do so in people with lower vitamin D levels before treatment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22972103",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 102,
                    "text": "Vitamin D affects bone and muscle health and likely reduces the risk of falls in the elderly.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21795448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 734,
                    "offsetInEndSection": 1041,
                    "text": "We found 26 eligible trials of moderate quality that enrolled 45,782 participants, the majority of which were elderly and female. Vitamin D use was associated with statistically significant reduction in the risk of falls (odds ratio for suffering at least one fall, 0.86; 95% confidence interval, 0.77-0.96)",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21795448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1043,
                    "offsetInEndSection": 1193,
                    "text": "This effect was more prominent in patients who were vitamin D deficient at baseline and in studies in which calcium was coadministered with vitamin D.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21795448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1298,
                    "offsetInEndSection": 1356,
                    "text": "Vitamin D combined with calcium reduces the risk of falls.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21795448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1455,
                    "offsetInEndSection": 1531,
                    "text": "The majority of the evidence is derived from trials enrolling elderly women.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21795448",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 215,
                    "text": "Studies of vitamin D and calcium for fracture prevention have produced inconsistent results, as a result of different vitamin D status and calcium intake at baseline, different doses and poor to adequate compliance.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20796001",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 791,
                    "offsetInEndSection": 1081,
                    "text": "Despite significant increases in the provision of hip protectors and use of vitamin D supplementation in both intervention and control facilities, there was no difference in the number of falls or falls injuries between the intervention and control groups, nor a reduction in falls overall.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20230348",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 274,
                    "offsetInEndSection": 379,
                    "text": "Beyond fall and fracture prevention, vitamin D may also reduce overall morbidity by multiple mechanisms. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20136906",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1133,
                    "offsetInEndSection": 1341,
                    "text": "There is evidence to suggest that these agents may reduce the incidence of nonvertebral fractures and falls; however, their benefit on vertebral fracture reduction may depend on the type of active vitamin D. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18979152",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "In clinical trials, the H3 R antagonist CEP-26401 has a positive effect on cognition, yes or no?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/27222271",
                "http://www.ncbi.nlm.nih.gov/pubmed/18469850",
                "http://www.ncbi.nlm.nih.gov/pubmed/22001260"
            ],
            "ideal_answer": [
                "The H3 R antagonist CEP-26401 had an effect on cognition.",
                "CEP-26401 is a novel orally active, brain-penetrant, high-affinity histamine H3 receptor (H3R) antagonist, with potential therapeutic utility in cognition enhancement"
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c57216e07647bbc4b000018",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "CEP-26401 is a novel orally active, brain-penetrant, high-affinity histamine H3 receptor (H3R) antagonist, with potential therapeutic utility in cognition enhancement",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27222271",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1357,
                    "offsetInEndSection": 1565,
                    "text": "hese results demonstrate potent behavioral effects of CEP-26401 in rodent models and suggest that this novel H\u2083R antagonist may have therapeutic utility in the treatment of cognitive and attentional disorders",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22001260",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 167,
                    "text": "CEP-26401 is a novel orally active, brain-penetrant, high-affinity histamine H3 receptor (H3R) antagonist, with potential therapeutic utility in cognition enhancement.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27222271",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "CEP-26401 (irdabisant), a potent and selective histamine H\u2083 receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22001260",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1208,
                    "offsetInEndSection": 1451,
                    "text": "However, although a number of clinical studies examining the efficacy of H3 receptor antagonists for a variety of cognitive disorders are currently underway, no clinical proof of concept for an H3 receptor antagonist has been reported to date.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18469850",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1511,
                    "offsetInEndSection": 1627,
                    "text": "Further clinical studies are required to establish the potential of low-dose CEP-26401 in cognition enhancement.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27222271",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are microtubules marked by glutamylation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26227334",
                "http://www.ncbi.nlm.nih.gov/pubmed/19700636",
                "http://www.ncbi.nlm.nih.gov/pubmed/23973077",
                "http://www.ncbi.nlm.nih.gov/pubmed/26000474",
                "http://www.ncbi.nlm.nih.gov/pubmed/25959773",
                "http://www.ncbi.nlm.nih.gov/pubmed/25030760"
            ],
            "ideal_answer": [
                "Yes, glutamylation is the most prevalent tubulin posttranslational modification and marks stable microtubules."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "58aa0a62396a458e50000007",
            "snippets": [
                {
                    "offsetInBeginSection": 1220,
                    "offsetInEndSection": 1385,
                    "text": "Together with detyrosination, glutamylation and other modifications, tubulin acetylation may form a unique 'language' to regulate microtubule structure and function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26227334",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 176,
                    "text": "Glutamylation, the most prevalent tubulin posttranslational modification, marks stable microtubules and regulates recruitment and activity of microtubule- interacting proteins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25959773",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208,
                    "text": "Enzymes of the tubulin tyrosine ligase-like (TTLL) family posttranslationally modify and thereby mark microtubules by glutamylation, generating specific recognition sites for microtubule-interacting proteins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26000474",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 705,
                    "offsetInEndSection": 942,
                    "text": " PTMs of the cytoskeleton, including phosphorylation, glycosylation, ubiquitination, detyrosination/tyrosination, (poly)glutamylation and (poly)glycylation, acetylation, sumoylation, and palmitoylation, will be addressed in this chapter.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25030760",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 250,
                    "offsetInEndSection": 408,
                    "text": "The tubulin posttranslational modifications: acetylation, detyrosination, polyglutamylation, and polyglycylation play important roles in microtubule functions",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23973077",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "In most eukaryotic cells, tubulin is subjected to posttranslational glutamylation, a conserved modification of unclear function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700636",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does temsirolimus improve survival of glioblastoma patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21493184",
                "http://www.ncbi.nlm.nih.gov/pubmed/24692729",
                "http://www.ncbi.nlm.nih.gov/pubmed/27143690",
                "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
                "http://www.ncbi.nlm.nih.gov/pubmed/16012795",
                "http://www.ncbi.nlm.nih.gov/pubmed/23099651",
                "http://www.ncbi.nlm.nih.gov/pubmed/22033322",
                "http://www.ncbi.nlm.nih.gov/pubmed/17538086"
            ],
            "ideal_answer": [
                "No. Temsirolimus does not prolong survival of gliobalstoma patients."
            ],
            "exact_answer": "no",
            "concepts": [
                "https://meshb.nlm.nih.gov/record/ui?ui=D010361",
                "http://www.biosemantics.org/jochem#4239515",
                "https://meshb.nlm.nih.gov/record/ui?ui=D005909",
                "https://meshb.nlm.nih.gov/record/ui?ui=D013534"
            ],
            "type": "yesno",
            "id": "5a733a672dc08e987e000014",
            "snippets": [
                {
                    "offsetInBeginSection": 542,
                    "offsetInEndSection": 1013,
                    "text": "RESULTS: fourteen randomized clinical trials were identified (7 with bevacizumab, 2 cilengitide, 1 enzastaurin, 1 dasatinib, 1 vandetanib, 1 temsirolimus, 1 cediranib) including 4330 patients. Antiangiogenic drugs showed no improvement in overall survival with a pooled HR of 1.00, a trend for an inferior outcome, in terms of overall survival, was observed in the group of patients receiving antiangiogenic drug alone compared to cytotoxic drug alone (HR=1.24, p=0.056).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28259301",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1604,
                    "offsetInEndSection": 1710,
                    "text": "CONCLUSIONS: Temsirolimus was not superior to temozolomide in patients with an unmethylated MGMT promoter.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27143690",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1164,
                    "offsetInEndSection": 1378,
                    "text": "The actuarial 1-year survival was 72.2% [95% confidence interval (CI), 58.2-82.2] in the temozolomide arm and 69.6% (95% CI, 55.8-79.9) in the temsirolimus arm [hazard ratio (HR) 1.16; 95% CI, 0.77-1.76; P = 0.47].",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27143690",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1227,
                    "offsetInEndSection": 1450,
                    "text": "CONCLUSION: The combination of bevacizumab with temsirolimus was well-tolerated and resulted in stable disease of at least four months/partial response in three out of six pediatric patients with chemorefractory CNS tumors.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24692729",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1363,
                    "offsetInEndSection": 1654,
                    "text": "CONCLUSIONS: Temsirolimus administered weekly at the dose of 75 mg/m(2) did not meet the primary objective efficacy threshold in children with high-grade glioma, neuroblastoma or rhabdomyosarcoma; however, meaningful prolonged stable disease merits further evaluation in combination therapy.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22033322",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1244,
                    "offsetInEndSection": 1476,
                    "text": "Novel targeted agents such as bevacizumab, imatinib, erlotinib, temsirolimus, immunotherapy, cilengitide, talampanel, etc. are helping classical chemotherapeutic agents, like temozolomide, to achieve an increase in overall survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21493184",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1295,
                    "offsetInEndSection": 1431,
                    "text": "CONCLUSIONS: CCI-779 was well tolerated at this dose schedule; however, there was no evidence of efficacy in patients with recurrent GBM",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16012795",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1823,
                    "offsetInEndSection": 1891,
                    "text": "The addition of temsirolimus to interferon did not improve survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17538086",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1611,
                    "offsetInEndSection": 1716,
                    "text": "CONCLUSIONS Temsirolimus was not superior to temozolomide in patients with an unmethylated MGMT promoter.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27143690",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1778,
                    "offsetInEndSection": 1846,
                    "text": "The addition of temsirolimus to interferon did not improve survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17538086",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is statin use associated with improved outcomes after aneurysmal subarachnoid hemorrhage?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/16051891",
                "http://www.ncbi.nlm.nih.gov/pubmed/19875741",
                "http://www.ncbi.nlm.nih.gov/pubmed/19614959",
                "http://www.ncbi.nlm.nih.gov/pubmed/24323051",
                "http://www.ncbi.nlm.nih.gov/pubmed/19439205",
                "http://www.ncbi.nlm.nih.gov/pubmed/23392270",
                "http://www.ncbi.nlm.nih.gov/pubmed/20934152",
                "http://www.ncbi.nlm.nih.gov/pubmed/19458605",
                "http://www.ncbi.nlm.nih.gov/pubmed/16049199",
                "http://www.ncbi.nlm.nih.gov/pubmed/22709377",
                "http://www.ncbi.nlm.nih.gov/pubmed/23298376",
                "http://www.ncbi.nlm.nih.gov/pubmed/19199459",
                "http://www.ncbi.nlm.nih.gov/pubmed/19231192",
                "http://www.ncbi.nlm.nih.gov/pubmed/23633351",
                "http://www.ncbi.nlm.nih.gov/pubmed/19912325",
                "http://www.ncbi.nlm.nih.gov/pubmed/18382320",
                "http://www.ncbi.nlm.nih.gov/pubmed/18658040",
                "http://www.ncbi.nlm.nih.gov/pubmed/23691312",
                "http://www.ncbi.nlm.nih.gov/pubmed/22929438",
                "http://www.ncbi.nlm.nih.gov/pubmed/17413047",
                "http://www.ncbi.nlm.nih.gov/pubmed/17029334",
                "http://www.ncbi.nlm.nih.gov/pubmed/21125471",
                "http://www.ncbi.nlm.nih.gov/pubmed/21926584",
                "http://www.ncbi.nlm.nih.gov/pubmed/18691455",
                "http://www.ncbi.nlm.nih.gov/pubmed/19197830",
                "http://www.ncbi.nlm.nih.gov/pubmed/21556312",
                "http://www.ncbi.nlm.nih.gov/pubmed/17986515",
                "http://www.ncbi.nlm.nih.gov/pubmed/15730572",
                "http://www.ncbi.nlm.nih.gov/pubmed/21755120"
            ],
            "ideal_answer": [
                "Statin use after subarachnoid hemorrhage has been shown be associated with improved outcomes by some prospective clinical trials. It has been reported that statin use after subarachnoid hemorrhage reduced rates of vasospasm, delayed cerebral ischemia, and mortality. However, other authors have failed to find beneficial effect of statin use in subarachnoid hemorrhage patients."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D019161",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D013345",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017063",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D010043"
            ],
            "type": "yesno",
            "id": "530e131b5937551c09000002",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 217,
                    "text": "Statins have been shown in two recent small phase I/II trials to be associated with a marked reduction in clinical and transcranial Doppler (TCD) evidence of vasospasm after aneurysmal subarachnoid haemorrhage (SAH). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19231192",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 503,
                    "offsetInEndSection": 658,
                    "text": "Statins did not result in reduced TCD velocities, clinical or angiographic vasospasm, or improvements in global outcome at the time of hospital discharge. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19231192",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 802,
                    "offsetInEndSection": 900,
                    "text": "There remains significant uncertainty as to the role of statins in preventing vasospasm after SAH.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19231192",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 110,
                    "offsetInEndSection": 308,
                    "text": "Although the results of 2 randomized clinical trials demonstrated that statin decreases the incidence of symptomatic cerebral vasospasm after aSAH, retrospective studies have failed to confirm this.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19199459",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1473,
                    "offsetInEndSection": 1825,
                    "text": "There were no differences in the incidence of symptomatic vasospasm (25.3 vs 30.5%; p = 0.277), in-hospital mortality rate (18 vs 15%; p = 0.468), length of hospitalization (21 +/- 15 vs 19 +/- 12 days; p = 0.281), or poor outcome at discharge (Glasgow Outcome Scale Scores 1-2: 21.7 vs 18.2%; p = 0.416) between the simvastatin and nonstatin cohorts. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19199459",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1882,
                    "offsetInEndSection": 2126,
                    "text": "The uniform introduction of simvastatin did not reduce the incidence of symptomatic cerebral vasospasm, death, or poor outcome in patients with aSAH. Simvastatin was well tolerated, but its benefit may be less than has been previously reported.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19199459",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 190,
                    "offsetInEndSection": 254,
                    "text": "Cholesterol-reducing agents might improve unfavourable outcomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633351",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2150,
                    "offsetInEndSection": 2326,
                    "text": "We cannot draw any conclusions about the effectiveness and safety of lowering cholesterol in aneurysmal SAH because of insufficient reliable evidence from only one small trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23633351",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 119,
                    "text": "Experimental evidence has indicated the benefit of simvastatin in the treatment of subarachnoid hemorrhage.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23392270",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1293,
                    "offsetInEndSection": 1466,
                    "text": "There was an improvement in the functional outcome in the simvastatin group at 1, 3 or 6 months in the follow-up; however, this difference was not statistically significant.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23298376",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1479,
                    "offsetInEndSection": 1648,
                    "text": " There was benefit of simvastatin in terms of reduction in clinical vasospasm, mortality or improved functional outcome, however, this was not statistically significant.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23298376",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 498,
                    "offsetInEndSection": 713,
                    "text": "Cerebral vasomotor reactivity, however, is significantly improved after long-term statin administration in most patients with severe small vessel disease, aneurysmal subarachnoid hemorrhage, or impaired baseline CA.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22929438",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 138,
                    "text": "Atorvastatin decreases computed tomography and S100-assessed brain ischemia after subarachnoid aneurysmal hemorrhage: a comparative study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926584",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1232,
                    "offsetInEndSection": 1845,
                    "text": "In the overall population, cerebral vasospasm was significantly less common in the statin-treated group. Severity of vasospasm, as assessed on the most severe angiogram, was lowered with statin. Statins significantly reduced volume of ischemia in patients with vasospasm and an uncomplicated coiling procedure. S100B levels were significantly lower in statin-treated patients, and the decrease was greatest among high-grade patients (World Federation of Neurological Surgeons 3-5). No differences were found between statin-treated and untreated groups regarding rescue therapy intensity or 1-yr clinical outcomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1859,
                    "offsetInEndSection": 2321,
                    "text": "Atorvastatin reduces the incidence, the severity and the ischemic consequences of vasospasm as assessed on computed tomography. In high-grade World Federation of Neurological Surgeons patients, atorvastatin decreases serum levels of S100B, a biomarker of brain ischemia. Despite these positive effects on biomarkers, no improvement of outcome was seen in the overall population, although there was a tendency for a better clinical outcome in high-grade patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21926584",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 281,
                    "text": "3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, or statins, have been associated with improved clinical outcomes after ischemic stroke and subarachnoid hemorrhage, but with an increased risk of incidental spontaneous intracerebral hemorrhage (ICH).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21755120",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 325,
                    "offsetInEndSection": 536,
                    "text": "Statins are known to have pleiotropic vascular effects, some of which may interrupt the pathogenesis of DNDs. Based on promising preliminary reports, many clinicians routinely administer statins to prevent DNDs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1186,
                    "offsetInEndSection": 1504,
                    "text": "However, observational studies have not revealed an association between statin-use and reduced DNDs or improved neurological outcomes. Results of RCTs have been inconsistent and limited by small sample size, but together suggest that statins may reduce DNDs, with no clear impact on mortality or neurological recovery.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1639,
                    "offsetInEndSection": 1797,
                    "text": "the role of statins in the management of patients with SAH remains unclear. Although promising, statins should not, at this time, be considered standard care.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 525,
                    "offsetInEndSection": 660,
                    "text": "In patients with SAH, they may decrease the incidence of symptomatic vasospasm, although the effects on overall outcome are less clear.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20934152",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 202,
                    "text": "Statins treatment may have potential clinical impact in vascular disease beyond cholesterol lowering. Its benefits have been documented in cerebral ischaemia and in subarachnoid haemorrhage.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19912325",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 24,
                    "offsetInEndSection": 257,
                    "text": "A recent meta-analysis investigating the efficacy of statin treatment in patients with aneurysmal subarachnoid hemorrhage reported a reduced incidence of vasospasm, delayed cerebral ischemia, and mortality in statin-treated patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19875741",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1479,
                    "offsetInEndSection": 1711,
                    "text": "The results of the present systematic review do not lend statistically significant support to the finding of a beneficial effect of statins in patients with aneurysmal subarachnoid hemorrhage as reported in a previous meta-analysis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19875741",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 253,
                    "text": "Pre-treatment with cholesterol lowering drugs of the statin family may exert protective effects in patients with ischaemic stroke and subarachnoid haemorrhage but their effects are not clear in patients with intracerebral haemorrhage (ICH). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19614959",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 288,
                    "text": "Recently, two randomized controlled phase II studies showed that acute initiation of statin treatment directly after aneurysmal subarachnoid hemorrhage (SAH) decreases the incidence of radiologic vasospasm and clinical signs of delayed cerebral ischemia (DCI), and even reduces mortality.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458605",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1218,
                    "offsetInEndSection": 1367,
                    "text": "We conclude that both the primary and secondary outcome results of this study do not support a beneficial effect of simvastatin in patients with SAH.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19458605",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1051,
                    "offsetInEndSection": 1215,
                    "text": "Novel uses of their anti-inflammatory properties in sepsis and vasomotor properties in subarachnoid haemorrhage are being further investigated by randomised trials.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19439205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 793,
                    "offsetInEndSection": 970,
                    "text": "A trend towards a lower mortality within 14 days in patients receiving solely simvastatin and those receiving statin and magnesium as compared with the control group was found. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18691455",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1405,
                    "offsetInEndSection": 1546,
                    "text": "Initiation of statin therapy after aneurysmal SAH significantly reduces the incidence of vasospasm, delayed ischemic deficits, and mortality.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18658040",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1806,
                    "offsetInEndSection": 1986,
                    "text": "The addition of statins to standard care was not associated with any reduction in the development of vasospasm or improvement in outcomes after aneurysmal subarachnoid hemorrhage. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18382320",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 24,
                    "offsetInEndSection": 184,
                    "text": "We have previously demonstrated that acute pravastatin therapy after aneurysmal subarachnoid hemorrhage ameliorates vasospasm-related delayed ischemic deficits.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17413047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1335,
                    "offsetInEndSection": 1617,
                    "text": " This trial demonstrates that acute statin treatment reduces traditional rescue therapy for vasospasm after aneurysmal subarachnoid hemorrhage. Improvement in early outcome has proved robust at 6 months, particularly in relation to physical and psychosocial (Short Form 36) outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17413047",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 8,
                    "offsetInEndSection": 214,
                    "text": "The authors previously have demonstrated that acute treatment with pravastatin after aneurysmal subarachnoid hemorrhage (SAH) can ameliorate vasospasm-related delayed ischemic neurological deficits (DINDs).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17029334",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1715,
                    "offsetInEndSection": 1853,
                    "text": "The neuroprotective effects of acute treatment with pravastatin following aneurysmal SAH are associated with enhancement of autoregulation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17029334",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16051891",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1580,
                    "offsetInEndSection": 1861,
                    "text": "The use of simvastatin as prophylaxis against delayed cerebral ischemia after aneurysmal SAH is a safe and well-tolerated intervention. Its use attenuates serum markers associated with brain injury and decreases the incidence of radiographic vasospasm and delayed ischemic deficit.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16051891",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1553,
                    "offsetInEndSection": 1709,
                    "text": "Acute treatment with pravastatin after aSAH is safe and ameliorates cerebral vasospasm, improves cerebral autoregulation, and reduces vasospasm-related DID.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16049199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1557,
                    "offsetInEndSection": 1911,
                    "text": " SAH statin users demonstrated significant improvement in 14-day functional outcome, a significantly lower incidence of DCI and cerebral infarctions of any type, as well as prevention of TCD highest mean velocity elevation. However, we did not find a significant statin impact on mortality or global outcome (Modified Rankin Scale) in this small sample. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15730572",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can antisense threapy be used for Huntington's disease?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22726826"
            ],
            "ideal_answer": [
                "Yes, antisense oligonucleotide therapy has been shown to lower Huntingtin mRNA levels and be beneficial against Huntington's disease."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c900779ecadf2e73f000001",
            "snippets": [
                {
                    "offsetInBeginSection": 89,
                    "offsetInEndSection": 290,
                    "text": "In this issue of Neuron, Kordasiewicz et\u00a0al. (2012) show the benefit of transient antisense oligonucleotide (ASO) therapy to degrade Huntingtin mRNA and elicit sustained therapeutic benefit in HD mice.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22726826",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 84,
                    "text": "\"Huntingtin holiday\": progress toward an antisense therapy for Huntington's disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22726826",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                "http://www.ncbi.nlm.nih.gov/pubmed/24950205"
            ],
            "ideal_answer": [
                "Yes. Activation-induced miR-155 targets the chromatin protein Jarid2 to regulate proinflammatory cytokine production in T helper 17 cells."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.uniprot.org/uniprot/JARD2_CHICK",
                "http://www.uniprot.org/uniprot/JARD2_HUMAN",
                "http://amigo.geneontology.org/amigo/term/GO:2000317",
                "http://www.uniprot.org/uniprot/JARD2_MOUSE",
                "http://amigo.geneontology.org/amigo/term/GO:0072538",
                "http://amigo.geneontology.org/amigo/term/GO:2000318",
                "http://amigo.geneontology.org/amigo/term/GO:2000316",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D058504",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018417"
            ],
            "type": "yesno",
            "id": "56b8f28a156496395c000006",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 50,
                    "text": "Jarid2 links MicroRNA and chromatin in Th17 cells.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950205",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 236,
                    "text": "In this issue of Immunity, Escobar et\u00a0al. (2014) bring microRNAs and chromatin together by showing how activation-induced miR-155 targets the chromatin protein Jarid2 to regulate proinflammatory cytokine production in T helper 17 cells.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24950205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "miR-155 activates cytokine gene expression in Th17 cells by regulating the DNA-binding protein Jarid2 to relieve polycomb-mediated repression.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 340,
                    "offsetInEndSection": 1032,
                    "text": "Mir155 was bound by Th17 cell transcription factors and was highly expressed during Th17 cell differentiation. miR-155-deficient Th17 and T regulatory (Treg) cells expressed increased amounts of Jarid2, a DNA-binding protein that recruits the Polycomb Repressive Complex 2 (PRC2) to chromatin. PRC2 binding to chromatin and H3K27 histone methylation was increased in miR-155-deficient cells, coinciding with failure to express Il22, Il10, Il9, and Atf3. Defects in Th17 cell cytokine expression and Treg cell homeostasis in the absence of Mir155 could be partially suppressed by Jarid2 deletion. Thus, miR-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1026,
                    "offsetInEndSection": 1122,
                    "text": "Thus, miR-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 936,
                    "offsetInEndSection": 1032,
                    "text": "Thus, miR-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 795,
                    "offsetInEndSection": 1033,
                    "text": "Defects in Th17 cell cytokine expression and Treg cell homeostasis in the absence of Mir155 could be partially suppressed by Jarid2 deletion. Thus, miR-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 937,
                    "offsetInEndSection": 1033,
                    "text": "Thus, miR-155 contributes to Th17 cell function by suppressing the inhibitory effects of Jarid2.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24856900",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there any role of 5hmC in T-cell development and differentiation?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25071199",
                "http://www.ncbi.nlm.nih.gov/pubmed/27346350"
            ],
            "ideal_answer": [
                "Yes. 5hmC is enriched in the gene body of highly expressed genes at all different stages of T-cell development in the thymus and that its presence correlates positively with gene expression. Further emphasizing the connection with gene expression, 5hmC is enriched in active thymus-specific enhancers and genes encoding key transcriptional regulators display high intragenic 5hmC levels in precursor cells at those developmental stages where they exert a positive effect."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/amigo/term/GO:0030217",
                "http://amigo.geneontology.org/amigo/term/GO:0045580",
                "http://amigo.geneontology.org/amigo/term/GO:0045589"
            ],
            "type": "yesno",
            "id": "5a6d0727b750ff445500002b",
            "snippets": [
                {
                    "offsetInBeginSection": 173,
                    "offsetInEndSection": 927,
                    "text": "We have mapped 5-hydroxymethylcytosine (5hmC) at different stages of T-cell development in the thymus and T-cell differentiation in the periphery. We show that 5hmC is enriched in the gene body of highly expressed genes at all developmental stages and that its presence correlates positively with gene expression. Further emphasizing the connection with gene expression, we find that 5hmC is enriched in active thymus-specific enhancers and that genes encoding key transcriptional regulators display high intragenic 5hmC levels in precursor cells at those developmental stages where they exert a positive effect. Our data constitute a valuable resource that will facilitate detailed analysis of the role of 5hmC in T-cell development and differentiation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25071199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 320,
                    "offsetInEndSection": 486,
                    "text": "We show that 5hmC is enriched in the gene body of highly expressed genes at all developmental stages and that its presence correlates positively with gene expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25071199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 487,
                    "offsetInEndSection": 785,
                    "text": "Further emphasizing the connection with gene expression, we find that 5hmC is enriched in active thymus-specific enhancers and that genes encoding key transcriptional regulators display high intragenic 5hmC levels in precursor cells at those developmental stages where they exert a positive effect.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25071199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 486,
                    "text": "We show that 5hmC is enriched in the gene body of highly expressed genes at all developmental stages and that its presence correlates positively with gene expression.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25071199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 313,
                    "offsetInEndSection": 488,
                    "text": "Here, we report early and widespread 5mC/5hmC remodeling during human CD4(+) T\u00a0cell differentiation ex\u00a0vivo at genes and cell-specific enhancers with known T\u00a0cell function.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346350",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 949,
                    "offsetInEndSection": 1129,
                    "text": "Our results support 5hmC-mediated DNA de-methylation as a key component of CD4(+) T\u00a0cell biology in humans, with important implications for gene regulation and lineage commitment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346350",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 167,
                    "offsetInEndSection": 311,
                    "text": "5hmC plays important roles in regulation of gene expression and differentiation and has been implicated in T\u00a0cell malignancies and autoimmunity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27346350",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there any link between conserved noncoding elements and alternative splicing in vertebrates?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24681619"
            ],
            "ideal_answer": [
                "Yes. Some of the most highly conserved sequences occur in genes encoding RNA binding proteins, particularly the RNA splicing-associated SR genes."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017124",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D017398",
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014714",
                "http://amigo.geneontology.org/amigo/term/GO:0000381",
                "http://amigo.geneontology.org/amigo/term/GO:0000380"
            ],
            "type": "yesno",
            "id": "56b8ed4b156496395c000004",
            "snippets": [
                {
                    "offsetInBeginSection": 803,
                    "offsetInEndSection": 1245,
                    "text": "Some of the most highly conserved sequences occur in genes encoding RNA binding proteins, particularly the RNA splicing-associated SR genes. Differences in sequence conservation between plants and animals are likely to reflect differences in the biology of the organisms, with plants being much more able to tolerate genomic deletions and whole-genome duplication events due, in part, to their far greater fecundity compared with vertebrates.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24681619",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is adenosine signaling prognostic for cancer outcome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31953314"
            ],
            "ideal_answer": [
                "Yes, adenosine signaling has been shown to be prognostic for cancer outcome.",
                "Yes, adenosine signaling is prognostic for cancer outcome.",
                "Yes. Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "601ecab41cb411341a000065",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 111,
                    "text": "Adenosine Signaling Is Prognostic for Cancer Outcome and Has Predictive Utility for Immunotherapeutic Response.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31953314",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 9,
                    "offsetInEndSection": 1845,
                    "text": "There are several agents in early clinical trials targeting components of the adenosine pathway including A2AR and CD73. The identification of cancers with a significant adenosine drive is critical to understand the potential for these molecules. However, it is challenging to measure tumor adenosine levels at scale, thus novel, clinically tractable biomarkers are needed.EXPERIMENTAL DESIGN: We generated a gene expression signature for the adenosine signaling using regulatory networks derived from the literature and validated this in patients. We applied the signature to large cohorts of disease from The Cancer Genome Atlas (TCGA) and cohorts of immune checkpoint inhibitor-treated patients.RESULTS: The signature captures baseline adenosine levels in vivo (r 2 = 0.92, P = 0.018), is reduced after small-molecule inhibition of A2AR in mice (r 2 = -0.62, P = 0.001) and humans (reduction in 5 of 7 patients, 70%), and is abrogated after A2AR knockout. Analysis of TCGA confirms a negative association between adenosine and overall survival (OS, HR = 0.6, P < 2.2e-16) as well as progression-free survival (PFS, HR = 0.77, P = 0.0000006). Further, adenosine signaling is associated with reduced OS (HR = 0.47, P < 2.2e-16) and PFS (HR = 0.65, P = 0.0000002) in CD8+ T-cell-infiltrated tumors. Mutation of TGF\u03b2 superfamily members is associated with enhanced adenosine signaling and worse OS (HR = 0.43, P < 2.2e-16). Finally, adenosine signaling is associated with reduced efficacy of anti-PD1 therapy in published cohorts (HR = 0.29, P = 0.00012).CONCLUSIONS: These data support the adenosine pathway as a mediator of a successful antitumor immune response, demonstrate the prognostic potential of the signature for immunotherapy, and inform patient selection strategies for adenosine pathway modulators currently in development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31953314",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is Hunter's disease is associated with the X Chromosome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3100113",
                "http://www.ncbi.nlm.nih.gov/pubmed/31046699",
                "http://www.ncbi.nlm.nih.gov/pubmed/23634718",
                "http://www.ncbi.nlm.nih.gov/pubmed/25044788",
                "http://www.ncbi.nlm.nih.gov/pubmed/21062272",
                "http://www.ncbi.nlm.nih.gov/pubmed/22246721",
                "http://www.ncbi.nlm.nih.gov/pubmed/9604546",
                "http://www.ncbi.nlm.nih.gov/pubmed/9611068",
                "http://www.ncbi.nlm.nih.gov/pubmed/1481858",
                "http://www.ncbi.nlm.nih.gov/pubmed/6418082",
                "http://www.ncbi.nlm.nih.gov/pubmed/9375851",
                "http://www.ncbi.nlm.nih.gov/pubmed/20052546",
                "http://www.ncbi.nlm.nih.gov/pubmed/8807335",
                "http://www.ncbi.nlm.nih.gov/pubmed/17345554",
                "http://www.ncbi.nlm.nih.gov/pubmed/21834048",
                "http://www.ncbi.nlm.nih.gov/pubmed/2499679",
                "http://www.ncbi.nlm.nih.gov/pubmed/1908009",
                "http://www.ncbi.nlm.nih.gov/pubmed/1294876",
                "http://www.ncbi.nlm.nih.gov/pubmed/1642233",
                "http://www.ncbi.nlm.nih.gov/pubmed/1678247"
            ],
            "ideal_answer": [
                "Yes, Hunter's disease is associated with the X Chromosome.",
                "Yes, the X Chromosome is associated with the X chromosome.",
                "Hunter's disease is associated with the X chromosome."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "60327e541cb411341a00013e",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 198,
                    "text": "Segregation analysis on five samples of families with Hunter's syndrome (158 cases overall) shows that the mutant allele segregates in agreement with Mendelian expectations for an X linked recessive",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1908009",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 281,
                    "text": "The utility of polymerase chain reaction (PCR) amplification of amelogenin gene as a reliable and rapid means of determination of sex chromosomes was tested in 20 patients of X-linked disorders (Duchenne muscular dystrophy, haemophilia and Wiscott-Aldrich and Hunter's syndromes), ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9604546",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 118,
                    "text": "We describe a 3 year old girl with the typical clinical features of the X linked recessive condition, Hunter's disease",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6418082",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "We describe a 3 year old girl with the typical clinical features of the X linked recessive condition, Hunter's disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6418082",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "Hunter's disease in a girl: association with X:5 chromosomal translocation disrupting the Hunter gene.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6418082",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Further evidence localising the gene for Hunter's syndrome to the distal region of the X chromosome long arm.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2499679",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "Full expression of Hunter's disease in a female with an X-chromosome deletion leading to non-random inactivation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3100113",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 155,
                    "text": "Hunter disease in a girl caused by R468Q mutation in the iduronate-2-sulfatase gene and skewed inactivation of the X chromosome carrying the normal allele.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9375851",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1060,
                    "offsetInEndSection": 1333,
                    "text": "These findings strongly suggest that the severe form of Hunter disease in this girl was the result of selective expression of the maternal allele carrying the missense mutation R468Q, which in turn resulted from skewed X inactivation of the paternal nonmutant X chromosome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9375851",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1336,
                    "offsetInEndSection": 1463,
                    "text": "LUSIONS: This is a report of a female with a 10.6 Mb Xq27-28 deletion with skewed inactivation of the deleted X chromosome. Con",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23634718",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Brother/sister siblings affected with Hunter disease: evidence for skewed X chromosome inactivation.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9611068",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 277,
                    "offsetInEndSection": 406,
                    "text": "The normal X chromosome was preferentially inactivated, supporting the view that the translocation had disrupted the Hunter gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2499679",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 140,
                    "text": "Hunter disease (mucopolysaccharidosis type II) associated with unbalanced inactivation of the X chromosomes in a karyotypically normal girl.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1678247",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 256,
                    "text": "INTRODUCTION: Hunter syndrome, or mucopolysaccharidosis type II, is an inherited disease linked to the X chromosome that is caused by a deficit of the enzyme iduronate-2-sulfatase and its main symptoms affect the bones, neurological system and the viscera.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17345554",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 247,
                    "text": "INTRODUCTION: Hunter syndrome, or mucopolysaccharidosis type II, is an inherited disease linked to the X chromosome that is caused by a deficit of the enzyme iduronate-2-sulfatase and its main symptoms affect the bones, neurological system and the",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17345554",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 301,
                    "text": "Mucopolysaccharidosis type II (MPS II, Hunter disease) is an X chromosome-linked inherited metabolic disease caused by mutations resulting in deficiency of activity of iduronate-2-sulfatase (IDS) and accumulation of undegraded glycosaminoglycans (GAGs), heparan sulfate, and dermatan sulfate. Previous",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21834048",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "text": "Mucopolysaccharidosis type II (MPS-II, Hunter disease) is a X-linked recessive disorder. Affe",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20052546",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "Mucopolysaccharidosis type II (MPS II or Hunter syndrome) is a rare X-linked disorder caused by deficient activity of the lysosomal enzyme, iduronate-2-sulfatase (IDS). Pheno",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25044788",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 151,
                    "text": "Hunter disease or mucopolysaccharidosis type II is an X-linked disease caused by the deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS). Th",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/8807335",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 157,
                    "text": "Mucopolysaccharidosis type II (MPS II, Hunter syndrome) is an X-linked lysosomal storage disease caused by a deficiency of iduronate-2-sulfatase (IDS). Two a",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22246721",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 232,
                    "text": "We report the results of studies on the characterization of the mutation associated with marked unbalanced expression of the mutant X chromosome in a karyotypically normal girl with Hunter disease (mucopolysaccharidosis type II). So",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1642233",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 143,
                    "text": "BACKGROUND: Hunter syndrome (mucopolysaccharidosis type II) is a recessive X-linked disorder due to mutations in the iduronate 2-sulfatase (IDS",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31046699",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 199,
                    "text": "Familial X-chromosome inactivation (XCI) skewing was investigated in a family in which a female mucopolysaccharidosis type II (MPS II) (Hunter syndrome, an X-linked genetic disease) occurred. Among e",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21062272",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1180,
                    "offsetInEndSection": 1352,
                    "text": "Studies using BrdU indicated that the deleted X chromosome was consistently late replicating, and as a result the Hunter gene was fully expressed on the other X chromosome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3100113",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1358,
                    "offsetInEndSection": 1479,
                    "text": "All mucopolysaccharidosis are autosomal recessive disorders, except for Hunter's syndrome that is X-linked and recessive.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1294876",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Female twin with Hunter disease due to nonrandom inactivation of the X-chromosome: a consequence of twinning.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1481858",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 150,
                    "text": "Hunter syndrome (mucopolysaccharidosis type II) is a recessive X-linked disorder due to mutations in the iduronate 2-sulfatase (IDS) gene.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31046699",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 142,
                    "text": "Hunter disease is an X-linked recessive mucopolysaccharide storage disorder caused by iduronate-2-sulfatase deficiency and is rare in females.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9375851",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 106,
                    "text": "Hunter disease is an X-linked recessive disorder caused by a deficiency of iduronate-2-sulfatase activity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9611068",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are ultraconserved enhancers important for normal development?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/29358049"
            ],
            "ideal_answer": [
                "Yes, ultraconserved enhancers are required for normal development."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c531e887e3cb0e231000018",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 61,
                    "text": "Ultraconserved Enhancers Are Required for Normal Development.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358049",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 177,
                    "offsetInEndSection": 403,
                    "text": "However, initial deletion studies in mice revealed that loss of such extraordinarily constrained sequences had no immediate impact on viability. Here, we show that ultraconserved enhancers are required for normal development. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358049",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 322,
                    "offsetInEndSection": 402,
                    "text": "Here, we show that ultraconserved enhancers are required for normal development.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29358049",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is autophagy modulated in a circadian fashion?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28514207",
                "http://www.ncbi.nlm.nih.gov/pubmed/28721811",
                "http://www.ncbi.nlm.nih.gov/pubmed/28196106",
                "http://www.ncbi.nlm.nih.gov/pubmed/29113329",
                "http://www.ncbi.nlm.nih.gov/pubmed/28865774",
                "http://www.ncbi.nlm.nih.gov/pubmed/27171500"
            ],
            "ideal_answer": [
                "Yes, metabolic pathways, bile acid synthesis, and autophagic and immune/inflammatory processes are driven by the biological clock."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5a87fd0561bb38fb24000010",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 174,
                    "text": "TOR signaling pathway and autophagy are involved in the regulation of circadian rhythms in behavior and plasticity of L2 interneurons in the brain of Drosophila melanogaster.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28196106",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1404,
                    "offsetInEndSection": 1593,
                    "text": " Our results indicate that the TOR signaling pathway and autophagy are involved in the regulation of circadian rhythms in the behavior and plasticity of neurons in the brain of adult flies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28196106",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1843,
                    "offsetInEndSection": 1930,
                    "text": "the pathways of autophagy, mTOR, SIRT1, and Wnt that control mammalian circadian rhythm",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28721811",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 276,
                    "offsetInEndSection": 402,
                    "text": "Metabolic pathways, bile acid synthesis, and autophagic and immune/inflammatory processes are driven by the biological clock. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28865774",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 832,
                    "offsetInEndSection": 1007,
                    "text": "our findings suggest that the clock geneBmal1is a positive regulator of autophagy through the mTOR signaling pathway and protects cardiomyocytes against high-glucose toxicity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29113329",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 127,
                    "text": "Autophagy is a highly conserved intracellular degradation system, and recently was shown to display circadian rhythms in mice. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27171500",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is autism one of the characteristics of Moebius syndrome?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15736079",
                "http://www.ncbi.nlm.nih.gov/pubmed/22832772",
                "http://www.ncbi.nlm.nih.gov/pubmed/20621443",
                "http://www.ncbi.nlm.nih.gov/pubmed/19255803",
                "http://www.ncbi.nlm.nih.gov/pubmed/1623312",
                "http://www.ncbi.nlm.nih.gov/pubmed/2929356"
            ],
            "ideal_answer": [
                "Moebius syndrome is a rare congenital disorder usually defined as a combination of facial weakness with impairment of ocular abduction. A strong association of Moebius syndrome with autism spectrum disorders (ASDs) has been suggested in early studies with heterogenous age groups."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5727b6410fd6f91b6800001b",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 410,
                    "text": "The diagnosis of Moebius syndrome, a rare congenital disorder, is primarily based on congenital facial and abducent nerve palsy. Involvement of other cranial nerves is also common. Occasionally the V, X, XI, and XII cranial nerves are involved, resulting in a difficulty to chew, swallow, and cough, which often leads to respiratory complications. Mental retardation and autism have been reported in some cases",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22832772",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 281,
                    "text": "Moebius sequence is a rare congenital disorder usually defined as a combination of facial weakness with impairment of ocular abduction. A strong association of Moebius sequence with autism spectrum disorders (ASDs) has been suggested in earlier studies with heterogenous age groups",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19255803",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 175,
                    "offsetInEndSection": 1069,
                    "text": "Certain genetic syndromes are providing us with extremely valuable information about the role played by genetics in autism. This is the case of the following syndromes: Angelman syndrome, Prader-Willi syndrome, 15q11-q13 duplication, fragile X syndrome, fragile X premutation, deletion of chromosome 2q, XYY syndrome, Smith-Lemli-Opitz syndrome, Apert syndrome, mutations in the ARX gene, De Lange syndrome, Smith-Magenis syndrome, Williams syndrome, Rett syndrome, Noonan syndrome, Down syndrome, velo-cardio-facial syndrome, myotonic dystrophy, Steinert disease, tuberous sclerosis, Duchenne's disease, Timothy syndrome, 10p terminal deletion, Cowden syndrome, 45,X/46,XY mosaicism, Myhre syndrome, Sotos syndrome, Cohen syndrome, Goldenhar syndrome, Joubert syndrome, Lujan-Fryns syndrome, Moebius syndrome, hypomelanosis of Ito, neurofibromatosis type 1, CHARGE syndrome and HEADD syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15736079",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 200,
                    "text": "Seventeen children and young adults with Moebius syndrome were examined with a view to finding symptoms of autism. Some 40% of the group showed all or many of the symptoms typical of autistic disorder",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2929356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 283,
                    "text": "Fifty-nine cases with infantile autism/autistic disorder were subclassified according to associated medical condition (fragile-X, tuberous sclerosis, neurofibromatosis, hypo-melanosis of Ito, Moebius syndrome, Rett syndrome, and a 'new' syndrome associated with a marker chromosome).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/1623312",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 76,
                    "text": "Autism spectrum disorders in children and adolescents with Moebius sequence.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19255803",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Moebius sequence and autism spectrum disorders--less frequently associated than formerly thought.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621443",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 281,
                    "offsetInEndSection": 427,
                    "text": "A strong association of Moebius sequence with autism spectrum disorders (ASDs) has been suggested in earlier studies with heterogenous age groups.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19255803",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 39,
                    "text": "Autistic behaviour in Moebius syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2929356",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 202,
                    "offsetInEndSection": 393,
                    "text": "The high frequency of autistic symptoms in Moebius syndrome might be a marked overrepresentation and could be suggestive of a common underlying neurobiological deficit at the brainstem level.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2929356",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 77,
                    "text": "Autism spectrum disorders in children and adolescents with Moebius sequence.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19255803",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Moebius sequence and autism spectrum disorders--less frequently associated than formerly thought.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20621443",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 40,
                    "text": "Autistic behaviour in Moebius syndrome.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/2929356",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Are histone deacetylase (HDAC) inhibitors good candidates to control metastasis of solid tumors?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/19417021",
                "http://www.ncbi.nlm.nih.gov/pubmed/20884621",
                "http://www.ncbi.nlm.nih.gov/pubmed/22279574",
                "http://www.ncbi.nlm.nih.gov/pubmed/21041383",
                "http://www.ncbi.nlm.nih.gov/pubmed/22038994",
                "http://www.ncbi.nlm.nih.gov/pubmed/22811583",
                "http://www.ncbi.nlm.nih.gov/pubmed/10893438",
                "http://www.ncbi.nlm.nih.gov/pubmed/15800932",
                "http://www.ncbi.nlm.nih.gov/pubmed/21452015",
                "http://www.ncbi.nlm.nih.gov/pubmed/19861438",
                "http://www.ncbi.nlm.nih.gov/pubmed/19789319",
                "http://www.ncbi.nlm.nih.gov/pubmed/19509253",
                "http://www.ncbi.nlm.nih.gov/pubmed/18981013",
                "http://www.ncbi.nlm.nih.gov/pubmed/22161747",
                "http://www.ncbi.nlm.nih.gov/pubmed/18506586",
                "http://www.ncbi.nlm.nih.gov/pubmed/15318170"
            ],
            "ideal_answer": [
                "Yes, some HDAC inhibitors, such as Vorinostat, are on trial for human treatment after proving successful in animal models. Combination with other drugs is likely to be needed to control metastasis."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D056572"
            ],
            "type": "yesno",
            "id": "517404878ed59a060a000023",
            "snippets": [
                {
                    "offsetInBeginSection": 1227,
                    "offsetInEndSection": 1375,
                    "text": "JNJ-26481585 also fully inhibited the growth of C170HM2 colorectal liver metastases, whereas again 5-fluorouracil/Leucovorin showed modest activity.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19861438",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1368,
                    "offsetInEndSection": 1722,
                    "text": "Although not meeting the RECIST response criteria for adequate single-agent activity, the observed tolerable toxicities and the potential for clinical benefit in terms of stable disease suggest that further assessment of vorinostat as a part of combination therapy with either chemotherapeutic or targeted agents in metastatic breast might be undertaken.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18981013",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1518,
                    "offsetInEndSection": 1832,
                    "text": "Treatments of different structural classes of HDACi simultaneously induced cell death and promoted cell migration and metastasis in multiple cancer cell types. Suppression of HDACi-induced PKCs leads to development of low toxic and long-term therapeutic strategies to potentially treat cancer as a chronic disease.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22811583",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1396,
                    "offsetInEndSection": 1665,
                    "text": "mRNA expression analysis of lung tumor bearing mice suggested that the enhanced chemopreventive activity of the combination is related to atorvastatin modulation of DNA repair, SAHA modulation of angiogenesis, and both drugs modulating invasion and metastasis pathways.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22161747",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1039,
                    "offsetInEndSection": 1268,
                    "text": "Histone deacetylase (HDAC) inhibitors induced morphologic differentiation, cell-cycle exit, and a shift to a differentiated, melanocytic gene expression profile in cultured UM cells. VPA inhibited the growth of UM tumors in vivo.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22038994",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1061,
                    "offsetInEndSection": 1422,
                    "text": "When both drugs were used in concert additive effects were observed on the migratory and invasive behavior but not on tumor-endothelium and tumor-matrix interaction. Separate mTOR or HDAC inhibition slows processes related to tumor metastasis. The RAD001-VPA combination showed advantage over VPA monotreatment with particular respect to migration and invasion.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21452015",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1555,
                    "offsetInEndSection": 1793,
                    "text": "In conclusion, sequential treatments of mice with MS-275 followed by TRAIL may target multiple pathways to reverse EMT and inhibit tumor progression, angiogenesis, and metastasis and represent a novel therapeutic approach to treat cancer.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21041383",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1345,
                    "offsetInEndSection": 1425,
                    "text": "In vivo, AA98 synergized with vorinostat to inhibit tumor growth and metastasis.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20884621",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1440,
                    "offsetInEndSection": 1782,
                    "text": "We report the first preclinical data for the prevention of brain metastasis of triple-negative breast cancer. Vorinostat is brain permeable and can prevent the formation of brain metastases by 62%. Its mechanism of action involves the induction of DNA double-strand breaks, suggesting rational combinations with DNA active drugs or radiation.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789319",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1483,
                    "offsetInEndSection": 1616,
                    "text": "Combining vorinostat with radiation may be a potential treatment option for patients with breast cancer who develop brain metastases.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19509253",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1604,
                    "offsetInEndSection": 1748,
                    "text": "Although single-agent PCI-24781 had modest effects on STS growth and metastasis, marked inhibition was observed when combined with chemotherapy.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19417021",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1042,
                    "offsetInEndSection": 1367,
                    "text": "In a 4T1 metastatic breast carcinoma model, AN-7 inhibited the formation of lung lesions by 76% and AN-9 by 47%, further demonstrating the greater efficacy of AN-7 compared to AN-9 (P<0.02). Both AN-7 and AN-9 exhibited antimetastatic and antiangiogenic activities by reducing vascularization, bFGF expression and HIF-1alpha.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18506586",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1228,
                    "offsetInEndSection": 1507,
                    "text": "Since prolonged oral administration with 50 mg/kg or a single oral dose of 1.2 g/kg AN-7 did not cause adverse effects and the former exhibited significant anticancer activity, AN-7 is likely to display a high therapeutic index and may be beneficial for prostate cancer patients.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15800932",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 435,
                    "offsetInEndSection": 801,
                    "text": "We show that apicidin significantly inhibits H-ras-induced invasive phenotype of MCF10A human breast epithelial cells in parallel with a specific downregulation of matrix metalloproteinase (MMP)-2, but not MMP-9. We also show that apicidin induces a morphological reversal and growth inhibition of H-ras MCF10A cells similar to that induced by other HDAC inhibitors.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10893438",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1397,
                    "offsetInEndSection": 1553,
                    "text": "We also found that NaB induced three genes, which are known metastatic suppressors, and downregulated 11 genes, which have been shown to promote metastasis.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15318170",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Is tocilizumab a csDMARD?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31969328"
            ],
            "ideal_answer": [
                "No, tocilizumab is a biological DMARD (bDMARD)."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "60259fe91cb411341a0000b3",
            "snippets": [
                {
                    "offsetInBeginSection": 730,
                    "offsetInEndSection": 1251,
                    "text": "The task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic (cs) DMARDs (methotrexate (MTX), leflunomide, sulfasalazine); glucocorticoids (GCs); biological (b) DMARDs (tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, etanercept, golimumab, infliximab), abatacept, rituximab, tocilizumab, sarilumab and biosimilar (bs) DMARDs) and targeted synthetic (ts) DMARDs (the Janus kinase (JAK) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31969328",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Can radiation induced meningiomas be treated with radiosurgery?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/15850899",
                "http://www.ncbi.nlm.nih.gov/pubmed/20418026",
                "http://www.ncbi.nlm.nih.gov/pubmed/18447746",
                "http://www.ncbi.nlm.nih.gov/pubmed/9032855",
                "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                "http://www.ncbi.nlm.nih.gov/pubmed/28731398",
                "http://www.ncbi.nlm.nih.gov/pubmed/19240608",
                "http://www.ncbi.nlm.nih.gov/pubmed/29104836"
            ],
            "ideal_answer": [
                "Yes, radiation induced meningiomas be treated with radiosurgery. Radiosurgery provides satisfactory control of radiation induced meningiomas."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e3234e0fbd6abf43b000054",
            "snippets": [
                {
                    "offsetInBeginSection": 257,
                    "offsetInEndSection": 401,
                    "text": "This is a case report of a patient treated with radiosurgery for radiation induced\u00a0meningiomas, 30 years after childhood whole brain radiation. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 861,
                    "offsetInEndSection": 984,
                    "text": "This article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "text": "Gamma knife stereotactic radiosurgery for radiation-induced meningiomas.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 760,
                    "offsetInEndSection": 995,
                    "text": "RESULTS: We present our series of 12 patients with radiation-induced meningiomas treated with Gamma Knife stereotactic radiosurgery over a 12-year period at our institution. With a median follow-up of 35 months, local control was 100%.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1303,
                    "offsetInEndSection": 1414,
                    "text": "CONCLUSIONS: Gamma Knife radiosurgery is both a safe and effective treatment for radiation-induced meningiomas.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "text": "Favorable outcomes of pediatric patients treated with radiotherapy to the central nervous system who develop radiation-induced meningiomas.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20418026",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 692,
                    "offsetInEndSection": 838,
                    "text": "All cases were managed with a single modality: resection alone (n = 7), fractionated radiotherapy (n = 2), and stereotactic radiosurgery (n = 1). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20418026",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 60,
                    "text": "Stereotactic radiosurgery for radiation-induced meningiomas.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19240608",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 386,
                    "offsetInEndSection": 487,
                    "text": "The patients met criteria for a radiation-induced meningioma and underwent gamma knife radiosurgery. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19240608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1453,
                    "offsetInEndSection": 1563,
                    "text": "CONCLUSION: SRS provides satisfactory control rates either after resection or as an alternative to resection. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19240608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 257,
                    "offsetInEndSection": 400,
                    "text": "This is a case report of a patient treated with radiosurgery for radiation induced\u00a0meningiomas, 30 years after childhood whole brain radiation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 861,
                    "offsetInEndSection": 983,
                    "text": "This article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1311,
                    "offsetInEndSection": 1422,
                    "text": "CONCLUSIONS\n\nGamma Knife radiosurgery is both a safe and effective treatment for radiation-induced meningiomas.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 766,
                    "offsetInEndSection": 939,
                    "text": "RESULTS\n\nWe present our series of 12 patients with radiation-induced meningiomas treated with Gamma Knife stereotactic radiosurgery over a 12-year period at our institution.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1303,
                    "offsetInEndSection": 1413,
                    "text": "CONCLUSIONS Gamma Knife radiosurgery is both a safe and effective treatment for radiation-induced meningiomas.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 861,
                    "offsetInEndSection": 982,
                    "text": "This article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 59,
                    "text": "Stereotactic radiosurgery for radiation-induced meningiomas",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19240608",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1345,
                    "offsetInEndSection": 1463,
                    "text": "Also, LC rates with radiosurgery are at least comparable to those of surgical series for radiation-induced meningiomas",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15850899",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Gamma Knife radiosurgery for meningiomas: four cases of radiation-induced edema.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/9032855",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 402,
                    "text": "This is a case report of a patient treated with radiosurgery for radiation induced\u00a0meningiomas , 30 years after childhood whole brain radiation",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 91,
                    "offsetInEndSection": 295,
                    "text": "Stereotactic radiosurgery ( SRS ) has become an important primary or adjuvant management for patients with intracranial meningiomas , but the value of this approach for radiation-induced tumors is unclear",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19240608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 870,
                    "offsetInEndSection": 991,
                    "text": "This article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29104836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 766,
                    "offsetInEndSection": 939,
                    "text": "RESULTS\nWe present our series of 12 patients with radiation-induced meningiomas treated with Gamma Knife stereotactic radiosurgery over a 12-year period at our institution.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 336,
                    "offsetInEndSection": 462,
                    "text": "OBJECTIVES\nTo ascertain the safety and efficacy of Gamma Knife radiosurgery as a treatment for radiation-induced meningiomas.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 179,
                    "offsetInEndSection": 334,
                    "text": "As such, traditional radiotherapy is limited by lifetime tissue tolerances to radiation, leaving surgery and radiosurgery as attractive treatment options.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1311,
                    "offsetInEndSection": 1422,
                    "text": "CONCLUSIONS\nGamma Knife radiosurgery is both a safe and effective treatment for radiation-induced meningiomas.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 100,
                    "offsetInEndSection": 303,
                    "text": "Stereotactic radiosurgery (SRS) has become an important primary or adjuvant management for patients with intracranial meningiomas, but the value of this approach for radiation-induced tumors is unclear.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19240608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 387,
                    "offsetInEndSection": 488,
                    "text": "The patients met criteria for a radiation-induced meningioma and underwent gamma knife radiosurgery.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19240608",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 334,
                    "offsetInEndSection": 460,
                    "text": "OBJECTIVES: To ascertain the safety and efficacy of Gamma Knife radiosurgery as a treatment for radiation-induced meningiomas.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 760,
                    "offsetInEndSection": 933,
                    "text": "RESULTS: We present our series of 12 patients with radiation-induced meningiomas treated with Gamma Knife stereotactic radiosurgery over a 12-year period at our institution.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 460,
                    "offsetInEndSection": 650,
                    "text": "METHODS: A retrospective chart review was conducted to identify patients who received Gamma Knife radiosurgery for a meningioma and met the criteria for this being a radiation-induced tumor.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 730,
                    "offsetInEndSection": 894,
                    "text": "We present our series of 12 patients with radiation-induced meningiomas treated with Gamma Knife stereotactic radiosurgery over a 12-year period at our institution.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22922437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 90,
                    "offsetInEndSection": 292,
                    "text": "Stereotactic radiosurgery (SRS) has become an important primary or adjuvant management for patients with intracranial meningiomas, but the value of this approach for radiation-induced tumors is unclear.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19240608",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are splicing speckles associated with transcription?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26496460",
                "http://www.ncbi.nlm.nih.gov/pubmed/12011111",
                "http://www.ncbi.nlm.nih.gov/pubmed/16467386",
                "http://www.ncbi.nlm.nih.gov/pubmed/21086038",
                "http://www.ncbi.nlm.nih.gov/pubmed/20514231"
            ],
            "ideal_answer": [
                "Speckles contain little detectable transcriptional activity.",
                "yes"
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5a8965f6fcd1d6a10c000005",
            "snippets": [
                {
                    "offsetInBeginSection": 254,
                    "offsetInEndSection": 388,
                    "text": "We show here that RNA splicing speckled domains (splicing speckles) fluctuate in constrained nuclear volumes and remodel their shapes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26496460",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1121,
                    "offsetInEndSection": 1339,
                    "text": "We present a model where recycling splicing factors return as part of small sub-speckles from distal sites of RNA processing to larger splicing speckles by a directed ATP-driven mechanism through interchromatin spaces.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26496460",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 462,
                    "offsetInEndSection": 630,
                    "text": "Analysis of a HeLa cell line stably expressing EYFP-NHPX showed that the nucleolar accumulation of NHPX was preceded by its transient accumulation in splicing speckles.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12011111",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "In vivo analysis of NHPX reveals a novel nucleolar localization pathway involving a transient accumulation in splicing speckles.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12011111",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 319,
                    "text": "\"Splicing speckles\" are major nuclear domains rich in components of the splicing machinery and polyA(+) RNA. Although speckles contain little detectable transcriptional activity, they are found preferentially associated with specific mRNA-coding genes and gene-rich R bands, and they accumulate some unspliced pre-mRNAs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 321,
                    "offsetInEndSection": 474,
                    "text": "RNA polymerase II transcribes mRNAs and is required for splicing, with some reports suggesting that the inactive complexes are stored in splicing speckle",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 412,
                    "offsetInEndSection": 565,
                    "text": "In normal cell growth conditions GFPeIF4A-III was mainly nucleoplasmic, but in hypoxia stress conditions it moved to the nucleolus and splicing speckles.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20514231",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 97,
                    "text": "Localization of eIF4A-III in the nucleolus and splicing speckles is an indicator of plant stress.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20514231",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 328,
                    "offsetInEndSection": 618,
                    "text": " Using antibodies raised against mouse RBM6 to immunostain mammalian cell lines we found that the endogenous protein was both distributed diffusely in the nucleus and concentrated in a small number of nuclear foci that corresponded to splicing speckles/interchromatin granule clusters (IGCs",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21086038",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "Subnuclear targeting of the RNA-binding motif protein RBM6 to splicing speckles and nascent transcripts.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21086038",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is carpal tunnel syndrome a type of nerve entrapment?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/3618059",
                "http://www.ncbi.nlm.nih.gov/pubmed/25526716",
                "http://www.ncbi.nlm.nih.gov/pubmed/15605660",
                "http://www.ncbi.nlm.nih.gov/pubmed/12475522",
                "http://www.ncbi.nlm.nih.gov/pubmed/19534294",
                "http://www.ncbi.nlm.nih.gov/pubmed/32174033",
                "http://www.ncbi.nlm.nih.gov/pubmed/22492102",
                "http://www.ncbi.nlm.nih.gov/pubmed/32477509",
                "http://www.ncbi.nlm.nih.gov/pubmed/24740988",
                "http://www.ncbi.nlm.nih.gov/pubmed/23997744",
                "http://www.ncbi.nlm.nih.gov/pubmed/19756731",
                "http://www.ncbi.nlm.nih.gov/pubmed/31634868",
                "http://www.ncbi.nlm.nih.gov/pubmed/16558255",
                "http://www.ncbi.nlm.nih.gov/pubmed/28447963",
                "http://www.ncbi.nlm.nih.gov/pubmed/24422297",
                "http://www.ncbi.nlm.nih.gov/pubmed/21845587",
                "http://www.ncbi.nlm.nih.gov/pubmed/29218119",
                "http://www.ncbi.nlm.nih.gov/pubmed/31632712",
                "http://www.ncbi.nlm.nih.gov/pubmed/28718333",
                "http://www.ncbi.nlm.nih.gov/pubmed/31736403",
                "http://www.ncbi.nlm.nih.gov/pubmed/18050074",
                "http://www.ncbi.nlm.nih.gov/pubmed/23799199",
                "http://www.ncbi.nlm.nih.gov/pubmed/28824352",
                "http://www.ncbi.nlm.nih.gov/pubmed/10918251",
                "http://www.ncbi.nlm.nih.gov/pubmed/21320832",
                "http://www.ncbi.nlm.nih.gov/pubmed/32082444",
                "http://www.ncbi.nlm.nih.gov/pubmed/28928252",
                "http://www.ncbi.nlm.nih.gov/pubmed/33141768",
                "http://www.ncbi.nlm.nih.gov/pubmed/23113142",
                "http://www.ncbi.nlm.nih.gov/pubmed/33151661",
                "http://www.ncbi.nlm.nih.gov/pubmed/6756339",
                "http://www.ncbi.nlm.nih.gov/pubmed/19280893"
            ],
            "ideal_answer": [
                "Carpal tunnel syndrome (CTS) is the most frequent entrapment neuropathy in humans.",
                "Carpal tunnel syndrome (CTS) is a type of nerve entrapment due to compression of the nerve root extraforaminally between the wrist and the wrist at the carpal tunnel.",
                "Carpal tunnel syndrome is a neuropathy resulting from compression of the median nerve as it passes through a narrow tunnel in the wrist on its way to the hand.",
                "Carpal tunnel syndrome (CTS) is the most common focal entrapment mononeuropathy, comprising medium nerve chronic inflammation and fibrosis.",
                "Carpal tunnel syndrome (CTS) is a focal compressive neuropathy of the central nervous system causing hemorrhage-prone multiple lumen vascular malformation and very severe neurological consequences",
                "Carpal tunnel syndrome (CTS) is an entrapment neuropathy accounting for up to 90% of nerve compression syndromes",
                "Carpal tunnel syndrome (CTS) is a type of nerve entrapment due to compression of the nerve root ganglion as it travels through the wrist at the carpal tunnel."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "601d73ee1cb411341a00003f",
            "snippets": [
                {
                    "offsetInBeginSection": 8,
                    "offsetInEndSection": 125,
                    "text": " Carpal tunnel syndrome (CTS) is a common entrapment neuropathy, often requiring carpal tunnel release (CTR) surgery.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33141768",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 126,
                    "text": "Carpal tunnel syndrome (CTS) is an entrapment neuropathy accounting for up to 90% of nerve compression syndromes",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31736403",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 11,
                    "offsetInEndSection": 95,
                    "text": " Carpal tunnel syndrome (CTS) is the most frequent entrapment neuropathy in humans. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31634868",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 139,
                    "text": "Carpal tunnel syndrome (CTS) is the most common focal entrapment mononeuropathy, comprising medium nerve chronic inflammation and fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32174033",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 161,
                    "text": "Carpal tunnel syndrome (CTS) is the most common nerve entrapment neuropathy which is the result of the compression of the median nerve in the wrist. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32477509",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 223,
                    "text": "Dear sir, one of the most common entrapment neuropathy syndromes in clinical practice is \"Entrapment of median nerve in carpal tunnel\" also called \"Carpal tunnel syndrome (CTS)\" (Aydin et al., 2007; Huisstede et al., 2010).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28447963",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "BACKGROUND: Carpal tunnel syndrome (CTS) is the most common type of peripheral nerve entrapment and is a significant cause of morbidity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19534294",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "BACKGROUND: Carpal tunnel syndrome and ulnar nerve entrapment at the elbow are the most common entrapment neuropathies seen in adults.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21320832",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 289,
                    "offsetInEndSection": 386,
                    "text": "Entrapment neuropathies are of various types, but the most common type is carpal tunnel syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29218119",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 57,
                    "text": "Carpal Tunnel Syndrome and Other Entrapment Neuropathies.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29218119",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 259,
                    "offsetInEndSection": 378,
                    "text": "Unlike Guyon's canal syndrome, carpal tunnel syndrome (CTS) is the most common nerve entrapment of the upper extremity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21845587",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 465,
                    "offsetInEndSection": 636,
                    "text": " chronic renal failure tend to develop peripheral nerve entrapment and carpal tunnel syndrome is the best-known peripheral entrapment neuropathy among them. Contrary to ca",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18050074",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 187,
                    "text": "Carpal tunnel syndrome (CTS) is a common form of peripheral nerve entrapment, which is observed due to compression of the median nerve at the level of the carpal tunnel in the wrist. Bifi",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28928252",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 108,
                    "text": "INTRODUCTION: Carpal tunnel syndrome (CTS) is considered a simple entrapment of the median nerve at the carp",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22492102",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 208,
                    "text": "Compressive neuropathy of the median nerve at the level of the carpal tunnel, known as carpal tunnel syndrome, is the most common entrapment neuropathy, affecting about 0.1-1% of the general population. Magne",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32082444",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 93,
                    "text": "BACKGROUND: Carpal tunnel syndrome (CTS) is entrapment of median nerve in carpal tunnel of th",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23113142",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 234,
                    "text": "Dear sir, one of the most common entrapment neuropathy syndromes in clinical practice is \"Entrapment of median nerve in carpal tunnel\" also called \"Carpal tunnel syndrome (CTS)\" (Aydin et al., 2007; Huisstede et al., 2010). This syndr",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28447963",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 224,
                    "text": "OBJECTIVE: Carpal tunnel syndrome (CTS) is a common median nerve entrapment neuropathy characterized by pain, paresthesias, diminished peripheral nerve conduction velocity (NCV) and maladaptive functional brain neuroplastici",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23799199",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "Carpal tunnel syndrome (CTS), caused by entrapment of the median nerve in the carpal tunnel, impairs hand function including dexterous manipulation. The ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28824352",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 368,
                    "offsetInEndSection": 655,
                    "text": "This review focuses on three of the most common entrapment neuropathies in the upper limbs: carpal tunnel syndrome (median nerve entrapment at the wrist), cubital tunnel syndrome (ulnar nerve entrapment at the elbow), and radial tunnel syndrome (posterior interosseous nerve entrapment).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/10918251",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 423,
                    "text": "Electrodiagnostic (EDX) testing is usually an essential part of the evaluation of entrapment neuropathies, and examinations for the most common entrapment neuropathies, carpal tunnel syndrome and ulnar neuropathy at the elbow, constitute a significant part of the daily work in EDX laboratories.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33151661",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 627,
                    "offsetInEndSection": 985,
                    "text": "This study reviews the existing, more or less, detailed EDX criteria or practice parameters that are suggested by consensus groups in peer-reviewed journals for the most common entrapment neuropathies: carpal tunnel syndrome, ulnar neuropathy at the elbow, common peroneal (fibular) neuropathy at the fibular head, and tibial neuropathy at the tarsal tunnel.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33151661",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 142,
                    "offsetInEndSection": 355,
                    "text": "This report demonstrates that the Semmes-Weinstein monofilament test and nerve conduction studies can identify entrapment of the palmar cutaneous branch of the median nerve concomitant with carpal tunnel syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12475522",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 128,
                    "text": "Entrapment neuropathy of the palmar cutaneous branch of the median nerve concomitant with carpal tunnel syndrome: a case report.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12475522",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 141,
                    "text": "A case of the entrapment neuropathy of the palmar cutaneous branch of the median nerve, concomitant with carpal tunnel syndrome is presented.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/12475522",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 476,
                    "offsetInEndSection": 686,
                    "text": "The entrapment syndromes discussed are suprascapular nerve entrapment, carpal tunnel syndrome, cubital tunnel syndrome, meralgia paraesthetica, thoracic outlet syndrome and anterior interosseous nerve syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25526716",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 159,
                    "text": "Carpal tunnel syndrome is a neuropathy resulting from compression of the median nerve as it passes through a narrow tunnel in the wrist on its way to the hand.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16558255",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 472,
                    "offsetInEndSection": 587,
                    "text": "More typically, carpal tunnel syndrome is the most common peripheral entrapment neuropathy encountered in industry.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16558255",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 162,
                    "offsetInEndSection": 248,
                    "text": "Carpal tunnel syndrome is the most frequently encountered peripheral nerve entrapment.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19280893",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 98,
                    "text": "Carpal tunnel syndrome, an entrapment neuropathy of the median nerve, is rarely seen in childhood.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19756731",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 136,
                    "text": "Carpal tunnel syndrome (CTS) is the most common type of peripheral nerve entrapment and is a significant cause of morbidity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19534294",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 134,
                    "text": "Carpal tunnel syndrome (CTS) is a nerve entrapment disorder, involving the median nerve when it passes the carpal tunnel at the wrist.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15605660",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "The carpal tunnel syndrome is the most frequent entrapment syndrome of peripheral nerves.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3618059",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 131,
                    "text": "BACKGROUND: Compression of the median nerve at the wrist, or carpal tunnel syndrome, is the most commonly recognized nerve entrapme",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28718333",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1022,
                    "offsetInEndSection": 1096,
                    "text": "Carpal tunnel syndrome is the most common of the median nerve entrapments.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/6756339",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 90,
                    "text": "BACKGROUND: Carpal tunnel syndrome (CTS) is by far the most common entrapment neuropathy (",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23997744",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 152,
                    "text": "Introduction: Carpal tunnel syndrome, entrapment of median nerve at the wrist, is one of the most commonly encountered peripheral neuropathies in the up",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31632712",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 104,
                    "text": "Carpal tunnel syndrome, a median nerve entrapment neuropathy, is characterized by sensorimotor deficits.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24740988",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 182,
                    "text": "Carpal tunnel syndrome (CTS) is a common form of peripheral nerve entrapment, which is observed due to compression of the median nerve at the level of the carpal tunnel in the wrist.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28928252",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 62,
                    "text": "[Carpal tunnel syndrome and other nerve entrapment syndromes].",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24422297",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Is the yeast (Saccharomyces cerevisiae) genome organized into topologically associated domains (TADs)?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28348222",
                "http://www.ncbi.nlm.nih.gov/pubmed/28780612"
            ],
            "ideal_answer": [
                "Yes. By analyzing Hi-C data for budding yeast, 200-kb scale topologically associated domains (TADs) have been identified, whose boundaries are enriched for transcriptional activity."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c62a529e842deac6700000b",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 739,
                    "text": "Recent advances in our understanding of the three-dimensional organization of the eukaryotic nucleus have rendered the spatial distribution of genes increasingly relevant. In a recent work (Tsochatzidou et al., Nucleic Acids Res 45:5818-5828, 2017), we proposed the existence of a functional compartmentalization of the yeast genome according to which, genes occupying the chromosomal regions at the nuclear periphery have distinct structural, functional and evolutionary characteristics compared to their centromeric-proximal counterparts. Around the same time, it was also shown that the genome of Saccharomyces cerevisiae is organized in topologically associated domains (TADs), which are largely associated with the replication timing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28780612",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 80,
                    "text": "Form and function of topologically associating genomic domains in budding yeast.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28348222",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 178,
                    "offsetInEndSection": 1427,
                    "text": "Although similar structures appear to be conserved in fission yeast, computational modeling and analysis of high-throughput chromosome conformation capture (Hi-C) data have been used to argue that the small, highly constrained budding yeast chromosomes could not have these structures. In contrast, herein we analyze Hi-C data for budding yeast and identify 200-kb scale TADs, whose boundaries are enriched for transcriptional activity. Furthermore, these boundaries separate regions of similarly timed replication origins connecting the long-known effect of genomic context on replication timing to genome architecture. To investigate the molecular basis of TAD formation, we performed Hi-C experiments on cells depleted for the Forkhead transcription factors, Fkh1 and Fkh2, previously associated with replication timing. Forkhead factors do not regulate TAD formation, but do promote longer-range genomic interactions and control interactions between origins near the centromere. Thus, our work defines spatial organization within the budding yeast nucleus, demonstrates the conserved role of genome architecture in regulating DNA replication, and identifies a molecular mechanism specifically regulating interactions between pericentric origins.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28348222",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 541,
                    "offsetInEndSection": 739,
                    "text": "Around the same time, it was also shown that the genome of Saccharomyces cerevisiae is organized in topologically associated domains (TADs), which are largely associated with the replication timing.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28780612",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 649,
                    "offsetInEndSection": 847,
                    "text": "Around the same time, it was also shown that the genome of Saccharomyces cerevisiae is organized in topologically associated domains (TADs), which are largely associated with the replication timing. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28780612",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 464,
                    "offsetInEndSection": 614,
                    "text": "In contrast, herein we analyze Hi-C data for budding yeast and identify 200-kb scale TADs, whose boundaries are enriched for transcriptional activity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28348222",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is progeria caused by an autosomal recessive gene?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/17664768",
                "http://www.ncbi.nlm.nih.gov/pubmed/28660486",
                "http://www.ncbi.nlm.nih.gov/pubmed/17028399",
                "http://www.ncbi.nlm.nih.gov/pubmed/22971867",
                "http://www.ncbi.nlm.nih.gov/pubmed/27617860",
                "http://www.ncbi.nlm.nih.gov/pubmed/29149836",
                "http://www.ncbi.nlm.nih.gov/pubmed/32360386",
                "http://www.ncbi.nlm.nih.gov/pubmed/21365542",
                "http://www.ncbi.nlm.nih.gov/pubmed/32596971",
                "http://www.ncbi.nlm.nih.gov/pubmed/3228132",
                "http://www.ncbi.nlm.nih.gov/pubmed/32528764",
                "http://www.ncbi.nlm.nih.gov/pubmed/33087645",
                "http://www.ncbi.nlm.nih.gov/pubmed/27931782",
                "http://www.ncbi.nlm.nih.gov/pubmed/19432833",
                "http://www.ncbi.nlm.nih.gov/pubmed/16598422",
                "http://www.ncbi.nlm.nih.gov/pubmed/16838330",
                "http://www.ncbi.nlm.nih.gov/pubmed/17219342",
                "http://www.ncbi.nlm.nih.gov/pubmed/19875478",
                "http://www.ncbi.nlm.nih.gov/pubmed/17375009"
            ],
            "ideal_answer": [
                "Yes. Progeria is caused by an autosomal recessive gene.",
                "yes, progeria is caused by an autosomal recessive gene."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "601d72e61cb411341a000039",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Hutchinson-Gilford progeria syndrome (HGPS) is an autosomal-dominant genetic disease that leads to accelerated aging and often premature death caused by cardiovascular complications. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32596971",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 119,
                    "text": "Hutchinson-Gilford progeria syndrome is an autosomal dominant, rare, fatal pediatric segmental premature aging disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32360386",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 81,
                    "text": "Progeria is sporadic, very rare, autosomal dominant, deadly childhood disorder. I",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28660486",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 233,
                    "text": "Werner syndrome (i.e., adult progeria) is a rare autosomal recessive disorder caused by mutations of the WRN gene, which is characterized by the premature appearance of features associated with normal aging and cancer predisposition.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27931782",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 121,
                    "offsetInEndSection": 316,
                    "text": "Among them, the most studied is Werner's syndrome, \"adult progeria\", caused by a recessive autosomal mutation with a frequency of 1 in 10 million, which affects a helicase involved in DNA repair.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29149836",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1829,
                    "offsetInEndSection": 1915,
                    "text": "Pattern of inheritance of non-classical progeria is most probably autosomal recessive.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16838330",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 179,
                    "text": "INTRODUCTION: Werner Syndrome, or adult progeria, is a rare autosomal recessive disorder caused by a mutation in the Werner Syndrome Gene belonging to the family of RecQ helicase.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16598422",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 772,
                    "offsetInEndSection": 921,
                    "text": "SION: Werner's syndrome is a rare form of progeria with an autosomal recessive mode of inheritance mimicking the symptoms of accelerated aging. The r",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17219342",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 166,
                    "text": "Werner's Syndrome (WS) or adult-onset progeria is an autosomal recessive disorder of accelerated aging caused by mutations of the DNA RecQ helicase/exonuclease (WRN).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21365542",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 126,
                    "text": "Homozygous LMNA mutation R527C in atypical Hutchinson-Gilford progeria syndrome: evidence for autosomal recessive inheritance.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19432833",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 100,
                    "text": "Progeria (Hutchison-Gilford syndrome) in siblings: in an autosomal recessive pattern of inheritance.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664768",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 276,
                    "offsetInEndSection": 379,
                    "text": "The present case highlights rarity of progeria in siblings with a possible autosomal recessive pattern.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664768",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 239,
                    "text": "Werner syndrome (i.e., adult progeria) is a rare autosomal recessive disorder caused by mutations of the WRN gene, which is characterized by the premature appearance of features associated with normal aging and cancer predisposition. Patie",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27931782",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 218,
                    "text": "CONTEXT: Hutchinson-Gilford progeria syndrome (HGPS) and mandibuloacral dysplasia are well-recognized allelic autosomal dominant and recessive progeroid disorders, respectively, due to mutations in lamin A/C (LMNA) gen",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19875478",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 163,
                    "text": "Werner's syndrome (adult onset progeria) is a rare form of autosomal recessive genodermatosis associated in almost 80% of cases with mutation of the WRN gene. This",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17375009",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 285,
                    "text": "Werner syndrome, also called adult progeria, is a heritable autosomal recessive human disorder characterized by the premature onset of numerous age-related diseases including juvenile cataracts, dyslipidemia, diabetes mellitus (DM), osteoporosis, atherosclerosis, and cancer. Werner sy",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33087645",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Werner's syndrome (WS) or progeria adultorum is a heritable autosomal recessive disease in which the aging process is accelerated, just after puberty. It is",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32528764",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "text": "Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant genetic disease that is caused by a silent mutation of the LMNA gene encoding lamins A and C (lamin A/C).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27617860",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1017,
                    "offsetInEndSection": 1201,
                    "text": "Furthermore, administration of JH4 to LmnaG609G/G609G-mutant mice, which phenocopy human HGPS, resulted in a marked improvement of several progeria phenotypes and an extended lifespan.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27617860",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27617860",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 60,
                    "text": "Progeria is an autosomal dominant, premature aging syndrome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17664768",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 178,
                    "text": "INTRODUCTION: Werner Syndrome, or adult progeria, is a rare autosomal recessive disorder caused by a mutation in the Werner Syndrome Gene belonging to the family of RecQ helicase",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16598422",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 78,
                    "text": "Evidence for autosomal recessive inheritance of progeria (Hutchinson Gilford).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/3228132",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 165,
                    "text": "INTRODUCTION: Werner Syndrome, or adult progeria, is a rare autosomal recessive disorder caused by a mutation in the Werner Syndrome Gene belonging to the family of ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16598422",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "Hutchinson-Gilford progeria causing premature aging of children is a genetic disease and according to most authors has an autosomal dominant inheritance.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17028399",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 150,
                    "text": "Werner's syndrome (WS) or progeria adultorum is a heritable autosomal recessive disease in which the aging process is accelerated, just after puberty.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32528764",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 275,
                    "text": "Werner syndrome, also called adult progeria, is a heritable autosomal recessive human disorder characterized by the premature onset of numerous age-related diseases including juvenile cataracts, dyslipidemia, diabetes mellitus (DM), osteoporosis, atherosclerosis, and cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/33087645",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does ESN364 activate the hypothalamic-pituitary-gonadal axis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26653113"
            ],
            "ideal_answer": [
                "No, the NK3R antagonist, ESN364, suppressed the hypothalamic-pituitary-gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion"
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e5508e2b761aafe09000006",
            "snippets": [
                {
                    "offsetInBeginSection": 1798,
                    "offsetInEndSection": 2042,
                    "text": "Oral administration of the NK3R antagonist, ESN364, suppressed the hypothalamic-pituitary-gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26653113",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is lithium effective for treatment of amyotrophic lateral sclerosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23453347",
                "http://www.ncbi.nlm.nih.gov/pubmed/26892289",
                "http://www.ncbi.nlm.nih.gov/pubmed/22091594",
                "http://www.ncbi.nlm.nih.gov/pubmed/21936930",
                "http://www.ncbi.nlm.nih.gov/pubmed/29399045",
                "http://www.ncbi.nlm.nih.gov/pubmed/22378918",
                "http://www.ncbi.nlm.nih.gov/pubmed/29400298",
                "http://www.ncbi.nlm.nih.gov/pubmed/18367867",
                "http://www.ncbi.nlm.nih.gov/pubmed/18250315",
                "http://www.ncbi.nlm.nih.gov/pubmed/20702794",
                "http://www.ncbi.nlm.nih.gov/pubmed/23582371",
                "http://www.ncbi.nlm.nih.gov/pubmed/28978660",
                "http://www.ncbi.nlm.nih.gov/pubmed/20363190"
            ],
            "ideal_answer": [
                "No, lithium is not effective for treatment of amyotrophic lateral sclerosis."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5c662c507c78d6947100000d",
            "snippets": [
                {
                    "offsetInBeginSection": 125,
                    "offsetInEndSection": 331,
                    "text": "In terms of disease-modifying treatment options, several drugs such as dexpramipexole, pioglitazone, lithium, and many others have been tested in large multicenter trials, albeit with disappointing results.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29399045",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1153,
                    "offsetInEndSection": 1343,
                    "text": "Despite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29400298",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 949,
                    "offsetInEndSection": 1211,
                    "text": "The effect of lithium was different for UNC13A carriers (p = 0.027), but not for C9orf72 carriers (p = 0.22). The 12-month survival probability for UNC13A carriers treated with lithium carbonate improved from 40.1% (95% CI 23.2-69.1) to 69.7% (95% CI 50.4-96.3).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28978660",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1038,
                    "offsetInEndSection": 1174,
                    "text": "Studies in ALS showed consistently negative results and presented evidence against the use of lithium for the treatment of this disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26892289",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "BACKGROUND\nLithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a significant effect of lithium on survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453347",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 169,
                    "text": "In a pilot clinical study that we recently published we found that lithium administration slows the progression of Amyotrophic Lateral Sclerosis (ALS) in human patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18367867",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "BACKGROUND Lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a significant effect of lithium on survival.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453347",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 113,
                    "text": "BACKGROUND A neuroprotective effect of lithium in amyotrophic lateral sclerosis (ALS) has been recently reported.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20702794",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 136,
                    "text": "Lithium delays progression of amyotrophic lateral sclerosis.ALS is a devastating neurodegenerative disorder with no effective treatment. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250315",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 395,
                    "text": "Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial.<AbstractText Label=\"BACKGROUND\" NlmCategory=\"BACKGROUND\">Lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a significant effect of lithium on survival. ",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23453347",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 310,
                    "text": "<b>INTRODUCTION</b>: Lithium was proposed in 2008 as an effective candidate in the treatment of ALS after a report claimed that it was able to delay functional deterioration by 40% and that none of the 16 patients treated with a combination of lithium plus riluzole had died during a 15-month follow-up period.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1474,
                    "offsetInEndSection": 1643,
                    "text": "A recently published study also ruled out any possible modest effect.<br><b>CONCLUSIONS</b>: There is evidence to suggest that lithium has no short-term benefits in ALS.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1644,
                    "offsetInEndSection": 1898,
                    "text": "A comparison of the group of patients treated with lithium+riluzole and the control group treated with riluzole alone showed no statistically significant differences in rates of functional decline, deterioration of respiratory function, or survival time.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23582371",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 258,
                    "offsetInEndSection": 519,
                    "text": "None of the patients treated with lithium died during the 15 months of the follow-up, and disease progression was markedly attenuated when compared with age-, disease duration-, and sex-matched control patients treated with riluzole for the same amount of time.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18250315",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is microRNA(miRNA) 30 involved in post-ischemic cardiac remodeling?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22352753",
                "http://www.ncbi.nlm.nih.gov/pubmed/21434842",
                "http://www.ncbi.nlm.nih.gov/pubmed/22038740",
                "http://www.ncbi.nlm.nih.gov/pubmed/19096030"
            ],
            "ideal_answer": [
                "Myocardial remodeling after an ischemic insult involves extracellular matrix proteins with increased fibrosis\nInitial experimental data indicate that miRNA 30 decreases CTGF a key molecule in the process of fibrosis, by directly downregulating the production of CTGF"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://amigo.geneontology.org/cgi-bin/amigo/term_details?term=0010586",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020257",
                "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D035683"
            ],
            "type": "yesno",
            "id": "513f4249bee46bd34c000012",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 206,
                    "text": "The myocardium of the failing heart undergoes a number of structural alterations, most notably hypertrophy of cardiac myocytes and an increase in extracellular matrix proteins, often seen as primary fibrosi",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 209,
                    "offsetInEndSection": 345,
                    "text": "Connective tissue growth factor (CTGF) is a key molecule in the process of fibrosis and therefore seems an attractive therapeutic target",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 571,
                    "offsetInEndSection": 659,
                    "text": "CTGF is importantly regulated by 2 major cardiac microRNAs (miRNAs), miR-133 and miR-30.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 667,
                    "offsetInEndSection": 1060,
                    "text": "the expression of both miRNAs was inversely related to the amount of CTGF in 2 rodent models of heart disease and in human pathological left ventricular hypertrophy. Second, in cultured cardiomyocytes and fibroblasts, knockdown of these miRNAs increased CTGF levels. Third, overexpression of miR-133 or miR-30c decreased CTGF levels, which was accompanied by decreased production of collagens.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1249,
                    "offsetInEndSection": 1296,
                    "text": "miR-30 importantly limit the production of CTGF",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                },
                {
                    "offsetInBeginSection": 1531,
                    "offsetInEndSection": 1733,
                    "text": "miR-30 directly downregulate CTGF, a key profibrotic protein, and thereby establish an important role for these miRNAs in the control of structural changes in the extracellular matrix of the myocardium.",
                    "beginSection": "sections.0",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19096030",
                    "endSection": "sections.0"
                }
            ]
        },
        {
            "body": "Does protein ALEX1 contain armadillo repeats?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26464700",
                "http://www.ncbi.nlm.nih.gov/pubmed/20398052"
            ],
            "ideal_answer": [
                "Yes,\nALEX1 (Arm protein lost in epithelial cancers, on chromosome X), contains two armadillo repeats domains."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e94a8250d431b5f73000001",
            "snippets": [
                {
                    "offsetInBeginSection": 461,
                    "offsetInEndSection": 622,
                    "text": "ALEX1 (Arm protein lost in epithelial cancers, on chromosome X), contains two armadillo repeats domains, is expressed different in normal and carcinomas tissues.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26464700",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 247,
                    "offsetInEndSection": 465,
                    "text": "Arm protein lost in epithelial cancers, on chromosome X 1 (ALEX1) is a novel member of the Armadillo family which has two Armadillo repeats as opposed to more than six repeats in the classical Armadillo family members.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20398052",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Was modafinil tested for schizophrenia treatment?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21412225",
                "http://www.ncbi.nlm.nih.gov/pubmed/15085092",
                "http://www.ncbi.nlm.nih.gov/pubmed/19572020",
                "http://www.ncbi.nlm.nih.gov/pubmed/23983964",
                "http://www.ncbi.nlm.nih.gov/pubmed/17151173",
                "http://www.ncbi.nlm.nih.gov/pubmed/22820555",
                "http://www.ncbi.nlm.nih.gov/pubmed/22820554",
                "http://www.ncbi.nlm.nih.gov/pubmed/23938173",
                "http://www.ncbi.nlm.nih.gov/pubmed/24964814",
                "http://www.ncbi.nlm.nih.gov/pubmed/20810469",
                "http://www.ncbi.nlm.nih.gov/pubmed/19689921",
                "http://www.ncbi.nlm.nih.gov/pubmed/17503979",
                "http://www.ncbi.nlm.nih.gov/pubmed/25306261",
                "http://www.ncbi.nlm.nih.gov/pubmed/18516718",
                "http://www.ncbi.nlm.nih.gov/pubmed/17712350",
                "http://www.ncbi.nlm.nih.gov/pubmed/20653641",
                "http://www.ncbi.nlm.nih.gov/pubmed/16013898",
                "http://www.ncbi.nlm.nih.gov/pubmed/17077439",
                "http://www.ncbi.nlm.nih.gov/pubmed/19914296",
                "http://www.ncbi.nlm.nih.gov/pubmed/16634707",
                "http://www.ncbi.nlm.nih.gov/pubmed/18729534",
                "http://www.ncbi.nlm.nih.gov/pubmed/21947320",
                "http://www.ncbi.nlm.nih.gov/pubmed/16965205",
                "http://www.ncbi.nlm.nih.gov/pubmed/19026265",
                "http://www.ncbi.nlm.nih.gov/pubmed/18392753",
                "http://www.ncbi.nlm.nih.gov/pubmed/21565464",
                "http://www.ncbi.nlm.nih.gov/pubmed/17634412",
                "http://www.ncbi.nlm.nih.gov/pubmed/15994572",
                "http://www.ncbi.nlm.nih.gov/pubmed/21109234",
                "http://www.ncbi.nlm.nih.gov/pubmed/21909634",
                "http://www.ncbi.nlm.nih.gov/pubmed/15090936"
            ],
            "ideal_answer": [
                "Yes. Modafinil has been shown to improve attention, memory, executive function and antipsychotic-induced parkinsonism in  patients with schizophrenia. However, some authors have failed to demonstrate beneficial action of modafinil for schizophrenia."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.biosemantics.org/jochem#4259639",
                "http://www.disease-ontology.org/api/metadata/DOID:5419"
            ],
            "type": "yesno",
            "id": "54fc845e6ea36a810c000005",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 226,
                    "text": "Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23938173",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1382,
                    "offsetInEndSection": 1565,
                    "text": "CONCLUSION: The data suggest that modafinil was a safe adjunctive treatment which improved parkinsonian symptoms and signs in patients with schizophrenia or schizoaffective disorder. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23938173",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 747,
                    "offsetInEndSection": 1027,
                    "text": "A review of its effects in schizophrenia suggests that modafinil facilitates cognitive functions, with pro-mnemonic effects and problem solving improvements. Emotional processing also appears to be enhanced by the drug, although to date there are only a limited number of studies.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22820555",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 242,
                    "text": "BACKGROUND: Modafinil, a putative cognitive enhancing drug, has previously been shown to improve performance of healthy volunteers as well as patients with attention deficit disorder and schizophrenia, mainly in tests of executive functions. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22820554",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "A review of modafinil and armodafinil as add-on therapy in antipsychotic-treated patients with schizophrenia.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983964",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 224,
                    "offsetInEndSection": 487,
                    "text": "It has been suggested that modafinil and its isomer armodafinil as an add-on strategy to antipsychotic treatment in patients with schizophrenia may improve cognitive functioning, attenuate fatigue, inactiveness and other negative functions as well as weight gain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983964",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 794,
                    "offsetInEndSection": 1235,
                    "text": "Evidence for the use of modafinil or armodafinil as add-on therapy to antipsychotic drugs to alleviate fatigue, sleepiness and inactivity is inconclusive. One cohort study and one out of two single-dose crossover RCTs in which modafinil addition was studied could demonstrate a positive effect. All five RCTs of modafinil (three RCTs) and armodafinil (two RCTs) addition with a longer study duration could not demonstrate a positive effect. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983964",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1351,
                    "offsetInEndSection": 2139,
                    "text": "In RCTs with a treatment duration of 4 weeks or more, however, no positive effect could be demonstrated on cognitive functioning with modafinil and armodafinil addition. Yet, four single-dose crossover RCTs of modafinil addition show significant positive effects on executive functioning, verbal memory span, visual memory, working memory, spatial planning, slowing in latency, impulse control and recognition of faces expressing sadness and sadness misattribution in the context of disgust recognition. The addition of modafinil or armodafinil to an antipsychotic regime, despite theoretical and preclinical considerations, has not been proved to enhance cognitive function, attenuate fatigue, enhance activity, improve negative symptoms and reduce weight in patients with schizophrenia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983964",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 172,
                    "text": "RATIONAL: In recent years, evidence suggests that modafinil may be useful for certain symptom domains of schizophrenia, especially for the negative and cognitive symptoms. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21947320",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1243,
                    "offsetInEndSection": 1405,
                    "text": "CONCLUSION: The present study indicates modafinil as a potential adjunctive treatment strategy for treatment of schizophrenia particularly the negative symptoms. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21947320",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 156,
                    "offsetInEndSection": 324,
                    "text": "Modafinil is a wake-promoting drug that has been shown to improve attention, memory and executive function in the healthy population and in patients with schizophrenia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21909634",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1097,
                    "offsetInEndSection": 1261,
                    "text": "CONCLUSIONS: Results of this pilot trial do not support routine use of modafinil to counteract increased weight and metabolic diseases in patients taking clozapine.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21565464",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "Modafinil (2-((diphenylmethyl)sulfinyl)acetamide) is described as an atypical stimulant and is a putative cognition enhancer for schizophrenia, but the precise mechanisms of action remain unclear.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21412225",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 152,
                    "offsetInEndSection": 319,
                    "text": "Modafinil is a wake-promoting drug that has been shown to improve emotion discrimination in healthy individuals and attention and executive function in schizophrenia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21109234",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1613,
                    "offsetInEndSection": 1900,
                    "text": "CONCLUSIONS: These data support clinical evidence that modafinil may alleviate cognitive deficits in schizophrenia and also demonstrate the benefit of applying PLSR modeling to characterize functional brain networks in translational models relevant to central nervous system dysfunction.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20810469",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 257,
                    "text": "Modafinil improves working memory in healthy subjects and individuals diagnosed with schizophrenia and Attention Deficit/Hyperactivity Disorder, though the effects of modafinil have not been evaluated on working memory in methamphetamine-dependent subjects.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20653641",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 221,
                    "text": "Modafinil is a psychostimulant approved for treating excessive sleepiness in adults; off-label uses (e.g., treatment of cognitive impairment in schizophrenia, ADHD and age-related dementias) are currently being explored. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19914296",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1064,
                    "offsetInEndSection": 1241,
                    "text": "CONCLUSIONS: Results of this pilot trial do not support routine use of modafinil to treat negative symptoms, cognitive deficits, or wakefulness/fatigue in patients on clozapine.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19689921",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 81,
                    "offsetInEndSection": 316,
                    "text": "We have previously shown that the amount of movement exhibited by patients with schizophrenia is positively correlated with the volume of left anterior cingulate cortex and that this quantity of movement can be increased by modafinil. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19572020",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 456,
                    "text": "OBJECTIVE: Given recent reports about the off-label use of modafinil as an adjuvant for the treatment of antipsychotic-associated sedation in schizophrenia patients and the recent interest in its putative cognitive-enhancing effects in this population, we present a systematic review of available data on trials of modafinil as an adjuvant in the treatment of cognitive deficits, negative symptoms, and antipsychotic-induced fatigue, and its tolerability. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1281,
                    "offsetInEndSection": 1648,
                    "text": "RESULTS: One of 4 reviewed studies found a significant effect of modafinil as an alerting agent for antipsychotic-induced fatigue and sedation. Neither of 2 reviewed studies found modafinil to improve negative symptoms of schizophrenia. Three of 6 reviewed studies showed that modafinil may improve short-term memory, attention, and the ability to shift mental sets. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1972,
                    "offsetInEndSection": 2439,
                    "text": "CONCLUSIONS: While the available data suggest that modafinil is generally well tolerated and may have some efficacy in the treatment of antipsychotic-induced sedation and cognitive domains, the small sample sizes, contradictory results, and methodological differences between trials, especially with respect to cognitive testing, make it difficult to draw firm conclusions about the overall effectiveness of modafinil as an adjunct in the treatment of schizophrenia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2743,
                    "offsetInEndSection": 2883,
                    "text": "Hence, before prescribing modafinil to a schizophrenia patient, the possible risks and benefits of each particular case should be evaluated.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2211,
                    "offsetInEndSection": 2506,
                    "text": "Modafinil had a substantial placebo effect on outcomes such as fatigue, excessive sleepiness and depression in patients with traumatic brain injury, major depressive disorder, schizophrenia, post-polio fatigue and multiple sclerosis; however, it did not provide any benefit greater than placebo.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18729534",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 211,
                    "text": "RATIONALE: The wake-promoting agent modafinil selectively improves neuropsychological task performance in healthy volunteers, in adults with attention deficit hyperactivity disorder (ADHD) and in schizophrenia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18516718",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 271,
                    "offsetInEndSection": 394,
                    "text": "Recently, however, modafinil has been shown to improve attentional set-shifting performance in patients with schizophrenia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18392753",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 261,
                    "offsetInEndSection": 462,
                    "text": "In addition, modafinil shows initial promise for a variety of off-label indications in psychiatry, including treatment-resistant depression, attention-deficit/hyperactivity disorder, and schizophrenia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17712350",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 226,
                    "offsetInEndSection": 396,
                    "text": "There is increasing interest in the use of modafinil to improve cognition in schizophrenia as well as in other disorders such as attention-deficit/hyperactivity disorder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17634412",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 560,
                    "offsetInEndSection": 702,
                    "text": "Initial findings indicate that modafinil may lead to better executive functioning and attentional performance in patients with schizophrenia. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17634412",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1501,
                    "offsetInEndSection": 1701,
                    "text": "CONCLUSIONS: Although no effect on negative symptoms was found, adjunctive therapy with modafinil may result in global improvements in patients with schizophrenia who have prominent negative symptoms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17503979",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 972,
                    "offsetInEndSection": 1059,
                    "text": "CONCLUSIONS: Modafinil did not improve cognitive control in all schizophrenia patients.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17151173",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 364,
                    "offsetInEndSection": 492,
                    "text": ". These data suggest that modafinil increases quantifiable motor behaviour in schizophrenia and may have an impact on avolition.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17077439",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1537,
                    "offsetInEndSection": 1784,
                    "text": "One patient was on treatment with both modafinil and trazodone and reported no change after tapering each in separate discontinuation trials, while another 3 patients were taking sleeping medications and also noted no change after discontinuation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16965205",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 551,
                    "offsetInEndSection": 743,
                    "text": " Neuroprotective agents as add-on therapies (e.g., modafinil, erythropoietin, glycine, D-serine, memantine and celecoxib) are currently being evaluated in schizophrenia and related disorders. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16634707",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 666,
                    "offsetInEndSection": 887,
                    "text": "In the modafinil (N = 10) and placebo (N = 10) groups, fatigue improved significantly over time (p < .01), but there were no differences between groups on changes in fatigue, positive and negative symptoms, or cognition. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16013898",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 929,
                    "offsetInEndSection": 1136,
                    "text": "CONCLUSIONS: Modafinil modulates anterior cingulate cortex function in chronic schizophrenia but its beneficial cognitive effects may be restricted to a subset of patients requiring further characterisation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15994572",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 687,
                    "offsetInEndSection": 873,
                    "text": "Modafinil significantly improved overall clinical condition, with 64% and 82% of patients rated as clinically improved at week 4 by a blinded clinician and the investigator respectively.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15090936",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 955,
                    "offsetInEndSection": 1068,
                    "text": "Modafinil significantly improved fatigue (P = 0.025, week 3) and tended to improve cognitive functioning scores. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15090936",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1349,
                    "offsetInEndSection": 1597,
                    "text": "Although preliminary, these results suggest modafinil may be an effective and well-tolerated adjunct treatment that improves global functioning and clinical condition, and reduces fatigue in patients with schizophrenia or schizoaffective disorder. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15090936",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 666,
                    "offsetInEndSection": 807,
                    "text": "Modafinil had some cognitive enhancing properties in schizophrenia similar to those observed in healthy adults and adult patients with ADHD. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15085092",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1222,
                    "offsetInEndSection": 1407,
                    "text": "Modafinil may have potential as an important therapy for cognitive impairment in patients with schizophrenia, particularly because of its beneficial effects on attentional set shifting.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15085092",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1887,
                    "offsetInEndSection": 2340,
                    "text": "While the available data suggest that modafinil is generally well tolerated and may have some efficacy in the treatment of antipsychotic-induced sedation and cognitive domains, the small sample sizes, contradictory results, and methodological differences between trials, especially with respect to cognitive testing, make it difficult to draw firm conclusions about the overall effectiveness of modafinil as an adjunct in the treatment of schizophrenia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 444,
                    "text": "Given recent reports about the off-label use of modafinil as an adjuvant for the treatment of antipsychotic-associated sedation in schizophrenia patients and the recent interest in its putative cognitive-enhancing effects in this population, we present a systematic review of available data on trials of modafinil as an adjuvant in the treatment of cognitive deficits, negative symptoms, and antipsychotic-induced fatigue, and its tolerability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1190,
                    "offsetInEndSection": 1339,
                    "text": "The present study indicates modafinil as a potential adjunctive treatment strategy for treatment of schizophrenia particularly the negative symptoms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21947320",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 221,
                    "offsetInEndSection": 485,
                    "text": " It has been suggested that modafinil and its isomer armodafinil as an add-on strategy to antipsychotic treatment in patients with schizophrenia may improve cognitive functioning, attenuate fatigue, inactiveness and other negative functions as well as weight gain.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23983964",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1243,
                    "offsetInEndSection": 1404,
                    "text": "CONCLUSION: The present study indicates modafinil as a potential adjunctive treatment strategy for treatment of schizophrenia particularly the negative symptoms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21947320",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 455,
                    "text": "OBJECTIVE: Given recent reports about the off-label use of modafinil as an adjuvant for the treatment of antipsychotic-associated sedation in schizophrenia patients and the recent interest in its putative cognitive-enhancing effects in this population, we present a systematic review of available data on trials of modafinil as an adjuvant in the treatment of cognitive deficits, negative symptoms, and antipsychotic-induced fatigue, and its tolerability.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1971,
                    "offsetInEndSection": 2437,
                    "text": "CONCLUSIONS: While the available data suggest that modafinil is generally well tolerated and may have some efficacy in the treatment of antipsychotic-induced sedation and cognitive domains, the small sample sizes, contradictory results, and methodological differences between trials, especially with respect to cognitive testing, make it difficult to draw firm conclusions about the overall effectiveness of modafinil as an adjunct in the treatment of schizophrenia.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 149,
                    "text": "The present study indicates modafinil as a potential adjunctive treatment strategy for treatment of schizophrenia particularly the negative symptoms.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21947320",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1349,
                    "offsetInEndSection": 1596,
                    "text": "Although preliminary, these results suggest modafinil may be an effective and well-tolerated adjunct treatment that improves global functioning and clinical condition, and reduces fatigue in patients with schizophrenia or schizoaffective disorder.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15090936",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1909,
                    "offsetInEndSection": 2361,
                    "text": "While the available data suggest that modafinil is generally well tolerated and may have some efficacy in the treatment of antipsychotic-induced sedation and cognitive domains, the small sample sizes, contradictory results, and methodological differences between trials, especially with respect to cognitive testing, make it difficult to draw firm conclusions about the overall effectiveness of modafinil as an adjunct in the treatment of schizophrenia",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026265",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1208,
                    "offsetInEndSection": 1356,
                    "text": "The present study indicates modafinil as a potential adjunctive treatment strategy for treatment of schizophrenia particularly the negative symptoms",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21947320",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 228,
                    "text": "Modafinil, a putative cognitive enhancing drug, has previously been shown to improve performance of healthy volunteers as well as patients with attention deficit disorder and schizophrenia, mainly in tests of executive functions",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22820554",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is there a crystal structure of the full-length of the flaviviridae NS5(Methyltransferase - RNA depended RNA Polymerase) ?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/22365326",
                "http://www.ncbi.nlm.nih.gov/pubmed/19710254",
                "http://www.ncbi.nlm.nih.gov/pubmed/23355615",
                "http://www.ncbi.nlm.nih.gov/pubmed/22757685",
                "http://www.ncbi.nlm.nih.gov/pubmed/17287213",
                "http://www.ncbi.nlm.nih.gov/pubmed/23950717"
            ],
            "ideal_answer": [
                "Yes, there is the crystal Structure of the full-length Japanese encephalitis virus (Flaviviridae) NS5 - PDB:4K6M"
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018067",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D003460",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D018178",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006127"
            ],
            "type": "yesno",
            "id": "532aad53d6d3ac6a34000010",
            "snippets": [
                {
                    "offsetInBeginSection": 3,
                    "offsetInEndSection": 456,
                    "text": " flavivirus NS5 harbors a methyltransferase (MTase) in its N-terminal \u2248 265 residues and an RNA-dependent RNA polymerase (RdRP) within the C-terminal part. One of the major interests and challenges in NS5 is to understand the interplay between RdRP and MTase as a unique natural fusion protein in viral genome replication and cap formation. Here, we report the first crystal structure of the full-length flavivirus NS5 from Japanese encephalitis virus. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23950717",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 13,
                    "offsetInEndSection": 980,
                    "text": "(DENV) nonstructural protein 5 (NS5) is composed of two globular domains separated by a 10-residue linker. The N-terminal domain participates in the synthesis of a mRNA cap 1 structure ((7Me)GpppA(2'OMe)) at the 5' end of the viral genome and possesses guanylyltransferase, guanine-N7-methyltransferase, and nucleoside-2'O-methyltransferase activities. The C-terminal domain is an RNA-dependent RNA polymerase responsible for viral RNA synthesis. Although crystal structures of the two isolated domains have been obtained, there are no structural data for full-length NS5. It is also unclear whether the two NS5 domains interact with each other to form a stable structure in which the relative orientation of the two domains is fixed. To investigate the structure and dynamics of DENV type 3 NS5 in solution, we conducted small-angle X-ray scattering experiments with the full-length protein. NS5 was found to be monomeric and well-folded under the conditions tested.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22757685",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 4,
                    "offsetInEndSection": 1391,
                    "text": "West Nile virus (WNV) NS5 protein contains a methyltransferase (MTase) domain involved in RNA capping and an RNA-dependent RNA polymerase (RdRp) domain essential for virus replication. Crystal structures of individual WNV MTase and RdRp domains have been solved; however, the structure of full-length NS5 has not been determined. To gain more insight into the structure of NS5 and interactions between the MTase and RdRp domains, we generated a panel of seven monoclonal antibodies (mAbs) to the NS5 protein of WNV (Kunjin strain) and mapped their binding sites using a series of truncated NS5 proteins and synthetic peptides. Binding sites of four mAbs (5D4, 4B6, 5C11 and 6A10) were mapped to residues 354-389 in the fingers subdomain of the RdRp. This is consistent with the ability of these mAbs to inhibit RdRp activity in vitro and suggests that this region represents a potential target for RdRp inhibitors. Using a series of synthetic peptides, we also identified a linear epitope (bound by mAb 5H1) that mapped to a 13 aa stretch surrounding residues 47 and 49 in the MTase domain, a region predicted to interact with the palm subdomain of the RdRp. The failure of one mAb (7G6) to bind both N- and C-terminally truncated NS5 recombinants indicates that the antibody recognizes a conformational epitope that requires the presence of residues in both the MTase and RdRp domains. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19710254",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Do yeast LTR give rise to circular DNA?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/26681518",
                "http://www.ncbi.nlm.nih.gov/pubmed/22977178",
                "http://www.ncbi.nlm.nih.gov/pubmed/28090380",
                "http://www.ncbi.nlm.nih.gov/pubmed/26979517"
            ],
            "ideal_answer": [
                "A recent study on circular DNAs in yeast found that transposable element sequence residing in circular structures mostly corresponded to full-length transposable elements. Circular retrotransposition products are generated by a LINE retrotransposon. Yeast LTR elements generate circular DNAs through recombination events between their flanking long terminal repeats (LTRs). Circular DNAs can be generated by recombination between LTRs residing at different genomic loci, in which case the circular DNA will contain the intervening sequence."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c34794fda8336e21a000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 72,
                    "text": "Circular retrotransposition products generated by a LINE retrotransposon",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22977178",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 117,
                    "text": "Formation of Extrachromosomal Circular DNA from Long Terminal Repeats of Retrotransposons in Saccharomyces cerevisiae",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26681518",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 128,
                    "offsetInEndSection": 304,
                    "text": "Ty eccDNA can arise from the circularization of extrachromosomal linear DNA during the transpositional life cycle of retrotransposons, or from circularization of genomic Ty DNA",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26681518",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 306,
                    "offsetInEndSection": 478,
                    "text": "Circularization may happen through nonhomologous end-joining (NHEJ) of long terminal repeats (LTRs) flanking Ty elements, by Ty autointegration, or by LTR-LTR recombination",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26681518",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 104,
                    "offsetInEndSection": 255,
                    "text": "We have recently shown that yeast LTR elements generate circular DNAs through recombination events between their flanking long terminal repeats (LTRs).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090380",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 433,
                    "text": "Similarly, circular DNAs can be generated by recombination between LTRs residing at different genomic loci, in which case the circular DNA will contain the intervening sequence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28090380",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 343,
                    "offsetInEndSection": 514,
                    "text": "A recent study on circular DNAs in yeast found that transposable element sequence residing in circular structures mostly corresponded to full-length transposable elements.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26979517",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does nintedanib hold promise for lung disease associated with systemic sclerosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23265249",
                "http://www.ncbi.nlm.nih.gov/pubmed/28664834",
                "http://www.ncbi.nlm.nih.gov/pubmed/31747840",
                "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
                "http://www.ncbi.nlm.nih.gov/pubmed/31423560",
                "http://www.ncbi.nlm.nih.gov/pubmed/27560196",
                "http://www.ncbi.nlm.nih.gov/pubmed/31112379",
                "http://www.ncbi.nlm.nih.gov/pubmed/26973429",
                "http://www.ncbi.nlm.nih.gov/pubmed/31573469",
                "http://www.ncbi.nlm.nih.gov/pubmed/31285305",
                "http://www.ncbi.nlm.nih.gov/pubmed/28814429"
            ],
            "ideal_answer": [
                "Yes, nintedanib holds promise for lung disease associated with systemic sclerosis. It is being tested in a clinical trial."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5e30f76afbd6abf43b000046",
            "snippets": [
                {
                    "offsetInBeginSection": 616,
                    "offsetInEndSection": 1214,
                    "text": "The patient developed progressive lung fibrosis under several immunosuppressants and was started on nintedanib, with clinical and functional stabilization. Nintedanib is a tyrosine-kinase inhibitor that blocks several profibrotic pathways, inhibiting proliferation and migration of fibroblasts and decreasing the synthesis of extracellular matrix proteins. It is approved for idiopathic lung fibrosis and has demonstrated good results in inhibiting migration and proliferation of systemic sclerosis dermal fibroblasts, constituting a promising agent for systemic sclerosis-associated lung fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 273,
                    "text": "BACKGROUND: Nintedanib is an inhibitor targeting platelet-derived growth factor receptor, fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases that has recently been approved for the treatment of idiopathic pulmonary fibrosis. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28814429",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1618,
                    "offsetInEndSection": 1974,
                    "text": "CONCLUSION: Nintedanib targets core features of SSc in Fra2-transgenic mice and ameliorates histological features of pulmonary arterial hypertension, destructive microangiopathy and pulmonary and dermal fibrosis. These data might have direct implications for the ongoing phase III clinical trial with nintedanib in SSc-associated interstitial lung disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28814429",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1076,
                    "offsetInEndSection": 1453,
                    "text": "In light of the ongoing advances in our understanding of the pathogenic mechanisms underlying interstitial lung disease in systemic sclerosis, this review also summarizes novel treatment approaches, presenting clinical and preclinical evidence for rituximab, tocilizumab, pirfenidone, and nintedanib, as well as hematopoietic stem cell transplantation and lung transplantation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/27560196",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 775,
                    "offsetInEndSection": 910,
                    "text": "Pirfenidone and nintedanib are emerging agents that exert pleiotropic effects, reflective of the multiple mechanistic pathways of IPF. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23265249",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 156,
                    "text": "Design of a randomised, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENSCIS\u2122).",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28664834",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 377,
                    "offsetInEndSection": 544,
                    "text": "The SENSCIS\u2122 trial is a randomised, placebo-controlled Phase III trial that will evaluate the efficacy and safety of nintedanib in patients with SSc-ILD (NCT02597933).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28664834",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1652,
                    "offsetInEndSection": 1751,
                    "text": "CONCLUSIONS: This trial will assess the efficacy and safety of nintedanib in patients with SSc-ILD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28664834",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 71,
                    "text": "Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31112379",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 149,
                    "offsetInEndSection": 307,
                    "text": "Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31112379",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 309,
                    "offsetInEndSection": 493,
                    "text": "METHODS\n\nWe conducted a randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of nintedanib in patients with ILD associated with systemic sclerosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31112379",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2154,
                    "offsetInEndSection": 2400,
                    "text": "CONCLUSIONS\n\nAmong patients with ILD associated with systemic sclerosis, the annual rate of decline in FVC was lower with nintedanib than with placebo; no clinical benefit of nintedanib was observed for other manifestations of systemic sclerosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31112379",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 89,
                    "text": "Potential of Nintedanib in Treatment of Progressive Fibrosing Interstitial Lung Diseases.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31285305",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 75,
                    "text": "Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/29038968",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 1159,
                    "offsetInEndSection": 1309,
                    "text": "Newer agents with anti-fibrotic properties, such as pirfenidone or nintedanib, might hold promise also for the pulmonary fibrosis seen in sarcoidosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26973429",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1344,
                    "offsetInEndSection": 1437,
                    "text": "This suggests that nintedanib inhibits fundamental processes in the pathogenesis of fibrosis.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31285305",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 932,
                    "offsetInEndSection": 1150,
                    "text": "This suggests that nintedanib and pirfenidone , drugs known to slow disease progression in patients with idiopathic pulmonary fibrosis , may also slow the progression of ILD associated with systemic autoimmune diseases",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31423560",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1153,
                    "offsetInEndSection": 1274,
                    "text": "In the SENSCIS\u00ae trial , nintedanib reduced the rate of ILD progression in patients with systemic sclerosis-associated ILD",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31423560",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 148,
                    "offsetInEndSection": 307,
                    "text": "Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31112379",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 399,
                    "offsetInEndSection": 543,
                    "text": "The goal of the present study was to determine the effects of nintedanib on a cellular model of SSc-associated interstitial lung disease (ILD).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31573469",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 214,
                    "text": "OBJECTIVES\nNintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF) and was demonstrated to slow disease progression in patients with IPF by reducing decline in forced vital capacity by 50%.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31573469",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 87,
                    "text": "Nintedanib: new indication for systemic sclerosis-associated interstitial lung disease.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31747840",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 153,
                    "text": "Nintedanib (Ofev\u2122), an oral triple kinase inhibitor targeting pro-fibrotic pathways, has been used for treatment of idiopathic pulmonary fibrosis (IPF).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31747840",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1831,
                    "offsetInEndSection": 1974,
                    "text": "These data might have direct implications for the ongoing phase III clinical trial with nintedanib in SSc-associated interstitial lung disease.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28814429",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 153,
                    "offsetInEndSection": 446,
                    "text": "Based on positive results from phase III, placebo-controlled, randomized comparative clinical trial conducted in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), nintedanib received marketing approval in the United States and Japan for the treatment of SSc-ILD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31747840",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 495,
                    "offsetInEndSection": 738,
                    "text": "Nintedanib is an intracellular inhibitor of tyrosine kinases that has been approved for treatment of IPF and has recently been shown to reduce the rate of lung function decline in patients with ILD associated with systemic sclerosis (SSc-ILD).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31285305",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are Drosophila ultraconserved elements candidate ncRNAs?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/25618141"
            ],
            "ideal_answer": [
                "Yes. Highly constrained intergenic Drosophila ultraconserved elements are candidate ncRNAs."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D004330"
            ],
            "type": "yesno",
            "id": "56d1accb67f0cb3d66000001",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 86,
                    "text": "Highly constrained intergenic Drosophila ultraconserved elements are candidate ncRNAs.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25618141",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 306,
                    "offsetInEndSection": 1403,
                    "text": "Here, we report the discovery and characterization of UCEs from 12 sequenced Drosophila species. We identified 98 elements \u226580 bp long with very high conservation across the Drosophila phylogeny. Population genetic analyses reveal that these UCEs are not present in mutational cold spots. Instead we infer that they experience a level of selective constraint almost 10-fold higher compared with missense mutations in protein-coding sequences, which is substantially higher than that observed previously for human UCEs. About one-half of these Drosophila UCEs overlap the transcribed portion of genes, with many of those that are within coding sequences likely to correspond to sites of ADAR-dependent RNA editing. For the remaining UCEs that are in nongenic regions, we find that many are potentially capable of forming RNA secondary structures. Among ten chosen for further analysis, we discovered that the majority are transcribed in multiple tissues of Drosophila melanogaster. We conclude that Drosophila species are rich with UCEs and that many of them may correspond to novel noncoding RNAs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25618141",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 85,
                    "text": "Highly Constrained Intergenic Drosophila Ultraconserved Elements Are Candidate ncRNAs",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25618141",
                    "endSection": "title"
                }
            ]
        },
        {
            "body": "Does magnesium sulfate improve outcomes of subarachnoid hemorrhage patients?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/21299874",
                "http://www.ncbi.nlm.nih.gov/pubmed/19398856",
                "http://www.ncbi.nlm.nih.gov/pubmed/18705917",
                "http://www.ncbi.nlm.nih.gov/pubmed/21125466",
                "http://www.ncbi.nlm.nih.gov/pubmed/22170177",
                "http://www.ncbi.nlm.nih.gov/pubmed/16463831",
                "http://www.ncbi.nlm.nih.gov/pubmed/15790946",
                "http://www.ncbi.nlm.nih.gov/pubmed/19658274",
                "http://www.ncbi.nlm.nih.gov/pubmed/16759446",
                "http://www.ncbi.nlm.nih.gov/pubmed/16628069",
                "http://www.ncbi.nlm.nih.gov/pubmed/21748496",
                "http://www.ncbi.nlm.nih.gov/pubmed/23931043",
                "http://www.ncbi.nlm.nih.gov/pubmed/12632115",
                "http://www.ncbi.nlm.nih.gov/pubmed/16164489",
                "http://www.ncbi.nlm.nih.gov/pubmed/22633825",
                "http://www.ncbi.nlm.nih.gov/pubmed/24619389",
                "http://www.ncbi.nlm.nih.gov/pubmed/11883835",
                "http://www.ncbi.nlm.nih.gov/pubmed/22890635",
                "http://www.ncbi.nlm.nih.gov/pubmed/20538692",
                "http://www.ncbi.nlm.nih.gov/pubmed/17121134",
                "http://www.ncbi.nlm.nih.gov/pubmed/20228677",
                "http://www.ncbi.nlm.nih.gov/pubmed/19828484",
                "http://www.ncbi.nlm.nih.gov/pubmed/16159090",
                "http://www.ncbi.nlm.nih.gov/pubmed/23002400",
                "http://www.ncbi.nlm.nih.gov/pubmed/17536487",
                "http://www.ncbi.nlm.nih.gov/pubmed/19370322",
                "http://www.ncbi.nlm.nih.gov/pubmed/15753761",
                "http://www.ncbi.nlm.nih.gov/pubmed/21608279",
                "http://www.ncbi.nlm.nih.gov/pubmed/17636626",
                "http://www.ncbi.nlm.nih.gov/pubmed/19812935",
                "http://www.ncbi.nlm.nih.gov/pubmed/25201463",
                "http://www.ncbi.nlm.nih.gov/pubmed/16427437",
                "http://www.ncbi.nlm.nih.gov/pubmed/22966500",
                "http://www.ncbi.nlm.nih.gov/pubmed/20378868",
                "http://www.ncbi.nlm.nih.gov/pubmed/20334471",
                "http://www.ncbi.nlm.nih.gov/pubmed/18054611",
                "http://www.ncbi.nlm.nih.gov/pubmed/22059101",
                "http://www.ncbi.nlm.nih.gov/pubmed/11426093",
                "http://www.ncbi.nlm.nih.gov/pubmed/21489317",
                "http://www.ncbi.nlm.nih.gov/pubmed/19700328",
                "http://www.ncbi.nlm.nih.gov/pubmed/16463861",
                "http://www.ncbi.nlm.nih.gov/pubmed/16723884"
            ],
            "ideal_answer": [
                "No. Although initial studies have provided with encouraging findings regarding administration of magnesium sulphate in aneurysmal subarachnoid haemorrhage patients, but subsequent larger studies have reported that intravenous magnesium sulphate does not improve clinical outcome after aneurysmal subarachnoid haemorrhage, therefore routine administration of magnesium cannot be recommended."
            ],
            "exact_answer": "no",
            "concepts": [
                "http://www.biosemantics.org/jochem#4073442"
            ],
            "type": "yesno",
            "id": "54d62ede3706e89528000002",
            "snippets": [
                {
                    "offsetInBeginSection": 1687,
                    "offsetInEndSection": 1937,
                    "text": "CONCLUSION: Patients assigned a higher serum magnesium concentration had a reduced incidence of vasospasm as seen by angiography, but the difference was not statistically significant. Clinically significant outcomes were not different between groups.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23931043",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1605,
                    "offsetInEndSection": 2174,
                    "text": "158 patients (26\u00b72%) had poor outcome in the magnesium group compared with 151 (25\u00b73%) in the placebo group (risk ratio [RR] 1\u00b703, 95% CI 0\u00b785-1\u00b725). Our updated meta-analysis of seven randomised trials involving 2047 patients shows that magnesium is not superior to placebo for reduction of poor outcome after aneurysmal subarachnoid haemorrhage (RR 0\u00b796, 95% CI 0\u00b786-1\u00b708). INTERPRETATION: Intravenous magnesium sulphate does not improve clinical outcome after aneurysmal subarachnoid haemorrhage, therefore routine administration of magnesium cannot be recommended. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22633825",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1109,
                    "offsetInEndSection": 1177,
                    "text": "There is a tendency in the magnesium group to have better outcomes. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22170177",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 592,
                    "offsetInEndSection": 865,
                    "text": "Due to inconsistently reported benefits and the occurrence of side effects, phase II data suggested that intravenous magnesium for SAH provided either no overall net benefit or uncertain trade-offs. Benefit was likewise not supported in the single phase III clinical trial.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21748496",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1923,
                    "offsetInEndSection": 2262,
                    "text": "tatistically significant clinical benefits could not be demonstrated for the other drugs (clazosentan, statins, and magnesium). CONCLUSIONS: Insufficient evidence is available to support the use of the triple-H therapy, clazosentan, statins, or magnesium sulfate for the prevention of cerebral vasospasm following subarachnoid hemorrhage. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21608279",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 448,
                    "offsetInEndSection": 679,
                    "text": "Magnesium sulfate decreased the rate of cerebral infarction, but not of DCI or poor functional outcome. Regarding outcome, a beneficial effect of magnesium sulfate on outcome can not be ruled out because of sample size limitations.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21489317",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1497,
                    "offsetInEndSection": 1901,
                    "text": "CONCLUSIONS: The present findings do not lend support to a beneficial effect of magnesium sulphate infusion on delayed cerebral infarction. The reduction in DCI and improvement in the clinical outcomes of aneurysmal SAH patients following magnesium sulphate infusion observed in previous pilot studies are not confirmed, although a beneficial effect cannot be ruled out because of sample size limitation.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21299874",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1145,
                    "offsetInEndSection": 1422,
                    "text": "Favorable outcome (Good recovery and moderate disability, as defined by Glasgow Outcome Scale) was achieved in 20 of 30 (67%) patients receiving magnesium sulfate infusion and 16 of 30 (53%) patients receiving placebo treatment, p = 0.292, odds ratio 1.750, 95% CI 0.616-4.974.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125466",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1739,
                    "offsetInEndSection": 1851,
                    "text": "Similarly, the pooled odds ratio for favorable outcome is 1.598, 95% CI 1.074-2.377, statistically significant. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/21125466",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 671,
                    "offsetInEndSection": 1156,
                    "text": "RESULTS: The worst clinical outcomes at 6 months were seen in MgSO(4) group patients, with mean plasma magnesium concentrations in the fourth quartile, and in placebo group patients, with mean such concentrations in the third and fourth quartiles. CONCLUSIONS: No evidence was found to suggest that a higher mean plasma magnesium concentration improves clinical outcomes. On the contrary, we found an association between high plasma magnesium concentration and worse clinical outcomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20538692",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1009,
                    "offsetInEndSection": 1388,
                    "text": "The proportions of patients with a favorable outcome at 6 months (Extended Glasgow Outcome Scale 5 to 8) were similar, 64% in the magnesium sulfate group and 63% in the saline group (OR, 1.0; 95% CI, 0.7 to 1.6). Secondary outcome analyses (modified Rankin Scale, Barthel Index, Short Form 36, and clinical vasospasm) also showed no significant differences between the 2 groups. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20378868",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1726,
                    "offsetInEndSection": 1907,
                    "text": "CONCLUSIONS: The results do not support a clinical benefit of intravenous magnesium sulfate infusion over placebo infusion in patients with acute aneurysmal subarachnoid hemorrhage.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20378868",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 752,
                    "offsetInEndSection": 952,
                    "text": "Magnesium infusion reduced the risk of poor outcome and delayed cerebral ischemia (DCI): the relative risk was 0.62 (95% confidence interval (CI) 0.46-0.83) and 0.73 (95% CI 0.53-1.00), respectively. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20334471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1153,
                    "offsetInEndSection": 1290,
                    "text": "CONCLUSION: The meta-analysis suggests that intravenous magnesium therapy reduces the risk of DCI and poor outcome after aneurysmal SAH. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20334471",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1361,
                    "offsetInEndSection": 1575,
                    "text": "The incidence of delayed ischemic infarction was significantly lower in magnesium-treated patients (22% vs. 51%; p = .002); 34 of 54 magnesium patients and 27 of 53 control patients reached good outcome (p = .209).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20228677",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 209,
                    "text": "BACKGROUND: A meta-analysis of current data suggests that magnesium sulfate infusion improves the outcome after aneurysmal subarachnoid hemorrhage through a reduction in delayed ischemic neurological deficit. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19812935",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1505,
                    "offsetInEndSection": 1701,
                    "text": "These data imply that intravenous magnesium therapy, besides a supposed beneficial effect on outcome, also provides pain relief for SAH patients, for whom it might also improve functional outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19828484",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 185,
                    "text": "Preliminary evidence has suggested that magnesium sulfate infusion reduces delayed ischemic neurological deficit and improves clinical outcome after aneurysmal subarachnoid hemorrhage. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19658274",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 238,
                    "offsetInEndSection": 373,
                    "text": "In a phase II randomized clinical trial of 283 patients, magnesium treatment reduced the risk of DCI by 34% and of poor outcome by 23%.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18705917",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 145,
                    "text": "BACKGROUND: Recent studies suggest that high-dose MgSO4 therapy is safe and reduces the incidence of DIND and subsequent poor outcome after SAH. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18054611",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 863,
                    "offsetInEndSection": 1008,
                    "text": "On-treatment analysis showed a significantly better outcome after 3 months (P = .017) and a trend toward better outcome after 1 year (P = .083). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18054611",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1316,
                    "offsetInEndSection": 1455,
                    "text": " CONCLUSIONS: High-dose MgSO4 therapy might be efficient as a prophylactic adjacent therapy after SAH to reduce the risk for poor outcome. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/18054611",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1229,
                    "offsetInEndSection": 1652,
                    "text": "There was no significant difference in mortality rate at discharge (p = 0.328). A trend toward improved outcome as measured by the modifed Rankin Scale (p = 0.084), but not the Glasgow Outcome Scale (p = 1.0), was seen in the MgSO4 treated group. CONCLUSIONS: Analysis of the results suggests that MgSO4 infusion may have a role in cerebral vasospasm prophylaxis if therapy is initiated within 48 hours of aneurysm rupture.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/17121134",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1040,
                    "offsetInEndSection": 1144,
                    "text": "There was, however, no difference between groups in functional recovery or Glasgow Outcome Scale score. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16628069",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1078,
                    "offsetInEndSection": 1204,
                    "text": "Patients receiving MgSO4 tended to have fewer neurological deficits, better functional recovery and an improved score in GOS. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16463861",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1419,
                    "offsetInEndSection": 1532,
                    "text": "CONCLUSIONS: MgSO4 infusion after aneurysmal SAH is well tolerated and may be useful in producing better outcome.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16463861",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1488,
                    "offsetInEndSection": 1642,
                    "text": "CONCLUSION: Magnesium did not seem to interfere in vasospasm frequency but apparently acted favorably in decreasing morbidity and length of hospital stay.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16427437",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1862,
                    "offsetInEndSection": 2011,
                    "text": "None of the patients died; no CT evidence of ischemic infarction was present; and most had good outcomes (GOS 5 in 10 patients; GOS 4 in 8 patients).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/16159090",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1110,
                    "offsetInEndSection": 1379,
                    "text": "At that time, 18 patients in the treatment group and 6 in the placebo group had an excellent outcome (risk ratio, 3.4; 95% CI, 1.3 to 8.9). CONCLUSIONS: This study suggests that magnesium reduces DCI and subsequent poor outcome, but the results are not yet definitive. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15790946",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2757,
                    "offsetInEndSection": 2944,
                    "text": "We observed a trend in which a higher percentage of patients obtained GOS scores of 4 or 5 in the group treated with MgSO4, but the trend did not reach a statistically significant level. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/11883835",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 109,
                    "text": "Magnesium sulfate treatment improves outcome in patients with subarachnoid hemorrhage: a meta-analysis study.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23002400",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 189,
                    "text": "BACKGROUND AND PURPOSE: Pilot clinical trials using magnesium sulfate in patients with acute aneurysmal subarachnoid hemorrhage have reported trends toward improvement in clinical outcomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20378868",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 184,
                    "text": "Preliminary evidence has suggested that magnesium sulfate infusion reduces delayed ischemic neurological deficit and improves clinical outcome after aneurysmal subarachnoid hemorrhage.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19658274",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1274,
                    "offsetInEndSection": 1446,
                    "text": "Our results indicate that although there was reduced likelihood of a poor outcome for patients treated with magnesium sulfate after SAH, patient mortality was not improved.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700328",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 2183,
                    "offsetInEndSection": 2405,
                    "text": "CONCLUSION: Administration of intra-arterial magnesium sulfate in combination with nicardipine was well tolerated in patients with subarachnoid hemorrhage and cerebral vasospasm without a significant change in MAP and ICP.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19370322",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1389,
                    "offsetInEndSection": 1502,
                    "text": "Current evidence does not support the prophylactic use of magnesium sulfate in aneurysmal subarachnoid hemorrhage",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24619389",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 183,
                    "text": "Preliminary evidence has suggested that magnesium sulfate infusion reduces delayed ischemic neurological deficit and improves clinical outcome after aneurysmal subarachnoid hemorrhage",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19658274",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 195,
                    "text": "A meta-analysis of current data suggests that magnesium sulfate infusion improves the outcome after aneurysmal subarachnoid hemorrhage through a reduction in delayed ischemic neurological deficit",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19812935",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 190,
                    "text": "Despite the publication of several randomized controlled studies, there is still much debate on whether magnesium sulfate improves outcome in patients with aneurysmal subarachnoid hemorrhage",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/19700328",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 196,
                    "text": "Magnesium sulphate is a neuroprotective agent that might improve outcome after aneurysmal subarachnoid haemorrhage by reducing the occurrence or improving the outcome of delayed cerebral ischaemia",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22633825",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is obesity related to cognitive decline?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/28837952",
                "http://www.ncbi.nlm.nih.gov/pubmed/26928024",
                "http://www.ncbi.nlm.nih.gov/pubmed/26638123",
                "http://www.ncbi.nlm.nih.gov/pubmed/28514983",
                "http://www.ncbi.nlm.nih.gov/pubmed/22258511",
                "http://www.ncbi.nlm.nih.gov/pubmed/26107577",
                "http://www.ncbi.nlm.nih.gov/pubmed/15591798",
                "http://www.ncbi.nlm.nih.gov/pubmed/23922324",
                "http://www.ncbi.nlm.nih.gov/pubmed/26163814",
                "http://www.ncbi.nlm.nih.gov/pubmed/25496905",
                "http://www.ncbi.nlm.nih.gov/pubmed/24119725",
                "http://www.ncbi.nlm.nih.gov/pubmed/28284174"
            ],
            "ideal_answer": [
                "Obesity is a common medical illness that is increasingly recognised as conferring risk of decline in cognitive performance, independent of other comorbid medical conditions. Overweight and obesity are associated with an increased risk of subnormal intellectual performance in young adult males. Subjects with low birth weight and adolescent overweight/obesity are at particular risk of subnormal performance."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "5c0e838b133db5eb7800002e",
            "snippets": [
                {
                    "offsetInBeginSection": 623,
                    "offsetInEndSection": 800,
                    "text": "The initial results suggests that obese children have higher cognitive scores and that this result is driven by those who are female, non-indigenous and live in an urban region.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28284174",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1111,
                    "offsetInEndSection": 1367,
                    "text": "On the other end of the weight distribution, indigenous children who are severely thin or thin have significantly lower cognitive scores, a relationship that holds after correcting for possible bias and appears to strengthen between ages of five and eight.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28284174",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1476,
                    "offsetInEndSection": 1651,
                    "text": "Obesity is associated with decreased cognitive function, reduced gray matter volume, and impaired white matter integrity in cognition-related brain areas in patients with MDD.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28837952",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 686,
                    "offsetInEndSection": 876,
                    "text": "The data suggest that being overweight or obese in midlife may be more detrimental to subsequent age-related cognitive decline than being overweight or obese at later stages of the life span",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26107577",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 371,
                    "offsetInEndSection": 645,
                    "text": "Poor cognitive performance was present in 37% of the sample. General obesity (BMI>or = 25) and poor cognition were strongly associated in the presence of abdominal obesity. Poor cognition was negatively associated with overweight (BMI 23-25) with normal waist circumference.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15591798",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1450,
                    "offsetInEndSection": 1622,
                    "text": "BMI could be used as a candidate risk marker to identify people at higher risk of cognitive deficits, and as an intervention target for modifications of cognitive outcomes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24119725",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 14,
                    "offsetInEndSection": 187,
                    "text": "Obesity is a common medical illness that is increasingly recognised as conferring risk of decline in cognitive performance, independent of other comorbid medical conditions.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26928024",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1164,
                    "offsetInEndSection": 1398,
                    "text": "Overweight and obesity are associated with an increased risk of subnormal intellectual performance in young adult males. Subjects with low birth weight and adolescent overweight/obesity are at particular risk of subnormal performance.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23922324",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1316,
                    "offsetInEndSection": 1411,
                    "text": "Impairments in cognitive function have been associated with obesity in both people and rodents.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/25496905",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 983,
                    "offsetInEndSection": 1203,
                    "text": "Obesity in the pre-school years was associated with poorer outcomes for some cognitive measures in this study. Stronger relationships between obesity and cognition or educational attainment may emerge later in childhood.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26638123",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 167,
                    "offsetInEndSection": 287,
                    "text": "There is parallel evidence that people who are overweight or obese tend to perform worse on a variety of cognitive tasks",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/28514983",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 256,
                    "offsetInEndSection": 402,
                    "text": "While research in this area is growing, our knowledge of obesity-related cognitive dysfunction and brain alterations has not yet been synthesized.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258511",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 403,
                    "offsetInEndSection": 613,
                    "text": "The present review integrates the recent literature regarding patterns of obesity-related cognitive dysfunction and brain alterations and also indicates potential mechanisms for these neuropathological changes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258511",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 614,
                    "offsetInEndSection": 813,
                    "text": "The review culminates in a preliminary model of obesity-related cognitive dysfunction and suggestions for future research, including the potential reversibility of these changes with weight-loss.<br>",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22258511",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 528,
                    "offsetInEndSection": 637,
                    "text": "Evidence for the increased prevalence of diabetes and obesity is reviewed as it relates to cognitive decline.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26163814",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 638,
                    "offsetInEndSection": 877,
                    "text": "These articles indicate that the age of onset of Type 1 diabetes may be relevant to future cognitive function and that disease duration of Type 2 diabetes and sociocultural factors are related to cognitive decline during the aging process.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26163814",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1246,
                    "offsetInEndSection": 1403,
                    "text": "This special issue concludes with a conceptual framework for linking obesity and diabetes with accelerated cognitive decline as related to the aging process.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26163814",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 169,
                    "offsetInEndSection": 271,
                    "text": "The adverse effects of diabetes and obesity on cognitive functioning are increasingly well recognized.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26163814",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1599,
                    "offsetInEndSection": 1761,
                    "text": "Moreover, these studies show that distressing environmental circumstances can adversely influence neurocognitive dysfunction associated with obesity and diabetes.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/26163814",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Is cadherin a plasma membrane marker?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/31838186",
                "http://www.ncbi.nlm.nih.gov/pubmed/32044971",
                "http://www.ncbi.nlm.nih.gov/pubmed/32939719",
                "http://www.ncbi.nlm.nih.gov/pubmed/32239671"
            ],
            "ideal_answer": [
                "Yes,\ncadherin is a plasma membrane protein marker."
            ],
            "exact_answer": "yes",
            "type": "yesno",
            "id": "6060c7c094d57fd879000046",
            "snippets": [
                {
                    "offsetInBeginSection": 966,
                    "offsetInEndSection": 1010,
                    "text": "the plasma membrane-bound E-cadherin protein",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32939719",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 933,
                    "offsetInEndSection": 1013,
                    "text": "VE-cadherin protein levels were also increased in the plasma membrane fraction. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/31838186",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 649,
                    "offsetInEndSection": 698,
                    "text": " recycling of VE-cadherin to the plasma membrane,",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32044971",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 102,
                    "text": "E-cadherin, a central component of the adherens junction (AJ), is a single-pass transmembrane protein ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/32239671",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Are there any urine biomarkers for bladder cancer diagnosis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/24139504",
                "http://www.ncbi.nlm.nih.gov/pubmed/24578952",
                "http://www.ncbi.nlm.nih.gov/pubmed/22559832",
                "http://www.ncbi.nlm.nih.gov/pubmed/24183881",
                "http://www.ncbi.nlm.nih.gov/pubmed/18070176",
                "http://www.ncbi.nlm.nih.gov/pubmed/24306957",
                "http://www.ncbi.nlm.nih.gov/pubmed/18923359",
                "http://www.ncbi.nlm.nih.gov/pubmed/24140246",
                "http://www.ncbi.nlm.nih.gov/pubmed/19181545",
                "http://www.ncbi.nlm.nih.gov/pubmed/22426337",
                "http://www.ncbi.nlm.nih.gov/pubmed/22615872",
                "http://www.ncbi.nlm.nih.gov/pubmed/22888342",
                "http://www.ncbi.nlm.nih.gov/pubmed/20960509",
                "http://www.ncbi.nlm.nih.gov/pubmed/23764080",
                "http://www.ncbi.nlm.nih.gov/pubmed/19565266",
                "http://www.ncbi.nlm.nih.gov/pubmed/23094052",
                "http://www.ncbi.nlm.nih.gov/pubmed/20082749",
                "http://www.ncbi.nlm.nih.gov/pubmed/24212086",
                "http://www.ncbi.nlm.nih.gov/pubmed/22792272",
                "http://www.ncbi.nlm.nih.gov/pubmed/23945108",
                "http://www.ncbi.nlm.nih.gov/pubmed/20657287",
                "http://www.ncbi.nlm.nih.gov/pubmed/24281040",
                "http://www.ncbi.nlm.nih.gov/pubmed/15341676",
                "http://www.ncbi.nlm.nih.gov/pubmed/23300915"
            ],
            "triples": [
                {
                    "p": "http://www.w3.org/2004/02/skos/core#notation",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7638941",
                    "o": "C16181"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#literalForm",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7638941",
                    "o": "Cancer Biomarkers Research Group"
                },
                {
                    "p": "http://www.w3.org/2008/05/skos-xl#prefLabel",
                    "s": "http://linkedlifedata.com/resource/umls/id/C1516166",
                    "o": "http://linkedlifedata.com/resource/umls/label/A7638941"
                },
                {
                    "p": "http://www.w3.org/2004/02/skos/core#note",
                    "s": "http://linkedlifedata.com/resource/umls/label/A7638941",
                    "o": "NCI Thesaurus"
                }
            ],
            "ideal_answer": [
                "Bladder cancer is any of several types of malignancy arising from the epithelial lining of the urinary bladder. Rarely the bladder is involved by non-epithelial cancers, such as lymphoma or sarcoma. It is a disease in which abnormal cells multiply without control in the bladder.The bladder is a hollow, muscular organ that stores urine; it is located in the pelvis. The most common type of bladder cancer recapitulates the normal histology of the urothelium and is known as transitional cell carcinoma or more properly urothelial cell carcinoma. It is estimated that there are 383,000 cases of bladder cancer worldwide",
                "Yes, there are. Urine biomarkers for bladder cancer diagnosis range from voided urine cytology and the UroVysion\u00ae cytogenetic test, to fluorescence in situ hybridisation (FISH), ImmunoCyt, NMP22, Bladder Tumor Antigen, BLCA-1, BLCA-4, hyaluronic acid, hyaluronidase, Lewis X antigen, microsatellite analysis, Quanticyt, soluble Fas, Survivin, telomerase, IL-8, MMP-9 and 10, PAI-1, VEGF, ANG, CA9 and APOE."
            ],
            "exact_answer": "yes",
            "concepts": [
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001749",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014554",
                "http://www.disease-ontology.org/api/metadata/DOID:6933",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D014556",
                "http://www.disease-ontology.org/api/metadata/DOID:4007",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D001743",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D055088",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D054316",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D042241",
                "http://www.nlm.nih.gov/cgi/mesh/2014/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015415",
                "http://www.uniprot.org/uniprot/BLCAP_HUMAN",
                "http://www.disease-ontology.org/api/metadata/DOID:11054"
            ],
            "type": "yesno",
            "id": "52cb9b9b03868f1b0600002d",
            "snippets": [
                {
                    "offsetInBeginSection": 1232,
                    "offsetInEndSection": 1517,
                    "text": "CONCLUSIONS: Several gene-based urinary biomarkers have demonstrated promise in initial studies, which now need to be rigorously validated in the clinical setting for them to be translated into clinically useful tests in diagnosis, surveillance or risk-stratification of bladder cancer",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24140246",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1606,
                    "offsetInEndSection": 1865,
                    "text": " Novel promising markers are in various stages of clinical testing, and a panel of biomarkers may serve in the future as a feasible alternative to urine cytology and cystoscopy for the screening, detection, and follow-up of non-muscle invasive bladder cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/15341676",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 866,
                    "offsetInEndSection": 1130,
                    "text": "RESULTS: Seven of the 8 urine biomarkers were increased in subjects with bladder cancer relative to those without bladder cancer. The 7 biomarkers were assessed in a new model, which had an AUROC of 0.88 (95% CI 0.84-0.93), and 74% sensitivity and 90% specificity.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23764080",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1426,
                    "offsetInEndSection": 1644,
                    "text": "The study provides further evidence that the reported panel of diagnostic biomarkers can reliably achieve the noninvasive detection of bladder cancer with higher sensitivity than currently available urine based assays.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23764080",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 545,
                    "offsetInEndSection": 1417,
                    "text": "The urinary concentrations of 14 biomarkers (IL-8, MMP-9, MMP-10, SDC1, CCL18, PAI-1, CD44, VEGF, ANG, CA9, A1AT, OPN, PTX3, and APOE) were assessed by enzyme-linked immunosorbent assay (ELISA). Diagnostic performance of each biomarker and multivariate models were compared using receiver operating characteristic curves and the chi-square test. An 8-biomarker model achieved the most accurate BCa diagnosis (sensitivity 92%, specificity 97%), but a combination of 3 of the 8 biomarkers (IL-8, VEGF, and APOE) was also highly accurate (sensitivity 90%, specificity 97%). For comparison, the commercial BTA-Trak ELISA test achieved a sensitivity of 79% and a specificity of 83%, and voided urine cytology detected only 33% of BCa cases in the same cohort. These data show that a multivariate urine-based assay can markedly improve the accuracy of non-invasive BCa detection",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23094052",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 10,
                    "offsetInEndSection": 401,
                    "text": ": Histopathological grading of papillary urothelial tumors (PUTs) of the urinary bladder is subjective and poorly reproducible. We investigated the relationship between the expression of frequently deregulated microRNAs (miRNAs) as well as their target genes (ZEB1/ZEB2) and bladder cancer histopathological grade in an attempt to find a miRNA that might allow more reliable grading of PUTs.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/24306957",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1429,
                    "offsetInEndSection": 1914,
                    "text": "The Mcm5 immunoassay is a non-invasive test for identifying patients with urothelial cancers with similar accuracy to the FDA-approved NMP22 ELISA Test Kit. The combination of Mcm5 plus NMP22 improves the detection of UCC and identifies 95% of clinically significant disease. Trials of a commercially developed Mcm5 assay suitable for an end-user laboratory alongside NMP22 are required to assess their potential clinical utility in improving diagnostic and surveillance care pathways.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22792272",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1738,
                    "offsetInEndSection": 1959,
                    "text": "HYAL-1 and HAS1 expression predicted BCa metastasis, and HYAL-1 expression also predicted disease-specific survival. Furthermore, the combined HAS2-HYAL-1 biomarker detected BCa and significantly predicted its recurrence.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20960509",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 12,
                    "offsetInEndSection": 124,
                    "text": "Cancer biomarkers are the backbone for the implementation of individualized approaches to bladder cancer (BCa). ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/20960509",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 138,
                    "offsetInEndSection": 676,
                    "text": "Through genomic and proteomic profiling of urine, we have identified a panel of biomarkers associated with the presence of BCa. In this study, we evaluated the utility of three of these biomarkers, interleukin 8 (IL-8), Matrix metallopeptidase 9 (MMP-9) and Syndecan in the diagnosis of BCa through urinalysis. METHODS: Voided urines from 127 subjects, cancer subjects (n = 64), non-cancer subjects (n = 63) were analyzed. The protein concentrations of IL-8, MMP-9, and Syndecan were assessed by enzyme-linked immunosorbent assay (ELISA).",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/22559832",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1653,
                    "offsetInEndSection": 1998,
                    "text": ". There was an association between differences in individual biomarkers and differences in protein levels over time, particularly in control patients. Collectively, our findings identify caveats intrinsic to the common practice of protein standardization in biomarker discovery studies conducted on urine, particularly in patients with hematuria",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23300915",
                    "endSection": "abstract"
                }
            ]
        },
        {
            "body": "Does saracatinib promote oncogenesis?",
            "documents": [
                "http://www.ncbi.nlm.nih.gov/pubmed/23144237"
            ],
            "ideal_answer": [
                "No, saracatinib has antitumor activity."
            ],
            "exact_answer": "no",
            "type": "yesno",
            "id": "5e540ed36d0a277941000054",
            "snippets": [
                {
                    "offsetInBeginSection": 0,
                    "offsetInEndSection": 146,
                    "text": "Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.",
                    "beginSection": "title",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23144237",
                    "endSection": "title"
                },
                {
                    "offsetInBeginSection": 459,
                    "offsetInEndSection": 939,
                    "text": "We evaluated the antitumor effect of a c-Src/Abl kinase inhibitor, saracatinib (AZD0530), alone or combined with chemotherapeutic agents in gastric cancer cell lines and a NCI-N87 xenograft model. Among 10 gastric cancer cell lines, saracatinib specifically inhibited the growth and migration/invasion of SNU216 and NCI-N87 cells. Saracatinib blocked the Src/FAK, HER family, and oncogenic signaling pathways, and it induced G(1) arrest and apoptosis in SNU216 and NCI-N87 cells. ",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23144237",
                    "endSection": "abstract"
                },
                {
                    "offsetInBeginSection": 1460,
                    "offsetInEndSection": 1767,
                    "text": "Consistent with our in vitro findings, cotreatment with saracatinib and 5-FU resulted in enhanced antitumor activity in the NCI-N87 xenografts. These data indicate that the inhibition of Src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.",
                    "beginSection": "abstract",
                    "document": "http://www.ncbi.nlm.nih.gov/pubmed/23144237",
                    "endSection": "abstract"
                }
            ]
        }
    ]
}